Compositions and methods for the therapy and diagnosis of lung cancer

ABSTRACT

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

BACKGROUND OF THE INVENTION

[0001] 1. Field of the Invention

[0002] The present invention relates generally to therapy and diagnosis of cancer, such as lung cancer. The invention is more specifically related to polypeptides, comprising at least a portion of a lung tumor protein, and to polynucleotides encoding such polypeptides. Such polypeptides and polynucleotides are useful in pharmaceutical compositions, e.g., vaccines, and other compositions for the diagnosis and treatment of lung cancer.

[0003] 2. Description of the Related Art

[0004] Cancer is a significant health problem throughout the world. Although advances have been made in detection and therapy of cancer, no vaccine or other universally successful method for prevention and/or treatment is currently available. Current therapies, which are generally based on a combination of chemotherapy or surgery and radiation, continue to prove inadequate in many patients.

[0005] Lung cancer is a significant health problem throughout the world. In the U.S., lung cancer is the primary cause of cancer death among both men and women, with an estimated 172,000 new cases being reported in 1994. The five-year survival rate among all lung cancer patients, regardless of the stage of disease at diagnosis, is only 13%. This contrasts with a five-year survival rate of 46% among cases detected while the disease is still localized. However, early detection of lung cancer is difficult since clinical symptoms are often not seen until the disease has reached an advanced stage, and only 16% of lung cancers are discovered before the disease has spread.

[0006] In spite of considerable research into therapies for these and other cancers, lung cancer remains difficult to diagnose and treat effectively. Accordingly, there is a need in the art for improved methods for detecting and treating such cancers. The present invention fulfills these needs and further provides other related advantages.

SUMMARY OF THE INVENTION

[0007] In one aspect, the present invention provides polynucleotide compositions comprising a sequence selected from the group consisting of:

[0008] (a) sequences provided in SEQ ID NOs:1-663, 667-668 and 670;

[0009] (b) complements of the sequences provided in SEQ ID NOs:1-663, 667-668 and 670;

[0010] (c) sequences consisting of at least 20, 25, 30, 35, 40, 45, 50, 75 and 100 contiguous residues of a sequence provided in SEQ ID NOs:1-663, 667-668 and 670;

[0011] (d) sequences that hybridize to a sequence provided in SEQ ID NOs:1-663, 667-668 and 670, under moderate or highly stringent conditions;

[0012] (e) sequences having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to a sequence of SEQ ID NOs:1-663, 667-668 and 670;

[0013] (f) degenerate variants of a sequence provided in SEQ ID NOs:1-663, 667-668 and 670.

[0014] In one preferred embodiment, the polynucleotide compositions of the invention are expressed in at least about 20%, more preferably in at least about 30%, and most preferably in at least about 50% of lung tumors samples tested, at a level that is at least about 2-fold, preferably at least about 5-fold, and most preferably at least about 10-fold higher than that for normal tissues.

[0015] The present invention, in another aspect, provides polypeptide compositions comprising an amino acid sequence that is encoded by a polynucleotide sequence described above.

[0016] The present invention further provides polypeptide compositions comprising an amino acid sequence selected from the group consisting of sequences recited in SEQ ID NOs:664-666 and 669.

[0017] In certain preferred embodiments, the polypeptides and/or polynucleotides of the present invention are immunogenic, i.e., they are capable of eliciting an immune response, particularly a humoral and/or cellular immune response, as further described herein.

[0018] The present invention further provides fragments, variants and/or derivatives of the disclosed polypeptide and/or polynucleotide sequences, wherein the fragments, variants and/or derivatives preferably have a level of immunogenic activity of at least about 50%, preferably at least about 70% and more preferably at least about 90% of the level of immunogenic activity of a polypeptide sequence set forth in SEQ ID NOs:664-666 and 669 or a polypeptide sequence encoded by a polynucleotide sequence set forth in SEQ ID NOs:1-663, 667-668 and 670.

[0019] The present invention further provides polynucleotides that encode a polypeptide described above, expression vectors comprising such polynucleotides and host cells transformed or transfected with such expression vectors.

[0020] Within other aspects, the present invention provides pharmaceutical compositions comprising a polypeptide or polynucleotide as described above and a physiologically acceptable carrier.

[0021] Within a related aspect of the present invention, the pharmaceutical compositions, e.g., vaccine compositions, are provided for prophylactic or therapeutic applications. Such compositions generally comprise an immunogenic polypeptide or polynucleotide of the invention and an immunostimulant, such as an adjuvant.

[0022] The present invention further provides pharmaceutical compositions that comprise: (a) an antibody or antigen-binding fragment thereof that specifically binds to a polypeptide of the present invention, or a fragment thereof; and (b) a physiologically acceptable carrier.

[0023] Within further aspects, the present invention provides pharmaceutical compositions comprising: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) a pharmaceutically acceptable carrier or excipient. Illustrative antigen presenting cells include dendritic cells, macrophages, monocytes, fibroblasts and B cells.

[0024] Within related aspects, pharmaceutical compositions are provided that comprise: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) an immunostimulant.

[0025] The present invention further provides, in other aspects, fusion proteins that comprise at least one polypeptide as described above, as well as polynucleotides encoding such fusion proteins, typically in the form of pharmaceutical compositions, e.g., vaccine compositions, comprising a physiologically acceptable carrier and/or an immunostimulant. The fusions proteins may comprise multiple immunogenic polypeptides or portions/variants thereof, as described herein, and may further comprise one or more polypeptide segments for facilitating the expression, purification and/or immunogenicity of the polypeptide(s).

[0026] Within further aspects, the present invention provides methods for stimulating an immune response in a patient, preferably a T cell response in a human patient, comprising administering a pharmaceutical composition described herein. The patient may be afflicted with lung cancer, in which case the methods provide treatment for the disease, or patient considered at risk for such a disease may be treated prophylactically.

[0027] Within further aspects, the present invention provides methods for inhibiting the development of a cancer in a patient, comprising administering to a patient a pharmaceutical composition as recited above. The patient may be afflicted with lung cancer, in which case the methods provide treatment for the disease, or patient considered at risk for such a disease may be treated prophylactically.

[0028] The present invention further provides, within other aspects, methods for removing tumor cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a polypeptide of the present invention, wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the protein from the sample.

[0029] Within related aspects, methods are provided for inhibiting the development of a cancer in a patient, comprising administering to a patient a biological sample treated as described above.

[0030] Methods are further provided, within other aspects, for stimulating and/or expanding T cells specific for a polypeptide of the present invention, comprising contacting T cells with one or more of: (i) a polypeptide as described above; (ii) a polynucleotide encoding such a polypeptide; and/or (iii) an antigen presenting cell that expresses such a polypeptide; under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells. Isolated T cell populations comprising T cells prepared as described above are also provided.

[0031] Within further aspects, the present invention provides methods for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a T cell population as described above.

[0032] The present invention further provides methods for inhibiting the development of a cancer in a patient, comprising the steps of: (a) incubating CD4⁺ and/or CD8⁺ T cells isolated from a patient with one or more of: (i) a polypeptide comprising at least an immunogenic portion of polypeptide disclosed herein; (ii) a polynucleotide encoding such a polypeptide; and (iii) an antigen-presenting cell that expressed such a polypeptide; and (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient. Proliferated cells may, but need not, be cloned prior to administration to the patient.

[0033] Within further aspects, the present invention provides methods for determining the presence or absence of a cancer, preferably a lung cancer, in a patient comprising: (a) contacting a biological sample obtained from a patient with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; and (c) comparing the amount of polypeptide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within preferred embodiments, the binding agent is an antibody, more preferably a monoclonal antibody.

[0034] The present invention also provides, within other aspects, methods for monitoring the progression of a cancer in a patient. Such methods comprise the steps of: (a) contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polypeptide detected in step (c) with the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

[0035] The present invention further provides, within other aspects, methods for determining the presence or absence of a cancer in a patient, comprising the steps of: (a) contacting a biological sample, e.g., tumor sample, serum sample, etc., obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a polypeptide of the present invention; (b) detecting in the sample a level of a polynucleotide, preferably mRNA, that hybridizes to the oligonucleotide; and (c) comparing the level of polynucleotide that hybridizes to the oligonucleotide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within certain embodiments, the amount of mRNA is detected via polymerase chain reaction using, for example, at least one oligonucleotide primer that hybridizes to a polynucleotide encoding a polypeptide as recited above, or a complement of such a polynucleotide. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing an oligonucleotide probe that hybridizes to a polynucleotide that encodes a polypeptide as recited above, or a complement of such a polynucleotide.

[0036] In related aspects, methods are provided for monitoring the progression of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a polypeptide of the present invention; (b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polynucleotide detected in step (c) with the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

[0037] Within further aspects, the present invention provides antibodies, such as monoclonal antibodies, that bind to a polypeptide as described above, as well as diagnostic kits comprising such antibodies. Diagnostic kits comprising one or more oligonucleotide probes or primers as described above are also provided.

[0038] These and other aspects of the present invention will become apparent upon reference to the following detailed description. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF THE SEQUENCE IDENTIFIERS

[0039] SEQ ID NO:1 is the determined cDNA sequence for clone 61571741.

[0040] SEQ ID NO:2 is the determined cDNA sequence for clone 61571742.

[0041] SEQ ID NO:3 is the determined cDNA sequence for clone 61571743.

[0042] SEQ ID NO:4 is the determined cDNA sequence for clone 61571744.

[0043] SEQ ID NO:5 is the determined cDNA sequence for clone 61571745.

[0044] SEQ ID NO:6 is the determined cDNA sequence for clone 61571746.

[0045] SEQ ID NO:7 is the determined cDNA sequence for clone 61571747.

[0046] SEQ ID NO:8 is the determined cDNA sequence for clone 61571748.

[0047] SEQ ID NO:9 is the determined cDNA sequence for clone 61571750.

[0048] SEQ ID NO:10 is the determined cDNA sequence for clone 61571752.

[0049] SEQ ID NO:11 is the determined cDNA sequence for clone 61571753.

[0050] SEQ ID NO:12 is the determined cDNA sequence for clone 61571754.

[0051] SEQ ID NO:13 is the determined cDNA sequence for clone 61571756.

[0052] SEQ ID NO:14 is the determined cDNA sequence for clone 61571757.

[0053] SEQ ID NO:15 is the determined cDNA sequence for clone 61571758.

[0054] SEQ ID NO:16 is the determined cDNA sequence for clone 61571759.

[0055] SEQ ID NO:17 is the determined cDNA sequence for clone 61571760.

[0056] SEQ ID NO:18 is the determined cDNA sequence for clone 61571761.

[0057] SEQ ID NO:19 is the determined cDNA sequence for clone 61571762.

[0058] SEQ ID NO:20 is the determined cDNA sequence for clone 61571763.

[0059] SEQ ID NO:21 is the determined cDNA sequence for clone 61571764.

[0060] SEQ ID NO:22 is the determined cDNA sequence for clone 61571765.

[0061] SEQ ID NO:23 is the determined cDNA sequence for clone 61571766.

[0062] SEQ ID NO:24 is the determined cDNA sequence for clone 61571767.

[0063] SEQ ID NO:25 is the determined cDNA sequence for clone 61571768.

[0064] SEQ ID NO:26 is the determined cDNA sequence for clone 61571770.

[0065] SEQ ID NO:27 is the determined cDNA sequence for clone 61571771.

[0066] SEQ ID NO:28 is the determined cDNA sequence for clone 61571772.

[0067] SEQ ID NO:29 is the determined cDNA sequence for clone 61571773.

[0068] SEQ ID NO:30 is the determined cDNA sequence for clone 61571774.

[0069] SEQ ID NO:31 is the determined cDNA sequence for clone 61571775.

[0070] SEQ ID NO:32 is the determined cDNA sequence for clone 61571776.

[0071] SEQ ID NO:33 is the determined cDNA sequence for clone 61571778.

[0072] SEQ ID NO:34 is the determined cDNA sequence for clone 61571780.

[0073] SEQ ID NO:35 is the determined cDNA sequence for clone 61571781.

[0074] SEQ ID NO:36 is the determined cDNA sequence for clone 61571782.

[0075] SEQ ID NO:37 is the determined cDNA sequence for clone 61571783.

[0076] SEQ ID NO:38 is the determined cDNA sequence for clone 61571786.

[0077] SEQ ID NO:39 is the determined cDNA sequence for clone 61571787.

[0078] SEQ ID NO:40 is the determined cDNA sequence for clone 61571788.

[0079] SEQ ID NO:41 is the determined cDNA sequence for clone 61571789.

[0080] SEQ ID NO:42 is the determined cDNA sequence for clone 61571790.

[0081] SEQ ID NO:43 is the determined cDNA sequence for clone 61571791.

[0082] SEQ ID NO:44 is the determined cDNA sequence for clone 61571793.

[0083] SEQ ID NO:45 is the determined cDNA sequence for clone 61571794.

[0084] SEQ ID NO:46 is the determined cDNA sequence for clone 61571795.

[0085] SEQ ID NO:47 is the determined cDNA sequence for clone 61571796.

[0086] SEQ ID NO:48 is the determined cDNA sequence for clone 61571797.

[0087] SEQ ID NO:49 is the determined cDNA sequence for clone 61571799.

[0088] SEQ ID NO:50 is the determined cDNA sequence for clone 61571800.

[0089] SEQ ID NO:51 is the determined cDNA sequence for clone 61571802.

[0090] SEQ ID NO:52 is the determined cDNA sequence for clone 61571803.

[0091] SEQ ID NO:53 is the determined cDNA sequence for clone 61571804.

[0092] SEQ ID NO:54 is the determined cDNA sequence for clone 61571805.

[0093] SEQ ID NO:55 is the determined cDNA sequence for clone 61571806.

[0094] SEQ ID NO:56 is the determined cDNA sequence for clone 61571807.

[0095] SEQ ID NO:57 is the determined cDNA sequence for clone 61571808.

[0096] SEQ ID NO:58 is the determined cDNA sequence for clone 61571810.

[0097] SEQ ID NO:59 is the determined cDNA sequence for clone 61571811.

[0098] SEQ ID NO:60 is the determined cDNA sequence for clone 61571813.

[0099] SEQ ID NO:61 is the determined cDNA sequence for clone 61571814.

[0100] SEQ ID NO:62 is the determined cDNA sequence for clone 61571816.

[0101] SEQ ID NO:63 is the determined cDNA sequence for clone 61571817.

[0102] SEQ ID NO:64 is the determined cDNA sequence for clone 61571818.

[0103] SEQ ID NO:65 is the determined cDNA sequence for clone 61571819.

[0104] SEQ ID NO:66 is the determined cDNA sequence for clone 61571820.

[0105] SEQ ID NO:67 is the determined cDNA sequence for clone 61571821.

[0106] SEQ ID NO:68 is the determined cDNA sequence for clone 61571822.

[0107] SEQ ID NO:69 is the determined cDNA sequence for clone 61571823.

[0108] SEQ ID NO:70 is the determined cDNA sequence for clone 61571824.

[0109] SEQ ID NO:71 is the determined cDNA sequence for clone 61571825.

[0110] SEQ ID NO:72 is the determined cDNA sequence for clone 61571826.

[0111] SEQ ID NO:73 is the determined cDNA sequence for clone 61571827.

[0112] SEQ ID NO:74 is the determined cDNA sequence for clone 61571828.

[0113] SEQ ID NO:75 is the determined cDNA sequence for clone 61571829.

[0114] SEQ ID NO:76 is the determined cDNA sequence for clone 61571830.

[0115] SEQ ID NO:77 is the determined cDNA sequence for clone 61571831.

[0116] SEQ ID NO:78 is the determined cDNA sequence for clone 61571832.

[0117] SEQ ID NO:79 is the determined cDNA sequence for clone 61571833.

[0118] SEQ ID NO:80 is the determined cDNA sequence for clone 61483098.

[0119] SEQ ID NO:81 is the determined cDNA sequence for clone 61483099.

[0120] SEQ ID NO:82 is the determined cDNA sequence for clone 61483100.

[0121] SEQ ID NO:83 is the determined cDNA sequence for clone 61483101.

[0122] SEQ ID NO:84 is the determined cDNA sequence for clone 61483102.

[0123] SEQ ID NO:85 is the determined cDNA sequence for clone 61483103.

[0124] SEQ ID NO:86 is the determined cDNA sequence for clone 61483104.

[0125] SEQ ID NO:87 is the determined cDNA sequence for clone 61483107.

[0126] SEQ ID NO:88 is the determined cDNA sequence for clone 61483108.

[0127] SEQ ID NO:89 is the determined cDNA sequence for clone 61483109.

[0128] SEQ ID NO:90 is the determined cDNA sequence for clone 61483110.

[0129] SEQ ID NO:91 is the determined cDNA sequence for clone 61483111.

[0130] SEQ ID NO:92 is the determined cDNA sequence for clone 61483112.

[0131] SEQ ID NO:93 is the determined cDNA sequence for clone 61483113.

[0132] SEQ ID NO:94 is the determined cDNA sequence for clone 61483114.

[0133] SEQ ID NO:95 is the determined cDNA sequence for clone 61483115.

[0134] SEQ ID NO:96 is the determined cDNA sequence for clone 61483116.

[0135] SEQ ID NO:97 is the determined cDNA sequence for clone 61483117.

[0136] SEQ ID NO:98 is the determined cDNA sequence for clone 61483118.

[0137] SEQ ID NO:99 is the determined cDNA sequence for clone 61483119.

[0138] SEQ ID NO:100 is the determined cDNA sequence for clone 61483120.

[0139] SEQ ID NO:101 is the determined cDNA sequence for clone 61483121.

[0140] SEQ ID NO:102 is the determined cDNA sequence for clone 61483122.

[0141] SEQ ID NO:103 is the determined cDNA sequence for clone 61483123.

[0142] SEQ ID NO:104 is the determined cDNA sequence for clone 61483124.

[0143] SEQ ID NO:105 is the determined cDNA sequence for clone 61483125.

[0144] SEQ ID NO:106 is the determined cDNA sequence for clone 61483126.

[0145] SEQ ID NO:107 is the determined cDNA sequence for clone 61483127.

[0146] SEQ ID NO:108 is the determined cDNA sequence for clone 61483129.

[0147] SEQ ID NO:109 is the determined cDNA sequence for clone 61483130.

[0148] SEQ ID NO:110 is the determined cDNA sequence for clone 61483132.

[0149] SEQ ID NO:111 is the determined cDNA sequence for clone 61483133.

[0150] SEQ ID NO:112 is the determined cDNA sequence for clone 61483134.

[0151] SEQ ID NO:113 is the determined cDNA sequence for clone 61483135.

[0152] SEQ ID NO:114 is the determined cDNA sequence for clone 61483136.

[0153] SEQ ID NO:115 is the determined cDNA sequence for clone 61483137.

[0154] SEQ ID NO:116 is the determined cDNA sequence for clone 61483138.

[0155] SEQ ID NO:117 is the determined cDNA sequence for clone 61483140.

[0156] SEQ ID NO:118 is the determined cDNA sequence for clone 61483141.

[0157] SEQ ID NO:119 is the determined cDNA sequence for clone 61483142.

[0158] SEQ ID NO:120 is the determined cDNA sequence for clone 61483143.

[0159] SEQ ID NO:121 is the determined cDNA sequence for clone 61483144.

[0160] SEQ ID NO:122 is the determined cDNA sequence for clone 61483145.

[0161] SEQ ID NO:123 is the determined cDNA sequence for clone 61483146.

[0162] SEQ ID NO:124 is the determined cDNA sequence for clone 61483147.

[0163] SEQ ID NO:125 is the determined cDNA sequence for clone 61483148.

[0164] SEQ ID NO:126 is the determined cDNA sequence for clone 61483150.

[0165] SEQ ID NO:127 is the determined cDNA sequence for clone 61483151.

[0166] SEQ ID NO:128 is the determined cDNA sequence for clone 61483152.

[0167] SEQ ID NO:129 is the determined cDNA sequence for clone 61483153.

[0168] SEQ ID NO:130 is the determined cDNA sequence for clone 61483154.

[0169] SEQ ID NO:131 is the determined cDNA sequence for clone 61483155.

[0170] SEQ ID NO:132 is the determined cDNA sequence for clone 61483156.

[0171] SEQ ID NO:133 is the determined cDNA sequence for clone 61483158.

[0172] SEQ ID NO:134 is the determined cDNA sequence for clone 61483159.

[0173] SEQ ID NO:135 is the determined cDNA sequence for clone 61483160.

[0174] SEQ ID NO:136 is the determined cDNA sequence for clone 61483161.

[0175] SEQ ID NO:137 is the determined cDNA sequence for clone 61483162.

[0176] SEQ ID NO:138 is the determined cDNA sequence for clone 61483164.

[0177] SEQ ID NO:139 is the determined cDNA sequence for clone 61483165.

[0178] SEQ ID NO:140 is the determined cDNA sequence for clone 61483167.

[0179] SEQ ID NO:141 is the determined cDNA sequence for clone 61483168.

[0180] SEQ ID NO:142 is the determined cDNA sequence for clone 61483169.

[0181] SEQ ID NO:143 is the determined cDNA sequence for clone 61483170.

[0182] SEQ ID NO:144 is the determined cDNA sequence for clone 61483172.

[0183] SEQ ID NO:145 is the determined cDNA sequence for clone 61483173.

[0184] SEQ ID NO:146 is the determined cDNA sequence for clone 61483174.

[0185] SEQ ID NO:147 is the determined cDNA sequence for clone 61483175.

[0186] SEQ ID NO:148 is the determined cDNA sequence for clone 61483176.

[0187] SEQ ID NO:149 is the determined cDNA sequence for clone 61483177.

[0188] SEQ ID NO:150 is the determined cDNA sequence for clone 61483178.

[0189] SEQ ID NO:151 is the determined cDNA sequence for clone 61483179.

[0190] SEQ ID NO:152 is the determined cDNA sequence for clone 61483180.

[0191] SEQ ID NO:153 is the determined cDNA sequence for clone 61483182.

[0192] SEQ ID NO:154 is the determined cDNA sequence for clone 61483183.

[0193] SEQ ID NO:155 is the determined cDNA sequence for clone 61483184.

[0194] SEQ ID NO:156 is the determined cDNA sequence for clone 61483185.

[0195] SEQ ID NO:157 is the determined cDNA sequence for clone 61483186.

[0196] SEQ ID NO:158 is the determined cDNA sequence for clone 61483187.

[0197] SEQ ID NO:159 is the determined cDNA sequence for clone 61483188.

[0198] SEQ ID NO:160 is the determined cDNA sequence for clone 61483189.

[0199] SEQ ID NO:161 is the determined cDNA sequence for clone 61483190.

[0200] SEQ ID NO:162 is the determined cDNA sequence for clone 61594542.

[0201] SEQ ID NO:163 is the determined cDNA sequence for clone 61594543.

[0202] SEQ ID NO:164 is the determined cDNA sequence for clone 61594544.

[0203] SEQ ID NO:165 is the determined cDNA sequence for clone 61594545.

[0204] SEQ ID NO:166 is the determined cDNA sequence for clone 61594546.

[0205] SEQ ID NO:167 is the determined cDNA sequence for clone 61594547.

[0206] SEQ ID NO:168 is the determined cDNA sequence for clone 61594549.

[0207] SEQ ID NO:169 is the determined cDNA sequence for clone 61594550.

[0208] SEQ ID NO:170 is the determined cDNA sequence for clone 61594551.

[0209] SEQ ID NO:171 is the determined cDNA sequence for clone 61594552.

[0210] SEQ ID NO:172 is the determined cDNA sequence for clone 61594553.

[0211] SEQ ID NO:173 is the determined cDNA sequence for clone 61594554.

[0212] SEQ ID NO:174 is the determined cDNA sequence for clone 61594555.

[0213] SEQ ID NO:175 is the determined cDNA sequence for clone 61594556.

[0214] SEQ ID NO:176 is the determined cDNA sequence for clone 61594557.

[0215] SEQ ID NO:177 is the determined cDNA sequence for clone 61594558.

[0216] SEQ ID NO:178 is the determined cDNA sequence for clone 61594559.

[0217] SEQ ID NO:179 is the determined cDNA sequence for clone 61594560.

[0218] SEQ ID NO:180 is the determined cDNA sequence for clone 61594561.

[0219] SEQ ID NO:181 is the determined cDNA sequence for clone 61594562.

[0220] SEQ ID NO:182 is the determined cDNA sequence for clone 61594563.

[0221] SEQ ID NO:183 is the determined cDNA sequence for clone 61594564.

[0222] SEQ ID NO:184 is the determined cDNA sequence for clone 61594565.

[0223] SEQ ID NO:185 is the determined cDNA sequence for clone 61594567.

[0224] SEQ ID NO:186 is the determined cDNA sequence for clone 61594568.

[0225] SEQ ID NO:187 is the determined cDNA sequence for clone 61594569.

[0226] SEQ ID NO:188 is the determined cDNA sequence for clone 61594570.

[0227] SEQ ID NO:189 is the determined cDNA sequence for clone 61594571.

[0228] SEQ ID NO:190 is the determined cDNA sequence for clone 61594573.

[0229] SEQ ID NO:191 is the determined cDNA sequence for clone 61594574.

[0230] SEQ ID NO:192 is the determined cDNA sequence for clone 61594575.

[0231] SEQ ID NO:193 is the determined cDNA sequence for clone 61594576.

[0232] SEQ ID NO:194 is the determined cDNA sequence for clone 61594577.

[0233] SEQ ID NO:195 is the determined cDNA sequence for clone 61594578.

[0234] SEQ ID NO:196 is the determined cDNA sequence for clone 61594579.

[0235] SEQ ID NO:197 is the determined cDNA sequence for clone 61594580.

[0236] SEQ ID NO:198 is the determined cDNA sequence for clone 61594582.

[0237] SEQ ID NO:199 is the determined cDNA sequence for clone 61594583.

[0238] SEQ ID NO:200 is the determined cDNA sequence for clone 61594584.

[0239] SEQ ID NO:201 is the determined cDNA sequence for clone 61594585.

[0240] SEQ ID NO:202 is the determined cDNA sequence for clone 61594586.

[0241] SEQ ID NO:203 is the determined cDNA sequence for clone 61594588.

[0242] SEQ ID NO:204 is the determined cDNA sequence for clone 61594589.

[0243] SEQ ID NO:205 is the determined cDNA sequence for clone 61594591.

[0244] SEQ ID NO:206 is the determined cDNA sequence for clone 61594592.

[0245] SEQ ID NO:207 is the determined cDNA sequence for clone 61594593.

[0246] SEQ ID NO:208 is the determined cDNA sequence for clone 61594594.

[0247] SEQ ID NO:209 is the determined cDNA sequence for clone 61594595.

[0248] SEQ ID NO:210 is the determined cDNA sequence for clone 61594596.

[0249] SEQ ID NO:211 is the determined cDNA sequence for clone 61594598.

[0250] SEQ ID NO:212 is the determined cDNA sequence for clone 61594601.

[0251] SEQ ID NO:213 is the determined cDNA sequence for clone 61594602.

[0252] SEQ ID NO:214 is the determined cDNA sequence for clone 61594604.

[0253] SEQ ID NO:215 is the determined cDNA sequence for clone 61594605.

[0254] SEQ ID NO:216 is the determined cDNA sequence for clone 61594606.

[0255] SEQ ID NO:217 is the determined cDNA sequence for clone 61594609.

[0256] SEQ ID NO:218 is the determined cDNA sequence for clone 61594611.

[0257] SEQ ID NO:219 is the determined cDNA sequence for clone 61594612.

[0258] SEQ ID NO:220 is the determined cDNA sequence for clone 61594613.

[0259] SEQ ID NO:221 is the determined cDNA sequence for clone 61594614.

[0260] SEQ ID NO:222 is the determined cDNA sequence for clone 61594615.

[0261] SEQ ID NO:223 is the determined cDNA sequence for clone 61594616.

[0262] SEQ ID NO:224 is the determined cDNA sequence for clone 61594617.

[0263] SEQ ID NO:225 is the determined cDNA sequence for clone 61594618.

[0264] SEQ ID NO:226 is the determined cDNA sequence for clone 61594620.

[0265] SEQ ID NO:227 is the determined cDNA sequence for clone 61594621.

[0266] SEQ ID NO:228 is the determined cDNA sequence for clone 61594622.

[0267] SEQ ID NO:229 is the determined cDNA sequence for clone 61594623.

[0268] SEQ ID NO:230 is the determined cDNA sequence for clone 61594625.

[0269] SEQ ID NO:231 is the determined cDNA sequence for clone 61594626.

[0270] SEQ ID NO:232 is the determined cDNA sequence for clone 61594627.

[0271] SEQ ID NO:233 is the determined cDNA sequence for clone 61594628.

[0272] SEQ ID NO:234 is the determined cDNA sequence for clone 61594629.

[0273] SEQ ID NO:235 is the determined cDNA sequence for clone 61594631.

[0274] SEQ ID NO:236 is the determined cDNA sequence for clone 61594632.

[0275] SEQ ID NO:237 is the determined cDNA sequence for clone 61594634.

[0276] SEQ ID NO:238 is the determined cDNA sequence for clone 61571928.

[0277] SEQ ID NO:239 is the determined cDNA sequence for clone 61571929.

[0278] SEQ ID NO:240 is the determined cDNA sequence for clone 61594630.

[0279] SEQ ID NO:241 is the determined cDNA sequence for clone 61571931.

[0280] SEQ ID NO:242 is the determined cDNA sequence for clone 61571932.

[0281] SEQ ID NO:243 is the determined cDNA sequence for clone 61571933.

[0282] SEQ ID NO:244 is the determined cDNA sequence for clone 61571934.

[0283] SEQ ID NO:245 is the determined cDNA sequence for clone 61571936.

[0284] SEQ ID NO:246 is the determined cDNA sequence for clone 61571937.

[0285] SEQ ID NO:247 is the determined cDNA sequence for clone 61571939.

[0286] SEQ ID NO:248 is the determined cDNA sequence for clone 61571940.

[0287] SEQ ID NO:249 is the determined cDNA sequence for clone 61571941.

[0288] SEQ ID NO:250 is the determined cDNA sequence for clone 61571942.

[0289] SEQ ID NO:251 is the determined cDNA sequence for clone 61571943.

[0290] SEQ ID NO:252 is the determined cDNA sequence for clone 61571944.

[0291] SEQ ID NO:253 is the determined cDNA sequence for clone 61571946.

[0292] SEQ ID NO:254 is the determined cDNA sequence for clone 61571947.

[0293] SEQ ID NO:255 is the determined cDNA sequence for clone 61571948

[0294] SEQ ID NO:256 is the determined cDNA sequence for clone 61571949.

[0295] SEQ ID NO:257 is the determined cDNA sequence for clone 61571950.

[0296] SEQ ID NO:258 is the determined cDNA sequence for clone 61571951.

[0297] SEQ ID NO:259 is the determined cDNA sequence for clone 61571952.

[0298] SEQ ID NO:260 is the determined cDNA sequence for clone 61571953.

[0299] SEQ ID NO:261 is the determined cDNA sequence for clone 61571954.

[0300] SEQ ID NO:262 is the determined cDNA sequence for clone 61571955.

[0301] SEQ ID NO:263 is the determined cDNA sequence for clone 61571956.

[0302] SEQ ID NO:264 is the determined cDNA sequence for clone 61571957.

[0303] SEQ ID NO:265 is the determined cDNA sequence for clone 61571958.

[0304] SEQ ID NO:266 is the determined cDNA sequence for clone 61571959.

[0305] SEQ ID NO:267 is the determined cDNA sequence for clone 61571963.

[0306] SEQ ID NO:268 is the determined cDNA sequence for clone 61571964.

[0307] SEQ ID NO:269 is the determined cDNA sequence for clone 61571965.

[0308] SEQ ID NO:270 is the determined cDNA sequence for clone 61571966.

[0309] SEQ ID NO:271 is the determined cDNA sequence for clone 61571967.

[0310] SEQ ID NO:272 is the determined cDNA sequence for clone 61571969.

[0311] SEQ ID NO:273 is the determined cDNA sequence for clone 61571970.

[0312] SEQ ID NO:274 is the determined cDNA sequence for clone 61571971.

[0313] SEQ ID NO:275 is the determined cDNA sequence for clone 61571973.

[0314] SEQ ID NO:276 is the determined cDNA sequence for clone 61571474.

[0315] SEQ ID NO:277 is the determined cDNA sequence for clone 61571976.

[0316] SEQ ID NO:278 is the determined cDNA sequence for clone 61571977.

[0317] SEQ ID NO:279 is the determined cDNA sequence for clone 61571978.

[0318] SEQ ID NO:280 is the determined cDNA sequence for clone 61571979.

[0319] SEQ ID NO:281 is the determined cDNA sequence for clone 61571980.

[0320] SEQ ID NO:282 is the determined cDNA sequence for clone 61571981.

[0321] SEQ ID NO:283 is the determined cDNA sequence for clone 61571982.

[0322] SEQ ID NO:284 is the determined cDNA sequence for clone 61571984.

[0323] SEQ ID NO:285 is the determined cDNA sequence for clone 61571985.

[0324] SEQ ID NO:286 is the determined cDNA sequence for clone 61571988.

[0325] SEQ ID NO:287 is the determined cDNA sequence for clone 61571987.

[0326] SEQ ID NO:288 is the determined cDNA sequence for clone 61571988.

[0327] SEQ ID NO:289 is the determined cDNA sequence for clone 61571989.

[0328] SEQ ID NO:290 is the determined cDNA sequence for clone 61571990.

[0329] SEQ ID NO:291 is the determined cDNA sequence for clone 61571991.

[0330] SEQ ID NO:292 is the determined cDNA sequence for clone 61571993.

[0331] SEQ ID NO:293 is the determined cDNA sequence for clone 61571994.

[0332] SEQ ID NO:294 is the determined cDNA sequence for clone 61571995.

[0333] SEQ ID NO:295 is the determined cDNA sequence for clone 61571997.

[0334] SEQ ID NO:296 is the determined cDNA sequence for clone 61571998.

[0335] SEQ ID NO:297 is the determined cDNA sequence for clone 61572000.

[0336] SEQ ID NO:298 is the determined cDNA sequence for clone 61572001.

[0337] SEQ ID NO:299 is the determined cDNA sequence for clone 61572003.

[0338] SEQ ID NO:300 is the determined cDNA sequence for clone 61572004.

[0339] SEQ ID NO:301 is the determined cDNA sequence for clone 61572005.

[0340] SEQ ID NO:302 is the determined cDNA sequence for clone 61572006.

[0341] SEQ ID NO:303 is the determined cDNA sequence for clone 61572007.

[0342] SEQ ID NO:304 is the determined cDNA sequence for clone 61572008.

[0343] SEQ ID NO:305 is the determined cDNA sequence for clone 61572009.

[0344] SEQ ID NO:306 is the determined cDNA sequence for clone 61572010.

[0345] SEQ ID NO:307 is the determined cDNA sequence for clone 61572011.

[0346] SEQ ID NO:308 is the determined cDNA sequence for clone 61572015.

[0347] SEQ ID NO:309 is the determined cDNA sequence for clone 61572016.

[0348] SEQ ID NO:310 is the determined cDNA sequence for clone 61572018.

[0349] SEQ ID NO:311 is the determined cDNA sequence for clone 61571834.

[0350] SEQ ID NO:312 is the determined cDNA sequence for clone 61571835.

[0351] SEQ ID NO:313 is the determined cDNA sequence for clone 61571836.

[0352] SEQ ID NO:314 is the determined cDNA sequence for clone 61571837.

[0353] SEQ ID NO:315 is the determined cDNA sequence for clone 61571838.

[0354] SEQ ID NO:316 is the determined cDNA sequence for clone 61571839.

[0355] SEQ ID NO:317 is the determined cDNA sequence for clone 61571840.

[0356] SEQ ID NO:318 is the determined cDNA sequence for clone 61571841.

[0357] SEQ ID NO:319 is the determined cDNA sequence for clone 61571842.

[0358] SEQ ID NO:320 is the determined cDNA sequence for clone 61571843.

[0359] SEQ ID NO:321 is the determined cDNA sequence for clone 61571844.

[0360] SEQ ID NO:322 is the determined cDNA sequence for clone 61571845.

[0361] SEQ ID NO:323 is the determined cDNA sequence for clone 61571846.

[0362] SEQ ID NO:324 is the determined cDNA sequence for clone 61571848.

[0363] SEQ ID NO:325 is the determined cDNA sequence for clone 61571849.

[0364] SEQ ID NO:326 is the determined cDNA sequence for clone 61571850.

[0365] SEQ ID NO:327 is the determined cDNA sequence for clone 61571851.

[0366] SEQ ID NO:328 is the determined cDNA sequence for clone 61571852.

[0367] SEQ ID NO:329 is the determined cDNA sequence for clone 61571853.

[0368] SEQ ID NO:330 is the determined cDNA sequence for clone 61571854.

[0369] SEQ ID NO:331 is the determined cDNA sequence for clone 61571855.

[0370] SEQ ID NO:332 is the determined cDNA sequence for clone 61571856.

[0371] SEQ ID NO:333 is the determined cDNA sequence for clone 61571857.

[0372] SEQ ID NO:334 is the determined cDNA sequence for clone 61571858.

[0373] SEQ ID NO:335 is the determined cDNA sequence for clone 61571859.

[0374] SEQ ID NO:336 is the determined cDNA sequence for clone 61571860.

[0375] SEQ ID NO:337 is the determined cDNA sequence for clone 61571861.

[0376] SEQ ID NO:338 is the determined cDNA sequence for clone 61571862.

[0377] SEQ ID NO:339 is the determined cDNA sequence for clone 61571863.

[0378] SEQ ID NO:340 is the determined cDNA sequence for clone 61571864.

[0379] SEQ ID NO:341 is the determined cDNA sequence for clone 61571865.

[0380] SEQ ID NO:342 is the determined cDNA sequence for clone 61571866.

[0381] SEQ ID NO:343 is the determined cDNA sequence for clone 61571867.

[0382] SEQ ID NO:344 is the determined cDNA sequence for clone 61571868.

[0383] SEQ ID NO:345 is the determined cDNA sequence for clone 61571869.

[0384] SEQ ID NO:346 is the determined cDNA sequence for clone 61571870.

[0385] SEQ ID NO:347 is the determined cDNA sequence for clone 61571871.

[0386] SEQ ID NO:348 is the determined cDNA sequence for clone 61571872.

[0387] SEQ ID NO:349 is the determined cDNA sequence for clone 61571873.

[0388] SEQ ID NO:350 is the determined cDNA sequence for clone 61571874.

[0389] SEQ ID NO:351 is the determined cDNA sequence for clone 61571875.

[0390] SEQ ID NO:352 is the determined cDNA sequence for clone 61571876.

[0391] SEQ ID NO:353 is the determined cDNA sequence for clone 61571877.

[0392] SEQ ID NO:354 is the determined cDNA sequence for clone 61571878.

[0393] SEQ ID NO:355 is the determined cDNA sequence for clone 61571879.

[0394] SEQ ID NO:356 is the determined cDNA sequence for clone 61571880.

[0395] SEQ ID NO:357 is the determined cDNA sequence for clone 61571881.

[0396] SEQ ID NO:358 is the determined cDNA sequence for clone 61571882.

[0397] SEQ ID NO:359 is the determined cDNA sequence for clone 61571883.

[0398] SEQ ID NO:360 is the determined cDNA sequence for clone 61571884.

[0399] SEQ ID NO:361 is the determined cDNA sequence for clone 61571885.

[0400] SEQ ID NO:362 is the determined cDNA sequence for clone 61571886.

[0401] SEQ ID NO:363 is the determined cDNA sequence for clone 61571887.

[0402] SEQ ID NO:364 is the determined cDNA sequence for clone 61571888.

[0403] SEQ ID NO:365 is the determined cDNA sequence for clone 61571889.

[0404] SEQ ID NO:366 is the determined cDNA sequence for clone 61571890.

[0405] SEQ ID NO:367 is the determined cDNA sequence for clone 61571891.

[0406] SEQ ID NO:368 is the determined cDNA sequence for clone 61571892.

[0407] SEQ ID NO:369 is the determined cDNA sequence for clone 61571894.

[0408] SEQ ID NO:370 is the determined cDNA sequence for clone 61571895.

[0409] SEQ ID NO:371 is the determined cDNA sequence for clone 61571896.

[0410] SEQ ID NO:372 is the determined cDNA sequence for clone 61571897.

[0411] SEQ ID NO:373 is the determined cDNA sequence for clone 61571899.

[0412] SEQ ID NO:374 is the determined cDNA sequence for clone 61571900.

[0413] SEQ ID NO:375 is the determined cDNA sequence for clone 61571901.

[0414] SEQ ID NO:376 is the determined cDNA sequence for clone 61571902.

[0415] SEQ ID NO:377 is the determined cDNA sequence for clone 61571903.

[0416] SEQ ID NO:378 is the determined cDNA sequence for clone 61571904.

[0417] SEQ ID NO:379 is the determined cDNA sequence for clone 61571905.

[0418] SEQ ID NO:380 is the determined cDNA sequence for clone 61571906.

[0419] SEQ ID NO:381 is the determined cDNA sequence for clone 61571907.

[0420] SEQ ID NO:382 is the determined cDNA sequence for clone 61571908.

[0421] SEQ ID NO:383 is the determined cDNA sequence for clone 61571909.

[0422] SEQ ID NO:384 is the determined cDNA sequence for clone 61571910.

[0423] SEQ ID NO:385 is the determined cDNA sequence for clone 61571912.

[0424] SEQ ID NO:386 is the determined cDNA sequence for clone 61571913.

[0425] SEQ ID NO:387 is the determined cDNA sequence for clone 61571914.

[0426] SEQ ID NO:388 is the determined cDNA sequence for clone 61571915.

[0427] SEQ ID NO:389 is the determined cDNA sequence for clone 61571916.

[0428] SEQ ID NO:390 is the determined cDNA sequence for clone 61571917.

[0429] SEQ ID NO:391 is the determined cDNA sequence for clone 61571918.

[0430] SEQ ID NO:392 is the determined cDNA sequence for clone 61571919.

[0431] SEQ ID NO:393 is the determined cDNA sequence for clone 61571920.

[0432] SEQ ID NO:394 is the determined cDNA sequence for clone 61571921.

[0433] SEQ ID NO:395 is the determined cDNA sequence for clone 61571922.

[0434] SEQ ID NO:396 is the determined cDNA sequence for clone 61571923.

[0435] SEQ ID NO:397 is the determined cDNA sequence for clone 61571924.

[0436] SEQ ID NO:398 is the determined cDNA sequence for clone 61571925.

[0437] SEQ ID NO:399 is the determined cDNA sequence for clone 61571926.

[0438] SEQ ID NO:400 is the determined cDNA sequence for clone 61594635.

[0439] SEQ ID NO:401 is the determined cDNA sequence for clone 61594636.

[0440] SEQ ID NO:402 is the determined cDNA sequence for clone 61594637.

[0441] SEQ ID NO:403 is the determined cDNA sequence for clone 61594638.

[0442] SEQ ID NO:404 is the determined cDNA sequence for clone 61594639.

[0443] SEQ ID NO:405 is the determined cDNA sequence for clone 61594640.

[0444] SEQ ID NO:406 is the determined cDNA sequence for clone 61594641.

[0445] SEQ ID NO:407 is the determined cDNA sequence for clone 61594644.

[0446] SEQ ID NO:408 is the determined cDNA sequence for clone 61594645.

[0447] SEQ ID NO:409 is the determined cDNA sequence for clone 61594646.

[0448] SEQ ID NO:410 is the determined cDNA sequence for clone 61594647.

[0449] SEQ ID NO:411 is the determined cDNA sequence for clone 61594648.

[0450] SEQ ID NO:412 is the determined cDNA sequence for clone 61594649.

[0451] SEQ ID NO:413 is the determined cDNA sequence for clone 61594650.

[0452] SEQ ID NO:414 is the determined cDNA sequence for clone 61594651.

[0453] SEQ ID NO:415 is the determined cDNA sequence for clone 61594652.

[0454] SEQ ID NO:416 is the determined cDNA sequence for clone 61594653.

[0455] SEQ ID NO:417 is the determined cDNA sequence for clone 61594654.

[0456] SEQ ID NO:418 is the determined cDNA sequence for clone 61594655.

[0457] SEQ ID NO:419 is the determined cDNA sequence for clone 61594656.

[0458] SEQ ID NO:420 is the determined cDNA sequence for clone 61594657.

[0459] SEQ ID NO:421 is the determined cDNA sequence for clone 61594658.

[0460] SEQ ID NO:422 is the determined cDNA sequence for clone 61594659.

[0461] SEQ ID NO:423 is the determined cDNA sequence for clone 61594661.

[0462] SEQ ID NO:424 is the determined cDNA sequence for clone 61594662.

[0463] SEQ ID NO:425 is the determined cDNA sequence for clone 61594663.

[0464] SEQ ID NO:426 is the determined cDNA sequence for clone 61594664.

[0465] SEQ ID NO:427 is the determined cDNA sequence for clone 61594665.

[0466] SEQ ID NO:428 is the determined cDNA sequence for clone 61594666.

[0467] SEQ ID NO:429 is the determined cDNA sequence for clone 61594667.

[0468] SEQ ID NO:430 is the determined cDNA sequence for clone 61594668.

[0469] SEQ ID NO:431 is the determined cDNA sequence for clone 61594669.

[0470] SEQ ID NO:432 is the determined cDNA sequence for clone 61594670.

[0471] SEQ ID NO:433 is the determined cDNA sequence for clone 61594671.

[0472] SEQ ID NO:434 is the determined cDNA sequence for clone 61594674.

[0473] SEQ ID NO:435 is the determined cDNA sequence for clone 61594675.

[0474] SEQ ID NO:436 is the determined cDNA sequence for clone 61594676.

[0475] SEQ ID NO:437 is the determined cDNA sequence for clone 61594677.

[0476] SEQ ID NO:438 is the determined cDNA sequence for clone 61594678.

[0477] SEQ ID NO:439 is the determined cDNA sequence for clone 61594679.

[0478] SEQ ID NO:440 is the determined cDNA sequence for clone 61594680.

[0479] SEQ ID NO:441 is the determined cDNA sequence for clone 61594681.

[0480] SEQ ID NO:442 is the determined cDNA sequence for clone 61594683.

[0481] SEQ ID NO:443 is the determined cDNA sequence for clone 61594684.

[0482] SEQ ID NO:444 is the determined cDNA sequence for clone 61594685.

[0483] SEQ ID NO:445 is the determined cDNA sequence for clone 61594686.

[0484] SEQ ID NO:446 is the determined cDNA sequence for clone 61594687.

[0485] SEQ ID NO:447 is the determined cDNA sequence for clone 61594688.

[0486] SEQ ID NO:448 is the determined cDNA sequence for clone 61594689.

[0487] SEQ ID NO:449 is the determined cDNA sequence for clone 61594690.

[0488] SEQ ID NO:450 is the determined cDNA sequence for clone 61594691.

[0489] SEQ ID NO:451 is the determined cDNA sequence for clone 61594692.

[0490] SEQ ID NO:452 is the determined cDNA sequence for clone 61594693.

[0491] SEQ ID NO:453 is the determined cDNA sequence for clone 61594694.

[0492] SEQ ID NO:454 is the determined cDNA sequence for clone 61594698.

[0493] SEQ ID NO:455 is the determined cDNA sequence for clone 61594699.

[0494] SEQ ID NO:456 is the determined cDNA sequence for clone 61594700.

[0495] SEQ ID NO:457 is the determined cDNA sequence for clone 61594701.

[0496] SEQ ID NO:458 is the determined cDNA sequence for clone 61594702.

[0497] SEQ ID NO:459 is the determined cDNA sequence for clone 61594703.

[0498] SEQ ID NO:460 is the determined cDNA sequence for clone 61594704.

[0499] SEQ ID NO:461 is the determined cDNA sequence for clone 61594706.

[0500] SEQ ID NO:462 is the determined cDNA sequence for clone 61594707.

[0501] SEQ ID NO:463 is the determined cDNA sequence for clone 61594708.

[0502] SEQ ID NO:464 is the determined cDNA sequence for clone 61594709.

[0503] SEQ ID NO:465 is the determined cDNA sequence for clone 61594710.

[0504] SEQ ID NO:466 is the determined cDNA sequence for clone 61594711.

[0505] SEQ ID NO:467 is the determined cDNA sequence for clone 61594712.

[0506] SEQ ID NO:468 is the determined cDNA sequence for clone 61594713.

[0507] SEQ ID NO:469 is the determined cDNA sequence for clone 61594714.

[0508] SEQ ID NO:470 is the determined cDNA sequence for clone 61594715.

[0509] SEQ ID NO:471 is the determined cDNA sequence for clone 61594716.

[0510] SEQ ID NO:472 is the determined cDNA sequence for clone 61594717.

[0511] SEQ ID NO:473 is the determined cDNA sequence for clone 61594718.

[0512] SEQ ID NO:474 is the determined cDNA sequence for clone 61594719.

[0513] SEQ ID NO:475 is the determined cDNA sequence for clone 61594720.

[0514] SEQ ID NO:476 is the determined cDNA sequence for clone 61594721.

[0515] SEQ ID NO:477 is the determined cDNA sequence for clone 61594722.

[0516] SEQ ID NO:478 is the determined cDNA sequence for clone 61594723.

[0517] SEQ ID NO:479 is the determined cDNA sequence for clone 61594724.

[0518] SEQ ID NO:480 is the determined cDNA sequence for clone 61594725.

[0519] SEQ ID NO:481 is the determined cDNA sequence for clone 61594726.

[0520] SEQ ID NO:482 is the determined cDNA sequence for clone 61594727.

[0521] SEQ ID NO:483 is the determined cDNA sequence for clone 61594728.

[0522] SEQ ID NO:484 is the determined cDNA sequence for clone 61594729.

[0523] SEQ ID NO:485 is the determined cDNA sequence for clone 61594730.

[0524] SEQ ID NO:486 is the determined cDNA sequence for clone 61594731.

[0525] SEQ ID NO:487 is the determined cDNA sequence for clone 61594732.

[0526] SEQ ID NO:488 is the determined cDNA sequence for clone 61594733.

[0527] SEQ ID NO:489 is the determined cDNA sequence for clone 61594734.

[0528] SEQ ID NO:490 is the determined cDNA sequence for clone 61594735.

[0529] SEQ ID NO:491 is the determined cDNA sequence for clone 61594736.

[0530] SEQ ID NO:492 is the determined cDNA sequence for clone 61594737.

[0531] SEQ ID NO:493 is the determined cDNA sequence for clone 61594738.

[0532] SEQ ID NO:494 is the determined cDNA sequence for clone 61594739.

[0533] SEQ ID NO:495 is the determined cDNA sequence for clone 61594741.

[0534] SEQ ID NO:496 is the determined cDNA sequence for clone 61594742.

[0535] SEQ ID NO:497 is the determined cDNA sequence for clone 61594743.

[0536] SEQ ID NO:498 is the determined cDNA sequence for clone 61594744.

[0537] SEQ ID NO:499 is the determined cDNA sequence for clone 61594745.

[0538] SEQ ID NO:500 is the determined cDNA sequence for clone 61594746.

[0539] SEQ ID NO:501 is the determined cDNA sequence for clone 61594747.

[0540] SEQ ID NO:502 is the determined cDNA sequence for clone 61594748.

[0541] SEQ ID NO:503 is the determined cDNA sequence for clone 61594749.

[0542] SEQ ID NO:504 is the determined cDNA sequence for clone 61594750.

[0543] SEQ ID NO:505 is the determined cDNA sequence for clone 61594751.

[0544] SEQ ID NO:506 is the determined cDNA sequence for clone 61594752.

[0545] SEQ ID NO:507 is the determined cDNA sequence for clone 61594753.

[0546] SEQ ID NO:508 is the determined cDNA sequence for clone 61594754.

[0547] SEQ ID NO:509 is the determined cDNA sequence for clone 61594755.

[0548] SEQ ID NO:510 is the determined cDNA sequence for clone 61594756.

[0549] SEQ ID NO:511 is the determined cDNA sequence for clone 61594757.

[0550] SEQ ID NO:512 is the determined cDNA sequence for clone 61594758.

[0551] SEQ ID NO:513 is the determined cDNA sequence for clone 61594759.

[0552] SEQ ID NO:514 is the determined cDNA sequence for clone 61594760.

[0553] SEQ ID NO:515 is the determined cDNA sequence for clone 61594761.

[0554] SEQ ID NO:516 is the determined cDNA sequence for clone 61594762.

[0555] SEQ ID NO:517 is the determined cDNA sequence for clone 61594763.

[0556] SEQ ID NO:518 is the determined cDNA sequence for clone 61594764.

[0557] SEQ ID NO:519 is the determined cDNA sequence for clone 61594765.

[0558] SEQ ID NO:520 is the determined cDNA sequence for clone 61594766.

[0559] SEQ ID NO:521 is the determined cDNA sequence for clone 61594767.

[0560] SEQ ID NO:522 is the determined cDNA sequence for clone 61594768.

[0561] SEQ ID NO:523 is the determined cDNA sequence for clone 61594769.

[0562] SEQ ID NO:524 is the determined cDNA sequence for clone 61594770.

[0563] SEQ ID NO:525 is the determined cDNA sequence for clone 61594771.

[0564] SEQ ID NO:526 is the determined cDNA sequence for clone 61594772.

[0565] SEQ ID NO:527 is the determined cDNA sequence for clone 61594773.

[0566] SEQ ID NO:528 is the determined cDNA sequence for clone 61594774.

[0567] SEQ ID NO:529 is the determined cDNA sequence for clone 61594775.

[0568] SEQ ID NO:530 is the determined cDNA sequence for clone 61594776.

[0569] SEQ ID NO:531 is the determined cDNA sequence for clone 61594777.

[0570] SEQ ID NO:532 is the determined cDNA sequence for clone 61594778.

[0571] SEQ ID NO:533 is the determined cDNA sequence for clone 61594779.

[0572] SEQ ID NO:534 is the determined cDNA sequence for clone 61594780.

[0573] SEQ ID NO:535 is the determined cDNA sequence for clone 61594781.

[0574] SEQ ID NO:536 is the determined cDNA sequence for clone 61594782.

[0575] SEQ ID NO:537 is the determined cDNA sequence for clone 61594783.

[0576] SEQ ID NO:538 is the determined cDNA sequence for clone 61594784.

[0577] SEQ ID NO:539 is the determined cDNA sequence for clone 61594785.

[0578] SEQ ID NO:540 is the determined cDNA sequence for clone 61594786.

[0579] SEQ ID NO:541 is the determined cDNA sequence for clone 61594787.

[0580] SEQ ID NO:542 is the determined cDNA sequence for clone 61594788.

[0581] SEQ ID NO:543 is the determined cDNA sequence for clone 61594789.

[0582] SEQ ID NO:544 is the determined cDNA sequence for clone 61594790.

[0583] SEQ ID NO:545 is the determined cDNA sequence for clone 61594791.

[0584] SEQ ID NO:546 is the determined cDNA sequence for clone 61594792.

[0585] SEQ ID NO:547 is the determined cDNA sequence for clone 61594793.

[0586] SEQ ID NO:548 is the determined cDNA sequence for clone 61594794.

[0587] SEQ ID NO:549 is the determined cDNA sequence for clone 61594796.

[0588] SEQ ID NO:550 is the determined cDNA sequence for clone 61594797.

[0589] SEQ ID NO:551 is the determined cDNA sequence for clone 61594798.

[0590] SEQ ID NO:552 is the determined cDNA sequence for clone 61594799.

[0591] SEQ ID NO:553 is the determined cDNA sequence for clone 61594800.

[0592] SEQ ID NO:554 is the determined cDNA sequence for clone 61594801.

[0593] SEQ ID NO:555 is the determined cDNA sequence for clone 61594802.

[0594] SEQ ID NO:556 is the determined cDNA sequence for clone 61594803.

[0595] SEQ ID NO:557 is the determined cDNA sequence for clone 61594804.

[0596] SEQ ID NO:558 is the determined cDNA sequence for clone 61594805.

[0597] SEQ ID NO:559 is the determined cDNA sequence for clone 61594806.

[0598] SEQ ID NO:560 is the determined cDNA sequence for clone 61594807.

[0599] SEQ ID NO:561 is the determined cDNA sequence for clone 61594808.

[0600] SEQ ID NO:562 is the determined cDNA sequence for clone 61594809.

[0601] SEQ ID NO:563 is the determined cDNA sequence for clone 61594810.

[0602] SEQ ID NO:564 is the determined cDNA sequence for clone 61594812.

[0603] SEQ ID NO:565 is the determined cDNA sequence for clone 61594813.

[0604] SEQ ID NO:566 is the determined cDNA sequence for clone 61594814.

[0605] SEQ ID NO:567 is the determined cDNA sequence for clone 61594815.

[0606] SEQ ID NO:568 is the determined cDNA sequence for clone 61594816.

[0607] SEQ ID NO:569 is the determined cDNA sequence for clone 61594817.

[0608] SEQ ID NO:570 is the determined cDNA sequence for clone 61594818.

[0609] SEQ ID NO:571 is the determined cDNA sequence for clone 61594819.

[0610] SEQ ID NO:572 is the determined cDNA sequence for clone 61823953.

[0611] SEQ ID NO:573 is the determined cDNA sequence for clone 61823954.

[0612] SEQ ID NO:574 is the determined cDNA sequence for clone 61823955.

[0613] SEQ ID NO:575 is the determined cDNA sequence for clone 61823956.

[0614] SEQ ID NO:576 is the determined cDNA sequence for clone 61823957.

[0615] SEQ ID NO:577 is the determined cDNA sequence for clone 61823959.

[0616] SEQ ID NO:578 is the determined cDNA sequence for clone 61823960.

[0617] SEQ ID NO:579 is the determined cDNA sequence for clone 61823961.

[0618] SEQ ID NO:580 is the determined cDNA sequence for clone 61823962.

[0619] SEQ ID NO:581 is the determined cDNA sequence for clone 61823963.

[0620] SEQ ID NO:582 is the determined cDNA sequence for clone 61823964.

[0621] SEQ ID NO:583 is the determined cDNA sequence for clone 61823965.

[0622] SEQ ID NO:584 is the determined cDNA sequence for clone 61823966.

[0623] SEQ ID NO:585 is the determined cDNA sequence for clone 61823967.

[0624] SEQ ID NO:586 is the determined cDNA sequence for clone 61823968.

[0625] SEQ ID NO:587 is the determined cDNA sequence for clone 61823969.

[0626] SEQ ID NO:588 is the determined cDNA sequence for clone 61823970.

[0627] SEQ ID NO:589 is the determined cDNA sequence for clone 61823971.

[0628] SEQ ID NO:590 is the determined cDNA sequence for clone 61823972.

[0629] SEQ ID NO:591 is the determined cDNA sequence for clone 61823973.

[0630] SEQ ID NO:592 is the determined cDNA sequence for clone 61823974.

[0631] SEQ ID NO:593 is the determined cDNA sequence for clone 61823975.

[0632] SEQ ID NO:594 is the determined cDNA sequence for clone 61823976.

[0633] SEQ ID NO:595 is the determined cDNA sequence for clone 61823978.

[0634] SEQ ID NO:596 is the determined cDNA sequence for clone 61823979.

[0635] SEQ ID NO:597 is the determined cDNA sequence for clone 61823980.

[0636] SEQ ID NO:598 is the determined cDNA sequence for clone 61823981.

[0637] SEQ ID NO:599 is the determined cDNA sequence for clone 61823982.

[0638] SEQ ID NO:600 is the determined cDNA sequence for clone 61823983.

[0639] SEQ ID NO:601 is the determined cDNA sequence for clone 61823984.

[0640] SEQ ID NO:602 is the determined cDNA sequence for clone 61823985.

[0641] SEQ ID NO:603 is the determined cDNA sequence for clone 61823986.

[0642] SEQ ID NO:604 is the determined cDNA sequence for clone 61823987.

[0643] SEQ ID NO:605 is the determined cDNA sequence for clone 61823988.

[0644] SEQ ID NO:606 is the determined cDNA sequence for clone 61823989.

[0645] SEQ ID NO:607 is the determined cDNA sequence for clone 61823990.

[0646] SEQ ID NO:608 is the determined cDNA sequence for clone 61823991.

[0647] SEQ ID NO:609 is the determined cDNA sequence for clone 61823992.

[0648] SEQ ID NO:610 is the determined cDNA sequence for clone 61823993.

[0649] SEQ ID NO:611 is the determined cDNA sequence for clone 61823994.

[0650] SEQ ID NO:612 is the determined cDNA sequence for clone 61823995.

[0651] SEQ ID NO:613 is the determined cDNA sequence for clone 61823996.

[0652] SEQ ID NO:614 is the determined cDNA sequence for clone 61823998.

[0653] SEQ ID NO:615 is the determined cDNA sequence for clone 61823999.

[0654] SEQ ID NO:616 is the determined cDNA sequence for clone 61824000.

[0655] SEQ ID NO:617 is the determined cDNA sequence for clone 61824001.

[0656] SEQ ID NO:618 is the determined cDNA sequence for clone 61824002.

[0657] SEQ ID NO:619 is the determined cDNA sequence for clone 61824003.

[0658] SEQ ID NO:620 is the determined cDNA sequence for clone 61824004.

[0659] SEQ ID NO:621 is the determined cDNA sequence for clone 61824005.

[0660] SEQ ID NO:622 is the determined cDNA sequence for clone 61824006.

[0661] SEQ ID NO:623 is the determined cDNA sequence for clone 61824007.

[0662] SEQ ID NO:624 is the determined cDNA sequence for clone 61824008.

[0663] SEQ ID NO:625 is the determined cDNA sequence for clone 61824009.

[0664] SEQ ID NO:626 is the determined cDNA sequence for clone 61824010.

[0665] SEQ ID NO:627 is the determined cDNA sequence for clone 61824011.

[0666] SEQ ID NO:628 is the determined cDNA sequence for clone 61824012.

[0667] SEQ ID NO:629 is the determined cDNA sequence for clone 61824013.

[0668] SEQ ID NO:630 is the determined cDNA sequence for clone 61824014.

[0669] SEQ ID NO:631 is the determined cDNA sequence for clone 61824015.

[0670] SEQ ID NO:632 is the determined cDNA sequence for clone 61824016.

[0671] SEQ ID NO:633 is the determined cDNA sequence for clone 61824017.

[0672] SEQ ID NO:634 is the determined cDNA sequence for clone 61824018.

[0673] SEQ ID NO:635 is the determined cDNA sequence for clone 61824019.

[0674] SEQ ID NO:636 is the determined cDNA sequence for clone 61824020.

[0675] SEQ ID NO:637 is the determined cDNA sequence for clone 61824021.

[0676] SEQ ID NO:638 is the determined cDNA sequence for clone 61824022.

[0677] SEQ ID NO:639 is the determined cDNA sequence for clone 61824023.

[0678] SEQ ID NO:640 is the determined cDNA sequence for clone 61824024.

[0679] SEQ ID NO:641 is the determined cDNA sequence for clone 61824025.

[0680] SEQ ID NO:642 is the determined cDNA sequence for clone 61824026.

[0681] SEQ ID NO:643 is the determined cDNA sequence for clone 61824027.

[0682] SEQ ID NO:644 is the determined cDNA sequence for clone 61824028.

[0683] SEQ ID NO:645 is the determined cDNA sequence for clone 61824029.

[0684] SEQ ID NO:646 is the determined cDNA sequence for clone 61824030.

[0685] SEQ ID NO:647 is the determined cDNA sequence for clone 61824031.

[0686] SEQ ID NO:648 is the determined cDNA sequence for clone 61824032.

[0687] SEQ ID NO:649 is the determined cDNA sequence for clone 61824033.

[0688] SEQ ID NO:650 is the determined cDNA sequence for clone 61824034.

[0689] SEQ ID NO:651 is the determined cDNA sequence for clone 61824036.

[0690] SEQ ID NO:652 is the determined cDNA sequence for clone 61824037.

[0691] SEQ ID NO:653 is the determined cDNA sequence for clone 61824038.

[0692] SEQ ID NO:654 is the determined cDNA sequence for clone 61824039.

[0693] SEQ ID NO:655 is the determined cDNA sequence for clone 61824040.

[0694] SEQ ID NO:656 is the determined cDNA sequence for clone 61824041.

[0695] SEQ ID NO:657 is the determined cDNA sequence for clone 61824042.

[0696] SEQ ID NO:658 is the determined cDNA sequence for clone 61824043.

[0697] SEQ ID NO:659 is the determined cDNA sequence for clone 61824044.

[0698] SEQ ID NO:660 is the determined cDNA sequence for clone 61824045.

[0699] SEQ ID NO:661 is the determined full length cDNA sequence for the lung specific tumor antigen L1477P, previously identified as clone number 61594579 (SEQ ID NO:196).

[0700] SEQ ID NO:662 is the determined full length cDNA sequence for the lung specific tumor antigen L1478P, previously identified as clone number 61594786 (SEQ ID NO:540).

[0701] SEQ ID NO:663 is the determined full length cDNA sequence for the lung specific tumor antigen L1479P, previously identified as clone number 61824006 (SEQ ID NO:622).

[0702] SEQ ID NO:664 is the determined full length amino acid sequence for the lung specific tumor antigen L1477P, previously identified as clone number 61594579 (SEQ ID NO:196).

[0703] SEQ ID NO:665 is the determined full length amino acid sequence for the lung specific tumor antigen L1477P, previously identified as clone number 61594786 (SEQ ID NO:196).

[0704] SEQ ID NO:666 is the determined full length amino acid sequence for the lung specific tumor antigen L1479P, previously identified as clone number 61824006 (SEQ ID NO:622).

[0705] SEQ ID NO:667 is the cDNA sequence for the homo sapiens kinesin family member 4A (KIF4A), which shows sequence identity to clone L1447P.

[0706] SEQ ID NO:668 is the cDNA sequence for clone L1447P.

[0707] SEQ ID NO:669 is the amino acid sequence for the human kinesin family member 4A (KIF4A), which shows sequence identity to clone L1447P.

[0708] SEQ ID NO:670 is the cDNA sequence for clone L1447P.

DETAILED DESCRIPTION OF THE INVENTION

[0709] U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety.

[0710] The present invention is directed generally to compositions and their use in the therapy and diagnosis of cancer, particularly lung cancer. As described further below, illustrative compositions of the present invention include, but are not restricted to, polypeptides, particularly immunogenic polypeptides, polynucleotides encoding such polypeptides, antibodies and other binding agents, antigen presenting cells (APCs) and immune system cells (e.g., T cells).

[0711] The practice of the present invention will employ, unless indicated specifically to the contrary, conventional methods of virology, immunology, microbiology, molecular biology and recombinant DNA techniques within the skill of the art, many of which are described below for the purpose of illustration. Such techniques are explained fully in the literature. See, e.g., Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Maniatis et al., Molecular Cloning: A Laboratory Manual (1982); DNA Cloning: A Practical Approach, vol. I & II (D. Glover, ed.); Oligonucleotide Synthesis (N. Gait, ed., 1984); Nucleic Acid Hybridization (B. Hames & S. Higgins, eds., 1985); Transcription and Translation (B. Hames & S. Higgins, eds., 1984); Animal Cell Culture (R. Freshney, ed., 1986); Perbal, A Practical Guide to Molecular Cloning (1984).

[0712] All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.

[0713] As used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural references unless the content clearly dictates otherwise.

[0714] Polypeptide Compositions

[0715] As used herein, the term “polypeptide”” is used in its conventional meaning, i.e., as a sequence of amino acids. The polypeptides are not limited to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide, and such terms may be used interchangeably herein unless specifically indicated otherwise. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. A polypeptide may be an entire protein, or a subsequence thereof. Particular polypeptides of interest in the context of this invention are amino acid subsequences comprising epitopes, i.e., antigenic determinants substantially responsible for the immunogenic properties of a polypeptide and being capable of evoking an immune response.

[0716] Particularly illustrative polypeptides of the present invention comprise those encoded by a polynucleotide sequence set forth in any one of SEQ ID NOs:1-663, 667-668 and 670, or a sequence that hybridizes under moderately stringent conditions, or, alternatively, under highly stringent conditions, to a polynucleotide sequence set forth in any one of SEQ ID NOs:1-663, 667-668 and 670. Certain other illustrative polypeptides of the invention comprise amino acid sequences as set forth in any one of SEQ ID NOs:664-666 and 669.

[0717] The polypeptides of the present invention are sometimes herein referred to as lung tumor proteins or lung tumor polypeptides, as an indication that their identification has been based at least in part upon their increased levels of expression in lung tumor samples. Thus, a “lung tumor polypeptide” or “lung tumor protein,” refers generally to a polypeptide sequence of the present invention, or a polynucleotide sequence encoding such a polypeptide, that is expressed in a substantial proportion of lung tumor samples, for example preferably greater than about 20%, more preferably greater than about 30%, and most preferably greater than about 50% or more of lung tumor samples tested, at a level that is at least two fold, and preferably at least five fold, greater than the level of expression in normal tissues, as determined using a representative assay provided herein. A lung tumor polypeptide sequence of the invention, based upon its increased level of expression in tumor cells, has particular utility both as a diagnostic marker as well as a therapeutic target, as further described below.

[0718] In certain preferred embodiments, the polypeptides of the invention are immunogenic, i.e., they react detectably within an immunoassay (such as an ELISA or T-cell stimulation assay) with antisera and/or T-cells from a patient with lung cancer. Screening for immunogenic activity can be performed using techniques well known to the skilled artisan. For example, such screens can be performed using methods such as those described in Harlow and Lane, Antibodies: A Laboratoty Manual, Cold Spring Harbor Laboratory, 1988. In one illustrative example, a polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A.

[0719] As would be recognized by the skilled artisan, immunogenic portions of the polypeptides disclosed herein are also encompassed by the present invention. An “immunogenic portion,” as used herein, is a fragment of an immunogenic polypeptide of the invention that itself is immunologically reactive (i.e., specifically binds) with the B-cells and/or T-cell surface antigen receptors that recognize the polypeptide. Immunogenic portions may generally be identified using well known techniques, such as those summarized in Paul, Fundamental Immunology, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are “antigen-specific” if they specifically bind to an antigen (i.e., they react with the protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well-known techniques.

[0720] In one preferred embodiment, an immunogenic portion of a polypeptide of the present invention is a portion that reacts with antisera and/or T-cells at a level that is not substantially less than the reactivity of the full-length polypeptide (e.g., in an ELISA and/or T-cell reactivity assay). Preferably, the level of immunogenic activity of the immunogenic portion is at least about 50%, preferably at least about 70% and most preferably greater than about 90% of the immunogenicity for the full-length polypeptide. In some instances, preferred immunogenic portions will be identified that have a level of immunogenic activity greater than that of the corresponding full-length polypeptide, e.g., having greater than about 100% or 150% or more immunogenic activity.

[0721] In certain other embodiments, illustrative immunogenic portions may include peptides in which an N-terminal leader sequence and/or transmembrane domain have been deleted. Other illustrative immunogenic portions will contain a small N- and/or C-terminal deletion (e.g., 1-30 amino acids, preferably 5-15 amino acids), relative to the mature protein.

[0722] In another embodiment, a polypeptide composition of the invention may also comprise one or more polypeptides that are immunologically reactive with T cells and/or antibodies generated against a polypeptide of the invention, particularly a polypeptide having an amino acid sequence disclosed herein, or to an immunogenic fragment or variant thereof.

[0723] In another embodiment of the invention, polypeptides are provided that comprise one or more polypeptides that are capable of eliciting T cells and/or antibodies that are immunologically reactive with one or more polypeptides described herein, or one or more polypeptides encoded by contiguous nucleic acid sequences contained in the polynucleotide sequences disclosed herein, or immunogenic fragments or variants thereof, or to one or more nucleic acid sequences which hybridize to one or more of these sequences under conditions of moderate to high stringency.

[0724] The present invention, in another aspect, provides polypeptide fragments comprising at least about 5, 10, 15, 20, 25, 50, or 100 contiguous amino acids, or more, including all intermediate lengths, of a polypeptide compositions set forth herein, such as those set forth in SEQ ID NOs:664-666 and 669, or those encoded by a polynucleotide sequence set forth in a sequence of SEQ ID NOs:1-663, 667-668 and 670.

[0725] In another aspect, the present invention provides variants of the polypeptide compositions described herein. Polypeptide variants generally encompassed by the present invention will typically exhibit at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity (determined as described below), along its length, to a polypeptide sequences set forth herein.

[0726] In one preferred embodiment, the polypeptide fragments and variants provided by the present invention are immunologically reactive with an antibody and/or T-cell that reacts with a full-length polypeptide specifically set forth herein.

[0727] In another preferred embodiment, the polypeptide fragments and variants provided by the present invention exhibit a level of immunogenic activity of at least about 50%, preferably at least about 70%, and most preferably at least about 90% or more of that exhibited by a full-length polypeptide sequence specifically set forth herein.

[0728] A polypeptide “variant,” as the term is used herein, is a polypeptide that typically differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of the above polypeptide sequences of the invention and evaluating their immunogenic activity as described herein and/or using any of a number of techniques well known in the art.

[0729] For example, certain illustrative variants of the polypeptides of the invention include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed. Other illustrative variants include variants in which a small portion (e.g., 1-30 amino acids, preferably 5-15 amino acids) has been removed from the N- and/or C-terminal of the mature protein.

[0730] In many instances, a variant will contain conservative substitutions. A “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. As described above, modifications may be made in the structure of the polynucleotides and polypeptides of the present invention and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics, e.g., with immunogenic characteristics. When it is desired to alter the amino acid sequence of a polypeptide to create an equivalent, or even an improved, immunogenic variant or portion of a polypeptide of the invention, one skilled in the art will typically change one or more of the codons of the encoding DNA sequence according to Table 1.

[0731] For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity. TABLE 1 Amino Acids Codons Alanine Ala A GCA GCC GCG GGU Cysteine Cys C UGC UGU Aspartic acid Asp D GAC GAU Glutamic acid Glu E GAA GAG Phenylalanine Phe F UUC UUU Glycine Gly G GGA GGC GGG GGU Histidine His H CAC CAU Isoleucine Ile I AUA AUC AUU Lysine Lys K AAA AAG Leucine Leu L UUA UUG CUA CUC CUG CUU Methionine Met M AUG Asparagine Asn N AAC AAU Proline Pro P CCA CCC CCG CCU Glutamine Gln Q CAA CAG Arginine Arg R AGA AGG CGA CGC CGG CGU Serine Ser S AGA AGU UCA UCC UCG UCU Threonine Thr T ACA ACC ACG ACU Valine Val V GUA GUC GUG GUU Tryptophan Trp W UGG Tyrosine Tyr Y UAC UAU

[0732] In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporated herein by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics (Kyte and Doolittle, 1982). These values are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (−4.5).

[0733] It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, i.e., still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are within ±2 is preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Pat. No. 4,554,101 (specifically incorporated herein by reference in its entirety), states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.

[0734] As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0±1); glutamate (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5±1); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5); tryptophan (−3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ±2 is preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.

[0735] As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

[0736] In addition, any polynucleotide may be further modified to increase stability in vivo. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends; the use of phosphorothioate or 2′ O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

[0737] Amino acid substitutions may further be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gin, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. In a preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydropathic nature of the polypeptide.

[0738] As noted above, polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein, which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

[0739] When comparing polypeptide sequences, two sequences are said to be “identical” if the sequence of amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

[0740] Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, Wis.), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M. O., (1978) A model of evolutionary change in proteins—Matrices for detecting distant relationships. In Dayhoff, M. O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington D.C. Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenes, pp. 626-645 Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, Calif.; Higgins, D. G. and Sharp, P. M., CABIOS 5:151-153 (1989); Myers, E. W. and Muller W., CABIOS 4:11-17 (1988); Robinson, E. D., Comb. Theor 11:105 (1971); Saitou, N. Nei, M., Mol. Biol. Evol. 4:406-425 (1987); Sneath, P. H. A. and Sokal, R. R., Numerical Taxonomy—the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, Calif. (1973); Wilbur, W. J. and Lipman, D. J., Proc. Natl. Acad., Sci. USA 80:726-730 (1983).

[0741] Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman, Add. APL. Math 2:482 (1981), by the identity alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity methods of Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by inspection.

[0742] One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nucl. Acids Res. 25:3389-3402 (1977), and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.

[0743] In one preferred approach, the “percentage of sequence identity” is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

[0744] Within other illustrative embodiments, a polypeptide may be a xenogeneic polypeptide that comprises an polypeptide having substantial sequence identity, as described above, to the human polypeptide (also termed autologous antigen) which served as a reference polypeptide, but which xenogeneic polypeptide is derived from a different, non-human species. One skilled in the art will recognize that “self” antigens are often poor stimulators of CD8+ and CD4+ T-lymphocyte responses, and therefore efficient immunotherapeutic strategies directed against tumor polypeptides require the development of methods to overcome immune tolerance to particular self tumor polypeptides. For example, humans immunized with prostase protein from a xenogeneic (non human) origin are capable of mounting an immune response against the counterpart human protein, e.g., the human prostase tumor protein present on human tumor cells. Accordingly, the present invention provides methods for purifying the xenogeneic form of the tumor proteins set forth herein, such as the polypeptides set forth in SEQ ID NOs:664-666 and 669, or those encoded by polynucleotide sequences set forth in SEQ ID NOs:1-663, 667-668 and 670.

[0745] Therefore, one aspect of the present invention provides xenogeneic variants of the polypeptide compositions described herein. Such xenogeneic variants generally encompassed by the present invention will typically exhibit at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity along their lengths, to a polypeptide sequences set forth herein.

[0746] More particularly, the invention is directed to mouse, rat, monkey, porcine and other non-human polypeptides which can be used as xenogeneic forms of human polypeptides set forth herein, to induce immune responses directed against tumor polypeptides of the invention.

[0747] Within other illustrative embodiments, a polypeptide may be a fusion polypeptide that comprises multiple polypeptides as described herein, or that comprises at least one polypeptide as described herein and an unrelated sequence, such as a known tumor protein. A fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the polypeptide or to enable the polypeptide to be targeted to desired intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the polypeptide.

[0748] Fusion polypeptides may generally be prepared using standard techniques, including chemical conjugation. Preferably, a fusion polypeptide is expressed as a recombinant polypeptide, allowing the production of increased levels, relative to a non-fused polypeptide, in an expression system. Briefly, DNA sequences encoding the polypeptide components may be assembled separately, and ligated into an appropriate expression vector. The 3′ end of the DNA sequence encoding one polypeptide component is ligated, with or without a peptide linker, to the 5′ end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in phase. This permits translation into a single fusion polypeptide that retains the biological activity of both component polypeptides.

[0749] A peptide linker sequence may be employed to separate the first and second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion polypeptide using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; U.S. Pat. No. 4,935,233 and U.S. Pat. No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

[0750] The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5′ to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and transcription termination signals are only present 3′ to the DNA sequence encoding the second polypeptide.

[0751] The fusion polypeptide can comprise a polypeptide as described herein together with an unrelated immunogenic protein, such as an immunogenic protein capable of eliciting a recall response. Examples of such proteins include tetanus, tuberculosis and hepatitis proteins (see, for example, Stoute et al. New Engl. J. Med., 336:86-91,1997).

[0752] In one preferred embodiment, the immunological fusion partner is derived from a Mycobacterium sp., such as a Mycobacterium tuberculosis-derived Ra12 fragment. Ra12 compositions and methods for their use in enhancing the expression and/or immunogenicity of heterologous polynucleotide/polypeptide sequences is described in U.S. Patent Application No. 60/158,585, the disclosure of which is incorporated herein by reference in its entirety. Briefly, Ra12 refers to a polynucleotide region that is a subsequence of a Mycobacterium tuberculosis MTB32A nucleic acid. MTB32A is a serine protease of 32 KD molecular weight encoded by a gene in virulent and avirulent strains of M. tuberculosis. The nucleotide sequence and amino acid sequence of MTB32A have been described (for example, U.S. Patent Application No. 60/158,585; see also, Skeiky et al., Infection and Immun. 67:3998-4007 (1999), incorporated herein by reference). C-terminal fragments of the MTB32A coding sequence express at high levels and remain as a soluble polypeptides throughout the purification process. Moreover, Ra12 may enhance the immunogenicity of heterologous immunogenic polypeptides with which it is fused. One preferred Ra12 fusion polypeptide comprises a 14 KD C-terminal fragment corresponding to amino acid residues 192 to 323 of MTB32A. Other preferred Ra12 polynucleotides generally comprise at least about 15 consecutive nucleotides, at least about 30 nucleotides, at least about 60 nucleotides, at least about 100 nucleotides, at least about 200 nucleotides, or at least about 300 nucleotides that encode a portion of a Ra12 polypeptide. Ra12 polynucleotides may comprise a native sequence (i.e., an endogenous sequence that encodes a Ra12 polypeptide or a portion thereof) or may comprise a variant of such a sequence. Ra12 polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions such that the biological activity of the encoded fusion polypeptide is not substantially diminished, relative to a fusion polypeptide comprising a native Ra12 polypeptide. Variants preferably exhibit at least about 70% identity, more preferably at least about 80% identity and most preferably at least about 90% identity to a polynucleotide sequence that encodes a native Ra12 polypeptide or a portion thereof.

[0753] Within other preferred embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium Haemophilus influenza B (WO 91/18926). Preferably, a protein D derivative comprises approximately the first third of the protein (e.g., the first N-terminal 100-110 amino acids), and a protein D derivative may be lipidated. Within certain preferred embodiments, the first 109 residues of a Lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes and to increase the expression level in E. coli (thus functioning as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells. Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemaglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

[0754] In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from Streptococcus pneumoniae, which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the LytA gene; Gene 43:265-292, 1986). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E. coli C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see Biotechnology 10:795-798, 1992). Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion polypeptide. A repeat portion is found in the C-terminal region starting at residue 178. A particularly preferred repeat portion incorporates residues 188-305.

[0755] Yet another illustrative embodiment involves fusion polypeptides, and the polynucleotides encoding them, wherein the fusion partner comprises a targeting signal capable of directing a polypeptide to the endosomal/lysosomal compartment, as described in U.S. Pat. No. 5,633,234. An immunogenic polypeptide of the invention, when fused with this targeting signal, will associate more efficiently with MHC class II molecules and thereby provide enhanced in vivo stimulation of CD4⁺ T-cells specific for the polypeptide.

[0756] Polypeptides of the invention are prepared using any of a variety of well known synthetic and/or recombinant techniques, the lafter of which are further described below. Polypeptides, portions and other variants generally less than about 150 amino acids can be generated by synthetic means, using techniques well known to those of ordinary skill in the art. In one illustrative example, such polypeptides are synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, Calif.), and may be operated according to the manufacturer's instructions.

[0757] In general, polypeptide compositions (including fusion polypeptides) of the invention are isolated. An “isolated” polypeptide is one that is removed from its original environment. For example, a naturally-occurring protein or polypeptide is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are also purified, e.g., are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure.

[0758] Polynucleotide Compositions

[0759] The present invention, in other aspects, provides polynucleotide compositions. The terms “DNA” and “polynucleotide” are used essentially interchangeably herein to refer to a DNA molecule that has been isolated free of total genomic DNA of a particular species. “Isolated,” as used herein, means that a polynucleotide is substantially away from other coding sequences, and that the DNA molecule does not contain large portions of unrelated coding DNA, such as large chromosomal fragments or other functional genes or polypeptide coding regions. Of course, this refers to the DNA molecule as originally isolated, and does not exclude genes or coding regions later added to the segment by the hand of man.

[0760] As will be understood by those skilled in the art, the polynucleotide compositions of this invention can include genomic sequences, extra-genomic and plasmid-encoded sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides, peptides and the like. Such segments may be naturally isolated, or modified synthetically by the hand of man.

[0761] As will be also recognized by the skilled artisan, polynucleotides of the invention may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules may include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one manner, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

[0762] Polynucleotides may comprise a native sequence (i.e., an endogenous sequence that encodes a polypeptide/protein of the invention or a portion thereof) or may comprise a sequence that encodes a variant or derivative, preferably and immunogenic variant or derivative, of such a sequence.

[0763] Therefore, according to another aspect of the present invention, polynucleotide compositions are provided that comprise some or all of a polynucleotide sequence set forth in any one of SEQ ID NOs:1-663, 667-668 and 670, complements of a polynucleotide sequence set forth in any one of SEQ ID NOs:1-663, 667-668 and 670, and degenerate variants of a polynucleotide sequence set forth in any one of SEQ ID NOs:1-663, 667-668 and 670. In certain preferred embodiments, the polynucleotide sequences set forth herein encode immunogenic polypeptides, as described above.

[0764] In other related embodiments, the present invention provides polynucleotide variants having substantial identity to the sequences disclosed herein in SEQ ID NOs:1-663, 667-668 and 670, for example those comprising at least 70% sequence identity, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity compared to a polynucleotide sequence of this invention using the methods described herein, (e.g., BLAST analysis using standard parameters, as described below). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like.

[0765] Typically, polynucleotide variants will contain one or more substitutions, additions, deletions and/or insertions, preferably such that the immunogenicity of the polypeptide encoded by the variant polynucleotide is not substantially diminished relative to a polypeptide encoded by a polynucleotide sequence specifically set forth herein). The term “variants” should also be understood to encompasses homologous genes of xenogenic origin.

[0766] In additional embodiments, the present invention provides polynucleotide fragments comprising or consisting of various lengths of contiguous stretches of sequence identical to or complementary to one or more of the sequences disclosed herein. For example, polynucleotides are provided by this invention that comprise or consist of at least about 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of one or more of the sequences disclosed herein as well as all intermediate lengths there between. It will be readily understood that “intermediate lengths”, in this context, means any length between the quoted values, such as 16, 17, 18, 19, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.; including all integers through 200-500; 500-1,000, and the like. A polynucleotide sequence as described here may be extended at one or both ends by additional nucleotides not found in the native sequence. This additional sequence may consist of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides at either end of the disclosed sequence or at both ends of the disclosed sequence.

[0767] In another embodiment of the invention, polynucleotide compositions are provided that are capable of hybridizing under moderate to high stringency conditions to a polynucleotide sequence provided herein, or a fragment thereof, or a complementary sequence thereof. Hybridization techniques are well known in the art of molecular biology. For purposes of illustration, suitable moderately stringent conditions for testing the hybridization of a polynucleotide of this invention with other polynucleotides include prewashing in a solution of 5×SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50° C.-60° C., 5×SSC, overnight; followed by washing twice at 65° C. for 20 minutes with each of 2×, 0.5×and 0.2×SSC containing 0.1% SDS. One skilled in the art will understand that the stringency of hybridization can be readily manipulated, such as by altering the salt content of the hybridization solution and/or the temperature at which the hybridization is performed. For example, in another embodiment, suitable highly stringent hybridization conditions include those described above, with the exception that the temperature of hybridization is increased, e.g., to 60-65° C. or 65-70° C.

[0768] In certain preferred embodiments, the polynucleotides described above, e.g., polynucleotide variants, fragments and hybridizing sequences, encode polypeptides that are immunologically cross-reactive with a polypeptide sequence specifically set forth herein. In other preferred embodiments, such polynucleotides encode polypeptides that have a level of immunogenic activity of at least about 50%, preferably at least about 70%, and more preferably at least about 90% of that for a polypeptide sequence specifically set forth herein.

[0769] The polynucleotides of the present invention, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, illustrative polynucleotide segments with total lengths of about 10,000, about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base pairs in length, and the like, (including all intermediate lengths) are contemplated to be useful in many implementations of this invention.

[0770] When comparing polynucleotide sequences, two sequences are said to be “identical” if the sequence of nucleotides in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

[0771] Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, Wis.), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M. O. (1978) A model of evolutionary change in proteins—Matrices for detecting distant relationships. In Dayhoff, M. O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington D.C. Vol. 5, Suppl. 3, pp. 345-358; Hein J., Unified Approach to Alignment and Phylogenes, pp. 626-645 (1990); Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, Calif.; Higgins, D. G. and Sharp, P. M., CABIOS 5:151-153 (1989); Myers, E. W. and Muller W., CABIOS 4:11-17 (1988); Robinson, E. D., Comb. Theor 11:105 (1971); Santou, N. Nes, M., Mol. Biol. Evol. 4:406-425 (1987); Sneath, P. H. A. and Sokal, R. R., Numerical Taxonomy—the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, Calif. (1973); Wilbur, W. J. and Lipman, D. J., Proc. Natl. Acad., Sci. USA 80:726-730 (1983).

[0772] Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman, Add. APL. Math 2:482 (1981), by the identity alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity methods of Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by inspection.

[0773] One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nucl. Acids Res. 25:3389-3402 (1977), and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and a comparison of both strands.

[0774] Preferably, the “percentage of sequence identity” is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

[0775] It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).

[0776] Therefore, in another embodiment of the invention, a mutagenesis approach, such as site-specific mutagenesis, is employed for the preparation of immunogenic variants and/or derivatives of the polypeptides described herein. By this approach, specific modifications in a polypeptide sequence can be made through mutagenesis of the underlying polynucleotides that encode them. These techniques provides a straightforward approach to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the polynucleotide.

[0777] Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Mutations may be employed in a selected polynucleotide sequence to improve, alter, decrease, modify, or otherwise change the properties of the polynucleotide itself, and/or alter the properties, activity, composition, stability, or primary sequence of the encoded polypeptide.

[0778] In certain embodiments of the present invention, the inventors contemplate the mutagenesis of the disclosed polynucleotide sequences to alter one or more properties of the encoded polypeptide, such as the immunogenicity of a polypeptide vaccine. The techniques of site-specific mutagenesis are well-known in the art, and are widely used to create variants of both polypeptides and polynucleotides. For example, site-specific mutagenesis is often used to alter a specific portion of a DNA molecule. In such embodiments, a primer comprising typically about 14 to about 25 nucleotides or so in length is employed, with about 5 to about 10 residues on both sides of the junction of the sequence being altered.

[0779] As will be appreciated by those of skill in the art, site-specific mutagenesis techniques have often employed a phage vector that exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage are readily commercially-available and their use is generally well-known to those skilled in the art. Double-stranded plasmids are also routinely employed in site directed mutagenesis that eliminates the step of transferring the gene of interest from a plasmid to a phage.

[0780] In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart of two strands of a double-stranded vector that includes within its sequence a DNA sequence that encodes the desired peptide. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as E. coli polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as E. coli cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

[0781] The preparation of sequence variants of the selected peptide-encoding DNA segments using site-directed mutagenesis provides a means of producing potentially useful species and is not meant to be limiting as there are other ways in which sequence variants of peptides and the DNA sequences encoding them may be obtained. For example, recombinant vectors encoding the desired peptide sequence may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants. Specific details regarding these methods and protocols are found in the teachings of Maloy et al., 1994; Segal, 1976; Prokop and Bajpai, 1991; Kuby, 1994; and Maniatis et al., 1982, each incorporated herein by reference, for that purpose.

[0782] As used herein, the term “oligonucleotide directed mutagenesis procedure” refers to template-dependent processes and vector-mediated propagation which result in an increase in the concentration of a specific nucleic acid molecule relative to its initial concentration, or in an increase in the concentration of a detectable signal, such as amplification. As used herein, the term “oligonucleotide directed mutagenesis procedure” is intended to refer to a process that involves the template-dependent extension of a primer molecule. The term template dependent process refers to nucleic acid synthesis of an RNA or a DNA molecule wherein the sequence of the newly synthesized strand of nucleic acid is dictated by the well-known rules of complementary base pairing (see, for example, Watson, 1987). Typically, vector mediated methodologies involve the introduction of the nucleic acid fragment into a DNA or RNA vector, the clonal amplification of the vector, and the recovery of the amplified nucleic acid fragment. Examples of such methodologies are provided by U.S. Pat. No. 4,237,224, specifically incorporated herein by reference in its entirety.

[0783] In another approach for the production of polypeptide variants of the present invention, recursive sequence recombination, as described in U.S. Pat. No. 5,837,458, may be employed. In this approach, iterative cycles of recombination and screening or selection are performed to “evolve” individual polynucleotide variants of the invention having, for example, enhanced immunogenic activity.

[0784] In other embodiments of the present invention, the polynucleotide sequences provided herein can be advantageously used as probes or primers for nucleic acid hybridization. As such, it is contemplated that nucleic acid segments that comprise or consist of a sequence region of at least about a 15 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 15 nucleotide long contiguous sequence disclosed herein will find particular utility. Longer contiguous identical or complementary sequences, e.g., those of about 20, 30, 40, 50, 100, 200, 500, 1000 (including all intermediate lengths) and even up to full length sequences will also be of use in certain embodiments. The ability of such nucleic acid probes to specifically hybridize to a sequence of interest will enable them to be of use in detecting the presence of complementary sequences in a given sample. However, other uses are also envisioned, such as the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic constructions.

[0785] Polynucleotide molecules having sequence regions consisting of contiguous nucleotide stretches of 10-14, 15-20, 30, 50, or even of 100-200 nucleotides or so (including intermediate lengths as well), identical or complementary to a polynucleotide sequence disclosed herein, are particularly contemplated as hybridization probes for use in, e.g., Southern and Northern blotting. This would allow a gene product, or fragment thereof, to be analyzed, both in diverse cell types and also in various bacterial cells. The total size of fragment, as well as the size of the complementary stretch(es), will ultimately depend on the intended use or application of the particular nucleic acid segment. Smaller fragments will generally find use in hybridization embodiments, wherein the length of the contiguous complementary region may be varied, such as between about 15 and about 100 nucleotides, but larger contiguous complementarity stretches may be used, according to the length complementary sequences one wishes to detect.

[0786] The use of a hybridization probe of about 15-25 nucleotides in length allows the formation of a duplex molecule that is both stable and selective.

[0787] Molecules having contiguous complementary sequences over stretches greater than 15 bases in length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of 15 to 25 contiguous nucleotides, or even longer where desired.

[0788] Hybridization probes may be selected from any portion of any of the sequences disclosed herein. All that is required is to review the sequences set forth herein, or to any continuous portion of the sequences, from about 15-25 nucleotides in length up to and including the full length sequence, that one wishes to utilize as a probe or primer. The choice of probe and primer sequences may be governed by various factors. For example, one may wish to employ primers from towards the termini of the total sequence.

[0789] Small polynucleotide segments or fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer. Also, fragments may be obtained by application of nucleic acid reproduction technology, such as the PCR™ technology of U.S. Pat. No. 4,683,202 (incorporated herein by reference), by introducing selected sequences into recombinant vectors for recombinant production, and by other recombinant DNA techniques generally known to those of skill in the art of molecular biology.

[0790] The nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of the entire gene or gene fragments of interest. Depending on the application envisioned, one will typically desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, e.g., one will select relatively low salt and/or high temperature conditions, such as provided by a salt concentration of from about 0.02 M to about 0.15 M salt at temperatures of from about 50° C. to about 70° C. Such selective conditions tolerate little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating related sequences.

[0791] Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template, less stringent (reduced stringency) hybridization conditions will typically be needed in order to allow formation of the heteroduplex. In these circumstances, one may desire to employ salt conditions such as those of from about 0.15 M to about 0.9 M salt, at temperatures ranging from about 20° C. to about 55° C. Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide, which serves to destabilize the hybrid duplex in the same manner as increased temperature. Thus, hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results.

[0792] According to another embodiment of the present invention, polynucleotide compositions comprising antisense oligonucleotides are provided. Antisense oligonucleotides have been demonstrated to be effective and targeted inhibitors of protein synthesis, and, consequently, provide a therapeutic approach by which a disease can be treated by inhibiting the synthesis of proteins that contribute to the disease. The efficacy of antisense oligonucleotides for inhibiting protein synthesis is well established. For example, the synthesis of polygalactauronase and the muscarine type 2 acetylcholine receptor are inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U.S. Pat. No. 5,739,119 and U.S. Pat. No. 5,759,829). Further, examples of antisense inhibition have been demonstrated with the nuclear protein cyclin, the multiple drug resistance gene (MDG1), ICAM-1, E-selectin, STK-1, striatal GABA_(A) receptor and human EGF (Jaskulski et al., Science Jun. 10, 1988;240(4858):1544-6; Vasanthakumar and Ahmed, Cancer Commun. 1989;1(4):225-32; Peris et al., Brain Res Mol Brain Res. Jun. 15, 1998;57(2):310-20; U.S. Pat. No. 5,801,154; U.S. Pat. No. 5,789,573; U.S. Pat. No. 5,718,709 and U.S. Pat. No. 5,610,288). Antisense constructs have also been described that inhibit and can be used to treat a variety of abnormal cellular proliferations, e.g., cancer (U.S. Pat. No. 5,747,470; U.S. Pat. No. 5,591,317 and U.S. Pat. No. 5,783,683).

[0793] Therefore, in certain embodiments, the present invention provides oligonucleotide sequences that comprise all, or a portion of, any sequence that is capable of specifically binding to polynucleotide sequence described herein, or a complement thereof. In one embodiment, the antisense oligonucleotides comprise DNA or derivatives thereof. In another embodiment, the oligonucleotides comprise RNA or derivatives thereof. In a third embodiment, the oligonucleotides are modified DNAs comprising a phosphorothioated modified backbone. In a fourth embodiment, the oligonucleotide sequences comprise peptide nucleic acids or derivatives thereof. In each case, preferred compositions comprise a sequence region that is complementary, and more preferably substantially-complementary, and even more preferably, completely complementary to one or more portions of polynucleotides disclosed herein. Selection of antisense compositions specific for a given gene sequence is based upon analysis of the chosen target sequence and determination of secondary structure, Tm, binding energy, and relative stability. Antisense compositions may be selected based upon their relative inability to form dimers, hairpins, or other secondary structures that would reduce or prohibit specific binding to the target mRNA in a host cell. Highly preferred target regions of the mRNA, are those which are at or near the AUG translation initiation codon, and those sequences which are substantially complementary to 5′ regions of the mRNA. These secondary structure analyses and target site selection considerations can be performed, for example, using v.4 of the OLIGO primer analysis software and/or the BLASTN 2.0.5 algorithm software (Altschul et al., Nucleic Acids Res. 1997, 25(17):3389-402).

[0794] The use of an antisense delivery method employing a short peptide vector, termed MPG (27 residues), is also contemplated. The MPG peptide contains a hydrophobic domain derived from the fusion sequence of HIV gp4l and a hydrophilic domain from the nuclear localization sequence of SV40 T-antigen (Morris et al., Nucleic Acids Res. Jul. 15, 1997;25(14):2730-6). It has been demonstrated that several molecules of the MPG peptide coat the antisense oligonucleotides and can be delivered into cultured mammalian cells in less than 1 hour with relatively high efficiency (90%). Further, the interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and the ability to cross the plasma membrane.

[0795] According to another embodiment of the invention, the polynucleotide compositions described herein are used in the design and preparation of ribozyme molecules for inhibiting expression of the tumor polypeptides and proteins of the present invention in tumor cells. Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim and Cech, Proc. Natl. Acad. Sci. USA. 1987 December;84(24):8788-92; Forster and Symons, Cell. Apr. 24, 1987;49(2):211-20). For example, a large number of ribozymes accelerate phosphoester transfer reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech et al., Cell. 1981 December;27(3 Pt 2):487-96; Michel and Westhof, J. Mol. Biol. Dec. 5, 1990;216(3):585-610; Reinhold-Hurek and Shub, Nature. May 14, 1992;357(6374):173-6). This specificity has been attributed to the requirement that the substrate bind via specific base-pairing interactions to the internal guide sequence (“IGS”) of the ribozyme prior to chemical reaction.

[0796] Six basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds in trans (and thus can cleave other RNA molecules) under physiological conditions. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

[0797] The enzymatic nature of a ribozyme is advantageous over many technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the concentration of ribozyme necessary to affect a therapeutic treatment is lower than that of an antisense oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. Similar mismatches in antisense molecules do not prevent their action (Woolf et al., Proc. Natl. Acad. Sci. USA. Aug. 15, 1992;89(16):7305-9). Thus, the specificity of action of a ribozyme is greater than that of an antisense oligonucleotide binding the same RNA site.

[0798] The enzymatic nucleic acid molecule may be formed in a hammerhead, hairpin, a hepatitis δ virus, group I intron or RNaseP RNA (in association with an RNA guide sequence) or Neurospora VS RNA motif. Examples of hammerhead motifs are described by Rossi et al. Nucleic Acids Res. Sep. 11, 1992;20(17):4559-65. Examples of hairpin motifs are described by Hampel et al. (Eur. Pat. Appl. Publ. No. EP 0360257), Hampel and Tritz, Biochemistry Jun. 13, 1989;28(12):4929-33; Hampel et al., Nucleic Acids Res. Jan. 25, 1990;18(2):299-304 and U.S. Pat. No. 5,631,359. An example of the hepatitis δ virus motif is described by Perrofta and Been, Biochemistry. Dec. 1, 1992;31(47):11843-52; an example of the RNaseP motif is described by Guerrier-Takada et al., Cell. 1983 December;35(3 Pt 2):849-57; Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, Cell. May 18, 1990;61(4):685-96; Saville and Collins, Proc. Natl. Acad. Sci. USA, 88(19):8826-30 (Oct. 1, 1991); Collins and Olive, Biochemistry 32(11):2795-9 (Mar 23, 1993); and an example of the Group I intron is described in (U.S. Pat. No. 4,987,071). All that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule. Thus the ribozyme constructs need not be limited to specific motifs mentioned herein.

[0799] Ribozymes may be designed as described in Int. Pat. Appl. Publ. No. WO 93/23569 and Int. Pat. Appl. Publ. No. WO 94/02595, each specifically incorporated herein by reference) and synthesized to be tested in vitro and in vivo, as described. Such ribozymes can also be optimized for delivery. While specific examples are provided, those in the art will recognize that equivalent RNA targets in other species can be utilized when necessary.

[0800] Ribozyme activity can be optimized by altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications that prevent their degradation by serum ribonucleases (see e.g., Int. Pat. Appl. Publ. No. WO 92/07065; Int. Pat. Appl. Publ. No. WO 93/15187; Int. Pat. Appl. PubI. No. WO 91/03162; Eur. Pat. Appl. Publ. No. 92110298.4; U.S. Pat. No. 5,334,711; and Int. Pat. Appl. Publ. No. WO 94/13688, which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules), modifications which enhance their efficacy in cells, and removal of stem II bases to shorten RNA synthesis times and reduce chemical requirements.

[0801] Sullivan et al. (Int. Pat. Appl. Publ. No. WO 94/02595) describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered ex vivo to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination may be locally delivered by direct inhalation, by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Int. Pat. Appl. Publ. No. WO 94/02595 and Int. Pat. Appl. Publ. No. WO 93/23569, each specifically incorporated herein by reference.

[0802] Another means of accumulating high concentrations of a ribozyme(s) within cells is to incorporate the ribozyme-encoding sequences into a DNA expression vector. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters may also be used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells Ribozymes expressed from such promoters have been shown to function in mammalian cells. Such transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated vectors), or viral RNA vectors (such as retroviral, semliki forest virus, sindbis virus vectors).

[0803] In another embodiment of the invention, peptide nucleic acids (PNAs) compositions are provided. PNA is a DNA mimic in which the nucleobases are attached to a pseudopeptide backbone (Good and Nielsen, Antisense Nucleic Acid Drug Dev. 19977(4) 431-37). PNA is able to be utilized in a number methods that traditionally have used RNA or DNA. Often PNA sequences perform better in techniques than the corresponding RNA or DNA sequences and have utilities that are not inherent to RNA or DNA. A review of PNA including methods of making, characteristics of, and methods of using, is provided by Corey (Trends Biotechnol 15(6):224-9 (Jun 1997)). As such, in certain embodiments, one may prepare PNA sequences that are complementary to one or more portions of the ACE mRNA sequence, and such PNA compositions may be used to regulate, alter, decrease, or reduce the translation of ACE-specific mRNA, and thereby alter the level of ACE activity in a host cell to which such PNA compositions have been administered.

[0804] PNAs have 2-aminoethyl-glycine linkages replacing the normal phosphodiester backbone of DNA (Nielsen et al., Science 254(5037):1497-500 (Dec 6, 1991); Hanvey et al., Science 258(5087):1481-5 (Nov. 27, 1992); Hyrup and Nielsen, Bioorg. Med. Chem. 4(1):5-23 (Jan 1996). This chemistry has three important consequences: firstly, in contrast to DNA or phosphorothioate oligonucleotides, PNAs are neutral molecules; secondly, PNAs are achiral, which avoids the need to develop a stereoselective synthesis; and thirdly, PNA synthesis uses standard Boc or Fmoc protocols for solid-phase peptide synthesis, although other methods, including a modified Merrifield method, have been used.

[0805] PNA monomers or ready-made oligomers are commercially available from PerSeptive Biosystems (Framingham, Mass.). PNA syntheses by either Boc or Fmoc protocols are straightforward using manual or automated protocols (Norton et al., Bioorg. Med. Chem. 3(4):437-45 (Apr 1995)). The manual protocol lends itself to the production of chemically modified PNAs or the simultaneous synthesis of families of closely related PNAs.

[0806] As with peptide synthesis, the success of a particular PNA synthesis will depend on the properties of the chosen sequence. For example, while in theory PNAs can incorporate any combination of nucleotide bases, the presence of adjacent purines can lead to deletions of one or more residues in the product. In expectation of this difficulty, it is suggested that, in producing PNAs with adjacent purines, one should repeat the coupling of residues likely to be added inefficiently. This should be followed by the purification of PNAs by reverse-phase high-pressure liquid chromatography, providing yields and purity of product similar to those observed during the synthesis of peptides.

[0807] Modifications of PNAs for a given application may be accomplished by coupling amino acids during solid-phase synthesis or by attaching compounds that contain a carboxylic acid group to the exposed N-terminal amine. Alternatively, PNAs can be modified after synthesis by coupling to an introduced lysine or cysteine. The ease with which PNAs can be modified facilitates optimization for better solubility or for specific functional requirements. Once synthesized, the identity of PNAs and their derivatives can be confirmed by mass spectrometry. Several studies have made and utilized modifications of PNAs (for example, Norton et al., Bioorg Med Chem 3(4):437-45 (Apr 1995); Petersen et al., J Pept Sci 1(3):175-83 (May-Jun 1995); Orum et al., Biotechniques 19(3):472-80 (Sep 1995); Footer et al., Biochemistry. Aug. 20, 1996;35(33):10673-9; Griffith et al., Nucleic Acids Res 23(15):3003-8 (Aug. 11, 1995); Pardridge et al., Proc. Natl. Acad. Sci. USA. 92(12):5592-6 (Jun. 6, 1995); Boffa et al., Proc. Natl. Acad. Sci. USA. 92(6):1901-5 (Mar. 14, 1995); Gambacorti-Passerini et al., Blood 88(4):1411-7 (Aug. 15, 1996); Armitage et al., Proc. Natl. Acad. Sci. USA. 94(23):12320-5 (Nov. 11, 1997); Seeger et al., Biotechniques 23(3):512-7 (Sep 1997)). U.S. Pat. No. 5,700,922 discusses PNA-DNA-PNA chimeric molecules and their uses in diagnostics, modulating protein in organisms, and treatment of conditions susceptible to therapeutics.

[0808] Methods of characterizing the antisense binding properties of PNAs are discussed in Rose (Anal Chem 65(24):3545-9 (Dec. 15, 1993) and Jensen et al. (Biochemistry. Apr. 22, 1997;36(16):5072-7). Rose uses capillary gel electrophoresis to determine binding of PNAs to their complementary oligonucleotide, measuring the relative binding kinetics and stoichiometry. Similar types of measurements were made by Jensen et al. using BIAcore T technology.

[0809] Other applications of PNAs that have been described and will be apparent to the skilled artisan include use in DNA strand invasion, antisense inhibition, mutational analysis, enhancers of transcription, nucleic acid purification, isolation of transcriptionally active genes, blocking of transcription factor binding, genome cleavage, biosensors, in situ hybridization, and the like.

[0810] Polynucleotide Identification, Characterization and Expression

[0811] Polynucleotides compositions of the present invention may be identified, prepared and/or manipulated using any of a variety of well established techniques (see generally, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989, and other like references). For example, a polynucleotide may be identified, as described in more detail below, by screening a microarray of cDNAs for tumor-associated expression (i.e., expression that is at least two fold greater in a tumor than in normal tissue, as determined using a representative assay provided herein). Such screens may be performed, for example, using the microarray technology of Affymetrix, Inc. (Santa Clara, Calif.) according to the manufacturer's instructions (and essentially as described by Schena et al., Proc. Natl. Acad. Sci. USA 93:10614-10619, 1996 and Heller et al., Proc. Natl. Acad. Sci. USA 94:2150-2155, 1997). Alternatively, polynucleotides may be amplified from cDNA prepared from cells expressing the proteins described herein, such as tumor cells.

[0812] Many template dependent processes are available to amplify a target sequences of interest present in a sample. One of the best known amplification methods is the polymerase chain reaction (PCR™) which is described in detail in U.S. Pat. Nos. 4,683,195, 4,683,202 and 4,800,159, each of which is incorporated herein by reference in its entirety. Briefly, in PCR™, two primer sequences are prepared which are complementary to regions on opposite complementary strands of the target sequence. An excess of deoxynucleoside triphosphates is added to a reaction mixture along with a DNA polymerase (e.g., Taq polymerase). If the target sequence is present in a sample, the primers will bind to the target and the polymerase will cause the primers to be extended along the target sequence by adding on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction product and the process is repeated. Preferably reverse transcription and PCR™ amplification procedure may be performed in order to quantify the amount of mRNA amplified. Polymerase chain reaction methodologies are well known in the art.

[0813] Any of a number of other template dependent processes, many of which are variations of the PCR™ amplification technique, are readily known and available in the art. Illustratively, some such methods include the ligase chain reaction (referred to as LCR), described, for example, in Eur. Pat. Appl. Publ. No. 320,308 and U.S. Pat. No. 4,883,750; Qbeta Replicase, described in PCT Intl. Pat. Appl. Publ. No. PCT/US87/00880; Strand Displacement Amplification (SDA) and Repair Chain Reaction (RCR). Still other amplification methods are described in Great Britain Pat. Appl. No. 2 202 328, and in PCT Intl. Pat. Appl. Publ. No. PCT/US89/01025. Other nucleic acid amplification procedures include transcription-based amplification systems (TAS) (PCT Intl. Pat. Appl. Publ. No. WO 88/10315), including nucleic acid sequence based amplification (NASBA) and 3SR. Eur. Pat. Appl. Publ. No. 329,822 describes a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA (“ssRNA”), ssDNA, and double-stranded DNA (dsDNA). PCT Intl. Pat. Appl. Publ. No. WO 89/06700 describes a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA (“ssDNA”) followed by transcription of many RNA copies of the sequence. Other amplification methods such as “RACE” (Frohman, 1990), and “one-sided PCR” (Ohara, 1989) are also well-known to those of skill in the art.

[0814] An amplified portion of a polynucleotide of the present invention may be used to isolate a full length gene from a suitable library (e.g., a tumor cDNA library) using well known techniques. Within such techniques, a library (cDNA or genomic) is screened using one or more polynucleotide probes or primers suitable for amplification. Preferably, a library is size-selected to include larger molecules. Random primed libraries may also be preferred for identifying 5′ and upstream regions of genes. Genomic libraries are preferred for obtaining introns and extending 5′ sequences.

[0815] For hybridization techniques, a partial sequence may be labeled (e.g., by nick-translation or end-labeling with ³²P) using well known techniques. A bacterial or bacteriophage library is then generally screened by hybridizing filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe (see Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989). Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis. cDNA clones may be analyzed to determine the amount of additional sequence by, for example, PCR using a primer from the partial sequence and a primer from the vector. Restriction maps and partial sequences may be generated to identify one or more overlapping clones. The complete sequence may then be determined using standard techniques, which may involve generating a series of deletion clones. The resulting overlapping sequences can then assembled into a single contiguous sequence. A full length cDNA molecule can be generated by ligating suitable fragments, using well known techniques.

[0816] Alternatively, amplification techniques, such as those described above, can be useful for obtaining a full length coding sequence from a partial cDNA sequence. One such amplification technique is inverse PCR (see Triglia et al., Nucl. Acids Res. 16:8186, 1988), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a known region. The amplified sequences are typically subjected to a second round of amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591. Another such technique is known as “rapid amplification of cDNA ends” or RACE. This technique involves the use of an internal primer and an external primer, which hybridizes to a polyA region or vector sequence, to identify sequences that are 5′ and 3′ of a known sequence. Additional techniques include capture PCR (Lagerstrom et al., PCR Methods Applic. 1:111-19, 1991) and walking PCR (Parker et al., Nucl. Acids. Res. 19:3055-60, 1991). Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

[0817] In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known programs (e.g., NCBI BLAST searches), and such ESTs may be used to generate a contiguous full length sequence. Full length DNA sequences may also be obtained by analysis of genomic fragments.

[0818] In other embodiments of the invention, polynucleotide sequences or fragments thereof which encode polypeptides of the invention, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent. amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide.

[0819] As will be understood by those of skill in the art, it may be advantageous in some instances to produce polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

[0820] Moreover, the polynucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter polypeptide encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. For example, DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. In addition, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

[0821] In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of polypeptide activity, it may be useful to encode a chimeric protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the polypeptide-encoding sequence and the heterologous protein sequence, so that the polypeptide may be cleaved and purified away from the heterologous moiety.

[0822] Sequences encoding a desired polypeptide may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M. H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of a polypeptide, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J. Y. et al. (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer, Palo Alto, Calif.).

[0823] A newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, W H Freeman and Co., New York, N.Y.) or other comparable techniques available in the art. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure). Additionally, the amino acid sequence of a polypeptide, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

[0824] In order to express a desired polypeptide, the nucleotide sequences encoding the polypeptide, or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding a polypeptide of interest and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described, for example, in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York. N.Y.

[0825] A variety of expression vector/host systems may be utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

[0826] The “control elements” or “regulatory sequences” present in an expression vector are those non-translated regions of the vector-enhancers, promoters, 5′ and 3′ untranslated regions-which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the pBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or pSPORT1 plasmid (Gibco BRL, Gaithersburg, Md.) and the like may be used. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are generally preferred. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding a polypeptide, vectors based on SV40 or EBV may be advantageously used with an appropriate selectable marker.

[0827] In bacterial systems, any of a number of expression vectors may be selected depending upon the use intended for the expressed polypeptide. For example, when large quantities are needed, for example for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional E. coli cloning and expression vectors such as pBLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of .beta.-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX Vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

[0828] In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) Methods Enzymol. 153:516-544.

[0829] In cases where plant expression vectors are used, the expression of sequences encoding polypeptides may be driven by any of a number of promoters. For example, viral promoters such as the ³⁵S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L. E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, N.Y.; pp. 191-196).

[0830] An insect system may also be used to express a polypeptide of interest. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding the polypeptide may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the polypeptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which the polypeptide of interest may be expressed (Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. 91 :3224-3227).

[0831] In mammalian host cells, a number of viral-based expression systems are generally available. For example, in cases where an adenovirus is used as an expression vector, sequences encoding a polypeptide of interest may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing the polypeptide in infected host cells (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

[0832] Specific initiation signals may also be used to achieve more efficient translation of sequences encoding a polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

[0833] In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, COS, HeLa, MDCK, HEK293, and W138, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

[0834] For long-term, high-yield production of recombinant proteins, stable expression is generally preferred. For example, cell lines which stably express a polynucleotide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

[0835] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1990) Cell 22:817-23) genes which can be employed in tk.sup.- or aprt.sup.-cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et al. (1995) Methods Mol. Biol. 55:121-131).

[0836] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding a polypeptide is inserted within a marker gene sequence, recombinant cells containing sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a polypeptide-encoding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[0837] Alternatively, host cells that contain and express a desired polynucleotide sequence may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include, for example, membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

[0838] A variety of protocols for detecting and measuring the expression of polynucleotide-encoded products, using either polyclonal or monoclonal antibodies specific for the product are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on a given polypeptide may be preferred for some applications, but a competitive binding assay rhay also be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul. Minn.) and Maddox, D. E. et al. (1983; J. Exp. Med. 158:1211-1216).

[0839] A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits. Suitable reporter molecules or labels, which may be used include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[0840] Host cells transformed with a polynucleotide sequence of interest may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides of the invention may be designed to contain signal sequences which direct secretion of the encoded polypeptide through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding a polypeptide of interest to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen. San Diego, Calif.) between the purification domain and the encoded polypeptide may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a polypeptide of interest and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography) as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3:263-281) while the enterokinase cleavage site provides a means for purifying the desired polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D. J. et al. (1993; DNA Cell Biol. 12:441-453).

[0841] In addition to recombinant production methods, polypeptides of the invention, and fragments thereof, may be produced by direct peptide synthesis using solid-phase techniques (Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Alternatively, various fragments may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

[0842] Antibody Compositions, Fragments Thereof and Other Binding Agents

[0843] According to another aspect, the present invention further provides binding agents, such as antibodies and antigen-binding fragments thereof, that exhibit immunological binding to a tumor polypeptide disclosed herein, or to a portion, variant or derivative thereof. An antibody, or antigen-binding fragment thereof, is said to “specifically bind,” “imriunogically bind,” and/or is “immunologically reactive” to a polypeptide of the invention if it reacts at a detectable level (within, for example, an ELISA assay) with the polypeptide, and does not react detectably with unrelated polypeptides under similar conditions.

[0844] Immunological binding, as used in this context, generally refers to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (K_(d)) of the interaction, wherein a smaller Kd represents a greater affinity. Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen-binding site/antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and on geometric parameters that equally influence the rate in both directions. Thus, both the “on rate constant” (K_(on)) and the “off rate constant” (K_(off)) can be determined by calculation of the concentrations and the actual rates of association and dissociation. The ratio of K_(off)/K_(on) enables cancellation of all parameters not related to affinity, and is thus equal to the dissociation constant K_(d). See, generally, Davies et al. (1990) Annual Rev. Biochem. 59:439-473.

[0845] An “antigen-binding site,” or “binding portion” of an antibody refers to the part of the immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues of the N-terminal variable (“V”) regions of the heavy (“H”) and light (“L”) chains. Three highly divergent stretches within the V regions of the heavy and light chains are referred to as “hypervariable regions” which are interposed between more conserved flanking stretches known as “framework regions,” or “FRs”. Thus the term “FR” refers to amino acid sequences which are naturally found between and adjacent to hypervariable regions in immunoglobulins. In an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as “complementarity-determining regions,” or “CDRs.”

[0846] Binding agents may be further capable of differentiating between patients with and without a cancer, such as lung cancer, using the representative assays provided herein. For example, antibodies or other binding agents that bind to a tumor protein will preferably generate a signal indicating the presence of a cancer in at least about 20% of patients with the disease, more preferably at least about 30% of patients. Alternatively, or in addition, the antibody will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without the cancer. To determine whether a binding agent satisfies this requirement, biological samples (e.g., blood, sera, sputum, urine and/or tumor biopsies) from patients with and without a cancer (as determined using standard clinical tests) may be assayed as described herein for the presence of polypeptides that bind to the binding agent. Preferably, a statistically significant number of samples with and without the disease will be assayed. Each binding agent should satisfy the above criteria; however, those of ordinary skill in the art will recognize that binding agents may be used in combination to improve sensitivity.

[0847] Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome, with or without a peptide component, an RNA molecule or a polypeptide. In a preferred embodiment, a binding agent is an antibody or an antigen-binding fragment thereof. Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In general, antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

[0848] Monoclonal antibodies specific for an antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

[0849] Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

[0850] A number of therapeutically useful molecules are known in the art which comprise antigen-binding sites that are capable of exhibiting immunological binding properties of an antibody molecule. The proteolytic enzyme papain preferentially cleaves IgG molecules to yield several fragments, two of which (the “F(ab)” fragments) each comprise a covalent heterodimer that includes an intact antigen-binding site. The enzyme pepsin is able to cleave IgG molecules to provide several fragments, including the “F(ab′)₂” fragment which comprises both antigen-binding sites. An “Fv” fragment can be produced by preferential proteolytic cleavage of an IgM, and on rare occasions IgG or IgA immunoglobulin molecule. Fv fragments are, however, more commonly derived using recombinant techniques known in the art. The Fv fragment includes a non-covalent V_(H)::V_(L) heterodimer including an antigen-binding site which retains much of the antigen recognition and binding capabilities of the native antibody molecule. Inbar et al. (1972) Proc. Nat. Acad. Sci. USA 69:2659-2662; Hochman et al. (1976) Biochem 15:2706-2710; and Ehrlich et al. (1980) Biochem 19:4091-4096.

[0851] A single chain Fv (“sFv”) polypeptide is a covalently linked V_(H)::V_(L) heterodimer which is expressed from a gene fusion including V_(H)- and V_(L)-encoding genes linked by a peptide-encoding linker. Huston et al. (1988) Proc. Nat. Acad. Sci. USA 85(16):5879-5883. A number of methods have been described to discern chemical structures for converting the naturally aggregated—but chemically separated—light and heavy polypeptide chains from an antibody V region into an sFv molecule which will fold into a three dimensional structure substantially similar to the structure of an antigen-binding site. See, e.g., U.S. Pat. Nos. 5,091,513 and 5,132,405, to Huston et al.; and U.S. Pat. No. 4,946,778, to Ladner et al.

[0852] Each of the above-described molecules includes a heavy chain and a light chain CDR set, respectively interposed between a heavy chain and a light chain FR set which provide support to the CDRS and define the spatial relationship of the CDRs relative to each other. As used herein, the term “CDR set” refers to the three hypervariable regions of a heavy or light chain V region. Proceeding from the N-terminus of a heavy or light chain, these regions are denoted as “CDR1,” “CDR2,” and “CDR3” respectively. An antigen-binding site, therefore, includes six CDRs, comprising the CDR set from each of a heavy and a light chain V region. A polypeptide comprising a single CDR, (e.g., a CDR1, CDR2 or CDR3) is referred to herein as a “molecular recognition unit.” Crystallographic analysis of a number of antigen-antibody complexes has demonstrated that the amino acid residues of CDRs form extensive contact with bound antigen, wherein the most extensive antigen contact is with the heavy chain CDR3. Thus, the molecular recognition units are primarily responsible for the specificity of an antigen-binding site.

[0853] As used herein, the term “FR set” refers to the four flanking amino acid sequences which frame the CDRs of a CDR set of a heavy or light chain V region. Some FR residues may contact bound antigen; however, FRs are primarily responsible for folding the V region into the antigen-binding site, particularly the FR residues directly adjacent to the CDRS. Within FRs, certain amino residues and certain structural features are very highly conserved. In this regard, all V region sequences contain an internal disulfide loop of around 90 amino acid residues. When the V regions fold into a binding-site, the CDRs are displayed as projecting loop motifs which form an antigen-binding surface. It is generally recognized that there are conserved structural regions of FRs which influence the folded shape of the CDR loops into certain “canonical” structures—regardless of the precise CDR amino acid sequence. Further, certain FR residues are known to participate in non-covalent interdomain contacts which stabilize the interaction of the antibody heavy and light chains.

[0854] A number of “humanized” antibody molecules comprising an antigen-binding site derived from a non-human immunoglobulin have been described, including chimeric antibodies having rodent V regions and their associated CDRs fused to human constant domains (Winter et al. (1991) Nature 349:293-299; Lobuglio et al. (1989) Proc. Nat Acad. Sci. USA 86:4220-4224; Shaw et al. (1987) J. Immunol. 138:4534-4538; and Brown et al. (1987) Cancer Res. 47:3577-3583), rodent CDRs grafted into a human supporting FR prior to fusion with an appropriate human antibody constant domain (Riechmann et al. (1988) Nature 332:323-327; Verhoeyen et al. (1988) Science 239:1534-1536; and Jones et al. (1986) Nature 321:522-525), and rodent CDRs supported by recombinantly veneered rodent FRs (European Patent Publication No. 519,596, published Dec. 23,1992). These “humanized” molecules are designed to minimize unwanted immunological response toward rodent antihuman antibody molecules which limits the duration and effectiveness of therapeutic applications of those moieties in human recipients.

[0855] As used herein, the terms “veneered FRs” and “recombinantly veneered FRs” refer to the selective replacement of FR residues from, e.g., a rodent heavy or light chain V region, with human FR residues in order to provide a xenogeneic molecule comprising an antigen-binding site which retains substantially all of the native FR polypeptide folding structure. Veneering techniques are based on the understanding that the ligand binding characteristics of an antigen-binding site are determined primarily by the structure and relative disposition of the heavy and light chain CDR sets within the antigen-binding surface. Davies et al. (1990) Ann. Rev. Biochem. 59:439-473. Thus, antigen binding specificity can be preserved in a humanized antibody only wherein the CDR structures, their interaction with each other, and their interaction with the rest of the V region domains are carefully maintained. By using veneering techniques, exterior (e.g., solvent-accessible) FR residues which are readily encountered by the immune system are selectively replaced with human residues to provide a hybrid molecule that comprises either a weakly immunogenic, or substantially non-immunogenic veneered surface.

[0856] The process of veneering makes use of the available sequence data for human antibody variable domains compiled by Kabat et al., in Sequences of Proteins of Immunological Interest, 4th ed., (U.S. Dept. of Health and Human Services, U.S. Government Printing Office, 1987), updates to the Kabat database, and other accessible U.S. and foreign databases (both nucleic acid and protein). Solvent accessibilities of V region amino acids can be deduced from the known three-dimensional structure for human and murine antibody fragments. There are two general steps in veneering a murine antigen-binding site. Initially, the FRs of the variable domains of an antibody molecule of interest are compared with corresponding FR sequences of human variable domains obtained from the above-identified sources. The most homologous human V regions are then compared residue by residue to corresponding murine amino acids. The residues in the murine FR which differ from the human counterpart are replaced by the residues present in the human moiety using recombinant techniques well known in the art. Residue switching is only carried out with moieties which are at least partially exposed (solvent accessible), and care is exercised in the replacement of amino acid residues which may have a significant effect on the tertiary structure of V region domains, such as proline, glycine and charged amino acids.

[0857] In this manner, the resultant “veneered” murine antigen-binding sites are thus designed to retain the murine CDR residues, the residues substantially adjacent to the CDRs, the residues identified as buried or mostly buried (solvent inaccessible), the residues believed to participate in non-covalent (e.g., electrostatic and hydrophobic) contacts between heavy and light chain domains, and the residues from conserved structural regions of the FRs which are believed to influence the “canonical” tertiary structures of the CDR loops. These design criteria are then used to prepare recombinant nucleotide sequences which combine the CDRs of both the heavy and light chain of a murine antigen-binding site into human-appearing FRs that can be used to transfect mammalian cells for the expression of recombinant human antibodies which exhibit the antigen specificity of the murine antibody molecule.

[0858] In another embodiment of the invention, monoclonal antibodies of the present invention may be coupled to one or more therapeutic agents. Suitable agents in this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ⁹⁰Y, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, and ²¹²Bi. Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin, Shigella toxin, and pokeweed antiviral protein.

[0859] A therapeutic agent may be coupled (e.g., covalently bonded) to a suitable monoclonal antibody either directly or indirectly (e.g., via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (e.g., a halide) on the other.

[0860] Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

[0861] It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, Ill.), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, e.g., U.S. Pat. No. 4,671,958, to Rodwell et al.

[0862] Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (e.g., U.S. Pat. No. 4,489,710, to Spitler), by irradiation of a photolabile bond (e.g., U.S. Pat. No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (e.g., U.S. Pat. No. 4,638,045, to Kohn et al.), by serum complement-mediated hydrolysis (e.g., U.S. Pat. No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (e.g., U.S. Pat. No. 4,569,789, to Blattler et al.).

[0863] It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers that provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

[0864] A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (e.g., U.S. Pat. No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (e.g., U.S. Pat. No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (e.g., U.S. Pat. Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Pat. No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U.S. Pat. No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

[0865] T Cell Compositions

[0866] The present invention, in another aspect, provides T cells specific for a tumor polypeptide disclosed herein, or for a variant or derivative thereof. Such cells may generally be prepared in vitro or ex vivo, using standard procedures. For example, T cells may be isolated from bone marrow, peripheral blood, or a fraction of bone marrow or peripheral blood of a patient, using a commercially available cell separation system, such as the Isolex™ System, available from Nexell Therapeutics, Inc. (Irvine, Calif.; see also U.S. Pat. No. 5,240,856; U.S. Pat. No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). Alternatively, T cells may be derived from related or unrelated humans, non-human mammals, cell lines or cultures.

[0867] T cells may be stimulated with a polypeptide, polynucleotide encoding a polypeptide and/or an antigen presenting cell (APC) that expresses such a polypeptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the polypeptide of interest. Preferably, a tumor polypeptide or polynucleotide of the invention is present within a delivery vehicle, such as a microsphere, to facilitate the generation of specific T cells.

[0868] T cells are considered to be specific for a polypeptide of the present invention if the T cells specifically proliferate, secrete cytokines or kill target cells coated with the polypeptide or expressing a gene encoding the polypeptide. T cell specificity may be evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen et al., Cancer Res. 54:1065-1070, 1994. Alternatively, detection of the proliferation of T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (e.g., by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Contact with a tumor polypeptide (100 ng/ml-100 μg/ml, preferably 200 ng/ml-25 μg/ml) for 3-7 days will typically result in at least a two fold increase in proliferation of the T cells. Contact as described above for 2-3 hours should result in activation of the T cells, as measured using standard cytokine assays in which a two fold increase in the level of cytokine release (e.g., TNF or IFN-γ) is indicative of T cell activation (see Coligan et al., Current Protocols in Immunology, vol. 1, Wiley Interscience (Greene 1998)). T cells that have been activated in response to a tumor polypeptide, polynucleotide or polypeptide-expressing APC may be CD4⁺ and/or CD8⁺. Tumor polypeptide-specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient, a related donor or an unrelated donor, and are administered to the patient following stimulation and expansion.

[0869] For therapeutic purposes, CD4⁺ or CD8⁺ T cells that proliferate in response to a tumor polypeptide, polynucleotide or APC can be expanded in number either in vitro or in vivo. Proliferation of such T cells in vitro may be accomplished in a variety of ways. For example, the T cells can be re-exposed to a tumor polypeptide, or a short peptide corresponding to an immunogenic portion of such a polypeptide, with or without the addition of T cell growth factors, such as interleukin-2, and/or stimulator cells that synthesize a tumor polypeptide. Alternatively, one or more T cells that proliferate in the presence of the tumor polypeptide can be expanded in number by cloning. Methods for cloning cells are well known in the art, and include limiting dilution.

[0870] T Cell Receptor Compositions

[0871] The T cell receptor (TCR) consists of 2 different, highly variable polypeptide chains, termed the T-cell receptor α and β chains, that are linked by a disulfide bond (Janeway, Travers, Walport. Immunobiology. Fourth Ed., 148-159. Elsevier Science Ltd/Garland Publishing. 1999). The α/β heterodimer complexes with the invariant CD3 chains at the cell membrane. This complex recognizes specific antigenic peptides bound to MHC molecules. The enormous diversity of TCR specificities is generated much like immunoglobulin diversity, through somatic gene rearrangement. The β chain genes contain over 50 variable (V), 2 diversity (D), over 10 joining (J) segments, and 2 constant region segments (C). The α chain genes contain over 70 V segments, and over 60 J segments but no D segments, as well as one C segment. During T cell development in the thymus, the D to J gene rearrangement of the β chain occurs, followed by the V gene segment rearrangement to the DJ. This functional VDJβ exon is transcribed and spliced to join to a Cβ. For the α chain, a Vα gene segment rearranges to a Jα gene segment to create the functional exon that is then transcribed and spliced to the Cα. Diversity is further increased during the recombination process by the random addition of P and N-nucleotides between the V, D, and J segments of the b chain and between the V and J segments in the α chain (Janeway, Travers, Walport. Immunobiology. Fourth Ed., 98 and 150. Elsevier Science Ltd/Garland Publishing. 1999).

[0872] The present invention, in another aspect, provides TCRs specific for a polypeptide disclosed herein, or for a variant or derivative thereof. In accordance with the present invention, polynucleotide and amino acid sequences are provided for the V-J or V-D-J junctional regions or parts thereof for the alpha and beta chains of the T-cell receptor which recognize tumor polypeptides described herein. In general, this aspect of the invention relates to T-cell receptors which recognize or bind tumor polypeptides presented in the context of MHC. In a preferred embodiment the tumor antigens recognized by the T-cell receptors comprise a polypeptide of the present invention. For example, cDNA encoding a TCR specific for a lung tumor peptide can be isolated from T cells specific for a tumor polypeptide using standard molecular biological and recombinant DNA techniques.

[0873] This invention further includes the T-cell receptors or analogs thereof having substantially the same function or activity as the T-cell receptors of this invention which recognize or bind tumor polypeptides. Such receptors include, but are not limited to, a fragment of the receptor, or a substitution, addition or deletion mutant of a T-cell receptor provided herein. This invention also encompasses polypeptides or peptides that are substantially homologous to the T-cell receptors provided herein or that retain substantially the same activity. The term “analog” includes any protein or polypeptide having an amino acid residue sequence substantially identical to the T-cell receptors provided herein in which one or more residues, preferably no more than 5 residues, more preferably no more than 25 residues have been conservatively substituted with a functionally similar residue and which displays the functional aspects of the T-cell receptor as described herein.

[0874] The present invention further provides for suitable mammalian host cells, for example, non-specific T-cells, that are transfected with a polynucleotide encoding TCRs specific for a polypeptide described herein, thereby rendering the host cell specific for the polypeptide. The α and β chains of the TCR may be contained on separate expression vectors or alternatively, on a single expression vector that also contains an internal ribosome entry site (IRES) for cap-independent translation of the gene downstream of the IRES. Said host cells expressing TCRs specific for the polypeptide may be used, for example, for adoptive immunotherapy of lung cancer as discussed further below.

[0875] In further aspects of the present invention, cloned TCRs specific for a polypeptide recited herein may be used in a kit for the diagnosis of lung cancer. For example, the nucleic acid sequence or portions thereof, of tumor-specific TCRs can be used as probes or primers for the detection of expression of the rearranged genes encoding the specific TCR in a biological sample. Therefore, the present invention further provides for an assay for detecting messenger RNA or DNA encoding the TCR specific for a polypeptide.

[0876] Pharmaceutical Compositions

[0877] In additional embodiments, the present invention concerns formulation of one or more of the polynucleotide, polypeptide, T-cell, TCR, and/or antibody compositions disclosed herein in pharmaceutically-acceptable carriers for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy.

[0878] It will be understood that, if desired, a composition as disclosed herein may be administered in combination with other agents as well, such as, e.g., other proteins or polypeptides or various pharmaceutically-active agents. In fact, there is virtually no limit to other components that may also be included, given that the additional agents do not cause a significant adverse effect upon contact with the target cells or host tissues. The compositions may thus be delivered along with various other agents as required in the particular instance. Such compositions may be purified from host cells or other biological sources, or alternatively may be chemically synthesized as described herein. Likewise, such compositions may further comprise substituted or derivatized RNA or DNA compositions.

[0879] Therefore, in another aspect of the present invention, pharmaceutical compositions are provided comprising one or more of the polynucleotide, polypeptide, antibody, TCR, and/or T-cell compositions described herein in combination with a physiologically acceptable carrier. In certain preferred embodiments, the pharmaceutical compositions of the invention comprise immunogenic polynucleotide and/or polypeptide compositions of the invention for use in prophylactic and theraputic vaccine applications. Vaccine preparation is generally described in, for example, M. F. Powell and M. J. Newman, eds., “Vaccine Design (the subunit and adjuvant approach),” Plenum Press (NY, 1995). Generally, such compositions will comprise one or more polynucleotide and/or polypeptide compositions of the present invention in combination with one or more immunostimulants.

[0880] It will be apparent that any of the pharmaceutical compositions described herein can contain pharmaceutically acceptable salts of the polynucleotides and polypeptides of the invention. Such salts can be prepared, for example, from pharmaceutically acceptable non-toxic bases, including organic bases (e.g., salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases (e.g., sodium, potassium, lithium, ammonium, calcium and magnesium salts).

[0881] In another embodiment, illustrative immunogenic compositions, e.g., vaccine compositions, of the present invention comprise DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated in situ. As noted above, the polynucleotide may be administered within any of a variety of delivery systems known to those of ordinary skill in the art. Indeed, numerous gene delivery techniques are well known in the art, such as those described by Rolland, Crit. Rev. Therap. Drug Carrier Systems 15:143-198, 1998, and references cited therein. Appropriate polynucleotide expression systems will, of course, contain the necessary regulatory DNA regulatory sequences for expression in a patient (such as a suitable promoter and terminating signal). Alternatively, bacterial delivery systems may involve the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope.

[0882] Therefore, in certain embodiments, polynucleotides encoding immunogenic polypeptides described herein are introduced into suitable mammalian host cells for expression using any of a number of known viral-based systems. In one illustrative embodiment, retroviruses provide a convenient and effective platform for gene delivery systems. A selected nucleotide sequence encoding a polypeptide of the present invention can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to a subject. A number of illustrative retroviral systems have been described (e.g., U.S. Pat. No. 5,219,740; Miller and Rosman (1989) BioTechniques 7:980-990; Miller, A. D. (1990) Human Gene Therapy 1:5-14; Scarpa et al. (1991) Virology 180:849-852; Burns et al. (1993) Proc. Natl. Acad. Sci. USA 90:8033-8037; and Boris-Lawrie and Temin (1993) Cur. Opin. Genet. Develop. 3:102-109.

[0883] In addition, a number of illustrative adenovirus-based systems have also been described. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj-Ahmad and Graham (1986) J. Virol. 57:267-274; Bett et al. (1993) J. Virol. 67:5911-5921; Mittereder et al. (1994) Human Gene Therapy 5:717-729; Seth et al. (1994) J. Virol. 68:933-940; Barr et al. (1994) Gene Therapy 1:51-58; Berkner, K. L. (1988) BioTechniques 6:616-629; and Rich et al. (1993) Human Gene Therapy 4:461-476).

[0884] Various adeno-associated virus (AAV) vector systems have also been developed for polynucleotide delivery. AAV vectors can be readily constructed using techniques well known in the art. See, e.g., U.S. Pat. Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92/01070 and WO 93/03769; Lebkowski et al. (1988) Molec. Cell. Biol. 8:3988-3996; Vincent et al. (1990) Vaccines 90 (Cold Spring Harbor Laboratory Press); Carter, B. J. (1992) Current Opinion in Biotechnology 3:533-539; Muzyczka, N. (1992) Current Topics in Microbiol. and Immunol. 158:97-129; Kotin, R. M. (1994) Human Gene Therapy 5:793-801; Shelling and Smith (1994) Gene Therapy 1:165-169; and Zhou et al. (1994) J. Exp. Med. 179:1867-1875.

[0885] Additional viral vectors useful for delivering the polynucleotides encoding polypeptides of the present invention by gene transfer include those derived from the pox family of viruses, such as vaccinia virus and avian poxyirus. By way of example, vaccinia virus recombinants expressing the novel molecules can be constructed as follows. The DNA encoding a polypeptide is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is then used to transfect cells which are simultaneously infected with vaccinia. Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the polypeptide of interest into the viral genome. The resulting TK.sup.(−) recombinant can be selected by culturing the cells in the presence of 5-bromodeoxyuridine and picking viral plaques resistant thereto.

[0886] A vaccinia-based infection/transfection system can be conveniently used to provide for inducible, transient expression or coexpression of one or more polypeptides described herein in host cells of an organism. In this particular system, cells are first infected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the polynucleotide or polynucleotides of interest, driven by a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into polypeptide by the host translational machinery. The method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation products. See, e.g., Elroy-Stein and Moss, Proc. Natl. Acad. Sci. USA 87:6743-6747 (1990); Fuerst et al., Proc. Natl. Acad. Sci. USA 83:8122-8126 (1986).

[0887] Alternatively, avipoxyiruses, such as the fowlpox and canarypox viruses, can also be used to deliver the coding sequences of interest. Recombinant avipox viruses, expressing immunogens from mammalian pathogens, are known to confer protective immunity when administered to non-avian species. The use of an Avipox vector is particularly desirable in human and other mammalian species since members of the Avipox genus can only productively replicate in susceptible avian species and therefore are not infective in mammalian cells. Methods for producing recombinant Avipoxyiruses are known in the art and employ genetic recombination, as described above with respect to the production of vaccinia viruses. See, e.g., WO 91/12882; WO 89/03429; and WO 92/03545.

[0888] Any of a number of alphavirus vectors can also be used for delivery of polynucleotide compositions of the present invention, such as those vectors described in U.S. Pat. Nos. 5,843,723; 6,015,686; 6,008,035 and 6,015,694. Certain vectors based on Venezuelan Equine Encephalitis (VEE) can also be used, illustrative examples of which can be found in U.S. Pat. Nos. 5,505,947 and 5,643,576.

[0889] Moreover, molecular conjugate vectors, such as the adenovirus chimeric vectors described in Michael et al. J. Biol. Chem. 268:6866-6869 (1993) and Wagner et al., Proc. Natl. Acad. Sci. USA 89:6099-6103 (1992), can also be used for gene delivery under the invention.

[0890] Additional illustrative information on these and other known viral-based delivery systems can be found, for example, in Fisher-Hoch et al., Proc. Natl. Acad. Sci. USA 86:317-321, 1989; Flexner et al., Ann. N.Y. Acad. Sci. 569:86-103,1989; Flexner et al., Vaccine 8:17-21, 1990; U.S. Pat. Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Pat. No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, Biotechniques 6:616-627,1988; Rosenfeld et al., Science 252:431-434,1991; Kolls et al., Proc. Natl. Acad. Sci. USA 91:215-219,1994; Kass-Eisler et al., Proc. Natl. Acad. Sci. USA 90:11498-11502,1993; Guzman et al., Circulation 88:2838-2848,1993; and Guzman et al., Cir. Res. 73:1202-1207, 1993.

[0891] In certain embodiments, a polynucleotide may be integrated into the genome of a target cell. This integration may be in the specific location and orientation via homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation). In yet further embodiments, the polynucleotide may be stably maintained in the cell as a separate, episomal segment of DNA. Such polynucleotide segments or “episomes” encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle. The manner in which the expression construct is delivered to a cell and where in the cell the polynucleotide remains is dependent on the type of expression construct employed.

[0892] In another embodiment of the invention,a polynucleotide is administered/delivered as “naked” DNA, for example as described in Ulmer et al., Science 259:1745-1749, 1993 and reviewed by Cohen, Science 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.

[0893] In still another embodiment, a composition of the present invention can be delivered via a particle bombardment approach, many of which have been described. In one illustrative example, gas-driven particle acceleration can be achieved with devices such as those manufactured by Powderject Pharmaceuticals PLC (Oxford, UK) and Powderject Vaccines Inc. (Madison, Wis.), some examples of which are described in U.S. Pat. Nos. 5,846,796; 6,010,478; 5,865,796; 5,584,807; and EP Patent No. 0500 799. This approach offers a needle-free delivery approach wherein a dry powder formulation of microscopic particles, such as polynucleotide or polypeptide particles, are accelerated to high speed within a helium gas jet generated by a hand held device, propelling the particles into a target tissue of interest.

[0894] In a related embodiment, other devices and methods that may be useful for gas-driven needle-less injection of compositions of the present invention include those provided by Bioject, Inc. (Portland, Oreg.), some examples of which are described in U.S. Pat. Nos. 4,790,824; 5,064,413; 5,312,335; 5,383,851; 5,399,163; 5,520,639 and 5,993,412.

[0895] According to another embodiment, the pharmaceutical compositions described herein will comprise one or more immunostimulants in addition to the immunogenic polynucleotide, polypeptide, antibody, T-cell, TCR, and/or APC compositions of this invention. An immunostimulant refers to essentially any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. One preferred type of immunostimulant comprises an adjuvant. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis derived proteins. Certain adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.); AS-2 (SmithKline Beecham, Philadelphia, Pa.); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

[0896] Within certain embodiments of the invention, the adjuvant composition is preferably one that induces an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (e.g., IFN-γ, TNFα, IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following application of a vaccine as provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, Ann. Rev. Immunol. 7:145-173, 1989.

[0897] Certain preferred adjuvants for eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A, together with an aluminum salt. MPL® adjuvants are available from Corixa Corporation (Seattle, Wash.; see, for example, U.S. Pat. Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Pat. Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example, by Sato et al., Science 273:352, 1996. Another preferred adjuvant comprises a saponin, such as Quil A, or derivatives thereof, including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, MA); Escin; Digitonin; or Gypsophila or Chenopodium quinoa saponins. Other preferred formulations include more than one saponin in the adjuvant combinations of the present invention, for example combinations of at least two of the following group comprising QS21, QS7, Quil A, β-escin, or digitonin.

[0898] Alternatively the saponin formulations may be combined with vaccine vehicles composed of chitosan or other polycationic polymers, polylactide and polylactide-co-glycolide particles, poly-N-acetyl glucosamine-based polymer matrix, particles composed of polysaccharides or chemically modified polysaccharides, liposomes and lipid-based particles, particles composed of glycerol monoesters, etc. The saponins may also be formulated in the presence of cholesterol to form particulate structures such as liposomes or ISCOMs. Furthermore, the saponins may be formulated together with a polyoxyethylene ether or ester, in either a non-particulate solution or suspension, or in a particulate structure such as a paucilamelar liposome or ISCOM. The saponins may also be formulated with excipients such as Carbopol^(R) to increase viscosity, or may be formulated in a dry powder form with a powder excipient such as lactose.

[0899] In one preferred embodiment, the adjuvant system includes the combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPL® adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations comprise an oil-in-water emulsion and tocopherol. Another particularly preferred adjuvant formulation employing QS21, 3D-MPL® adjuyant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

[0900] Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of CpG and QS21 is disclosed in WO 00/09159. Preferably the formulation additionally comprises an oil in water emulsion and tocopherol.

[0901] Additional illustrative adjuvants for use in the pharmaceutical compositions of the invention include Montamide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), Detox (Enhanzyn®) (Corixa, Hamilton, Mont.), RC-529 (Corixa, Hamilton, Mont.) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. patent application Ser. Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene ether adjuvants such as those described in WO 99/52549A1.

[0902] Other preferred adjuvants include adjuvant molecules of the general formula

HO(CH₂CH₂O)_(n)-A-R,  (I):

[0903] wherein, n is 1-50, A is a bond or —C(O)—, R is C₁₋₅₀ alkyl or Phenyl C₁₋₅₀ alkyl.

[0904] One embodiment of the present invention consists of a vaccine formulation comprising a polyoxyethylene ether of general formula (I), wherein n is between 1 and 50, preferably 4-24, most preferably 9; the R component is C₁₋₅₀, preferably C₄-C₂₀ alkyl and most preferably C₁₋₂ alkyl, and A is a bond. The concentration of the polyoxyethylene ethers should be in the range 0.1-20%, preferably from 0.1-10%, and most preferably in the range 0.1-1%. Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether, polyoxyethylene-9-steoryl ether, polyoxyethylene-8-steoryl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether. Polyoxyethylene ethers such as polyoxyethylene lauryl ether are described in the Merck index (12^(th) edition: entry 7717). These adjuvant molecules are described in WO 99/52549.

[0905] The polyoxyethylene ether according to the general formula (I) above may, if desired, be combined with another adjuvant. For example, a preferred adjuvant combination is preferably with CpG as described in the pending UK patent application GB 9820956.2.

[0906] According to another embodiment of this invention, an immunogenic composition described herein is delivered to a host via antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-tumor effects per se and/or to be immunologically compatible with the receiver (i.e., matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

[0907] Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, Nature 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (see Timmerman and Levy, Ann. Rev. Med. 50:507-529, 1999). In general, dendritic cells may be identified based on their typical shape (stellate in situ, with marked cytoplasmic processes (dendrites) visible in vitro), their ability to take up, process and present antigens with high efficiency and their ability to activate naive T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells in vivo or ex vivo, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (see Zitvogel et al., Nature Med. 4:594-600,1998).

[0908] Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated ex vivo by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNFα to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNFα, CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

[0909] Dendritic cells are conveniently categorized as “immature” and “mature” cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fcy receptor and mannose receptor. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (e.g., CD54 and CD11) and costimulatory molecules (e.g., CD40, CD80, CD86 and 4-1BB).

[0910] APCs may generally be transfected with a polynucleotide of the invention (or portion or other variant thereof) such that the encoded polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place ex vivo, and a pharmaceutical composition comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be administered to a patient, resulting in transfection that occurs in vivo. In vivo and ex vivo transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., Immunology and cell Biology 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the tumor polypeptide, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (e.g., vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (e.g., a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

[0911] While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will typically vary depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, mucosal, intravenous, intracranial, intraperitoneal, subcutaneous and intramuscular administration.

[0912] Carriers for use within such pharmaceutical compositions are biocompatible, and may also be biodegradable. In certain embodiments, the formulation preferably provides a relatively constant level of active component release. In other embodiments, however, a more rapid rate of release immediately upon administration may be desired. The formulation of such compositions is well within the level of ordinary skill in the art using known techniques. Illustrative carriers useful in this regard include microparticles of poly(lactide-co-glycolide), polyacrylate, latex, starch, cellulose, dextran and the like. Other illustrative delayed-release carriers include supramolecular biovectors, which comprise a non-liquid hydrophilic core (e.g., a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer comprising an amphiphilic compound, such as a phospholipid (see e.g., U.S. Pat. No. 5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

[0913] In another illustrative embodiment, biodegradable microspheres (e.g., polylactate polyglycolate) are employed as carriers for the compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Pat. Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763; 5,814,344, 5,407,609 and 5,942,252. Modified hepatitis B core protein carrier systems. such as described in WO/99 40934, and references cited therein, will also be useful for many applications. Another illustrative carrier/delivery system employs a carrier comprising particulate-protein complexes, such as those described in U.S. Pat. No. 5,928,647, which are capable of inducing a class I-restricted cytotoxic T lymphocyte responses in a host.

[0914] In another illustrative embodiment, calcium phosphate core particles are employed as carriers, vaccine adjuvants, or as controlled release matrices for the compositions of this invention. Exemplary calcium phosphate particles are disclosed, for example, in published patent application No. WO/0046147.

[0915] The pharmaceutical compositions of the invention will often further comprise one or more buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate.

[0916] The pharmaceutical compositions described herein may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are typically sealed in such a way to preserve the sterility and stability of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

[0917] The development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including e.g., oral, parenteral, intravenous, intranasal, and intramuscular administration and formulation, is well known in the art, some of which are briefly discussed below for general purposes of illustration.

[0918] In certain applications, the pharmaceutical compositions disclosed herein may be delivered via oral administration to an animal. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.

[0919] The active compounds may even be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (see, for example, Mathiowitz et al., Nature Mar. 27, 1997;386(6623):410-4; Hwang et al., Crit Rev Ther Drug Carrier Syst 1998;15(3):243-84; U.S. Pat. No. 5,641,515; U.S. Pat. No. 5,580,579 and U.S. Pat. No. 5,792,451). Tablets, troches, pills, capsules and the like may also contain any of a variety of additional components, for example, a binder, such as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations.

[0920] Typically, these formulations will contain at least about 0. 1% of the active compound or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

[0921] For oral administration the compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, oral spray, or sublingual orally-administered formulation. Alternatively, the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically-effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants. Alternatively the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.

[0922] In certain circumstances it will be desirable to deliver the pharmaceutical compositions disclosed herein parenterally, intravenously, intramuscularly, or even intraperitoneally. Such approaches are well known to the skilled artisan, some of which are further described, for example, in U.S. Pat. No. 5,543,158; U.S. Pat. No. 5,641,515 and U.S. Pat. No. 5,399,363. In certain embodiments, solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations generally will contain a preservative to prevent the growth of microorganisms.

[0923] Illustrative pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (for example, see U.S. Pat. No. 5,466,468). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and/or by the use of surfactants. The prevention of the action of microorganisms can be facilitated by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0924] In one embodiment, for parenteral administration in an aqueous solution, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. Moreover, for human administration, preparations will of course preferably meet sterility, pyrogenicity, and the general safety and purity standards as required by FDA Office of Biologics standards.

[0925] In another embodiment of the invention, the compositions disclosed herein may be formulated in a neutral or salt form. Illustrative pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.

[0926] The carriers can further comprise any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. The phrase “pharmaceutically-acceptable” refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.

[0927] In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering genes, nucleic acids, and peptide compositions directly to the lungs via nasal aerosol sprays has been described, e.g., in U.S. Pat. No. 5,756,353 and U.S. Pat. No. 5,804,212. Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga et al., J Controlled Release Mar. 2, 1998;52(1-2):81-7) and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725,871) are also well-known in the pharmaceutical arts. Likewise, illustrative transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Pat. No. 5,780,045.

[0928] In certain embodiments, liposomes, nanocapsules, microparticles, lipid particles, vesicles, and the like, are used for the introduction of the compositions of the present invention into suitable host cells/organisms. In particular, the compositions of the present invention may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like. Alternatively, compositions of the present invention can be bound, either covalently or non-covalently, to the surface of such carrier vehicles.

[0929] The formation and use of liposome and liposome-like preparations as potential drug carriers is generally known to those of skill in the art (see for example, Lasic, Trends Biotechnol 1998 July;16(7):307-21; Takakura, Nippon Rinsho 1998 March;56(3):691-5; Chandran et al., Indian J Exp Biol. 1997 August;35(8):801-9; Margalit, Crit Rev Ther Drug Carrier Syst. 1995;12(2-3):233-61; U.S. Pat. No. 5,567,434; U.S. Pat. No. 5,552,157; U.S. Pat. No. 5,565,213; U.S. Pat. No. 5,738,868 and U.S. Pat. No. 5,795,587, each specifically incorporated herein by reference in its entirety).

[0930] Liposomes have been used successfully with a number of cell types that are normally difficult to transfect by other procedures, including T cell suspensions, primary hepatocyte cultures and PC 12 cells (Renneisen et al., J. Biol. Chem. Sep. 25, 1990;265(27):16337-42; Muller et al., DNA Cell Biol. 1990 April;9(3):221-9). In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce genes, various drugs, radiotherapeutic agents, enzymes, viruses, transcription factors, allosteric effectors and the like, into a variety of cultured cell lines and animals. Furthermore, he use of liposomes does not appear to be associated with autoimmune responses or unacceptable toxicity after systemic delivery.

[0931] In certain embodiments, liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs).

[0932] Alternatively, in other embodiments, the invention provides for pharmaceutically-acceptable nanocapsule formulations of the compositions of the present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way (see, for example, Quintanar-Guerrero et al., Drug Dev Ind Pharm. 1998 Dec;24(12):1113-28). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μm) may be designed using polymers able to be degraded in vivo. Such particles can be made as described, for example, by Couvreur et al., Crit Rev Ther Drug Carrier Syst. 1988;5(1):1-20; zur Muhlen et al., Eur J Pharm Biopharm. 1998 March;45(2):149-55; Zambaux et al. J Controlled Release. Jan. 2, 1998;50(1-3):31-40; and U.S. Pat. No. 5,145,684.

[0933] Cancer Therapeutic Methods

[0934] Immunologic approaches to cancer therapy are based on the recognition that cancer cells can often evade the body's defenses against aberrant or foreign cells and molecules, and that these defenses might be therapeutically stimulated to regain the lost ground, e.g., pgs. 623-648 in Klein, Immunology (Wiley-Interscience, New York, 1982). Numerous recent observations that various immune effectors can directly or indirectly inhibit growth of tumors has led to renewed interest in this approach to cancer therapy, e.g., Jager, et al., Oncology 2001;60(1):1-7; Renner, et al., Ann Hematol 2000 Dec;79(12):651-9.

[0935] Four-basic cell types whose function has been associated with antitumor cell immunity and the elimination of tumor cells from the body are: i) B-lymphocytes which secrete immunoglobulins into the blood plasma for identifying and labeling the nonself invader cells; ii) monocytes which secrete the complement proteins that are responsible for lysing and processing the immunoglobulin-coated target invader cells; iii) natural killer lymphocytes having two mechanisms for the destruction of tumor cells, antibody-dependent cellular cytotoxicity and natural killing; and iv) T-lymphocytes possessing antigen-specific receptors and having the capacity to recognize a tumor cell carrying complementary marker molecules (Schreiber, H., 1989, in Fundamental Immunology (ed). W. E. Paul, pp. 923-955).

[0936] Cancer immunotherapy generally focuses on inducing humoral immune responses, cellular immune responses, or both. Moreover, it is well established that induction of CD4⁺ T helper cells is necessary in order to secondarily induce either antibodies or cytotoxic CD8⁺ T cells. Polypeptide antigens that are selective or ideally specific for cancer cells, particularly lung cancer cells, offer a powerful approach for inducing immune responses against lung cancer, and are an important aspect of the present invention.

[0937] Therefore, in further aspects of the present invention, the pharmaceutical compositions described herein may be used to stimulate an immune response against cancer, particularly for the immunotherapy of lung cancer. Within such methods, the pharmaceutical compositions described herein are administered to a patient, typically a warm-blooded animal, preferably a human. A patient may or may not be afflicted with cancer. Pharmaceutical compositions and vaccines may be administered either prior to or following surgical removal of primary tumors and/or treatment such as administration of radiotherapy or conventional chemotherapeutic drugs. As discussed above, administration of the pharmaceutical compositions may be by any suitable method, including administration by intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal, intradermal, anal, vaginal, topical and oral routes.

[0938] Within certain embodiments, immunotherapy may be active immunotherapy, in which treatment relies on the in vivo stimulation of the endogenous host immune system to react against tumors with the administration of immune response-modifying agents (such as polypeptides and polynucleotides as provided herein).

[0939] Within other embodiments, immunotherapy may be passive immunotherapy, in which treatment involves the delivery of agents with established tumor-immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate antitumor effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T cells as discussed above, T lymphocytes (such as CD8⁺ cytotoxic T lymphocytes and CD4⁺ T-helper tumor-infiltrating lymphocytes), killer cells (such as Natural Killer cells and lymphokine-activated killer cells), B cells and antigen-presenting cells (such as dendritic cells and macrophages) expressing a polypeptide provided herein. T cell receptors and antibody receptors specific for the polypeptides recited herein may be cloned, expressed and transferred into other vectors or effector cells for adoptive immunotherapy. The polypeptides provided herein may also be used to generate antibodies or anti-idiotypic antibodies (as described above and in U.S. Pat. No. 4,918,164) for passive immunotherapy.

[0940] Monoclonal antibodies may be labeled with any of a variety of labels for desired selective usages in detection, diagnostic assays or therapeutic applications (as described in U.S. Pat. Nos. 6,090,365; 6,015,542; 5,843,398; 5,595,721; and 4,708,930, hereby incorporated by reference in their entirety as if each was incorporated individually). In each case, the binding of the labelled monoclonal antibody to the determinant site of the antigen will signal detection or delivery of a particular therapeutic agent to the antigenic determinant on the non-normal cell. A further object of this invention is to provide the specific monoclonal antibody suitably labelled for achieving such desired selective usages thereof.

[0941] Effector cells may generally be obtained in sufficient quantities for adoptive immunotherapy by growth in vitro, as described herein. Culture conditions for expanding single antigen-specific effector cells to several billion in number with retention of antigen recognition in vivo are well known in the art. Such in vitro culture conditions typically use intermittent stimulation with antigen, often in the presence of cytokines (such as IL-2) and non-dividing feeder cells. As noted above, immunoreactive polypeptides as provided herein may be used to rapidly expand antigen-specific T cell cultures in order to generate a sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage, monocyte, fibroblast and/or B cells, may be pulsed with immunoreactive polypeptides or transfected with one or more polynucleotides using standard techniques well known in the art. For example, antigen-presenting cells can be transfected with a polynucleotide having a promoter appropriate for increasing expression in a recombinant virus or other expression system. Cultured effector cells for use in therapy must be able to grow and distribute widely, and to survive long term in vivo. Studies have shown that cultured effector cells can be induced to grow in vivo and to survive long term in substantial numbers by repeated stimulation with antigen supplemented with IL-2 (see, for example, Cheever et al., Immunological Reviews 157:177,1997).

[0942] Alternatively, a vector expressing a polypeptide recited herein may be introduced into antigen presenting cells taken from a patient and clonally propagated ex vivo for transplant back into the same patient. Transfected cells may be reintroduced into the patient using any means known in the art, preferably in sterile form by intravenous, intracavitary, intraperitoneal or intratumor administration.

[0943] Routes and frequency of administration of the therapeutic compositions described herein, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Preferably, between 1 and 10 doses may be administered over a 52 week period. Preferably, 6 doses are administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response, and is at least 10-50% above the basal (i.e., untreated) level. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells in vitro. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (e.g., more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 25 μg to 5 mg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

[0944] In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (e.g., more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. Increases in preexisting immune responses to a tumor protein generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which may be performed using samples obtained from a patient before and after treatment.

[0945] Cancer Detection and Diagnostic Compositions, Methods and Kits

[0946] In general, a cancer may be detected in a patient based on the presence of one or more lung tumor proteins and/or polynucleotides encoding such proteins in a biological sample (for example, blood, sera, sputum urine and/or tumor biopsies) obtained from the patient. In other words, such proteins may be used as markers to indicate the presence or absence of a cancer such as lung cancer. In addition, such proteins may be useful for the detection of other cancers. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the biological sample.

[0947] Polynucleotide primers and probes may be used to detect the level of mRNA encoding a tumor protein, which is also indicative of the presence or absence of a cancer. In general, a tumor sequence should be present at a level that is at least two-fold, preferably three-fold, and more preferably five-fold or higher in tumor tissue than in normal tissue of the same type from which the tumor arose. Expression levels of a particular tumor sequence in tissue types different from that in which the tumor arose are irrelevant in certain diagnostic embodiments since the presence of tumor cells can be confirmed by observation of predetermined differential expression levels, e.g., 2-fold, 5-fold, etc, in tumor tissue to expression levels in normal tissue of the same type.

[0948] Other differential expression patterns can be utilized advantageously for diagnostic purposes. For example, in one aspect of the invention, overexpression of a tumor sequence in tumor tissue and normal tissue of the same type, but not in other normal tissue types, e.g., PBMCs, can be exploited diagnostically. In this case, the presence of metastatic tumor cells, for example in a sample taken from the circulation or some other tissue site different from that in which the tumor arose, can be identified and/or confirmed by detecting expression of the tumor sequence in the sample, for example using RT-PCR analysis. In many instances, it will be desired to enrich for tumor cells in the sample of interest, e.g., PBMCs, using cell capture or other like techniques.

[0949] There are a variety of assay formats known to those of ordinary skill in the art for using a binding agent to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In general, the presence or absence of a cancer in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined cut-off value.

[0950] In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such assays include full length lung tumor proteins and polypeptide portions thereof to which the binding agent binds, as described above.

[0951] The solid support may be any material known to those of ordinary skill in the art to which the tumor protein may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Pat. No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term “immobilization” refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 μg, and preferably about 100 ng to about 1 μg, is sufficient to immobilize an adequate amount of binding agent.

[0952] Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

[0953] In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a detection reagent (preferably a second antibody capable of binding to a different site on the polypeptide) containing a reporter group is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

[0954] More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20™ (Sigma Chemical Co., St. Louis, Mo.). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (i.e., incubation time) is a period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with lung least about 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

[0955] Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. The second antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include those groups recited above.

[0956] The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

[0957] To determine the presence or absence of a cancer, such as lung cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value for the detection of a cancer is the average mean signal obtained when the immobilized antibody is incubated with samples from patients without the cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for the cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology. A Basic Science for Clinical Medicine, Little Brown and Co., 1985, p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (i.e., the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for a cancer.

[0958] In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the binding agent is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized binding agent as the sample passes through the membrane. A second, labeled binding agent then binds to the binding agent-polypeptide complex as a solution containing the second binding agent flows through the membrane. The detection of bound second binding agent may then be performed as described above. In the strip test format, one end of the membrane to which binding agent is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second binding agent and to the area of immobilized binding agent. Concentration of second binding agent at the area of immobilized antibody indicates the presence of a cancer. Typically, the concentration of second binding agent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of binding agent immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferred binding agents for use in such assays are antibodies and antigen-binding fragments thereof. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 μg, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

[0959] Of course, numerous other assay protocols exist that are suitable for use with the tumor proteins or binding agents of the present invention. The above descriptions are intended to be exemplary only. For example, it will be apparent to those of ordinary skill in the art that the above protocols may be readily modified to use tumor polypeptides to detect antibodies that bind to such polypeptides in a biological sample. The detection of such tumor protein specific antibodies may correlate with the presence of a cancer.

[0960] A cancer may also, or alternatively, be detected based on the presence of T cells that specifically react with a tumor protein in a biological sample. Within certain methods, a biological sample comprising CD4⁺ and/or CD8⁺ T cells isolated from a patient is incubated with a tumor polypeptide, a polynucleotide encoding such a polypeptide and/or an APC that expresses at least an immunogenic portion of such a polypeptide, and the presence or absence of specific activation of the T cells is detected. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated in vitro for 2-9 days (typically 4 days) at 37° C. with polypeptide (e.g., 5-25 μg/ml). It may be desirable to incubate another aliquot of a T cell sample in the absence of tumor polypeptide to serve as a control. For CD4⁺ T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8⁺ T cells, activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a cancer in the patient.

[0961] As noted above, a cancer may also, or alternatively, be detected based on the level of mRNA encoding a tumor protein in a biological sample. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify a portion of a tumor cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for (i.e., hybridizes to) a polynucleotide encoding the tumor protein. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis.

[0962] Similarly, oligonucleotide probes that specifically hybridize to a polynucleotide encoding a tumor protein may be used in a hybridization assay to detect the presence of polynucleotide encoding the tumor protein in a biological sample.

[0963] To permit hybridization under assay conditions, oligonucleotide primers and probes should comprise an oligonucleotide sequence that has at least about 60%, preferably at least about 75% and more preferably at least about 90%, identity to a portion of a polynucleotide encoding a tumor protein of the invention that is at least 10 nucleotides, and preferably at least 20 nucleotides, in length. Preferably, oligonucleotide primers and/or probes hybridize to a polynucleotide encoding a polypeptide described herein under moderately stringent conditions, as defined above. Oligonucleotide primers and/or probes which may be usefully employed in the diagnostic methods described herein preferably are at least 10-40 nucleotides in length. In a preferred embodiment, the oligonucleotide primers comprise at least 10 contiguous nucleotides, more preferably at least 15 contiguous nucleotides, of a DNA molecule having a sequence as disclosed herein. Techniques for both PCR based assays and hybridization assays are well known in the art (see, for example, Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51:263, 1987; Erlich ed., PCR Technology, Stockton Press, NY, 1989).

[0964] One preferred assay employs RT-PCR, in which PCR is applied in conjunction with reverse transcription. Typically, RNA is extracted from a biological sample, such as biopsy tissue, and is reverse transcribed to produce cDNA molecules. PCR amplification using at least one specific primer generates a cDNA molecule, which may be separated and visualized using, for example, gel electrophoresis. Amplification may be performed on biological samples taken from a test patient and from an individual who is not afflicted with a cancer. The amplification reaction may be performed on several dilutions of cDNA spanning two orders of magnitude. A two-fold or greater increase in expression in several dilutions of the test patient sample as compared to the same dilutions of the non-cancerous sample is typically considered positive.

[0965] In another aspect of the present invention, cell capture technologies may be used in conjunction, with, for example, real-time PCR to provide a more sensitive tool for detection of metastatic cells expressing lung tumor antigens. Detection of lung cancer cells in biological samples, e.g., bone marrow samples, peripheral blood, and small needle aspiration samples is desirable for diagnosis and prognosis in lung cancer patients.

[0966] Immunomagnetic beads coated with specific monoclonal antibodies to surface cell markers, or tetrameric antibody complexes, may be used to first enrich or positively select cancer cells in a sample. Various commercially available kits may be used, including Dynabeads® Epithelial Enrich (Dynal Biotech, Oslo, Norway), StemSep™ (StemCell Technologies, Inc., Vancouver, BC), and RosetteSep (StemCell Technologies). A skilled artisan will recognize that other methodologies and kits may also be used to enrich or positively select desired cell populations. Dynabeads® Epithelial Enrich contains magnetic beads coated with mAbs specific for two glycoprotein membrane antigens expressed on normal and neoplastic epithelial tissues. The coated beads may be added to a sample and the sample then applied to a magnet, thereby capturing the cells bound to the beads. The unwanted cells are washed away and the magnetically isolated cells eluted from the beads and used in further analyses.

[0967] RosetteSep can be used to enrich cells directly from a blood sample and consists of a cocktail of tetrameric antibodies that targets a variety of unwanted cells and crosslinks them to glycophorin A on red blood cells (RBC) present in the sample, forming rosettes. When centrifuged over Ficoll, targeted cells pellet along with the free RBC. The combination of antibodies in the depletion cocktail determines which cells will be removed and consequently which cells will be recovered. Antibodies that are available include, but are not limited to: CD2, CD3, CD4, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD24, CD25, CD29, CD33, CD34, CD36, CD38, CD41, CD45, CD45RA, CD45RO, CD56, CD66B, CD66e, HLA-DR, IgE, and TCRαβ.

[0968] Additionally, it is contemplated in the present invention that mAbs specific for lung tumor antigens can be generated and used in a similar manner. For example, mAbs that bind to tumor-specific cell surface antigens may be conjugated to magnetic beads, or formulated in a tetrameric antibody complex, and used to enrich or positively select metastatic lung tumor cells from a sample. Once a sample is enriched or positively selected, cells may be lysed and RNA isolated. RNA may then be subjected to RT-PCR analysis using lung tumor-specific primers in a real-time PCR assay as described herein. One skilled in the art will recognize that enriched or selected populations of cells may be analyzed by other methods (e.g., in situ hybridization or flow cytometry).

[0969] In another embodiment, the compositions described herein may be used as markers for the progression of cancer. In this embodiment, assays as described above for the diagnosis of a cancer may be performed over time, and the change in the level of reactive polypeptide(s) or polynucleotide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, a cancer is progressing in those patients in whom the level of polypeptide or polynucleotide detected increases over time. In contrast, the cancer is not progressing when the level of reactive polypeptide or polynucleotide either remains constant or decreases with time.

[0970] Certain in vivo diagnostic assays may be performed directly on a tumor. One such assay involves contacting tumor cells with a binding agent. The bound binding agent may then be detected directly or indirectly via a reporter group. Such binding agents may also be used in histological applications. Alternatively, polynucleotide probes may be used within such applications.

[0971] As noted above, to improve sensitivity, multiple tumor protein markers may be assayed within a given sample. It will be apparent that binding agents specific for different proteins provided herein may be combined within a single assay. Further, multiple primers or probes may be used concurrently. The selection of tumor protein markers may be based on routine experiments to determine combinations that results in optimal sensitivity. In addition, or alternatively, assays for tumor proteins provided herein may be combined with assays for other known tumor antigens.

[0972] The present invention further provides kits for use within any of the above diagnostic methods. Such kits typically comprise two or more components necessary for performing a diagnostic assay. Components may be compounds, reagents, containers and/or equipment. For example, one container within a kit may contain a monoclonal antibody or fragment thereof that specifically binds to a tumor protein. Such antibodies or fragments may be provided attached to a support material, as described above. One or more additional containers may enclose elements, such as reagents or buffers, to be used in the assay. Such kits may also, or alternatively, contain a detection reagent as described above that contains a reporter group suitable for direct or indirect detection of antibody binding.

[0973] Alternatively, a kit may be designed to detect the level of mRNA encoding a tumor protein in a biological sample. Such kits generally comprise at least one oligonucleotide probe or primer, as described above, that hybridizes to a polynucleotide encoding a tumor protein. Such an oligonucleotide may be used, for example, within a PCR or hybridization assay. Additional components that may be present within such kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate the detection of a polynucleotide encoding a tumor protein.

[0974] The following Examples are offered by way of illustration and not by way of limitation.

EXAMPLE 1 Isolation of cDNA Sequences from Lung Adenocarcinoma Libraries Using PCR-Based cDNA Library Subtraction

[0975] This PCR-based subtraction method was utilized to generate a library enriched for transcripts expressed in small cell lung carcinoma. A cDNA library was constructed in the PCR2.1 vector (Invitrogen, Carlsbad, Calif.) by subtracting a pool of cDNA from the small cell lung carcinoma cell-line (659-43) with a pool of cDNA from the normal tissues of lung, brain, liver, kidney, pancreas, trachea, heart, pituitary gland and bone marrow and from the lung mesothelial cell cell-line using PCR subtraction methodologies (Clontech, Palo Alto, Calif.). The tester cDNA for the library was prepared from poly A+ RNA from the small cell lung carcinoma cell-line (659-43). The driver cDNA was prepared from a pool of poly A+ RNA from nine normal tissues which include lung, brain, liver, kidney, pancreas, trachea, heart, pituitary gland and bone marrow and from the lung mesothelial cell cell-line (659-43-2). The driver cDNA also included cDNA for highly redundant genes identified from the earlier subtracted libraries, SCL2, SCL3 and SCL4. The substraction for the construction of this library was carried out essentially as outlined by Clontech with a few modifications. The tester and driver were digested with a different set of restriction enzymes which were PvuII, StuI and DraI. The ratio of tester and driver cDNA used was 1:60 whereas the Clontech protocol recommends 1:40. Two tester populations were then created with different adapters, and the driver library remained without adapters.

[0976] The tester and driver libraries were then hybridized using excess driver cDNA. In the first hybridization step, the driver was separately hybridized with each of the two tester cDNA populations. This resulted in populations of (a) unhybridized tester cDNAs, (b) tester cDNAs hybridized to other tester cDNAs, (c) tester cDNAs hybridized to driver cDNAs, and (d) unhybridized driver cDNAs. The two separate hybridization reactions were then combined, and rehybridized in the presence of additional denatured driver cDNA. Following this second hybridization, in addition to populations (a) through (d), a fifth population (e) was generated in which tester cDNA with one adapter hybridized to tester cDNA with the second adapter. Accordingly, the second hybridization step resulted in enrichment of differentially expressed sequences which could be used as templates for PCR amplification with adaptor-specific primers.

[0977] The ends were then filled in, and PCR amplification was performed using adaptor-specific primers. Only population (e), which contained tester cDNA that did not hybridize to driver cDNA, was amplified exponentially. A second PCR amplification step was then performed, to reduce background and further enrich differentially expressed sequences.

[0978] This PCR-based subtraction technique normalizes differentially expressed cDNAs so that rare transcripts that are over-expressed in lung tumor tissue may be recoverable. Such transcripts would be difficult to recover by traditional subtraction methods.

[0979] The library constructed as provided above is referred to as SCL5. Clones derived from this library were sequenced to determine the identity of the inserts. Sequence identifers for the determined cDNA sequences for these clones are set forth in SEQ ID NOs:1-660 and are listed in the section entitled “BRIEF DESCRIPTION OF THE SEQUENCE INDENTIFIERS. The respective sequences are provided in the attached Sequence Listing. These clones are useful for lung cancer immunotherapy and/or diagnostics. The expression profile of these clones in lung tumors and in normal human tissues was analyzed by microarray analysis as described in Example 2.

EXAMPLE 2 Analysis of cDNA Expression Using Microarray Technology

[0980] In additional studies, clones from the SCL5 library were evaluated for overexpression in specific tumor tissues by microarray analysis. Using this approach, cDNA sequences are PCR amplified and their mRNA expression profiles in tumor and normal tissues are examined using cDNA microarray technology essentially as described (Shena et al., 1995). In brief, the clones are arrayed onto glass slides as multiple replicas, with each location corresponding to a unique cDNA clone (as many as 5500 clones can be arrayed on a single slide, or chip). Each chip is hybridized with a pair of cDNA probes that are fluorescence-labeled with Cy3 and Cy5, respectively. Typically, 1 μg of polyA⁺ RNA is used to generate each cDNA probe. After hybridization, the chips are scanned and the fluorescence intensity recorded for both Cy3 and Cy5 channels. There are multiple built-in quality control steps. First, the probe quality is monitored using a panel of ubiquitously expressed genes. Secondly, the control plate also can include yeast DNA fragments of which complementary RNA may be spiked into the probe synthesis for measuring the quality of the probe and the sensitivity of the analysis. Currently, the technology offers a sensitivity of 1 in 100,000 copies of mRNA. Finally, the reproducibility of this technology can be ensured by including duplicated control cDNA elements at different locations.

[0981] A total of 785 randomly picked clones were arrayed on Lung Chip 8. cDNA inserts for arraying were amplified by PCR using vector specific primers. The resulting PCR products were sequenced in one direction and the trimmed sequences determined. The arrays were probed with 35 probe pairs (normal tissues and lung tumor and normal-specific probes; see Table 2). Analysis was performed using CorixArray computational analysis. Analysis consists of determining the ratio of the mean hybridization signal for a particular element (cDNA) using two sets of probe groups. The ratio is a reflection of the over- or under-expression of the element (cDNA) within the probe population. Probe groups were set up to identify elements (cDNAs) with high differential expression in lung tumor probe group (Mean Signal 1) compared to normal tissue probe group (Mean Signal 2). A threshold for the ratio of over-expression between tumor probe group (Mean Signal 1) and normal tissue probe group (Mean Signal 2) was set at 2.0. This threshold was set based on experience to identify elements with over-expression that could be reproducibly detected. Further elimination of cDNA elements was carried out by applying two additional filters. The first filter eliminated cDNA elements, which had mean hybridization signal of >0.2 in the normal tissue probe group (Mean Signal 2). The second filter eliminated cDNA elements, which had mean hybridization signal of <0.1 in the lung tumor probe group (Mean Signal 1). The elements identified were compared to sequences in publicly available databases (huESTdb and GenBank). Summary of the cDNA elements from the sequences disclosed herein and identified by this analysis are presented in Tables 3 and 4. Those sequences having some degree of similarity with known sequences are described in Table 3, while highly unique sequences are described in Table 4. TABLE 2 Cy3 Probe Cy5 Probe Lung Adenocarcinoma T2 Tumor Heart Normal Lung Adenocarcinoma T3 Tumor Liver Normal Lung Adenocarcinoma T4 Tumor Lung N2 Normal (SCID) Lung Adenocarcinoma T5 Tumor Skeletal Muscle Normal Lung Adenocarcinoma T6 Tumor Spleen Normal Lung Adenocarcinoma T7 Tumor Stomach Normal Lung Adenocarcinoma T1 Tumor Lung N1 Normal Lung Adenocarcinoma T8 Tumor Lymph Node Normal Lung Adenocarcinoma T9 Tumor Salivary Gland Normal Lung Adenocarcinoma T1 Tumor Lung N1 Normal Lung Adenocarcinoma LPE Tumor Bladder Normal Large Cell Lung Carcinoma Tumor Bone Marrow Normal Lung Squamouscell Carcinoma T1 Tumor Bronchus Normal Lung Squamouscell Carcinoma T2 Tumor Esophagus Normal Lung Squamouscell Carcinoma T3 Tumor Kidney Normal Lung Squamouscell Carcinoma T4 Tumor Lung N3 Normal Lung Squamouscell Carcinoma T5 Tumor PBMC activated T cell Normal (SCID) Lung Squamouscell Carcinoma T6 Tumor PBMC activated B cell Normal (SCID) Lung Squamouscell Carcinoma T6 Tumor PBMC resting pool (SCID) Lung Squamouscell Carcinoma T7 Tumor Skin Pool Normal Lung Squamouscell Carcinoma T8 Tumor Colon Normal Lung Squamouscell Carcinoma T9 Tumor Tonsil Normal Lung Squamouscell Carcinoma T10 Tumor Trachea Normal Small Cell Lung Carcinoma T1 Tumor Lung N4 Normal Neuroendocrine Atypical Carcinoid Tumor Pituitary Gland Normal Mets Small Cell Lung Carcinoma - Cell line Tumor Adrenal Gland Normal 1 Small Cell Lung Carcinoma - Cell line Tumor Brain Normal 2 Small Cell Lung Carcinoma - Cell line Tumor Pancreas Normal 3 Small Cell Lung Carcinoma - Cell line Tumor Thyroid Gland Normal 4 Small Cell Lung Carcinoma - Cell line Tumor Lung Mesothelial Cell line Normal 5 Small Cell Lung Carcinoma - Pool Tumor Small Intestine Normal primary + cell lines Fetal Lung Normal Adult Lung Normal Testis Normal Ovary Normal Placenta Normal Thymus Normal

[0982] TABLE 3 Mean Signal 1/ Mean Signal Mean Signal Mean Signal 2 1 (Tumor 2 (Normal humanES SEQ ID # Clone ID # Ratio Group) Tissues) GenBank Match T < 1e − 25 1 61571741 3.76 0.155 0.041 cDNA: FLJ23386 fis (AK027039) 12 2 61571742 2.35 0.165 0.07 topoisomerase II alpha (TOP2A) 35 4 61571744 6.03 0.286 0.047 DEK oncogene (NM_003472) 75 7 61571747 3.19 0.177 0.055 KIAA1563 protein, partial cds 7 (AB046783) 11 61571753 3.16 0.223 0.07 cDNA FLJ12780 fis (AK022842) 7 12 61571754 3.69 0.14 0.038 calcium/calmodulin-dependent 20 serine protein kinase (CASK)(AF035582) 15 61571758 3.56 0.313 0.088 Chromosome 12q 13.1 101 (AC004801) 17 61571760 3.59 0.194 0.054 ALEX3 protein (NM_016607) 27 18 61571761 3.82 0.14 0.037 MTG8-like protein: MTGR1a 47 (AF069747); MTGR1b (AF013970) 20 61571763 4.35 0.118 0.027 deoxyguanosine kinase (U41668) 101 21 61571764 2.24 0.151 0.068 KDEL (Lys-Asp-Glu-Leu) 112 endoplasmic reticulum protein retention receptor 1 (NM_006801) 25 61571768 3.53 0.244 0.069 CDNA: FLJ23494 fis (AK027147) 8 26 61571770 3.17 0.197 0.062 chromosome 9p11-13.3 7 (AL135785) 30 61571774 4.91 0.158 0.032 divalent cation tolerant protein 33 (AF106943) 31 61571775 2.64 0.107 0.04 thymopoietin 33 33 61571778 4.66 0.137 0.029 tousled-like kinase 2 (TLK2) 33 (AF162667) 34 61571780 2.26 0.191 0.084 apobec-1 binding protein 1 65 (U76713) 36 61571782 34.23 0.135 0.004 DNA polymerase zeta catalytic 19 subunit (AF179429) 38 61571786 8.12 0.18 0.022 proliferating cell nuclear antigen 140 (PCNA) 41 61571789 2.83 0.123 0.043 protein phosphatase 1B 20 (NM_002706) 42 61571790 2.15 0.167 0.078 cDNA: FLJ21925 fis (AK025578) 17 46 61571795 2.3 0.104 0.045 thyroid hormone receptor- 9 associated protein complex TRAP170 (AF135802) 53 61571804 2.81 0.128 0.045 mRNA export protein (RAE1) 109 (U84720) 57 61571808 3.04 0.226 0.075 K1AA0878 protein (XM_004037) 40 59 61571811 2.35 0.195 0.083 cDNA: FLJ21925 fis (AK025578) 21 65 61571819 5.64 0.145 0.026 chromosome X (AL050310) 0 70 61571824 2.25 0.209 0.093 DKFZP434A043 protein 58 (XM_003112) 71 61571825 3.34 0.142 0.042 cDNA DKFZp434N2O72 70 (AL133580) 72 61571826 2.75 0.11 0.04 cyclin B (M25753) 42 73 61571827 3.93 0.133 0.034 KIAA0840 protein (AB020647) 53 74 61571828 10.56 0.111 0.01 dynamin 2 (NM_004945); nt1-85 30 75 61571829 3.29 0.165 0.05 chromosome 9p11-13.3 7 (AL135785) 77 61571831 2.26 0.155 0.068 phosphoglycerate dehydrogenase 143 79 61571833 2.08 0.187 0.09 clone H17 unknown mRNA 43 (AF103801) 83 61483101 14.06 0.114 0.008 chromosome 9 (AL161628) 1 85 61483103 21.35 0.192 0.009 Mus musculus neuronal 1 differentiation related protein (AB049460) 86 61483104 8.23 0.18 0.022 ubiquitin-conjugating enzyme E2 80 (AF160215) 87 61483107 3.51 0.112 0.032 divalent cation tolerant protein 33 CUTA 88 61483108 2.83 0.155 0.055 myosin regulatory light chain 16 interacting protein (NM_013262) 90 61483110 2.48 0.187 0.076 serine/threonine-protein kinase 19 PRP4 homolog (XM_004079) 92 61483112 8.1 0.23 0.028 trinucleotide repeat DNA binding 14 protein p20-CGGBP (AF094481) 94 61483114 2.08 0.109 0.052 DNA (cytosine-5)- 17 methyltransferase 1 (NM_001379) 96 61483116 2.82 0.136 0.048 DNA (cytosine-5)- 17 methyltransferase 1 (NM_001379) 97 61483117 9.45 0.132 0.014 GOP dissociation inhibitor 1 63 (NM_001493) 99 61483119 2.85 0.179 0.063 KIAA0372 gene product 54 (NM_014639) 102 61483122 4.44 0.11 0.025 Cdc7-related kinase 15 108 61483129 7.38 0.122 0.016 K1AA1477 protein (AB040910) 6 109 61483130 7.1 0.143 0.02 short stature homeobox 2 0 (SHOX2), transcript variant SHOX2a (NM)_006884); SHOX2b (NM_003030) 110 61483132 7.43 0.166 0.022 chromosome Xq28 (AF003626) 23 111 61483133 5.83 0.143 0.024 protein tyrosine phosphatase, 28 receptor type, U (NM_005704) 112 61483134 2.29 0.107 0.047 chromosome 9p11-13.3 7 (AL135785) 114 61483136 2.32 0.242 0.104 Bcl-2-interacting protein beclin 62 (AF077301) 116 61483138 10.26 0.18 0.018 KIAA0169 protein (D79991) 29 117 61483140 7.34 0.115 0.016 chromosome 9p11-13.3 7 (AL135785) 124 61483147 2 0.118 0.059 phosphomannomutase 1 72 (XM_010019) 126 61483150 11.13 0.109 0.01 G-substrate (AF097730) 9 127 61483151 10.63 0.101 0.01 chromosome 1q24.1-25.3 3 (AL355520) 131 61483155 5.15 0.116 0.022 TRAF4 associated factor 1 26 (U81002) 135 61483160 3.97 0.268 0.068 cyclin B2 75 136 61483161 3.7 0.148 0.04 KIAA1171 protein (AB032997) 18 138 61483164 2.63 0.121 0.046 hypothetical protein FLJ13222 19 (NM_021943) 140 61483167 6.43 0.123 0.019 corticotropin releasing hormone- 6 binding protein (NM_001882) 141 61483168 2.85 0.138 0.048 DNA (cytosine-5-)- 19 methyltransferase 1 (NM_001379) 144 61483172 2.58 0.179 0.069 microtuble-associated protein 1B 10 (NM_005909) 148 61483176 2.59 0.274 0.106 Hfb1 protein, 3'UTR (Y15167) 18 149 61483177 2.59 0.151 0.058 proliferating cell nuclear antigen 107 (PCNA) 151 61483179 2.45 0.268 0.109 cDNA DKFZp586L081 18 (AL080234) 152 61483180 2.26 0.147 0.065 phosphoribosyl phyrophosphate 1 synthetase 2 (NM_002765) 153 61483182 17.65 0.102 0.006 threonyl-tRNA synthetase 18 156 61483185 9.22 0.136 0.015 chromosome 9 (AL161628) 37 160 61483189 3.09 0.136 0.044 cDNA: FLJ22351 fis (AK026004) 5 161 61483190 27.29 0.112 0.004 calcium/calmodulin-dependent 66 serine protein kinase (CASK)(AF035582) 165 61594545 5.95 0.198 0.033 cDNA FLJ12947 fis (AK023009) 20 167 61594547 6.01 0.106 0.018 deoxyhypusine synthase 52 (U40579) 172 61594553 8.87 0.175 0.02 neurogenic differentiation 1 17 (NeuroD)(NM_002500) 177 61594558 2.07 0.18 0.087 beta-glucocorticoid receptor 0 (X03348, M11050) 179 61594560 3.15 0.165 0.052 chromosome 5 (AC010457) 65 184 61594565 2.39 0.137 0.057 KIAA0826 protein (AB020633) 46 191 61594574 2.59 0.139 0.054 topoisomerase-related function 13 protein 4 (NM_006999) 193 61594576 7.11 0.258 0.036 kinesin family member 4A 16 (KIF4A), (NM_012310) 196 61594579 3.22 0.409 0.127 nuclear autoantigenic sperm 13 protein (histone-binding); (NM_002482) 197 61594582 5.16 0.256 0.05 cDNA DKFZp761A07121 104 (AL161957) 199 61594583 3.47 0.167 0.048 U6 snRNA-associated Sm-like 12 protein LSm7 (AF182293) 200 61594584 2.9 0.373 0.129 PTD011 protein (NM_014051) 67 201 61594585 2.89 0.195 0.067 KIAA0826 protein (AB020633) 81 202 61594586 4.62 0.106 0.023 G-substrate (AF097730) 13 204 61594589 2.57 0.135 0.052 14-3-3 protein epsilon isoform 9 (U20972) 206 61594592 2.31 0.188 0.081 nucleolar protein hNop56 133 (Y12065) 210 61594596 2.39 0.161 0.067 cDNA: FLJ22044 fis (AK025697) 70 212 61594601 3.17 0.105 0.033 Chromosome 12q22 (AC007298) 16 214 61594604 2.45 0.293 0.12 uncharacterized bone marrow 3 protein BM036 (AF217512) 218 61594611 2.41 0.168 0.07 KIAA0038 (D26068) 5 226 61S94620 3.72 0.192 0.052 chromosome 9 (AL161628) 127 227 61594621 2.22 0.15 0.068 KIAA0850 protein (AB020657) 5 230 61594625 2.64 0.113 0.043 kappa opioid receptor (U11053) 21 236 61594632 3.78 0.13 0.034 NB thymosin beta 2 239 61571929 2.58 0.111 0.043 KIAA1499 protein (AB040932) 25 242 61571932 2.23 0.146 0.065 protein tyrosine phosphatase,18 receptor type, U (NM_005704) 249 61571941 6.78 0.141 0.021 microtuble-associated protein-2 28 (U32996) 251 61571943 4.16 0.154 0.037 cDNA: FLJ21971 fis (AK025624) 17 253 61571946 3.58 0.122 0.034 chromosome 20 (AL121752) 52 254 61571947 2.21 0.233 0.105 TRF1-interacting ankyrin-related 11 ADP-ribose polymerase (AF082557) 260 61571953 5.73 0.124 0.022 chromosome 9 (AL161628) 10 266 61571959 3.13 0.151 0.048 proliferating cell nuclear antigen 5 (PCNA) 275 61571973 4.9 0.198 0.04 spermatogenesis-related protein 62 kinase (AF237709) 281 61571980 4.52 0.524 0.116 coronin, actin-binding protein, 1C 18 (NM_014325) 282 61571981 2.73 0.13 0.048 cyclin-dependent kinase inhibitor 51 p18 283 61571982 2.49 0.172 0.069 corticotropin releasing hormone- 6 binding protein (NM_001882) 290 61571990 2.5 0.155 0.062 Chromosome 14 PAC 2 (AC005924) 292 61571993 3.16 0.17 0.054 calcium-binding transporter 42 (AF123303) 294 61571995 2.57 0.138 0.054 ectodermal dysplasia 1, anhidrotic 1 (NM_001399) 296 61571998 2.46 0.144 0.059 mRNA, cDNA DKFZp586F071 0 (AL050125) 301 61572005 2.57 0.122 0.047 cDNA: FLJ22770 fis (AK026423) 0 302 61572006 5.03 0.146 0.029 protein tyrosine phosphatase 14 (CIP2) (L25876) 307 61572011 3.73 0.158 0.042 tumor protein p53-binding protein, 24 2 (NM_005426) 310 61572018 3.26 0.196 0.06 Pr22 protein 4 322 61571845 20.68 0.105 0.005 cyclin E2 (CCNE2), (NM_004702) 17 329 61571853 2.34 0.112 0.048 heterogeneous nuclear 20 ribonucleoprotein complex K (S74678) 332 61571856 4.74 0.101 0.021 CDC28 protein kinase 1 (CKS1), 117 (NM_001826) 347 61571871 4.94 0.2 0.04 tetraspanin TM4-A (AF133423) 158 349 61571873 9.96 0.108 0.011 NB thymosin beta 137 353 61571877 5.63 0.121 0.021 full length insert cDNA clone 59 EUROIMAGE 1977056 (AL390087) 359 61571883 2.8 0.139 0.05 heterogeneous nuclear 18 ribonucleoprotein D 369 61571894 2.07 0.102 0.049 ribosomal protein L23-related 86 (U26596) 373 61571899 13.95 0.176 0.013 beta-tubulin 63 397 61571924 17.76 0.116 0.007 ubiquitin-conjugating enzyme E2 91 (AF160215) 398 61571925 180.25 0.139 0.001 nuclear autoantigenic sperm 80 protein (histone- binding)(NM_002482) 402 61594637 16.62 0.181 0.011 chromosome Xq28 (AF003626) 114 405 61594640 4.98 0.301 0.06 chaperonin protein 23 (Tcp20)(L27706) 406 61594641 2.04 0.103 0.05 ubiquitin-activating enzyme E1 181 (M58028) 407 61594644 5.71 0.171 0.03 Pr22 protein 99 422 61594659 5.73 0.127 0.022 MEMA protein (Y09703) 100 444 61594685 3.92 0.199 0.051 fat facets protein, 3' end 94 (AJ012078) 445 61594686 2.87 0.283 0.099 human homolog of SNF2/SW12 24 (M88163) 452 61594693 3.37 0.124 0.037 MEMA protein (Y09703) 17 458 61594702 4.88 0.108 0.022 cDNA DKFZp434M232 27 (AL137407) 461 61594706 2.15 0.146 0.068 clone 24607 mRNA (AF070546) 5 469 61594714 3.34 0.335 0.1 corticotropin releasing hormone- 7 binding protein (NM_001882) 472 61594717 9.56 0.104 0.011 clone HB-2 mRNA (AF216077) 20 485 61594730 5.13 0.107 0.021 cDNA FLJ11685 fis (AK021747) 27 488 61594733 3.06 0.379 0.124 chromosome 6p22.2-23 10 (AL022726) 493 61594738 3.24 0.191 0.059 neurogenic differentiation 1 88 (NeuroD) (NM_002500) 497 61594743 4.71 0.116 0.025 replication factor C (activator 1) 9 4(37kD) (RFC4); (NM_002916) 520 61594766 4.5 0.193 0.043 lamin B receptor (L25931) 23 525 61594771 2.15 0.118 0.055 nucleoporin 214kD (CAIN) 22 (NUP214), (NM_005085) 530 61594776 3.41 0.194 0.057 GAP-associated tyrosine 63 phosphoprotein p62 (NM_006559) 536 61594782 4.8 0.62 0.129 mRNA for HNSPC (D82346); 107 some homology to voltage gated potassium channel 540 61594786 2.88 0.104 0.036 B lymphocyte chemoattractant 10 BLC (AF044197) 541 61594787 22.23 0.103 0.005 mitogen-activated protein kinase 4 38 (NM_002747) 544 61594790 4.22 0.155 0.037 phenylalanyl-tRNA synthetase 3 546 61594792 3.34 0.123 0.037 Human transcription factor (SC1) 25 (U25826) 547 61594793 2.93 0.135 0.046 heterogeneous nuclear 35 ribonucleoprotein M 555 61594802 2.83 0.188 0.066 mRNA for Fanconi anemia group 51 G (AJ007669) 562 61594809 4.64 0.139 0.03 rabkinesin6 (AF070672) 2 569 61594817 2.64 0.173 0.065 cDNA FLJ20647 fis, (AK000654) 2 583 61823965 2.24 0.211 0.094 HIV TAT specific factor 1 60 (NM_014500) 586 61823968 21.53 0.165 0.008 clone 24463 mRNA (AF070559) 74 588 61823970 2 0.154 0.077 hypothetical protein FLJ20391 61 (NM_017798) 593 61823975 2.36 0.106 0.045 splicing factor (CC1.4) (L10911) 3 604 61823987 3.24 0.209 0.065 hypothetical protein FLJ10914 2 (XM_009611) 609 61823992 4.95 0.16 0.032 chromosome 9p11-13.3 87 616 61824000 3.48 0.485 0.139 ubiquitin-specific protease 1 19 (USP1) 617 61824001 11.59 0.181 0.016 MAD2 (XM_001854) 52 619 61824003 3.83 0.136 0.035 cDNA: FLJ2197 fis, (AK025624) 45 621 61824005 15.33 0.286 0.019 TTK protein kinase (NM_003318) 27 622 61824006 4.08 0.121 0.03 cDNA DKFZp564D173 44 (AL110212) 623 61824007 2.06 0.166 0.08 partial mRNA for Spir-1 protein 28 (AJ277587) 625 61824009 5.72 0.167 0.029 KIAA0419 gene product 43 (NM_014711) 629 61824013 7.64 0.172 0.023 hypothetical protein (HSPC111), 88 (NM_016391) 631 61824015 3.58 0.144 0.04 synaptobrevin-like 1 (SYBL1), 16 (NM_005638) 633 61824017 6.08 0.126 0.021 XAP5, a candidate disease gene 28 (AD001530) 634 61824018 1518.64 0.149 0 cDNA:FLJ21800 fis, (AK025453) 8 635 61824019 6.86 0.157 0.023 spermatogenesis-related protein 20 kinase (AF237709) 640 61824024 4.51 0.128 0.028 neurogenic differentiation 1 12 (NeuroD) (NM_002500) 641 61824025 29.98 0.103 0.003 TTK protein kinase (NM_003318) 44 644 61824028 5.79 0.128 0.022 retinoblastoma-associated protein 32 HEC (AF017790) 645 61824029 4.58 0.317 0.069 phosducin-like protein 14 (NM_005388) 646 61824030 2.28 0.129 0.057 neurogenic differentiation 1 4 (NeuroD) (NM_002500) 651 61824036 3.48 0.399 0.115 cDNA: FLJ21439 fis, (AK025092) 16 652 61824037 12.89 0.314 0.024 KIAA0056 gene (D29954) 13 653 61824038 10.53 0.364 0.035 Chromosome 12p (AC009318) 6 655 61824040 4.89 0.164 0.034 chromosome 6q24.1-25.2 99 656 61824041 3.2 0.167 0.052 thymopoietin 39 659 61824044 2.59 0.124 0.048 hypothetical protein (FLJ11127), 14 (NM_019018)

[0983] TABLE 4 Mean Signal 1/ Mean Signal Mean Signal Mean Signal 2 1 (Tumor 2 (Normal humanES SEQ ID # Clone ID # Ratio Group) Tissues) GenBank Match T < 1e − 25 3 61571743 2.94 0.127 0.043 Novel 0 29 61571773 3.46 0.231 0.067 Novel 2 52 61571803 4.15 0.11 0.027 Novel 1 55 61571806 3.94 0.111 0.028 Novel 17 104 61483124 6.95 0.127 0.018 Novel 8 107 61483127 2.39 0.221 0.092 Novel 56 118 61483141 5.19 0.141 0.027 Novel 36 120 61483143 11.27 0.138 0.012 Novel 148 122 61483145 2.74 0.151 0.055 Novel 9 123 61483146 2.92 0.115 0.039 Novel 13 125 61483148 3.81 0.104 0.027 Novel 10 130 61483154 8.09 0.127 0.016 Novel 6 143 61483170 3.49 0.237 0.068 Novel 2 154 61483183 2.85 0.247 0.087 Novel 30 168 61694549 2.36 0.332 0.14 Novel 69 217 61694609 2.85 0.134 0.047 Novel 122 237 61594634 18.48 0.111 0.006 Novel 73 238 61571928 3.29 0.466 0.141 Novel 3 247 61571939 10.78 0.1 0.009 Novel 28 250 61571942 3.07 0.108 0.035 Novel 10 252 61571944 2.63 0.162 0.062 Novel 27 259 61571952 3.49 0.171 0.049 Novel 57 267 61571963 2.32 0.295 0.127 Novel 53 285 61571985 4.42 0.136 0.031 Novel 5 295 61571997 3.19 0.132 0.041 Novel 3 300 61572004 2.83 0.112 0.039 Novel 0 316 61571839 5.53 0.154 0.028 Novel 160 374 61571900 2.29 0.286 0.125 Novel 112 441 61594681 3.79 0.275 0.072 Novel 27 467 61594712 3.5 0.118 0.034 Novel 59 495 61594741 5.77 0.1 0.017 Novel 12 560 61594807 2.5 0.103 0.041 Novel 66 591 61823973 8.04 0.107 0.013 Novel 98 596 61823979 6.04 0.111 0.018 Novel 48 615 61823999 5.63 0.102 0.018 Novel 4

EXAMPLE 3 Analysis of cDNA Expression Using Real-Time PCR

[0984] Three of the clones identified in Example 1 were analyzed for their expression profiles using Real Time PCR analysis. This assay allows for the quantification of mRNA specific for each of these three clones. Real Time analysis was performed using the following method. The first-strand cDNA used in the quantitative real-time PCR was synthesized from 20 μg of total RNA that was treated with DNase I (Amplification Grade, Gibco BRL Life Technology, Gaithersburg, Md.), using Superscript Reverse Transcriptase (RT) (Gibco BRL Life Technology, Gaithersburg, Md.). Real-time PCR was performed with a GeneAmp™ 5700 sequence detection system (PE Biosystems, Foster City, Calif.). The 5700 system uses SYBR™ green, a fluorescent dye that only intercalates into double stranded DNA, and a set of gene-specific forward and reverse primers. The increase in fluorescence was monitored during the whole amplification process. The optimal concentration of primers was determined using a checkerboard approach and a pool of cDNAs from lung tumors was used in this process. The PCR reaction was performed in 25 μl volumes that included 2.5 μl of SYBR green buffer, 2 μl of cDNA template and 2.5 μl each of the forward and reverse primers for the gene of interest. The cDNAs used for RT reactions were diluted 1:10 for each gene of interest and 1:100 for the β-actin control. In order to quantitate the amount of specific cDNA (and hence initial mRNA) in the sample, a standard curve was generated for each run using plasmid DNA containing the gene of interest. Standard curves were generated using the Ct values determined in the real-time PCR which were related to the initial cDNA concentration used in the assay. Standard dilution ranging from 20-2×10⁶ copies of the gene of interest was used for this purpose. In addition, a standard curve was generated for β-actin ranging from 200 fg-2000 fg. This enabled standardization of the initial RNA content of a tissue sample to the amount of β-actin for comparison purposes. The mean copy number for each group of tissues tested was normalized to a constant amount of β-actin, allowing the evaluation of the over-expression levels seen with each of the genes. Numerous tissues were tested for the presence of the sequences specific for the candidate lung tumor antigens. These included a variety of lung tumors and normal lung tissues, as well as normal brain, pituitary gland, adrenal gland, thyroid gland, pancreas, heart, liver, skeletal muscle, stomach, kidney, small intestine, colon, bladder, esophagus, skin, salivary gland, trachea, bone marrow, resting PBMC, spleen, lymph node, thymus, and spinal cord.

[0985] Lung tumor candidate L1477P (previously identified as Clone number 61594579, SEQ ID NO:196) was found to be highly over expressed in the majority of lung tumor samples analyzed, with no detectable expression in normal lung. Of the normal tissues tested, there was low-level expression in pituitary gland, stomach, colon, trachea, bone marrow and thymus with no detectable expression in the remaining tissues tested. The full-length cDNA and protein sequences specific for this gene are disclosed in SEQ ID NO: 661 and 664, respectively.

[0986] Lung tumor candidate L1478P (previously identified as Clone number 61594786, SEQ ID NO:540) was found to be highly over expressed in a variety of lung tumor samples tested, with no detectable expression in normal lung. Of the normal tissues tested, there was moderate to high levels of expression in pituitary gland, brain, and adrenal gland. The remaining tissues were all negative. The full-length cDNA and protein sequences specific for this gene are disclosed in SEQ ID NO: 662 and 665, respectively.

[0987] Lung tumor candidate L1479P (previously identified as Clone number 61824006, SEQ ID NO:622) was found to be highly over expressed in the majority of lung tumor samples tested, with no detectable expression in normal lung. Of the normal tissues tested, there was a lower level of expression in adrenal gland, liver, stomach, colon, esophagus, trachea, bane marrow, lymph node, and thymus. The remaining tissues were all negative. The full-length cDNA and protein sequences specific for this gene are disclosed in SEQ ID NO: 663 and 666, respectively.

EXAMPLE 4 Characterization of Lung Tumor Antigen Clone L1477P

[0988] Lung tumor candidate L1477P (previously identified as Clone number 61594579, SEQ ID NO:196) was found to be highly over expressed in the majority of lung tumor samples analyzed, with no detectable expression in normal lung (see Example 3 for details). The sequence for L1477P (the cDNA sequence of which is disclosed in SEQ ID NO:668) was serched against publicly available databases and was shown to have significant sequence identity with the human kinesin family member 4A (KIF4A) gene (the sequence of which is disclosed in SEQ ID NO:667). However, the protein sequence obtained from L1477P (disclosed in SEQ ID NO:670) differs from the published sequence of KIF4A (the sequence of which is disclosed in SEQ ID NO:670) at 9 amino acid positions. The amino acid changes between L1477P and KIF4A are at positions: 235 (G to R), 298 (A to V), 434 (W to L), 576 (P to L), 680 (R to K), 1034 (Q to P), 1089 (N to K), 1098 (C to Y), and 1150 (S to G).

EXAMPLE 5 Peptide Priming of T-Helper Lines

[0989] Generation of CD4⁺ T helper lines and identification of peptide epitopes derived from tumor-specific antigens that are capable of being recognized by CD4⁺ T cells in the context of HLA class II molecules, is carried out as follows:

[0990] Fifteen-mer peptides overlapping by 10 amino acids, derived from a tumor-specific antigen, are generated using standard procedures. Dendritic cells (DC) are derived from PBMC of a normal donor using GM-CSF and IL-4 by standard protocols. CD4⁺ T cells are generated from the same donor as the DC using MACS beads (Miltenyi Biotec, Auburn, Calif.) and negative selection. DC are pulsed overnight with pools of the 15-mer peptides, with each peptide at a final concentration of 0.25 μg/ml. Pulsed DC are washed and plated at 1×10⁴ cells/well of 96-well V-bottom plates and purified CD4⁺ T cells are added at 1×10⁵/well. Cultures are supplemented with 60 ng/ml IL-6 and 10 ng/ml IL-12 and incubated at 37° C. Cultures are restimulated as above on a weekly basis using DC generated and pulsed as above as antigen presenting cells, supplemented with 5 ng/ml IL-7 and 10 U/ml IL-2. Following 4 in vitro stimulation cycles, resulting CD4⁺ T cell lines (each line corresponding to one well) are tested for specific proliferation and cytokine production in response to the stimulating pools of peptide with an irrelevant pool of peptides used as a control.

EXAMPLE 6 Generation of Tumor-Specific CTL Lines Using In Vitro Whole-Gene Priming

[0991] Using in vitro whole-gene priming with tumor antigen-vaccinia infected DC (see, for example, Yee et al, The Journal of Immunology, 157(9):4079-86, 1996), human CTL lines are derived that specifically recognize autologous fibroblasts transduced with a specific tumor antigen, as determined by interferon-γ ELISPOT analysis. Specifically, dendritic cells (DC) are differentiated from monocyte cultures derived from PBMC of normal human donors by growing for five days in RPMI medium containing 10% human serum, 50 ng/ml human GM-CSF and 30 ng/ml human IL-4. Following culture, DC are infected overnight with tumor antigen-recombinant vaccinia virus at a multiplicity of infection (M.O.I.) of five, and matured overnight by the addition of 3 μg/ml CD40 ligand. Virus is then inactivated by UV irradiation. CD8+T cells are isolated using a magnetic bead system, and priming cultures are initiated using standard culture techniques. Cultures are restimulated every 7-10 days using autologous primary fibroblasts retrovirally transduced with previously identified tumor antigens. Following four stimulation cycles, CD8+T cell lines are identified that specifically produce interferon-γ when stimulated with tumor antigen-transduced autologous fibroblasts. Using a panel of HLA-mismatched B-LCL lines transduced with a vector expressing a tumor antigen, and measuring interferon-γ production by the CTL lines in an ELISPOT assay, the HLA restriction of the CTL lines is determined.

EXAMPLE 7 Generation and Characterization of Anti-Tumor Antigen Monoclonal Antibodies

[0992] Mouse monoclonal antibodies are raised against E. coli derived tumor antigen proteins as follows: Mice are immunized with Complete Freund's Adjuvant (CFA) containing 50 μg recombinant tumor protein, followed by a subsequent intraperitoneal boost with Incomplete Freund's Adjuvant (IFA) containing 10 μg recombinant protein. Three days prior to removal of the spleens, the mice are immunized intravenously with approximately 50 μg of soluble recombinant protein. The spleen of a mouse with a positive titer to the tumor antigen is removed, and a single-cell suspension made and used for fusion to SP2/O myeloma cells to generate B cell hybridomas. The supernatants from the hybrid clones are tested by ELISA for specificity to recombinant tumor protein, and epitope mapped using peptides that spanned the entire tumor protein sequence. The mAbs are also tested by flow cytometry for their ability to detect tumor protein on the surface of cells stably transfected with the cDNA encoding the tumor protein.

EXAMPLE 8 Synthesis of Polypeptides

[0993] Polypeptides are synthesized on a Perkin Elmer/Applied Biosystems Division 430A peptide synthesizer using FMOC chemistry with HPTU (O-Benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence is attached to the amino terminus of the peptide to provide a method of conjugation, binding to an immobilized surface, or labeling of the peptide. Cleavage of the peptides from the solid support is carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides are precipitated in cold methyl-t-butyl-ether. The peptide pellets are then dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of 0%-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) is used to elute the peptides. Following lyophilization of the pure fractions, the peptides are characterized using electrospray or other types of mass spectrometry and by amino acid analysis.

[0994] From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 670 <210> SEQ ID NO 1 <211> LENGTH: 523 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 1 aaaaatctgc tttattgtgg tggcttaata attcaactag tcaaaatccc tccccttggt 60 actgaggtgc tatggtagta tcaggcagac cacaactaaa gttatttggt tttgccataa 120 agaaatgcat aaatgtgctt cagcaggtaa gtggaagaaa atatcactac ctagaaatgc 180 cagtgtgaaa atcctttcta aaaagctggg ttcttaggct ttcaaaaaca attctgacaa 240 tcgataaaac accaccaagc cctacaagaa gaaaagtagg gcacaaaagc ctattttata 300 gataaccaaa gcaatgactg aaaacattaa aatattaaat aaagtttcta aaatagtggt 360 cacaaaagta aaaataaata ctgttttatg caaagacttt tttactccta cagcacatga 420 gacctcctta cgtactgtgc gccaatatgt gaagtgttcc acacaacagg gcacttgaga 480 ggaacaggtt tcggacatgg tgtctgaagt ccttagcaag cgg 523 <210> SEQ ID NO 2 <211> LENGTH: 336 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 2 caaaacttag taacaaaggt ctgacacgac acttttctgt ggtttcagtt ctttgttact 60 aagttttgga gaagttttgg tcttaggtgg actagcatct gatgggacaa aatcttcatc 120 atcagttttt tcatcaaaat ctgagaaatc ttcatctgaa tccaaatcca ttgtgaattt 180 tgtttttgtt gctgctctcc gtggctctgt ttctcgtgga gggacatcaa aattactttc 240 gtcactgctc ctatctgatt ctgaatcaga ccagggattt ctcttctttc cttttttgat 300 tggcttaaat gccaatgtag tttgtttctt tgtctt 336 <210> SEQ ID NO 3 <211> LENGTH: 211 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 3 gaacgctgcc tgaccctcaa ggctccattc tgggccctcc tcctccagga agacccccgg 60 gctatcccaa gacaggccat cagtcatgac tccttgggta ttgggccaga gtccagcctc 120 tgctgacagc agattggggc cagcccttgc tctcagccca gctaccaaga aagaaaagcg 180 gcccctggtg gccaggagct ggcggccaca g 211 <210> SEQ ID NO 4 <211> LENGTH: 386 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 4 aaaaatacaa aaataacatc tgtcactttt gtcatgctga caatttgaca tatatacaca 60 tgcaggagaa aagttccaat tcagtgatct ggacaactgt agcttgtata tttttaatat 120 gatggacaca ctgccgctga attttcacac tgacagagat gtgtattcaa aatatttcat 180 atactaaata ctacaatctc tgtatgtata aatcctggtg ataatagttt ttgttctact 240 tgattaaaag tatgccttaa gcaagctaat attaagtgca ctaaaaacca caacagctca 300 agaatctatg accttatata aagaaatcca aaatgtacaa aatacaacta taaaagcaag 360 gaacaattaa tgccatgcaa gatttt 386 <210> SEQ ID NO 5 <211> LENGTH: 568 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 5 aaaactgggt aggactagag acactgatct gcccaacctc tgggtattca caactgcaca 60 ggtaaccaga tcctgtacgc gaggcatcac cattaaacag atgagcatta gatgaggagg 120 acacattctg agtagttgca tgatttccca ttcagaggca ggtgctgccc tcatatcaga 180 aaagtagcag atcaatgatg ggatgggtgg agatggagat gatatggaaa tattcatgga 240 ggagatgaga gaaatcagaa gaaaacttag ggagctgcag ttgaggaatt gtctgcgtat 300 ccttatgggg gagctctcta atcaccatga ccatcatgat gaattttgcc ttatgccttg 360 actcctgcca tttatcatga gattaatact gtgattcccg ctgttttctt tttccttgca 420 ttttcctaat atgcctttac tgatccgttt gctgtgaacc ctatgttatt tccatgtgtc 480 aagtgggtct tgtgttgcca gcttctattt gaagattgcc tttgcactca gtgtaagttt 540 ctgtcagcag tagtttcacc catttgca 568 <210> SEQ ID NO 6 <211> LENGTH: 465 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 46, 179, 258, 270, 449 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 6 aaaactgggt aggactagag acactgatct gcccaacctc tgggtnttca caactgcaca 60 ggtaaccaga tcctgtacgc gaggcatcac cattaaacag atgagcatta gatgaggagg 120 acacattctg agtagttgca tgatttccca ttcagaggca ggtgctgccc tcatatcana 180 aaagtagcag atcaatgatg ggatgggtgg agatggagat gatatggaaa tattcatgga 240 ggagatgaga gaaatcanaa gaaaacttan ggagctgcag ttgaggaatt gtctgcgtat 300 ccttatgggg gagctctcta atcaccatga ccatcatgat gaattttgcc ttatgccttg 360 actcctgcca tttatcatga gattaatact gtgattcccg ctgttttctt tttccttgca 420 ttttcctaat atgcctttac tgatccgtnt gctgtgaacc ctatg 465 <210> SEQ ID NO 7 <211> LENGTH: 250 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 7 aaactgcagt tttaactttt tctaagctgt ttcttgatgg gagaggttct gtgcaaaact 60 accacattct gtccccaaaa tgtggaatgc atccaaatag gagtcttctg cctcttaact 120 taaaagaaca taggaatttt gtttttggtt tctttatcat gctacagaga gtgaatacac 180 tggaattcag acaccgactc tgagctgcta ggaacctcat ttgtccatgt gcaaacgctg 240 tattccaagg 250 <210> SEQ ID NO 8 <211> LENGTH: 459 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 8 aaaagacaaa aacaaaacaa aaataccaca gctcaagata aagagtccta tacagaaatc 60 acaaaaagga cagaccatct aaggaaaaat taaaaagacg acacaaggac aggctgggca 120 gcctgggtca gggctcctgg ctggtgacct gctttgagta ggtttcttgc aggtacttct 180 taaaagctgt ggggtttttc cagagctcgg cagcatgtgt gttcaaggga ctatcaatgt 240 tgggttctcc tagaaggctc tggatggaga gcagaatggt cctgacatca tacagggcag 300 accacttttc cttcaggatg tccaggcata tgttaccctg ggtgtccacg ttggggtgat 360 agcagggcgt gaggaacttc actgtgggcg cattgtaagg gtagccactg gggaactcta 420 gcgagagctt atacctcagg tcttcatata ctgttccag 459 <210> SEQ ID NO 9 <211> LENGTH: 598 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 575 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 9 ctgatgcagt ccgagagcta gatggaagaa cactatgtgg ctgccgtgta agagtggaac 60 tgtcgaatgg tgaaaaaaga agtagaaatc gtggcccacc tccctcttgg ggtcgtcgcc 120 ctcgagatga ttatcgtagg aggagtcctc cacctcgtcg cagatctcca agaaggagaa 180 gcttctctcg cagccggagc aggtcccttt ctagagatag gagaagagag agatcgctgt 240 ctcgggagag aaatcacaag ccgtcccgat ccttctctag gtctcgtagt cgatctaggt 300 caaatgaaag gaaatagaag acagtttgca agagaagtgg tgtacaggaa attacttcat 360 ttgacaggag tatgtacaga aaattcaagt tttgtttgag acttcataag cttggtgcat 420 ttttaagatg ttttagctgt tcaaatctgt ttgtctcttg aaacagtgac acaaaggtgt 480 aattctctat ggtttgaaat ggatcatacg aggcatgtaa taccaagaat tgttacttta 540 caatgttccc ttaagcaaaa ttgaatttgc tttgnacttt tagttatgca cagactga 598 <210> SEQ ID NO 10 <211> LENGTH: 254 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 10 aaagtacttt taagaaaaaa agcagggcct tggaagtttt ggttcttttt tcctcccctg 60 ttgcaaattc tcatggtttg ggttgggtgg tggagagcgc gtgtcatctg cgggtggcac 120 tgcccacggt gggcgggcgg gcctctctac tcgaaggtga ccacgtttag attctgagac 180 gggaagtgga gggtgaatag gtcacggcgg cctttttttt tttttagttt aacttttcct 240 tttttgctgt ctag 254 <210> SEQ ID NO 11 <211> LENGTH: 372 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 11 aaaaattaca gttttgtgag acttaagggt ctttttaacc taggtaaatt tatatgacct 60 aacttaattg tagccatatt ctggtacctt ccattttgaa aagtagaggt tgcttaagca 120 agcaatggat aataagagac ttttcctgag gcacctgttt ggaatctggt tttctcagcg 180 gcagcttgac atgtgcaccc ttttgtatta aacactgcaa gggtgatgca ggggagcagg 240 aaagccatcc taaactcact actgagtacg attcagtatg ttcctgtgga tgtctgctgt 300 gactaatata aatttcttgc agaatcagct acacttaatt atgttgctga tagacaagca 360 tccacgcttc ag 372 <210> SEQ ID NO 12 <211> LENGTH: 181 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 12 cctctcccca gatatctgag cataactggg agcacctcat ttgtggaaaa gcctctttgt 60 tatcggcctt gtgtcagcag gtcatggtcc ctagagacta cctagttgta gtgtgaccta 120 catttataat tattgtcatg tccgaataga taggaggaga aaaacaatta cacactaatt 180 t 181 <210> SEQ ID NO 13 <211> LENGTH: 178 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 13 agaaatatga aattccagca ataagaaatg aacaaaagat tggagctgaa gacctaaagt 60 gcttgctttt tgcccgttga ccagataaat agaactatct gcattatcta tgcagcatgg 120 ggtttttatt atttttacct aaagacgtct ctttttggta ataacaaacg tgtttttt 178 <210> SEQ ID NO 14 <211> LENGTH: 413 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 14 ctggtcacca acccctacca ggccaccatt gatggagtca gatttttggg gacatcagga 60 cagaacgtga gtgacatttt ccgatacagc agcatggagg atcacttgga gatcctggag 120 tggaccctgc gggtccgtca catcagcccc acagcccctg acactctagg ttgttacccc 180 ttctacaaaa ctgacccgtt catcttccca gagtgcccgc atgtctactt ttgtggcaac 240 acccccagct ttggctccaa aatcatccga ggtcctgagg accagacagt gctgttggtg 300 actgtccctg acttcagtgc cacgcagacc gcctgccttg tgaacctgcg cagcctggcc 360 tgccagccca tcagcttctc gggcttcggg gcagaggacg atgacctggg agg 413 <210> SEQ ID NO 15 <211> LENGTH: 194 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 15 ctgttcttag ggcattataa atggaaatta taacgtggtt ctaggttatc aaaccatgga 60 gtgatgtgga gctaggattg tgagtgacct gcaggccatt atcagtgcct catctgtgca 120 gaagtcgcag cagagaggga ccatccaaat acctaagaga aaacagacct agtcaggata 180 tgaatttgtt tcag 194 <210> SEQ ID NO 16 <211> LENGTH: 483 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 16 aaacacccta gaggtctgtt tgttgttgct gttgtccttt attttgaaag agttgcaaga 60 gaagttacag tccaggtgaa cttggagatt gtgggattgg ttttgtttct gttttgtttt 120 gtttatcatt tacctgtagt gctattgctg ttgatactat cacctatacc ctgtttctag 180 tgagtgctga atacagtatg gtacaatgac agtaacagcc gcgtggtgct gccaggactg 240 cccttgggca tatcagtgac agcccaaatg tgggtggagg aaacctgtaa tttccttctt 300 aacatgtgtt tgaaatacca agtgaataat actgttctgg aaaaaaatga taaactagtg 360 gaaattaaag aaattaaggg ttttatataa tagacaggcc ccacctctca aaatattttt 420 agaagtcttt ttgtaaacta atttcttttg atcactattt tgcatcagta aaatgatttt 480 ttt 483 <210> SEQ ID NO 17 <211> LENGTH: 515 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 17 cctgcggtca cccagcctac tttcctggcg tagcccatgc aatcgtcccc gacaatagca 60 gggaccaagg aatagagtag tcactcaggc tgggggagga aggctgtggg actgggctca 120 agcctgtgga gggtgatcgt cttcagccac ttcaaggcca caagagctga ttctgggggt 180 tgacctcctc aagacaagca gttcgcccct tcttcttttc cctagtggtg tgccactccc 240 aacaatcttt ccaatctcta ctgatcggag gaaacttcct ccctcgcttc aagcggagcc 300 acctgctaca gcagaccctc aaatcgacct ccaccgatta ggattaaatt ccttcctctt 360 cttttgcctg gcgttgtgcc gcaacctaca gaaagactgg ccacccggga gaggcttgga 420 cccactgcag ggattcggga caatttcctt ctcctcttcc tttttccctc cgccgcaggc 480 cggcccgccc tcagggcagt ggggagctgg tactc 515 <210> SEQ ID NO 18 <211> LENGTH: 238 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 18 cctcttggcg cagcagccct ttcaatcatt cgcctaatgc ttattgctgc ttctctgccg 60 actccaaggt agggatgggg ctgtccccaa cagacaccag cgcacatgcc ctatttggta 120 taagcatcac tgagtgtaca ctgggcagcc gtaggctcga ccagatgggg tctgtgaggg 180 aagctccacc tcaggggctg tggaggggga ggaggggaca caaggcccgc ccctcagg 238 <210> SEQ ID NO 19 <211> LENGTH: 247 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 19 ctgtggaaac ctggggtgct gggtaaatgg agaactccag cttggacttc ttgccataat 60 caactgagag acgttccatg agcagggagg tgaacccaga accagttccc ccaccaaagc 120 tgtggaaaac caagaagccc tgaagaccgg tgcactggtc agccagcttg cgaattcggt 180 ccaacacaag gtcaatgatc tccttgccaa tggtgtagtg ccctcgggca tagttattgg 240 cagcatc 247 <210> SEQ ID NO 20 <211> LENGTH: 297 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 20 ctggagccct tccctgagaa actcttacag gccaggaagc cagtacagat ctttgagagg 60 tctgtgtaca gtgacaggta tatctttgca aagaatcttt ttgaaaatgg ttccctcagt 120 gacatcgagt ggcatatcta tcaggactgg cattcttttc tcctgtggga gtttgccagc 180 cggatcacat tacatggctt catctacctc caggcttctc cccaggtttg tttgaagaga 240 ctgtaccaga gggccaggga ggaggagaaa ggaattgagc tggcctatct agagcag 297 <210> SEQ ID NO 21 <211> LENGTH: 149 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 21 ctgttcatgg tgagcaagac cggcgaggcg gagaccatca ccagccacta cttgtttgcg 60 ctaggcgttt accgcacgct ctatctcttc aactggatct ggcgctacca tttcgagggc 120 ttcttcgacc tcatcgccat tgtggcagg 149 <210> SEQ ID NO 22 <211> LENGTH: 243 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 22 aaatgctccc tgcctggtgt ggggatgggg tccccctctt tgtgagggct ggagcatggc 60 acggcatgga ttaacacggc agaggaacaa aggtgtgctc tgagcttctt catatttcac 120 cttcaccctc acctgtgttc tcttccctct ctcccaataa aagggctccc attataaatg 180 ccatgtactt ctcttgggaa aatagacccc cttgcctaga gtaagttgtt aactgagggc 240 ttt 243 <210> SEQ ID NO 23 <211> LENGTH: 461 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 23 cggccgaggt cctatctggt tggccttttt gaagacacca acctgtgtgc tatccatgcc 60 aaacgtgtaa caattatgcc aaaagacatc cagctagcac gccgcatacg tggagaacgt 120 gcttaagaat ccactatgat gggaaacatt tcattctcaa aaaaaaaaaa aatttctctt 180 cttcctgtta ttggtagttc tgaacgttag atattttttt tccatggggt caaaaggtac 240 ctaagtatat gattgcgagt ggaaaaatag gggacagaaa tcaggtattg gcagtttttc 300 cattttcatt tgtgtgtgaa tttttaatat aaatgcggag acgtaaagca ttaatgcaag 360 ttaaaatgtt tcagtgaaca agtttcagcg gttcaacttt ataataatta taaataaacc 420 tgttaaattt ttctggacaa tgccagcatt tggatttttt t 461 <210> SEQ ID NO 24 <211> LENGTH: 460 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 24 cctcagcaat ggctgtggtg ttgctcagca tgcacacagc tctctgtacc ttggccaggt 60 ctccaccagg caccacagtg ggaggctggt agttgatgcc aaccttgaag ccagtggggc 120 accaatccac aaactggatg gtacgcttgg tcttgatggt ggcaatggca gcattgacat 180 ctttgggaac cacgtcacca cggtacaaca ggcagcaagc catgtattta ccatggcgag 240 ggtcacattt caccatctgg ttggctggct caaagcaagc attggtgatc tctgctacag 300 aaagctgttc atggtaggct ttctcagcag agatgacagg ggcatatgtg gccagaggga 360 agtggatgcg ggggtagggc accaggttgg tctggaattc tgtcaggtca acattcaggg 420 ctccatcaaa tctcagggaa gcagtgatgg aggacacaat 460 <210> SEQ ID NO 25 <211> LENGTH: 463 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 25 ctgctgtata aattctgtgt tgacgtagac ctccattggt gttccaaata ttgcagatga 60 atctctctct gcctccaaaa tcctcagtca tgcagtatga ataattaaca tacaaagtgg 120 tagattctga tactgggttt tcaaatcctg ataattggag ccattcagtc agtctctgtg 180 cctgatcctg aagaaaaaga acctggtccc taatgagttg gaagtcagaa aacccggctc 240 tcatttcctc ttatctggat cgcctgagaa gagactcgcg ctaccttttg tgcactcgcg 300 cctcgagata gcccctcact gacgcctgga cgcggtgagc gcgctgaagg ctgtgcggcc 360 tctaaagtct cagaattcct ccctgcggcc tcaaaattgg agagttggat tccagaccaa 420 gacactgtca ctagagctcc ctagccctgg cccaggaaga ttt 463 <210> SEQ ID NO 26 <211> LENGTH: 449 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 26 cctctgaaag aggagcagag ctcagggcac ctggccctcc ttggtcccct ctctactcca 60 cggtgctgct actcagggtc atctcaaaac tatgtaaagg cagatgttgc caatccacag 120 gcttcaggga ctcttatcaa gactcatccc aacttttaag gcacactttc acaccgctca 180 cattgtgcat tacattttgg agtccttgtt ggaagtgaac tttccgcctg taagcctgcc 240 attccatgtc taaaatattg ggatggcatc accttctgta ctatgcagca gaaggagact 300 ggcctgggat tctggaaaca tgagatccat ttgcatatta atccccggct cgctgtgtga 360 ccctgagcaa gtctccttca ctttctgtgc ctcagtgtcc ttatttgagt aaaaagggaa 420 taaaactaga tgagtggttt tcaaacttt 449 <210> SEQ ID NO 27 <211> LENGTH: 489 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 27 cctgtctgag gataccactg aagagacatt aaaggagtca tttgacggct ccgttcgggc 60 aaggatagtt actgaccggg aaactgggtc ctccaaaggg tttggttttg tagacttcaa 120 cagtgaggag gatgccaaag ctgccaagga ggccatggaa gacggtgaaa ttgatggaaa 180 taaagttacc ttggactggg ccaaacctaa gggtgaaggt ggcttcgggg gtcgtggtgg 240 aggcagaggc ggctttggag gacgaggtgg tggtagagga ggccgaggag gatttggtgg 300 cagaggccgg ggaggctttg gagggcgagg aggcttccga ggaggcagag gaggaggagg 360 tgaccacaag ccacaaggaa agaagacgaa gtttgaatag cttctgtccc tctgctttcc 420 cttttccatt tgaaagaaag gactctgggg tttttactgt tacctgatca atgacagagc 480 cttctgagg 489 <210> SEQ ID NO 28 <211> LENGTH: 482 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 28 cctgtaaact tacctccagc actaaaacat cctcaagaat tactataatg tgtccaaaat 60 atcactgcat acaatatctg gtatttgaag agaaaaactg acttttgtat agtataaaac 120 acaggctttc acaaattttg tattgctttt tttccagttt tgcagaaaat ttacattcta 180 gttctcttca cacagtagca gttgtaaata atttatgaat gacagtacac attaaaaggt 240 atgcattagc agcatattag tatgctgttt tatttgctga agaaaatact gtcttctatt 300 tttaatgata cattaggtac gatgtgtagt tcggtagagt cctaaaattt ttgtactact 360 ttcaatttgg tgaaaatgta ttaagttgtc taccatgttt tcttttctag ctgaataaac 420 cacatcaaag gaaagggacc acagtatttg aatgtttgaa agtctgtaaa gcttaaggtt 480 tt 482 <210> SEQ ID NO 29 <211> LENGTH: 151 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 29 aaaagttaag ctaaaacagc atcggtctta gaagtaaata caatttgcaa aaaggcatac 60 aaaatgtcct atcttttcag tctatctttt caagcctaac cacctagaaa taggctactt 120 tacctataat tgaatagaat aaagtgtctt t 151 <210> SEQ ID NO 30 <211> LENGTH: 170 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 30 cctgagagca ggaggcgaat tcgatctctc ctcacaaaca gcccaggaaa ttacacccgg 60 ggaagccttc gcttagatcc tcaggctctg ccctccctct gatgcacccc cgaagaatgc 120 ccctgaaggt gagagagaaa cttggaaaat aaagcaaaag ctcatttcac 170 <210> SEQ ID NO 31 <211> LENGTH: 379 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 31 aaaaaataat actttgcttt catgatatat tgtattttgt ggaaagttaa gtttagcaat 60 atagactcta aaagcaaatt aaattttttt aagccataag aaattatact atatcccagt 120 atctgtatgt ctgtataaag cagtgtatta tcatgttttc atttctgtga ttgtaagtta 180 aaagtcttaa ctgcagaggt attgtggaaa gtagtagcct taagcataat aaaatatggt 240 ctcttgggta ctccctctgg ccattaccac attcttagat tatatgtgtc catctttgca 300 gctttctgag agtaatttta tttgttgtct tctgaaatgt acatgtatac atgtacctac 360 tgagtgctat gtgattttt 379 <210> SEQ ID NO 32 <211> LENGTH: 170 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 32 ctgtctgggc tgctgcgcgc cgcctaggtg tctgggcgat ctatgggcaa gagcaagggc 60 cacgatgaca gattacggcg aggagcagcg caacgagctg gaggccctgg agtccatcta 120 ccctgactcc ttcacagtat tatcagaaaa tccacccagc ttcaccatta 170 <210> SEQ ID NO 33 <211> LENGTH: 317 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 33 ctggcctgtg atccctactt gttgcctcac atccgaaagt cagtctctac aagtagccct 60 gctggagctg ctattgcatc aacctctggg gcgtccaata acagttcttc taattgagac 120 tgactccaag gccacaaact gttcaacaca cacaaagtgg acaaatggcg ttcagcagcg 180 ggtttggaac atagcgaatc cgaatggatc tgatgaaacc tgtaccaggt gcttttattt 240 tcttgctttt ttcccatcca tagagcatga cagcatcgat tctcattgag gagaaacctt 300 gggcagctcc ggccagg 317 <210> SEQ ID NO 34 <211> LENGTH: 357 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 333, 334 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 34 aaagaagaag aacccgtgaa gaaggttctg gagaaaaagt tccatactgt cagtggaagc 60 aagtgtgaaa tcaaggtggc ccagcccaaa gaagtctatc agcagcagca gtatggctct 120 gggggccgtg gaaaccgcaa ccgagggaac cgaggcagcg gaggtggtgg tggaggtgga 180 ggtcagagtc agagttggaa tcagggctac ggcaactact ggaaccaggg ctacggctac 240 cagcagggct acgggcctgg ctatggcggc tacgactact cgccctatgg ctattacggc 300 tacggccccg gctacgacta cagtcagggt agnncaaact acggcaagag ccagcga 357 <210> SEQ ID NO 35 <211> LENGTH: 293 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 35 ctgtggtcat gggaaatcac ctacagcatg ttaaagtcct ctagtcatca tctcgtcacc 60 tgaaatggaa gtcctttttc cctcaccctc cacttctttc caaaggaggg catcaaggaa 120 cttaacctgc ctgcctggtg ggtttctatt taagacatct ttgtgattat atttaacctg 180 caattgtgct ttggcttaat gtctagctca ctgtacttgt aaatgattaa tattcaataa 240 aaccattttt acctgcccgg gcgccgctcg agccctatag tgagtcgtat tag 293 <210> SEQ ID NO 36 <211> LENGTH: 436 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 238, 239 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 36 aaaaaataat gtttcaaaat gctacacgtg gtactactgt ttgcacagtt tgatcaaaat 60 aacgatctac tttgagtcaa gcaaaaccta gaggaaatat accaaacaac ttgaaaatca 120 tttgtataaa aatcattgca cattatttta ctcatttgaa aagtaaaaaa gtgtatttac 180 aaaatatttt gcagtcaaaa ttataaagtg aatggatatc tcgaagtaac acgtcttnnt 240 acagacagtt caaggaaaac acacaaatgc tttttcttta agaggttttc agtgctcctt 300 ccactgggaa gtaaacatga tctactcaaa tgaatttaca agatggtacg catactggag 360 caaatccaac acctgcatta taaaacaatg tttacctgcc cgggcggccg ccgagcccta 420 tagtgagtcg tattag 436 <210> SEQ ID NO 37 <211> LENGTH: 273 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 37 gcttgaaaga gtagaggaaa gtccacgcta gcacaacctg cgatggttgt agtgatcatg 60 ctaggcccaa taagcctagg cttagacgac tagtgccaca gagacgagaa ttgtgaaacg 120 cggtaaactc catgagttag aaacccaaat atcggtaggg gaacttttca atggaaattg 180 aaccaaagaa aagagttgat taatcaacta gataaattgt tagcacctga gagggtacaa 240 aacgtggctt ataaatgcta aaacgcctgc tcg 273 <210> SEQ ID NO 38 <211> LENGTH: 325 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 38 cctgctggga tattagctcc agcggtgtaa acctgcagag catggactcg tcccacgtct 60 ctttggtgca gctcaccctg cggtctgagg gcttcgacac ctaccgctgc gaccgcaacc 120 tggccatggg cgtgaacctc accagtatgt ccaaaatact aaaatgcgcc ggcaatgaag 180 atatcattac actaagggcc gaagataacg cggatacctt ggcgctagta tttgaagcac 240 caaaccagga gaaagtttca gactatgaaa tgaagttgat ggatttagat gttgaacaac 300 ttggaattcc agaacaggag tacag 325 <210> SEQ ID NO 39 <211> LENGTH: 196 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 39 aaagacaaaa gaaagcagac tcaaaacaca gacaaagcag agaagaaaac aatgcccatg 60 agatggtcac tatttagaca gtattataaa aagctaaaga acacttgggc tttacttcac 120 tttgatgtct tgtactaaaa acaccttccc caaactaaat tcagagggga ggaagttaag 180 agcttcaggt aacttt 196 <210> SEQ ID NO 40 <211> LENGTH: 460 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 40 aaaagacaaa aacaaaacaa aaataccaca gctcaagata aagagtccta tacagaaatc 60 acaaaaagga cagaccatct aaggaaaaat taaaaagacg acacaaggac aggctgggca 120 gcctgggtca gggctcctgg ctggtgacct gctttgagta ggtttcttgc aggtacttct 180 taaaagctgt ggggtttttc cagagctcgg cagcatgtgt gttcaaggga ctatcaatgt 240 tgggttctcc tagaaggctc tggatggaga gcagaatggt cctgacatca tacagggcag 300 accgcttttc cttcaggatg tccaggcata tgttaccctg ggtgtccacg ttggggtgat 360 agcagggcgt gaggaacttc actgtgggcg cattgtaagg gtagccactt ggggaactct 420 agcgagagct tatacctcag gtcttcatat actgttccag 460 <210> SEQ ID NO 41 <211> LENGTH: 279 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 41 aaaaaacaag gctatctgaa tataataaaa ctagttttcc aagattcaaa taacaaaaca 60 gttatataaa tgcatacatt acacttccta ggttaaaaac catcaaagat cacaaaaata 120 ttaccaaaaa ggaaagtcat attttttcac cactcatctt tgtccctgca tcttcattag 180 agctgtctaa ttcagcaaga ccactttctg attcagtatg gctttcctgc attgtcactg 240 ggtttccagc atcactgttc gaagaagtag ctgtggcag 279 <210> SEQ ID NO 42 <211> LENGTH: 231 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 42 aaagatggaa tcagaaacta cgtggtgtgg aggctgttga tgtttctggt gtcaagttct 60 cagaagttgc tgccaccaac tctttaagaa ggcgacagga tcagtccttc tctcgggttc 120 tggcccccaa ggtcagagca agcatcttcc tgacagcatt ttgtcatcta aagtccagtg 180 acatggttcc ccgtggtggc ccgtggcagc ccgtggcatg gcgtggctca g 231 <210> SEQ ID NO 43 <211> LENGTH: 284 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 43 ccgctgccgc catgcaaggg gaggacgcca gatacctcaa aaggaaagtt aaaggaggga 60 atatagatgt acatccatca gaaaaggcac tcattgttca ctatgaagtg gaagctacca 120 ttcttggaga aatgggggac cccatgttgg gagaacgaaa agaatgtcaa aaaatcattc 180 gacttaagag tctcaatgcc aacacagata taacttccct ggcaaggaag gtggttgaag 240 aatgtaaact cattcatcct tcaaaactaa atgaggtaga acag 284 <210> SEQ ID NO 44 <211> LENGTH: 457 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 416, 418 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 44 ctgccagggg ggacctagag caacttacta gtttgttgca aaataatgta aacgtcaatg 60 cacaaaatgg atttggaagg actgcgctgc aggttatgaa acttggaaat cccgagattg 120 ccaggagact gctacttaga ggtgctaatc ccgatttgaa agaccgaact ggtttcgctg 180 tcattcatga tgcggccaga gcaggtttcc tggacacttt acagactttg ctggagtttc 240 aagctgatgt taacatcgag gataatgaag ggaacctgcc cttgcacttg gctgccaaag 300 aaggccacct ccgggtggtg gagttcctgg tgaagcacac ggccagcaat gtggggcatc 360 ggaaccataa gggggacacc gcctgtgatt tggccaggct ctatgggagg aatgangntg 420 ttagcctgat gcaggcaaac ggggctgggg gagccac 457 <210> SEQ ID NO 45 <211> LENGTH: 356 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 45 ctgtcgtcta tgccgtagaa tcacatgatc tgaggaccat tcatggaagc tgctaaatag 60 cctagtctgg ggagtcttcc ataaagtttt gcatggagca aacaaacagg attaaactag 120 gtttggttcc ttcagccctc taaaagcata gggcttagcc tgcaggcttc cttgggcttt 180 ctctgtgtgt gtagttttgt aaacactata gcatctgtta agatccagtg tccatggaaa 240 ccttcccaca tgccgtgact ctggactata tcagtttttg gaaagcaggg ttcctctgcc 300 tgctaacaag cccacgtgga ccagtctgaa tgtctttcct ttacacctat gttttt 356 <210> SEQ ID NO 46 <211> LENGTH: 192 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 46 aaatggtggt cctgcaactc ttgtttcaaa gaatttctcc aaaacttgaa gttcatcagg 60 tttccactgt cctgcatttt caggtgtcac ttttagctga agcgtttggt tggttttggg 120 actaagagct actctgcatt tcagtgcatc agtcttaaac atgatcactc cgggttcatt 180 agaatttatc ag 192 <210> SEQ ID NO 47 <211> LENGTH: 170 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 47 ctgctcatat tcatctgaca ccatgtggcc acaaagcgga aactcatcca cttttgcctt 60 tttccgcccc aggtcaaaaa tgcgaatctt ggcatcaggg acacctcggc agaagcgaga 120 ctttgggtac ggcttgttct tacaataccg gtaacaacgg gcggggcggc 170 <210> SEQ ID NO 48 <211> LENGTH: 254 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 48 cctgccagat atttgtgaga aatctgccat tcgatttcac atggaagatg ctaaaggaca 60 aattcaacga gtgcggccac gtgctgtacg ccgacatcaa gatggagaat gggaagtcca 120 aggggtgtgg tgtggttaag ttcgagtcgc cagaggtggc cgagagagcc tgccggatga 180 tgaatggcat gaagctgagt ggccgagaga ttgacgttcg aattgataga aacgcttaag 240 cagttgcctt tttt 254 <210> SEQ ID NO 49 <211> LENGTH: 379 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 49 aaacacaaga tgaaaatact ctgttctgtc caaagcatca cctaatggtg tgaggcatct 60 cacttagctg tggagaagtc cttggaatta gatcccagaa agacagcttt aagacagtaa 120 aaccttttgg caatgggcta attgccttaa aagaagagtt ctacctgaaa gaccttgcag 180 gtggagaaat tgtcctacaa agattcttgg atatgttagt ggagataact gacatgggta 240 gctgtgggtc aaccaggaac tgtcaacaac ctgatctctg caaaaccagg atggccagtt 300 aatggtttat tcagttctct gatggtcaca aatgtaattt tatttagcct tgtggaggtt 360 ctgcaacaaa tgtaatttt 379 <210> SEQ ID NO 50 <211> LENGTH: 185 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 50 gtgattggca ggatcctggt atccgctaac aggtcaaaat gcagatcttc gtgaaaaccc 60 ttaccggcaa gaccatcacc cttgaggtgg agcccagtga caccatcgaa aatgtgaagg 120 ccaagatcca ggataaggaa ggcattcccc ccgaccagca gaggctcatc tttgcaggca 180 agcag 185 <210> SEQ ID NO 51 <211> LENGTH: 111 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 51 aaaagttaaa acatccagat atataagcta ttttttccta aggataaagt acctttgagc 60 atgagtgtat cacagctttc attaggaaaa cttttcatta catacttgtt t 111 <210> SEQ ID NO 52 <211> LENGTH: 124 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 52 ggcagcagag tgcacatctt gtttccattt caatcatttg cattggaagt gctttttccc 60 cctaatgaat acatagtcat aaagaatcca gttcagcctg tcgtgctgtt gccactggca 120 tcag 124 <210> SEQ ID NO 53 <211> LENGTH: 144 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 53 agtggctgga gactctggct cagccagagt tgtttctctc cactctgcct catctctgta 60 cgaatttggg tcccagcctt gttgggttgt cagccatgga catggatttc aacccctgga 120 gaaaacgatg tcattgttca gcag 144 <210> SEQ ID NO 54 <211> LENGTH: 169 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 54 ctgattgttg gtgatgaaca tatttgtttt ccttaacatg tcccaacttc cataattatt 60 cagatgtaca acaagtggtc ctaatgtcct ggctgaaatt gcccaggcgt gcaacaaagc 120 aagctggttt tgttcctgaa ttatgcagtt aactgaggca cctcggccg 169 <210> SEQ ID NO 55 <211> LENGTH: 160 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 55 ccttctcccg gccctccagc gtctccttgt tccgcatccc atccttcagg cagtcgaaca 60 ccctgctcac gctggagcgc agcgcctgga tggcactaat ggcctgggaa aaggcctcca 120 ggttcacact gacatttatc acgtccgcca tgttgccgcc 160 <210> SEQ ID NO 56 <211> LENGTH: 517 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 56 aaaaccactt ggaaggccat ctctataaaa atgattttcc caggacagta accagatgta 60 acctaaccca acaccatctt aattggcaga ggttcagtgg gctggagttt tgtgctcctc 120 ccccacacca agtttttata atacaaatgc cacaagaaaa agaacttcgg tactgtttcc 180 tcagcagagg agaaaaactc aacctagtta tgagaccaac cacacaacac aatgaaaagc 240 tgcactaact agttcagaat gttagttaag atgatgctgg tgtgaataac tcgttttttc 300 tagagccctt ataaataaaa tcccccagtt agtgtttgca ttatcagcta gagggttaac 360 atgtggtaga atgaggactt atgcaagata taaatgcgca tagcatttta ctactatgag 420 aacaagtgca gtcagaagaa aaccaactgg actctaaatt acacacacct taatgacaag 480 actccccacc acttgtgaat gtaaaacatt taattta 517 <210> SEQ ID NO 57 <211> LENGTH: 230 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 57 cctgagccac catgcctgac ctaatgtttt actttggcag tgttggtata catacaaggg 60 ctaacggtat ggggtcccaa tattatacta taaaaccatt taatcaaatt tttgaaaagt 120 cggaaaaact gtgtgtattc taaagtcact ggaaattaaa agaaaaatat attccagtag 180 tgacttacag atgaaaatga tgctgacaat agacagtaat ctgtttttcc 230 <210> SEQ ID NO 58 <211> LENGTH: 251 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 58 aaaaattttg attgtttgcc atattgggtg ggtttactct tagaatcgca tgctgtagaa 60 atgctcaaaa gtgcatatgg gactcagtcc ttaggtgttc tttttctttt aagaaatagc 120 ctcttacagt tgtaaccatt gcggctctgt ccacttctcg ttgctgctct gtggcacata 180 tcggaagcag tacagcgcgc ggctctacac gcttgggtag cgggataagt cactgttttc 240 tttatttctt t 251 <210> SEQ ID NO 59 <211> LENGTH: 432 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 59 aaaaaatctt gtgttgtttc gtcgagaaat tgcaggcttt tatgttttca aagaactaaa 60 cacaatactg agaagtccaa cttttagcca gaatacataa attcctgaaa atgtatagat 120 ttgaaaaata aaaataaaaa aaaaaggaag acaaaccttt ttagggaacg gaggaaacac 180 tacctgttta agttaagccc actaagaaca aaatcagtgc cgatgaacga gccctccgac 240 acgttttcag caaaacgcct gtcgagaagt gcttggagat caccggccat tgccgtagcc 300 ggggaagagc tggttgagga cggtctgcag aggctggttc acctgcatgg catagctgcg 360 gcccaggtcg tagcggcagg cagggcagac ctgcccgggc ggccgcccga gccctatagt 420 gagtcgtatt ag 432 <210> SEQ ID NO 60 <211> LENGTH: 279 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 266 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 60 ctggtcgaaa gtgaggatct tgccccctgc cctgaggatg cggctgcggg cccggctggt 60 cacgcgcagt gcacatacct tcagtttggg tacctcctga acccgcacat catcagttat 120 ggtccccaca accacggccg tcttgttttc ccggccagga agcttcatct tccggatcat 180 ccgggaaagg gacagaggcg gccggttggt gcgactcata aacaacctct tcaacacaac 240 ctggttgaat gtggagttgg ttcttntggc cagaaacct 279 <210> SEQ ID NO 61 <211> LENGTH: 211 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 61 ctgtggccgc cagctcctgg ccaccagggg ccgcttttct ttcttggtag ctgggctgag 60 agcaagggct ggccccaatc tgctgtcagc agaggctgga ctctggccca atacccaagg 120 agtcatgact gatggcctgt cttgggatag cccgggggtc ttcctggagg aggagggccc 180 agaatggagc cttgagggtc aggcagcgtt c 211 <210> SEQ ID NO 62 <211> LENGTH: 206 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 62 ctgagccctt gagacagcag ggcttcgatg tcaggctcga tgtcaatggt ctggaagcgg 60 cggctgtacc tgcgtagggg cacaccgtca gggcccacca ggaacttctc aaagttccag 120 gcaacatcgt tgcgacacac cggagaccag gtgatgagct tggggtcggt cataagcgcg 180 gtggcgtcgt cgctgggagc tggcag 206 <210> SEQ ID NO 63 <211> LENGTH: 174 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 63 ccttactaag gctactgtcg agtctcctga gaggtaagct ggcttgcata gaggttggta 60 ctcgaaaaat cctctcctcc caaaaaggta cctgtaagcc tgaaaattaa ggctcaggag 120 gagcacagcc tctacctccc ctagctggtt aaggtccgcc tcctcttttt ttac 174 <210> SEQ ID NO 64 <211> LENGTH: 196 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 64 gggcgctgag gcagttgcag gcaggcagcc ctgtacttac cctgtactca cctcatccga 60 cagacgctgt ggatgaggag gggcttggcg gaggcgtgag caccgatgtc cctttgataa 120 cctgcactca ccaagatgaa ctatttgccg ccctgtcttt tcctgggttg gggggtggca 180 tctgatggtg gcagag 196 <210> SEQ ID NO 65 <211> LENGTH: 558 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 65 ctgacacttg acaaggaccc aacctcctcc ctgaccctct tcactgttaa gagacacatc 60 agtaatactt tgctctgcca tagcctctga tctaaactct cttcaccgca gttttctatc 120 agcccaactc cagaacagtg gtcaatgcag agaagttcca gattcgcatt tttgaagcat 180 tttgaaataa ggcagaataa agtattacta aattacattt actttcttaa agaacaaaaa 240 tgatcatcct tttattactg tgccatttgt tgaagataac caattttaag tgagagaaaa 300 cattttaatg gaaaaattca tgcatctcat tgttatgaaa tgattgatgc ccatctggaa 360 agtatgaaat aaacaatact ggtttcatat gttacactag ggatgcagga tagacatgaa 420 taactgggaa agagaaactt ctaataatgc atcttagaat atgcctcagg atttctgagg 480 cacaagagaa actagtaagc attctctcaa aattttaagt attcttttat taaaatagaa 540 gtgtttttct tgtgtcag 558 <210> SEQ ID NO 66 <211> LENGTH: 121 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 66 aaatgaggga cttcaagact agacagcatg gctcttttca gtttattgca tgaaggagtt 60 acactagtcc aagttaaaag cggaccccaa atggttacat tatacaagct gtgaggtttt 120 t 121 <210> SEQ ID NO 67 <211> LENGTH: 293 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 67 aaagtacaat gcagatgaag ctagaagcct gaaggcatat ggcgagcttc cagaacatgc 60 taaaatcaat gaaacagaca catttggtcc tggagatgat gatgaaatcc agtttgacga 120 tattggagat gatgatgaag acattgatga tatctaaatt gaaccaagtg tttttacatg 180 acaagttctc tgaggatggt tctacagttg ggattttggc catcatcaac caagaagaga 240 aattcattta gtgtgtagtt tctgaaagca aactgattta ttttcattgt ttt 293 <210> SEQ ID NO 68 <211> LENGTH: 196 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 68 aaagttacct gaagctctta acttcctccc ctctgaattt agtttgggga aggtgttttt 60 agtacaagac atcaaagtga agtaaagccc aagtgttctt tagcttttta taatactgtc 120 taaatagtga ccatctcatg ggcattgttt tcttctctgc tttgtctgtg ttttgagtct 180 gctttctttt gtcttt 196 <210> SEQ ID NO 69 <211> LENGTH: 277 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 69 ccttgtcaga gcagccctga tagacttggg gatcccagag gctaaaggga gccctggcaa 60 acaacagacc cagcttggag tcatggagcc tctccaaagg ttctgctgga tcttaggcat 120 cttctggtcc tcccttcctg ctctaatgat gaggaacttg agtccagaga agggaaggga 180 tgttattcaa gtccacacag ggactcagag gcagagctgg tgtcctgcac cttactccaa 240 ggctctcagc agctttgaag cagaggacta tgggagg 277 <210> SEQ ID NO 70 <211> LENGTH: 378 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 70 aaaataacat ttcattcaaa ctgtatataa ttcagtaaag ttttttatac agcaagcaat 60 gcttaaaccc tggagaatct gtagaaaaga gattttcaca caaaataaga aaagaaaaat 120 ctgaggtatc cctcacacac acacatccat tcattctggc ccatgtacgt gcacatacac 180 acgcatgcct gtgtgttcac acagacatat tcattctcac tcacaaagtg gctgcagcat 240 aggcaaaaat tgtaggtcca aaggaaaatg attgattgtt ctaataaaga gtccgagtag 300 ctcagaaaaa aaaaccaaaa caaaacacaa gagtcttttg aggtagtaat ttcctcagaa 360 aaatgttctc aagatgaa 378 <210> SEQ ID NO 71 <211> LENGTH: 357 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 71 aaagaaaaaa tgatcagcag caattccata aaacagaagg gtgtcaatcc cttactttct 60 tttgcttttt gtgtcagttg tttgaaaaac actagaagct gacatgagat tttctatata 120 ttgtccaaga acttggtttt ctgattttag cttcagattt tcttccttaa ctgcatctac 180 tcttgcagag agatcttcaa gtgtgtgttg gagttccaac acttgattaa taagtcttgt 240 tttttcctcc agttccactt gattttcagc atcaactgca tccatgtcag cattcatcat 300 cttgggtaac aaacttttgg gccttggata caaaattctt gaggaatggt cttccgc 357 <210> SEQ ID NO 72 <211> LENGTH: 143 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 72 aaagctctta gaatcttcat ttccatctgt ctgatttggt gcttagtata agtgttgtca 60 gtcacaaaag caaagtcacc aatttctgga gggtacattt cttcatattt gcttgcaata 120 aacatggcag tgacaccaac cag 143 <210> SEQ ID NO 73 <211> LENGTH: 401 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 73 aaaacagata aatttcctag tgagaccttt ggtttggtct ccaaaaatct gctgagctgt 60 ttccccagta acctccatca tagattccca ccccaaggga gaacagaatg gatgaacagg 120 agactgggag aaaagaagaa actggcaaga cggtatgtgc tgggcaatca gtgtgaacag 180 tcagctttgt ctcatgtttg gaagacagtt taggtgatgc ggtcagggat tcattctctg 240 gatctccctg ctcattctca gagtattaaa ccagctcact cggaagaccc cagggccaag 300 gattagggac aatcctttgt gacacccaaa tcctgaaact tcaaataggg tcacaagtca 360 cagagctgag gaatgctgcc ttcaacttct ttcatggttt t 401 <210> SEQ ID NO 74 <211> LENGTH: 199 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 74 ctgggcacta ccgagcccac tgggccaggc ttgccgctgg ggagctcctg ctaatgggaa 60 gttgatatac ccctgcaccc cagcaagcct gcggactgaa tctgggttaa aagccctggg 120 gggaattggg cctgtttgtc attgttctga taagggctgg cgcccaggaa ttttttaagg 180 gtccatcctt tggaggagg 199 <210> SEQ ID NO 75 <211> LENGTH: 449 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 75 aaagtttgaa aaccactcat ctagttttat tcccttttta ctcaaataag gacactgagg 60 cacagaaagt gaaggagact tgctcagggt cacacagcga gccggggatt aatatgcaaa 120 tggatctcat gtttccagaa tcccaggcca gtctccttct gctgcatagt acagaaggtg 180 atgccatccc aatattttag acatggaatg gcaggcttac aggcggaaag ttcacttcca 240 acaaggactc caaaatgtaa tgcacaatgt gagcggtgtg aaagtgtgcc ttaaaagttg 300 ggatgagtct tgataagagt ccctgaagcc tgtggattgg caacatctgc ctttacatag 360 ttttgagatg accctgagta gcagcaccgt ggagtagaga ggggaccaag gagggccagg 420 tgccctgagc tccgctcctc tttcagagg 449 <210> SEQ ID NO 76 <211> LENGTH: 503 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 76 ctgaaacagc ttttcaagct ctctctcctc gtcaaggatc atgagaggca ctccactcaa 60 ggggaggtgc gcaatctggt gctcttcagg caggtcaaaa ctctcaaagt ctagaggatt 120 gaagggaaag aatttttcta tttctggata ggcatcatct gaggcaggaa cagagctttt 180 tgctttaaca gtcttctcag tcatcttttt ggcagaaaag cttggctgtt tttgtttgag 240 gggtcccttg gtctttacag acttttctgt agctctgttg acagttccca aagcctttct 300 agtagcttta ggtaaggctg gtggggcatc gaacgttttg ccaaaacgtg gtgttgaaac 360 ttgagatctc ccatctaagg ctttgattga aggtccagac cccagcttca gcccatcctt 420 agcaaccaca cgggtgcctg gttctccatt ttccttatca acatagatca gagtagccat 480 tctggattat tgcaggtctt aac 503 <210> SEQ ID NO 77 <211> LENGTH: 371 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 77 ctgagaaact ccaggtggtg ggcagggctg gcacaggtgt ggacaatgtg gatctggagg 60 ccgcaacaag gaagggcatc ttggttatga acacccccaa tgggaacagc ctcagtgccg 120 cagaactcac ttgtggaatg atcatgtgcc tggccaggca gattccccag gcgacggctt 180 cgatgaagga cggcaaatgg gagcggaaga agttcatggg aacagagctg aatggaaaga 240 ccctgggaat tcttggcctg ggcaggattg ggagagaggt agctacccgg atgcagtcct 300 ttgggatgaa gactataggg tatgacccca tcatttcccc agaggtctcg gcctcctttg 360 gtgttcagca g 371 <210> SEQ ID NO 78 <211> LENGTH: 160 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 78 attcaacact ttaatattta tggtgtatca cataaaaaac aaagtcatat acttttgcat 60 taatcaaaaa atagcaaatc catataatgg caaaatcagg aaaaaaattc tagtatttcc 120 acaaaataca taatgtctta cagatgatta tgtgaacttt 160 <210> SEQ ID NO 79 <211> LENGTH: 547 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 79 cctggcacag tactggggaa gatggaagca gcaaacaagg ctgtgaacac agccaggatg 60 caagccagtg gaaccagtgc agagcacaca tgctcagatg atgttgttct cctggatctt 120 ctctcccaag taaaagcggg taaagaggaa ggggctcagg tcgatggtct ggaacctgcc 180 cttcagtacc atctctgcta cagctcgccc aatgccaggg gcctgctgga gcccgtgacc 240 actgaagcca gtagcaaagt acatgttgac aactagcggg tgggggccca ccacgccatt 300 ctggtcaaag gtgttgtagt cgtaatagcc ggcccaggcg ctctgaacct tcagagtctc 360 aaaagctggg accctcaggg ccaaatgggg ccacaccttg tcctggaaga aatcatggtc 420 cacttccagg ttcgccgggt ccggttcttc ctgctcagtg gggctacgac cacctaggta 480 gttgctacct aatccttccc ggcgaaaata ggctccactg gtgtctgcaa caagcggagt 540 ctctagg 547 <210> SEQ ID NO 80 <211> LENGTH: 386 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 80 agcgagtctg ggtctcagcc ccgcgaacag cctttcacga gtcttcaagc tttcaggcta 60 tcttctagtc aagatgagtg ataagccaga cttgtcggaa gtggagaagt ttgacaggtc 120 aaaactgaag aaaactaata ctgaagaaaa aaatactctt ccctcaaagg aaactatcca 180 gcaagagaaa gagtgtgttc aaacatcata aaatggggat cgcctcccaa cagcagattt 240 cgacattacc tgagagtctt gattttaggc ttgttttttg taaacccatg tgtttgtaga 300 gattttaggc gtcttcggat atcttctcac ctatgttccc tggctaagaa gtcagaggta 360 gccaatgttt ccttaaattc attttt 386 <210> SEQ ID NO 81 <211> LENGTH: 366 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 81 cctcttcttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 ttttat 366 <210> SEQ ID NO 82 <211> LENGTH: 387 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 320, 336, 345 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 82 aaatgacagt gaaaagcagc cttacatcac taaggcggca aagctgaagg agaagtatga 60 gaaggatgtt gctgactata agtcgaaagg aaagtttgat ggtgcaaagg gtcctgctaa 120 agttgcccgg aaaaaggtgg aagaggaaga tgaagaagag gaggaggaag aagaggagga 180 ggaggaggag gaggatgaat aaagaaactg tttatctgtc tccttgtgaa tacttagagt 240 aggggagcgc cgtaattgac acatctctta tttgagaagt gtctgttgcc ctcattaggt 300 ttaattacaa aatttgatcn cgatcatatt gtagtntctc aaagngctct agaattgtca 360 gtggtttaca tgaagtggcc atgggtg 387 <210> SEQ ID NO 83 <211> LENGTH: 212 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 83 ctgtttatgg tgatgctaca ttttcgttta taaatatgtt tgtggtataa aaaaatgagt 60 ataaccatag gttttgaaca aatttcctta catttttcat acaaaaatca taaatatctg 120 tatgctattg aaatttaact ttgtatgatg cttaaaaacc actatttggg gaaataataa 180 aataagtctt taccatgtat gaaagaaatt tt 212 <210> SEQ ID NO 84 <211> LENGTH: 125 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 84 taaaatcggc ttttaaggag aacaggagtc tgaaagggtt ccaaaaatct atattgtttg 60 catttcggta gtatagatta attagaaatg ataaactgta aaaagtattg gtattgactt 120 gacct 125 <210> SEQ ID NO 85 <211> LENGTH: 458 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 85 aaattgccaa atacgtgctg tcccatcacg actgccactt acaaacctgt tactagtgtt 60 ggaaaactgg atactgtcaa ctttgtcagt atgaaactcc aattctgata ttttctctgg 120 ctgacctgat ccaaaaaaat aaacccgaat aatatgatct gtgcttcccg tcgccagaaa 180 cattccacca gcactaaaag aagaacagat catttgaact ccaggccgag ggcgctctgt 240 aaattttgca ggtcttgggt ttattttaag ggttccagca tcccagagcc aaaaacaaat 300 agtgccatct gccccagtag aagatagata tctctttgag ccactgcaca atggtgagaa 360 ctgtagtgat gtaatagatg cactatggcc ctgaagaaca gccaaaggtg cacaggttcg 420 aagacaccag actcggatca ttttatcaca acttccag 458 <210> SEQ ID NO 86 <211> LENGTH: 406 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 86 gctcagtgca tcccaggcag ctcttagtgt ggagcagtga actgtgtgtg gttccttcta 60 cttggggatc gtgcagagag cttcacgtct gaagagagag ctgcacatgt tagccacaga 120 gccaccccca ggcatcacat gttggcaaga taaagaccaa atggatgacc tgcgagctca 180 aatattaggt ggagccaaca caccttatga gaaaggtgtt tttaagctag aagttatcat 240 tcctgagagg tacccatttg aacctcctca gatccgattt ctcactccaa tttatcatcc 300 aaacattgat tctgctggaa ggatttgtct ggatgttctc aaattgccac caaaaggtgc 360 ttggagacca tccctcaaca tcgcaactgt gttgacctct attcag 406 <210> SEQ ID NO 87 <211> LENGTH: 170 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 87 cctgagagca ggaggcgaat tcgatctctc ctcacaaaca gcccaggaaa ttacacccgg 60 ggaagccttc gcttagatcc tcaggctctg ccctccctct gatgcacccc cgaagaatgc 120 ccctgaaggt gagagagaaa cttggaaaat aaagcaaaag ctcatttcac 170 <210> SEQ ID NO 88 <211> LENGTH: 326 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 88 aaaatgatca gcaccagggc ggccagcggg ctctaccgag cgataacaga gacgcacgca 60 ttctacaggt gtgacacagt gaccagcgcc gtgatgatgc agtatagccg tgacttgaag 120 ggccacttgg catctctgtt tctgaatgaa aacattaacc ttggcaagaa atatgtcttt 180 gatattaaaa gaacatcaaa ggaggtgtat gaccatgcca ggagggctct gtacaatgct 240 ggcgttgtgg acctcgtttc aagaaacaac cagagccctt cacactcgcc tctgaagtcc 300 tcagaaagca gcatgaactg cagcag 326 <210> SEQ ID NO 89 <211> LENGTH: 171 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 169 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 89 aaattcctct ctggaaatgg atatggaagg actagaagat tactttagtg aagattctta 60 ggcagtttta taaccctttt tcctcaatag cctgtttcct gtttttaaga ttttgccttt 120 gttgttgaaa aagggtttca ctctgtcacc aaggcttagt gcagtgacnc a 171 <210> SEQ ID NO 90 <211> LENGTH: 421 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 407, 413 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 90 aaagctttgc gattttgggt cggcttcaca tgttgcggat aatgacataa caccttatct 60 tgtcagtaga ttttatcgtg ctcctgaaat cattataggt aaaagctatg actatggtat 120 agatatgtgg tctgtaggtt gcaccttata cgaactctat actggaaaaa ttttattccc 180 tggcaaaacc aataaccata tgctgaagct tgcaatggat ctcaaaggaa agatgccaaa 240 taagatgatt cgaaaaggtg tgttcaaaga tcagcatttt gatcaaaatc tcaacttcat 300 gtacatagaa gttgataaag taacagagag ggagaaagtt actgttatga gcaccattaa 360 tccaactaag gacctgttgg ctgacttgat tgggtgccag agacttnctg aanaccaacg 420 t 421 <210> SEQ ID NO 91 <211> LENGTH: 342 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 261, 334 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 91 gatgaatgcg gctgttaaga cctgcaataa tccagaatgg ctactctgat ctatgttgat 60 aaggaaaatg gagaaccagg cacccgtgtg gttgctaagg atgggctgaa gctggggtct 120 ggaccttcaa tcaaagcctt agatgggaga tctcaagttt caacatcacg ttttggcaaa 180 acgttcgatg ccccaccagc cttacctaaa gctactagaa aggctttggg aactgtcaac 240 agagctacag aaaagtctgt naagaccaag ggacccctca aacaaaaaca gccaagcttt 300 tctgccaaaa agatgactga gaagactgtt aaancaaaaa gc 342 <210> SEQ ID NO 92 <211> LENGTH: 336 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 92 aaaattaatg gtttttctcc tgaaatgttt gtgcatggaa gaactgccct gcttttttac 60 cctgttgcca tgtatgatta ttccttgtga gattacttaa ttacttggat tgaagactag 120 cctattgaag ctgctgccag gcaacaccac ttaacagtaa cttaaaggaa ttattttctt 180 tagaggatcc tcttcaaaaa ggaagggaga tagtggaaaa ctgttcttat atcttcagat 240 ccctagcaga aatgactgtt tatttcaaac tatgttttac ttgtatatga tgtagtcaac 300 tatctttcaa ttccatactt cccccgcccc catttt 336 <210> SEQ ID NO 93 <211> LENGTH: 301 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 93 attatttctg gtgatgaccc tgtccctatc cctacctttg actatattgc agggcggcag 60 aaacgagccg ttacactgat tcccctgcta gtaggattgg gtgtctctac agcagtcgct 120 accggtacag caggactcgg ggtggctgtt cgatcttaca caaaacttcc ccatcaactt 180 attaacgacg tccaagcctt gtctagcacc attaatgact tacaggacca actagattcc 240 ctagccgaag tagtcctcca aaacagaaga ggcttagacc tactcactgc agaacaggga 300 g 301 <210> SEQ ID NO 94 <211> LENGTH: 240 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 94 cccagcccgg gtgcccacac tggccgtccc ggccatctcg ctgcccgacg atgtccgcag 60 gcggctcaaa gatttggaaa gagacagctt aacagaaaag gaatgtgtga aggagaaatt 120 gaatctcttg cacgaatttc tgcaaacaga aataaagaat cagttatgtg acttggaaac 180 caaattacgt aaagaagaat tatccgagga gggctacctg gctaaagtca aatccctttt 240 <210> SEQ ID NO 95 <211> LENGTH: 166 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 95 cctccatcta aatgagacaa caaagcacaa tgttcactgt ttacaaccaa gacaactgcg 60 tgggtccaaa cactcctctt cctccaggtc atttgttttg catttttaat gtctttattt 120 tttgtaatga aaaagcacac taagctgccc ctggaatcgg gtgcag 166 <210> SEQ ID NO 96 <211> LENGTH: 240 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 96 cccagcccgg gtgcccacac tggccgtccc ggccatctcg ctgcccgacg atgtccgcag 60 gcggctcaaa gatttggaaa gagacagctt aacagaaaag gaatgtgtga aggagaaatt 120 gaatctcttg cacgaatttc tgcaaacaga aataaagaat cagttatgtg acttggaaac 180 caaattacgt aaagaagaat tatccgagga gggctacctg gctaaagtca aatccctttt 240 <210> SEQ ID NO 97 <211> LENGTH: 236 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 97 cctgccttga gaccgtcaac cgcatcaagt tgtacagtga gtccctggcc cggtatggca 60 agagcccata tttatacccg ctctacggct tgggcgagct gccccagggt tttgcaagat 120 tgagtgccat ctatgggggg acatatatgc tgaacaaacc tgtggatgac atcatcatgg 180 agaacggcaa ggtggtgggc gtgaagtctg agggagaggt ggcccgctgc aagcag 236 <210> SEQ ID NO 98 <211> LENGTH: 445 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 98 aaagatatga gcttgtgata atggatcttc atttaatgtt tactgttatg aggtagaata 60 aaaaagaata ctttgtaata gccacaagtt cttgtttaga gaccagagca ggattaataa 120 tttattttaa cattttagtg tttggtggca cattctaaaa tatagattaa gaatacttaa 180 aatgcctggg atagttcttg ggactaacaa catgatcttc tttgagttaa acctacctaa 240 gtagatttta ggtgggttcc tattaggtca gatttttagc ttccctaatt acctttcact 300 gacatataca gaaaaaggag cagttttagt tttaattaat taaaattaac agatgtgatg 360 aggattaaat gaatcaaaag acttaatttg tagattcttt tagagttatg agctaggtat 420 agtttgggga aactcaacct ggtgc 445 <210> SEQ ID NO 99 <211> LENGTH: 364 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 99 aaaaaaatgt tgctttgggt agaagtcttg attcattgct tcattcttac agctttttct 60 ttgcttcctt actataaaat aatccaatgt tattgtgagg acaatctctg attcagttcc 120 aatgctcttg tatctccatg agttttggca ttgtttacca gcacgtcaat aagctcatag 180 tcatctttgg tatataagtg tctcagtagg taccaacgtg cagttgatgc aatagatttg 240 ggatacccag gctgatatac cactctttcc aaaagacgcc gtgtctctct tgcccccatt 300 ttgcgtttga attgtaacaa agcttgtaaa agaacagcca gtggacaaaa gcaaagcttc 360 aagg 364 <210> SEQ ID NO 100 <211> LENGTH: 192 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 100 aaaaatgaac ttctcccgct acacagaagt aacaaatatg gtagtcagtt ttgtatttag 60 aaatgtattg gtagcaggga tgttttcata attttcagag attatgcatt cttcatgaat 120 acttttgtat tgctgcttgc aaatatgcat ttccaaactt gaaatatagg tgtgaacagt 180 gtgtaccagt tt 192 <210> SEQ ID NO 101 <211> LENGTH: 293 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 101 gcggctcgga ctgagcagga cttcccttat cccagttgat tgtgcagaat acactgcctg 60 tcgcttgtct tctattcacc atggcttctt ctgatatcca ggtgaaagaa ctggagaagc 120 gtgcctcagg ccaggctttt gagctgattc tcagccctcg gtcaaaagaa tctgttccag 180 aattccccct ttcccctcca aagaagaagg atctttccct ggaggaaatt cagaagaaat 240 tagaagctgc agaagaaaga cgcaagtccc atgaagctga ggtcttgaag cag 293 <210> SEQ ID NO 102 <211> LENGTH: 444 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 102 aaagatatga gcttgtgata atggatcttc atttaatgtt tactgttatg aggtagaata 60 aaaaagaata ctttgtaata gccacaagtt cttgtttaga gaccagagca ggattaataa 120 tttattttaa cattttagtg tttggtggca cattctaaaa tatagattaa gaatacttaa 180 aatgcctggg atagttcttg ggactaacaa catgatcttc tttgagttaa acctacctaa 240 gtagatttta ggtgggttcc tattaggtca gatttttagc ttccctaatt acctttcact 300 gacatataca gaaaaaggag cagttttagt tttaattaat taaaattaac agatgtgatg 360 aggattaaat gaatcaaaag acttaatttg tagattcttt tagagttatg agctaggtat 420 agtttgggga aactcaacct ggtg 444 <210> SEQ ID NO 103 <211> LENGTH: 516 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 103 gatgaatgcg gctgttaaga cctgcaataa tccagaatgg ctactctgat ctatgttgat 60 aaggaaaatg gagaaccagg cacccgtgtg gttgctaagg atgggctgaa gctggggtct 120 ggaccttcaa tcaaagcctt agatgggaga tctcaagttt caacaccacg ttttggcaaa 180 acgttcgatg ccccaccagc cttacctaaa gctactagaa aggctttggg aactgtcaac 240 agagctacag aaaagtctgt aaagaccaag ggacccctca aacaaaaaca gccaagcttt 300 tctgccaaaa agatgactga gaagactgtt aaagcaaaaa gctctgttcc tgcctcagat 360 gatgcctatc cagaaataga aaaattcttt cccttcaatc ctctagactt tgagagtttt 420 gacctgcctg aagagcacca gattgcgcac ctccccttga gtggagtgcc tctcatgatc 480 cttgacgagg agagagagct tgaaaagctg tttcag 516 <210> SEQ ID NO 104 <211> LENGTH: 85 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 39 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 104 cctttcccag ggcagagtgt ttggtttttg tgtgttacnt gcacttgggg atggagatgt 60 ttgattcgat gttggggttt ggaag 85 <210> SEQ ID NO 105 <211> LENGTH: 223 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 105 ccttagttct accatagagt atcttctcta attaaaatga ctgggaaata tatggaagca 60 gaaaccagca caaagcacta cccatctaga aataatcttt cagttaaaaa acaactctca 120 aaaccagcac tcatttctct aagataggtt ataagtattt tacgatttct tgttatatta 180 aattgagtta aaggtactga caagtcaata tgcaaatggg ttt 223 <210> SEQ ID NO 106 <211> LENGTH: 345 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 106 gagcgagtct gggtctcagc cccgcgaaca gcctttcacg agtcttcaag ctttcaggct 60 atcttctagt caagatgagt gataagccag acttgtcgga agtggagaag tttgacaggt 120 caaaactgaa gaaaactaat actgaagaaa aaaatactct tccctcaaag gaaactatcc 180 agcaagagaa agagtgtgtt caaacatcat aaaatgggga tcgcctccca acagcagatt 240 tcgacattac ctgagagtct tgattttagg cttgtttttt gtaaacccat gtgtttgtag 300 agattttagg cgtcttcgga tatcttctca cctatgttcc ctggc 345 <210> SEQ ID NO 107 <211> LENGTH: 414 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 107 ctgggaacct gcttggggtc cccctcaaac ctgtgtctgg ggtgtgggct cacagatccc 60 tatcagcctg gttcgtggga gggctcttcc taaagggacc cccatctcta agtcactctg 120 aaagggagtt gtggagagga gacgcctcca gactctcaga agttttgagg actgaactgg 180 gtcactcggg atctgtgttc gaatcctccc cacccctttc tttgtggagt ttcctaacct 240 gctgctgaag cacaatgttt tggtgctttc ttttctcatt tgttaaaggc agtgtccaaa 300 agccattcca gatgccaaga ccaggggctt atttctaggg aaggtaggtc ggtttccatg 360 tttccctccc gttattttta ttttttactt tttgcctgag acaagccgag tatg 414 <210> SEQ ID NO 108 <211> LENGTH: 279 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 108 aaatattttg ccagatttct tgtatttatt ccacatcatt atgcctataa tgtgccgctt 60 tgtgattggg catttgccta cttttctttc ataattagtg atatatgcga tgtaaaacca 120 ctagtaaagg tacattttaa tacttgttat tttatactga attagccttg gaggttgact 180 gtgcaatgtt atttactgtt gtaattactg taataccaac atatgggccc catctgcaca 240 ctcctgaaaa acagaaagtg tattcaaatt ttatcagtt 279 <210> SEQ ID NO 109 <211> LENGTH: 114 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 109 aaactcaaag catctgattc aacgtaaaag gaggcccgcc tctctcatca aatttctcgt 60 gttaacgtga acttcgcaga aaaaggtcag tttcaaaacc tgtgaacttc ccag 114 <210> SEQ ID NO 110 <211> LENGTH: 354 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 110 aaaaaactcg gttgtgaggt ttgcccagag gcacttgttc cagaatttcc cctcctgctt 60 cagccatgtc cttgtcactt ggcattctaa gctaaagctt tagcttccca attcgtgatg 120 tgctaggcca agattcggga gctgttgcca gcctcgtcaa atatggaaga gaaacaacct 180 gcggtcaaaa gggagtgatt tgttaagtgg tgcgcgtcta tctcataact agatgtacca 240 accagggaag ggccaaggat ggaaaggggt aacttttgtg cttccaaagt agctaagcag 300 aagtggggga gcagtttagc cagatgatct ttgattaggc aaacattgag tttt 354 <210> SEQ ID NO 111 <211> LENGTH: 211 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 111 cctcactggc ctgtcctgct cagcttgggc cagtgacaat ctgcaaggct gaacaacagc 60 ccctggggtt gaggcccctg tggctcctgg tcaggctgcc cgttgtgggg aggggcagtg 120 ttagagcagg gctggtcata ccctctggag ttcagaggaa gaggtaggac cagtgctttt 180 ttgtttcttt tgttattttt ggttgggtgg g 211 <210> SEQ ID NO 112 <211> LENGTH: 394 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 112 aaagtttgaa aaccactcat ctagttttat tcccttttta ctcaaataag gacactgagg 60 cacagaaagt gaaggagact tgctcagggt cacacagcga gccggggatt aatatgcaaa 120 tggatctcat gtttccagaa tcccaggcca gtctccttct gctgcatagt acagaaggtg 180 atgccatccc aatattttag acatggaatg gcaggcttac aggcggaaag ttcacttcca 240 acaaggactc caaaatgtaa tgcacaatgt gagcggtgtg aaagtgtgcc ttaaaagttg 300 ggatgagtct tgataagagt ccctgaagcc tgtggattgg caacatctgc ctttacatag 360 ttttgagatg accctgagta gcagcaccgt ggag 394 <210> SEQ ID NO 113 <211> LENGTH: 66 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 113 caagctgcaa agtttatttc aaaatgggtt ccttatatag ggaggggagc gggtagagac 60 ggcaaa 66 <210> SEQ ID NO 114 <211> LENGTH: 331 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 114 acaagtttga ccatgcaatg gtggctttcc tggactgtgt gcagcagttc aaagaagagg 60 ttgagaaagg cgagacacgt ttttgtcttc cctacaggat ggatgtggag aaaggcaaga 120 ttgaagacac aggaggcagt ggcggctcct attccatcaa aacccagttt aactctgagg 180 agcagtggac aaaagctctc aagttcatgc tgacgaatct taagtgggat cttgcttggg 240 tgtcctcaca attttataac aaatgacttt tttccttagg ggaggtttgc cttaaaggct 300 tttaattttg ttttgtttgc aaacatgttt t 331 <210> SEQ ID NO 115 <211> LENGTH: 156 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 115 aaaaacaaac tatacagaag acttcatacc gtaacaataa atgtatagtt tcttcaaagg 60 gagaagagat tcacatatct gataacaaaa taaactagca atctagtttt ctaatctact 120 ttatgaggct ggattttttt ttagaaaagc taattt 156 <210> SEQ ID NO 116 <211> LENGTH: 469 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 116 cctcatcgaa ctgtttctga acctggaagt taaggatggc agtgatggct caaaggaatt 60 cagccttggg atgtggagct gtctccatgc agtgctggag ctgattgatt cccaacagca 120 agatcgatac tggtgcccac ccctgctgca tcgtgccgcc attgcctttt tgcatgctct 180 gtggcaggat cggagggaca gtgccatgct ggtcctccga accaaaccca agttttggga 240 aaatttaacc agtccgctgt ttggaaccct ttctcctccc tctgaaacat cagagcccag 300 catcctggaa acctgcgccc taatcatgaa gataatttgc ttggagatat actatgtagt 360 aaagggttca ttagaccagt cattaaagga tacactgaag aaattttcca tcgagaaaca 420 ctttgcctac tggtcagggt atgtcaagtc attggcagtt cacgtggcc 469 <210> SEQ ID NO 117 <211> LENGTH: 426 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 117 aaagtttgaa aaccactcat ctagttttat tcccttttta ctcaaataag gacactgagg 60 cacagaaagt gaaggagact tgctcagggt cacacagcga gccggggatt aatatgcaaa 120 tggatctcat gtttccagaa tcccaggcca gtctccttct gctgcatagt acagaaggtg 180 atgccatccc aatattttag acatggaatg gcaggcttac aggcggaaag ttcacttcca 240 acaaggactc caaaatgtaa tgcacaatgt gagcggtgtg aaagtgtgcc ttaaaagttg 300 ggatgagtct tgataagagt ccttgaagcc tgtggattgg caacatctgc ctttacatag 360 ttttgagatg accctgagta gcagcaccgt ggagtagaga ggggaccaag gagggccagg 420 tgccct 426 <210> SEQ ID NO 118 <211> LENGTH: 502 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 439 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 118 aaaatttatt caccccagtg ttcactccca ccttagcccc attccatgcg cccttaccct 60 tactcatcgc agtatcaaaa taactcccaa atgggattgc tgtgcttgaa cacctcccat 120 catgcctctt accttctgca tgcatttagt tagttcctga agcatacagc cccctcacct 180 gcaagccccg cctcagcgca cacccttgcc aggttggagg aagtcctggt acccggagca 240 gtttgctttg tttttgcagt gtcagtgatc tcacaagcac ttggttggcc acacagtcct 300 atcgataact tccagcagat aacccaagtg ggtgactggg ggggtggaag ccaggtctcg 360 gttcctgtgt gtgacccaag gccccccagc acagggccca ccctctcatc tggctcagcc 420 aggtcttgca gaatgggcnt ctgctgagat ctaaccagac acatttgcta tctgttaggt 480 gagctcattc ctggaaccta gc 502 <210> SEQ ID NO 119 <211> LENGTH: 462 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 119 gtggggaaaa atgccctctt gtgggctcca atgtcccctg ggcctttatg caaggggaaa 60 ttgcaaccat ccttgctgga gatgtgaaag tgaaaaaaga gagagactcg tgacttttcc 120 ggtttcagaa aaacccaatg attaccctta attaaaactg cttgaattgt atatatatct 180 ccatatatat atatatccaa gacaagggaa atgtagactt cataaacatg gctgtataat 240 tttgattttt tttgaataca ttgtgtttct atattttttt tgacgacaaa aggtatgtac 300 ttataaagac atttttttct tttgttaacg ttattagcat atctttgtgc tttattatcc 360 tggtgacagt taccgttcta tgtaggctgt gacttgcgct gcttttttag agcacttggc 420 aaatcagaaa tgcttctagc tgtatttgta tgcacttatt tt 462 <210> SEQ ID NO 120 <211> LENGTH: 462 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 437 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 120 gtggggaaaa atgccctctt gtgggctcca atgtcccctg ggcctttatg caaggggaaa 60 ttgcaaccat ccttgctgga gatgtgaaag tgaaaaaaga gagagactcg tgacttttcc 120 ggtttcagaa aaacccaatg attaccctta attaaaactg cttgaattgt atatatatct 180 ccatatatat atatatccaa gacaagggaa atgtagactt cataaacatg gctgtataat 240 tttgattttt tttgaataca ttgtgtttct atattttttt tgacgacaaa aggtatgtac 300 ttataaagac atttttttct tttgttaacg ttattagcat atctttgtgc tttattatcc 360 tggtgacagt taccgttcta tgtaggctgt gacttgcgct gcttttttag agcacttggc 420 aaatcagaaa tgcttcnagc tgtatttgta tgcacttatt tt 462 <210> SEQ ID NO 121 <211> LENGTH: 219 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 121 cctgttcctc acaggcttcc aggttaggca ctgtgaatag gctcagctcc tctagagagc 60 tgaagccatc tggttcttag attcctctcc cagtcctctt tcccattgtt ctgttgctcc 120 accttattgt ctcaaggccg taatctcatc aggttgggac attaatcccc tcaactcctt 180 gtaagatttc ccggtttggt ttctctacat gtcctgcag 219 <210> SEQ ID NO 122 <211> LENGTH: 116 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 34 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 122 atgaggacgc tgggtaactt tcatggaacc ctgnatgaga tggcaagata tgaagacccc 60 agaggccagt ggtgatagcc agagctgctc ttcctgtccg tggtgaatgg ctcagg 116 <210> SEQ ID NO 123 <211> LENGTH: 446 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 123 ctggaaggcg ccatccaatc gtccttcccc tccccagcag aactccagag gtggggcggc 60 tgccgcaggg cccaaggctg cctcggcagg gggctttgtg ctttttgttg tggaggccac 120 cagggattca ggaagatcct gaatgggttg tcaattgact gaaaagtaaa ttcccagtga 180 gtttgaacct ccacggtttt tgagacagta ttaaaagctt gagaacggag attatggatg 240 gcaccaggct gggcactgcc attcttttac tttccttcat gcattttttc ggatccagag 300 tattaacacc acttttttta ctctgcccat tcaaaaacag taggcaaatt gggggaacca 360 atttataatc actcaagccc actgccaaag ttcggataag ccagggcaga ggggttagat 420 tccccccccc cgtaggcaga gagagg 446 <210> SEQ ID NO 124 <211> LENGTH: 424 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 124 cctaggccaa actcttcaga agtcacgaca cacagatgtg ggccccggtc acgcctcatg 60 agctgtctct gggaagaaaa tctcccggca tcgctgcacc gtgtcctgag gagacaccac 120 gctgtggcca acagtccggg ggtcggcaaa gatctcaaag tcgttcccac cagggctagt 180 ctcgttccca aagaagtgga tggtgtcgaa gctgtcctgg tccaggctat ccaggcagta 240 gcgcttgtcc cagccctcgg ggaagacgtc aaagctgatc atgcctcctc gagagaacct 300 cagccctttg ccagcaaact ctgttttcag ggcttccacg aacttctccc ggatcttctc 360 tttcttgtcc agttcggaga actcgatcct ctcctccagg gtgcagctcc ggccgatggg 420 cgag 424 <210> SEQ ID NO 125 <211> LENGTH: 172 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 125 aaatccttac gttcaggtgt ttgtaacttg gccttataat taggctgaat tatggcttca 60 aggtctacaa tttatgtgta tggttcacag cctagcttct atttacattt gaaaatacag 120 atttttacca actttggatt cttttttagt tatatgtttg tctttccttt tt 172 <210> SEQ ID NO 126 <211> LENGTH: 329 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 126 aaagatagtt cccctgagac cacttgtaaa taggttagat tggttccctg tggtgaccta 60 gagaaaaaat agacttgttt ctgctctcat ttttgtcatc gtctgacttg aagattcaga 120 caccttctcc ccaggagatg tatgccatca aattgccagt cacctctttg tctctctctt 180 ctttctgagt atggtttcta ttctgtgttt cgaattttta ttttctaatg cagtggaaaa 240 gaaacagatc atcctaaatg aggaggtaac agggaaagca ctggggttcg ggttctgcat 300 cttctggatc aattcacgga acagagatc 329 <210> SEQ ID NO 127 <211> LENGTH: 361 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 127 ccttttggaa aagccctaaa agaataagat acaaccagaa atatttgagt tttgttaaat 60 gtactgaaat cttgtaatga aaatcccttt ggccagaaat gagatttatt tccatttatt 120 tttacattta agtaacactc aaaacaaaca agtagtcact taacctgcca gttattattt 180 tcttgaaaat atacaagaaa gtaaaaatat ctctaatata taagttaaag gaaagttaag 240 agactaagct agttttttca gtgaaagcaa agttggaaat attttgcttc tctcagatta 300 ttggaagacc tagagctact ggatgttaac ctgaatcaag atgttctttt cacatttttt 360 t 361 <210> SEQ ID NO 128 <211> LENGTH: 482 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 398, 480 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 128 cctcagcaat ggctgtggtg ttgctcagca tgcacacagc tctctgtacc ttggccaggt 60 ctccaccagg caccacagtg ggaggctggt agttgatgcc aaccttgaag ccagtggggc 120 accaatccac aaactggatg gtacgcttgg tcttgatggt ggcaatggca gcattgacat 180 ctttgggaac cacgtcacca cggtacaaca ggcagcaagc catgtattta ccatggcgag 240 ggtcacattt caccatctgg ttggctggct caaagcaagc attggtgatc tctgctacag 300 aaagctgttc atggtaggct ttctcagcag agatgacagg ggcatatgtg gccagaggga 360 agtggatgcg gggatagggc accaggttgg tctggaantt ctgtcaggtc aacattcagg 420 gctccatcaa atctcaggga agcagtgatg gaggacacaa tttgacctat taacctattn 480 ag 482 <210> SEQ ID NO 129 <211> LENGTH: 164 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 129 ggaaagccca tacaaatcca ctatcaccaa ctagcaacgc gtgatctaga atatggcaga 60 ctgtagccgg ttcccctcct acgggagcag cataccgctc gacactatgc tttacgaagg 120 taatggacac cgctaggtgc aaggcaaggc actgcaagga gagg 164 <210> SEQ ID NO 130 <211> LENGTH: 173 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 130 aaaagcacat ccaactaaat caaaaaaggg aggattagaa atcacactag ttcatccttc 60 attatcaggg ctggcttcaa acctgaatgt ttctgagtgg gatatgttgc aaaaaaaaaa 120 attaaactag atccaagtta catttcctct aaaaaaaaaa tgtcaaagga cag 173 <210> SEQ ID NO 131 <211> LENGTH: 359 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 131 ccttaaaggt aaagctggag atgaaagagg aaagagtccg attcctagga cagcaaacct 60 tatgtaacaa tcaagtaaat gatttaacaa cagcccttaa ggaaatggag cagctattag 120 aaatgtaaga agaagcaagt ggccagatgg ctccctcttg ggcataaaat ctcagaggaa 180 gctacttagg acatcatctt ggccatgatc ttctgggact caccatctcc agaatgaaaa 240 caatttctac agtagactta aggacagttt atgctgaaat ggcaattcct catttaagca 300 agttttccca accttcaggt tggtcagccc tcctgagcct cacaggtgga taattgagg 359 <210> SEQ ID NO 132 <211> LENGTH: 165 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 132 cctctgaaag aggagcagag ctcagggcac ctggccctcc ttggtcccct ctctactcca 60 cggtgctgct actcagggtc atctcaaaac tatgtaaagg cagatgttgc caatccacag 120 gcttcaggga ctcttatcaa gactcatccc aacttttaag gcaca 165 <210> SEQ ID NO 133 <211> LENGTH: 287 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 133 aaaggaaaaa cgttatgtct tattacacca tgatcctgac taatagcttt tcaaaacttt 60 gagaaaaatc ttaaaaaagg tttcacatgt cacctgaaac ttacaaattt aacattatca 120 aagaaggaat gcttctacac tcttacaaag accactagaa agaaacaaca actaaaaagc 180 taagaaactg tctcaaaggc attttttttt acaatccttc ctccacagta aggtaatgtt 240 attaaataat ccaatccatt cacaaaatgg ctctctgcat ctgctct 287 <210> SEQ ID NO 134 <211> LENGTH: 344 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 134 ctcgaacaaa gacgcaaggc acttgcagac aatcccttcc tcaccggcct caatggactt 60 ctcccttacc tcctcccctt ccttggaccc ttattcgcta tcatcctgtt cttctctttt 120 gccccttgga tcctaagacg agtaacagcg ttaatcaggg atcagctcaa ttccctactg 180 ggaaagccca tacaaatcca ctatcaccaa ctagcaacgc gtgatctaga atatggcaga 240 ctgtagccgg ttcccctcct acgggagcag cataccgctc gacactatgc tttacgaagg 300 taatggacac cgctaggtgc aaggcaaggc actgcaagga gagg 344 <210> SEQ ID NO 135 <211> LENGTH: 212 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 135 ctgcttcctg cttgtctcag aaggttctag gacaaggaaa atggaactta aagcagcagt 60 attacacagg atacacagag aatgaagtat tggaagtcat gcagcacatg gccaagaatg 120 tggtgaaagt aaatgaaaac ttaactaaat tcatcgccat caagaataag tatgcaagca 180 gcaaactcct gaagatcagc atgatccctc ag 212 <210> SEQ ID NO 136 <211> LENGTH: 229 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 136 aaacaaagaa tggctacttc ataggcagag cagccacttt tggctaattt ttaacatcca 60 aagctaataa ataatcaaga agaaatagag aacattaaca aaataaatta tgttctattt 120 gggaatacct aatatcagat actaacaagt acagtgataa gaataaaaaa gataataatc 180 acacatacct tctaggttag tagaaaagtt aggaaaagat attaaattt 229 <210> SEQ ID NO 137 <211> LENGTH: 316 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 137 ctggacaaga agattatgac agattacgcc ccctatccta tccgcaaaca gatgtgttct 60 taatttgctt ttcccttgtg agtcctgcat catttgaaaa tgtccgtgca aagtggtatc 120 ctgaggtgcg gcaccactgt cccaacactc ccatcatcct agtgggaact aaacttgatc 180 ttagggatga taaagacacg atcgagaaac tgaaggagaa gaagctgact cccatcacct 240 atccgcaggg tctagccatg gctaaggaga ttggtgctgt aaaatacctg gagtgctcgg 300 cgctcacaca gcgagg 316 <210> SEQ ID NO 138 <211> LENGTH: 284 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 138 ctgctgaaat cctctgtgaa catgaggggg tacaggtgga gaaatgtacc ctcaggccct 60 cacctaccag agcaaatatc actctcggag ctgggccaca gccacaaacc gctgttctag 120 acagatccaa acccactgtc cctgggacgt atgctgcctt cccttactaa acttgctata 180 tggtagatgt ggactgggtg tccttggact atggggctgc atagaaacga gaatggaggc 240 cacgacatca tcctcttggc ccctggaggc acgggcggct ccag 284 <210> SEQ ID NO 139 <211> LENGTH: 248 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 139 acttgggtgt tgagattggc aaaaggggaa gcaagggaaa agccaaggaa agataaaata 60 ttcagaagaa agtcaaagtt atctgcaatt acatgttaga acagattttg caggttaaaa 120 agatgttgct taaatatatt cataagcctg ttgtaagatt ttcacttatg cagtttcaga 180 aaatttagct gcttaacata tgacagaact gtattttaac aaatgacatt aaaagtcagg 240 agagctac 248 <210> SEQ ID NO 140 <211> LENGTH: 166 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 140 ctgcactgcg cagccttctt catcagcgag cccgaggagt tcattaccat ccactacgac 60 caggtctcca tcgactgtca gggcggcgac ttcctgaagg tatttgatgg ttggattctc 120 aagggggaga agttccccag ttcccaggat catcctctcc cctcag 166 <210> SEQ ID NO 141 <211> LENGTH: 235 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 141 ctgtggtatg atcaagacta cgcgagattc gagtcccctc caaaaaccca gccaacagag 60 gacaacaagt tcaagttctg tgtgagctgt gcccgtctgg ctgagatgag gcaaaaagaa 120 atccccaggg tcctggagca gctcgaggac ctggatagcc gggtcctcta ctactcagcc 180 accaagaacg gcatcctgta ccgagttggt gatggtgtgt acctgccccc tgagg 235 <210> SEQ ID NO 142 <211> LENGTH: 212 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 40, 59, 86, 205 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 142 aagctttttt tttttttttt tttttttttt tgctactaan atgtttcagt ccacaaggng 60 tctcactcaa gttcctatga attcanaaca aggcaactag gcattaccct agttaggttt 120 ccccattcgg aaatccccgt ttcatagcat atttccggct ccacgaggct tatcgcaggt 180 aatcacgtcc ttcatcgact ttcanaccca ag 212 <210> SEQ ID NO 143 <211> LENGTH: 196 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 143 aagaaactta agtggggttc atacatagca tggcagaggg acactggaga ataaaatggc 60 atgcagagag gaacacgcgg gccagtggat gaggcttcta gacctggcag tgaactggag 120 tctatttgct tacacaaatt taaccttctc tccatgatgg aatacaagtg tttcttgcca 180 aaactcgcag ccccag 196 <210> SEQ ID NO 144 <211> LENGTH: 443 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 144 cctgggggca cagcagatga cttggtcgtc ttggtagttc ctggtcctgc agtggcggtc 60 ttggccgact tggatgcaga ggcattggca gcattcttgg tctccttgtc tttctcttcc 120 ccacgtgcag ctttgacctc aggagtggtg gtgggttttg ctgccttttc cacagattct 180 ttcttcttag gagaagccac cctggacact ttatccgagg attctttcaa gcccgctggt 240 tttggtgaag ctgccaaggg cttagacttc ccatcactct ttttgacagg tgaagatgac 300 ttggtctttg tacctggctt tttggttttg gtcttctctt tcagatcttt ctttagagct 360 ttgcccaggt tctgctcaat ggccaaggac ctgcccgggc ggccgctcca aaaggccagg 420 aaccgtaaaa aggccgcgtt gct 443 <210> SEQ ID NO 145 <211> LENGTH: 249 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 145 ggactgcaaa accccactct gcatcaactg aacgcaaatc agccacttta attaagctaa 60 gcccttacta gaccaatggg acttaaaccc acaaacactt agttaacagc taagcaccct 120 aatcaactgg cttcaatcta cttctcccgc cgccgggaaa aaaggcggga gaagccccgg 180 caggtttgaa gctgcttctt cgaatttgca attcaatatg aaaatcacct cggagctggt 240 aaaaagagg 249 <210> SEQ ID NO 146 <211> LENGTH: 185 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 146 ttgctactaa gatgtttcag ttcacaaggt gtctcactca agttcctatg aattcagaac 60 aaggcaacta ggcattaccc tagctaggtt tccccattcg gaaatccccg tttcatagca 120 tatttccggc tccacgaggc ttatcgcagg taatcacgtc cttcatcgac tttcagaccc 180 aaggc 185 <210> SEQ ID NO 147 <211> LENGTH: 283 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 169, 170, 280 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 147 ggagcacgta gtgcacagaa tacgtgagag ttgctctggc aggggcagaa tcctcacagg 60 atcgcctggg aggtgaggtg tgtgtgaccc actggatggg agggcaatga gtgtgcacat 120 acaaatgggg cagtgtgcat gcaacacact taggggagga gtggccccnn aattcagcac 180 gcacacaaca cacgagggag agaaccccca gatgagaaaa taggaaggag caatcatttg 240 tagatgggtg aaaaaagaat gaggttcaag ggagcgtgcn cca 283 <210> SEQ ID NO 148 <211> LENGTH: 429 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 148 ggagcacgta gtgcacagaa tacgtgagag ttgctctggc aggggcagaa tcctcacagg 60 atcgcctggg aggtgaggtg tgtgtgaccc actggatggg agggcaatga gtgtgcacat 120 acaaatgggg cagtgtgcat gcaacacact taggggagga gtggccccag aattcagcac 180 gcacacaaca cacgagggag agaaccccca gatgagaaaa taggaaggag caatcatttg 240 tagatgggtg aaaaaagaat gaggttcaag ggagcgtgca ccaggtgagg tgagcgtgtg 300 tgctctcagg gaagggccca ggatcccatg cctgggagga gctgccagag agaagcaaaa 360 aggcggctgt ggatcgccct gggctgggca ccagtgacag gtcaggatct ccaaacatgg 420 acgtcctcc 429 <210> SEQ ID NO 149 <211> LENGTH: 185 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 149 ccggtcgtcg cgacgttcgc ccgctcgctc tgaggctcct gaagccgaaa ccagctagac 60 tttcctcctt cccgcctgcc tgtagcggcg ttgttgccac tccgccacca tgttcgaggc 120 gcgcctggtc cagggctcca tcctcaagaa ggtgttggag gcactcaagg acctcatcaa 180 cgagg 185 <210> SEQ ID NO 150 <211> LENGTH: 263 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 244 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 150 aaaaaatcta caagaagacc tcgaacaaag acgcaaggca cttgcagaca atcccttcct 60 caccggcctc aatggacttc tcccttacct cctccccttc cttggaccct tattcgctat 120 catcctgttc ttctcttttg ccccttggat cctaagacga gtaacagcgt taatcaggga 180 tcagctcaat tccctactgg gaaagcccat acaaatccac tatcaccaac tagcaacgcg 240 tganctagaa tatggcagac tgt 263 <210> SEQ ID NO 151 <211> LENGTH: 107 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 151 aaaactttcc aagctagcta cttattttca ttttcagggt tgagtactct aagctctcta 60 cttactgtga gaagttttct acattgtaaa attaaaagat tatattt 107 <210> SEQ ID NO 152 <211> LENGTH: 306 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 152 ctagattccc tagccgaagt agtcctccaa aacagaagag gcttagacct actcactgca 60 gaacagggag gtatctgttt ggctctacag gaacgttgct gcttttatgc caacaagtca 120 ggaattgtcc gagataaaat aaaaaatcta caagaagacc tcgaacaaag acgcaaggca 180 cttgcagaca atcccttcct caccggcctc aatggacttc tcccttacct cctccccttc 240 cttggaccct tattcgctat catcctgttc ttctcttttg ccccttggat cctaagacga 300 gtaaca 306 <210> SEQ ID NO 153 <211> LENGTH: 85 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 153 ccttggcgat tgctcaatat aattttggaa ttttaggatg cagcatttca ggtaagtgac 60 agttatgttt tagaagaggt cattt 85 <210> SEQ ID NO 154 <211> LENGTH: 214 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 154 ctttgtgtaa gaaaatcatt aaagaaaaac aagcttttga aagactggga gttaagaaag 60 aaactttact ggcaatgttt aagtacaaca agttcaaatg ccggatattg aatgaaaagg 120 tgaatactcc aactaccaca gtctatagat gtggcccttt gatagatctc tgccggggtc 180 ctcatgttag acacacgggc aaaattaagg cttt 214 <210> SEQ ID NO 155 <211> LENGTH: 290 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 210, 211, 212 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 155 aaagtgagat taattgaaga tctcagaaaa actgtatctg atcaacacac atggctactc 60 acagaaagtt ctctcttctg ttaatagcag ctaaatttat acacacagaa aaaattccga 120 agaccatgca aattcaattg aattccatac attcattata ttcatcaaaa acctgcagta 180 atgttcatgc caaagtgtta atttaagacn nnaattaaaa atacacacca aaacatgacc 240 aagattaaac taaagaaaat aataaataag cataatttat attgtatttt 290 <210> SEQ ID NO 156 <211> LENGTH: 160 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 142 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 156 gcggcgcttg gctggtgggg cccgcggcgg gattttcccg ggcggcgaga gcggatctat 60 cttgggatcc catggctttc tttactgggc tctggggccc cttcacctgt gtaagcagag 120 tgctgagcca tcactgtttc ancaccactg ggagtctgag 160 <210> SEQ ID NO 157 <211> LENGTH: 145 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 132 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 157 aaggtgcaca aaacaacagc tttgatattc cggttggcgt tgccaacttt gtaaactgct 60 ccagtagttc caaccacagt gaggcccttt gccctggccc aggccaagct tttgtttgcg 120 gcaacaacct cncctttact gctct 145 <210> SEQ ID NO 158 <211> LENGTH: 294 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 158 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgagc cgcc 294 <210> SEQ ID NO 159 <211> LENGTH: 531 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 107, 108 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 159 aaacaaattg cagagaatag agaaaaaaat aggttattta cagaaaacaa tatctacata 60 tgtacttaga ggtacaaatt tagtgacaga aaagacttca gtatatnntg gcatcttaga 120 agcagttctc aaagagctta gttttatttt cttgaatttt aagaatgcct aagatccttc 180 ttcatcctcg atcttgggag ccaagtagta ttttaagtgt cccatatccg caattttata 240 ctctacaaca aggggtacat ctgcagacat actgagtgtc accgttgaag agagtggagt 300 ggcttttgta aagaagttca ggtacctcag tgcaaaagtt agttgaactg gttcattcat 360 ctctatggta acagcttcct cctctttatc gacattactt gtctgtgaca atttaatgtt 420 tccatttcca agttctccac ttgcagaaaa tttcactccg tcttttgcac aggaaattac 480 aacagcatct ccaatatggc tgagatctcg gcatatacgt gcaaattcac c 531 <210> SEQ ID NO 160 <211> LENGTH: 464 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 160 ctgaagctag actatctaca gacaaaattt gcaacaaatc tgatgcactg taaattcaag 60 tcctcaggac aacaaaagtg attaagcaag acctcaagta acaatgttaa tgccatttac 120 aaaggaaaaa actgatacaa aaacattcaa aacctgaaca tcacttggca tgtaagggaa 180 aaaaaattaa attagctgaa aggttcataa acacaaggtc ttatttacat tacacaaagc 240 tcaggtgtta gccttgaacg taactttcaa aataccttca aatatatcca actcagatca 300 cttttgctga tttgctgcag tacaaatcat gtgcaacgtc ttttttcctt aagacaaaac 360 aattcttcaa acaatactgc aagtacatca ctaaacacca tgagctctat ctgaagggat 420 ttctttagga agaacagatt ttttccccca tctctcggta attt 464 <210> SEQ ID NO 161 <211> LENGTH: 314 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 43, 44, 52, 71 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 161 cattgtccta caaaaaactc ataaccttcc cttcttgaca ganncacata gnaatgttgg 60 acaggactga ncccggttcc agatcaaatc aaacttttct gcctgtttta tttcttctgc 120 agttttttct tttaccatct caatgttaaa gattgaactg agagtcttgt ccttagtgaa 180 tcctctgttc acagactgtt tccccaaggc atctgtcttc tgttccacac atttgataaa 240 atcaccttgc ctggaatgcc ccactggctg cttccgaaat tcactgcgtt tctccaggcg 300 ggactcaaaa gcag 314 <210> SEQ ID NO 162 <211> LENGTH: 429 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 73, 83, 92, 148, 362 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 162 ctgacatccg gctgcctgag ggctacctgg agaagctgac cctcaatagc cccatctttg 60 acaagcccct canccgccgc ctncgtcgtg tnagcctatc tgagattggc tttgggaaac 120 tggagaccta cattaagctg gacaaacntg ggcgagggta cctatgccac cgtctacaaa 180 ggcaaaagca agctcacaga caaccttgtg gcactcaagg agatcagacc ggaacatgaa 240 gagggggcac cctgcaccgc catccgggaa gtgtccctgc tcaaggacct caaacacgcc 300 aacatcgtta cgctacatga cattatccac acggagaagt ccctcaccct tgtctttgag 360 tncctggaca aggacctgaa gcagtacctg gatgactgtg ggaacatcat caacatgcac 420 aacgtgaaa 429 <210> SEQ ID NO 163 <211> LENGTH: 349 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 163 aaaggtgata aacacaaaac ctcgtctttt gttcaacttt ggatccattg gcaattcaat 60 ggcctcaatc tccccaaact cgccaaagta ctccctgatc ttttcctcag tggcttcagg 120 attcagaccc ccaacgaaga ttttcttcac cgggtccttc ttcatagcca tggccttttt 180 agggtcaatg acacagccat ccagcctgtg ctccttctgg tctaggacct tctccacact 240 ggctgcatct ttgaacagga taaacccaaa ccctcttgac cgtccagtgt tgggatccat 300 ttttattgta cagtcaacga cctctccaaa tttagtaaaa tggtctttt 349 <210> SEQ ID NO 164 <211> LENGTH: 172 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 164 aaaaaaagag gaggcggacc ttaaccagct aggggaggta gaggctgtgc tcctcctgag 60 ccttaatttt caggcttaca ggtacctttt tgggaggaga ggatttttcg agtaccaacc 120 tctatgcaag ccagcttacc tctcaggaga ctcgacagta gccttagtaa gg 172 <210> SEQ ID NO 165 <211> LENGTH: 183 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 165 aaattagtgt gtaattgttt ttctcctcct atctattcgg acatgacaat aattataaat 60 gtaggtcaca ctacaactag gtagtctcta gggaccatga cctgctgaca caaggccgat 120 aacaaagagg cttttccaca aatgaggtgc tcccagttat gctcagatat ctggggagag 180 gcc 183 <210> SEQ ID NO 166 <211> LENGTH: 501 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 488 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 166 gctcgctatg acagggagat gaaaaattac gttcctccca aaggtgataa gaaggggaag 60 aaaaaggacc ccaatgctcc taaaaggcca ccatctgcct tcttcctgtt ttgctctgaa 120 catcgcccaa agattaaaag tgaacaccct ggcctatcca ttggggatac tgcaaagaaa 180 ttgggtgaaa tgtggtctga gcagtcagcc aaagataaac aaccatatga acagaaagca 240 gctaagctaa aggagaaata tgaaaaggat attgctgcat atcgtgccaa gggcaaaagt 300 gaagcaggaa agaagggccc tggcaggcca acaggctcaa agaagaagaa cgaaccagaa 360 gatgaggagg aggaggagga agaagaagat gaagatgagg aggaagagga tgaagatgaa 420 gaataaatgg ctatccttta atgatgcgtg tggaatgtgt gtgtgtgctc aggcaattat 480 tttgctanga atgtgaattc a 501 <210> SEQ ID NO 167 <211> LENGTH: 246 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 167 cctttttttg tttgttttaa tttttgctag attgatatta aaaactcatg tggaggaact 60 caaggaatgt ttagaagacc aaaagtcccc aatgacagga acaaaagcaa ccaattttta 120 actttctctt ctcattcctg ttttcattga tttcccacat gtagtccttt tgctcaggaa 180 gtctttgggg aaattaagga tctttgaagc tctgaaatag gtgatcaggt tagtggtgtc 240 tgtcag 246 <210> SEQ ID NO 168 <211> LENGTH: 145 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 168 ccttcggcac caccggcttc caagcaacca acttcgggcg cgctgtacag caagtcaatg 60 ccatgatcga gaagaagctg gaaccactgt cacaggatga agaccagcac gcggacctga 120 cccagagccg ccgcccactt accag 145 <210> SEQ ID NO 169 <211> LENGTH: 92 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 169 gacgagtaac agcgttaatc agggatcagc tcaattccct actgggaaag cccatacaaa 60 tccactatca ccaactagca acgcgtgatc ta 92 <210> SEQ ID NO 170 <211> LENGTH: 416 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 170 ttggtgcagc ttggtcaact ctagaggtgg tccctccagg tcagggttga ggcacatgga 60 cggggtggtg tggggaaagc tcgcactgtc gctgcctgtg ctgtacctgt cctgaccacc 120 tgcaaagatg accggagagc tggacggctt gggccggtac gggatggtca cgcccttcgg 180 gggggactcc aacatgacca cgcagatctg tttgacacac tcaatgatgg attgtggaat 240 gccagcaata gtgatggccc gctcagttga gttgggtagc atatcccctg ccacctggac 300 ctgagcccct gtactctctc gtatttcctt gatcttgcat ccaccttttc caatgagaga 360 gccacactga ctagcaggga ccaccagcct cagggtgacc gggggtctac tggcag 416 <210> SEQ ID NO 171 <211> LENGTH: 221 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 171 atttggagga aatgtgatca ggcaacaagt caaggataac gccaaatggt atatcactga 60 ttttgtagag ctgctgggag aactggaaga ataacatcca ttgtcgtaca gctccaaaca 120 acttcagatg aatttttaca agttatacag attgatactg tttgcttaca gttgcctatt 180 acaacttgct atagaaagtt ggtacaaatg atctgtactt t 221 <210> SEQ ID NO 172 <211> LENGTH: 255 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 172 cctacagggt tactctgggg acagtttaat aataatactg ctactttaga gcactaacac 60 acacaaagtg aatccaataa agctctgggc attgattcaa tatttagtat taattgcatg 120 accatcatag cacctcttta catcacacaa tcaccagaat tagaaattga tttgaaaact 180 aaaaacaggg cacagtccaa taattagaat tgcacactgt tactatatag aaaccaggtg 240 catggtacag tgcag 255 <210> SEQ ID NO 173 <211> LENGTH: 372 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 173 cgcggcgtcc ggaggcccca gggttatgag actatcactg ctcaggacct actaacaaca 60 aaggaaatcg aaacatgacc aaatcgtaca gcgagagtgg gctgatgggc gagcctcagc 120 cccaaggtcc tccaagctgg acagacgagt gtctcagttc tcaggacgag gagcacgagg 180 cagacaagaa ggaggacgac ctcgaaacca tgaacgcaga ggaggactca ctgaggaacg 240 ggggagagga ggaggacgaa gatgaggacc tggaagagga ggaagaagag gaagaggagg 300 atgacgatca aaagcccaag agacgcggcc ccaaaaagaa gaagatgact aaggctcgcc 360 tggagcgttt ta 372 <210> SEQ ID NO 174 <211> LENGTH: 243 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 174 cggatcggct cacgcagctt caggacgctg tgaattcgct tgcagatcag ttttgtaatg 60 ccattggagt attgcagcaa tgtggtcctc ctgcctcttt caataatatt cagacagcaa 120 ttaacaaaga ccagccagct aaccctacag aagagtatgc ccagcttttt gcagcactga 180 ttgcacgaac agcaaaagac attgatgttt tgatagattc cttacccagt gaagaatcta 240 cag 243 <210> SEQ ID NO 175 <211> LENGTH: 154 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 175 tacaaatcca ctatcaccaa ctagcaacgc gtgatctaga atatggcaga ctgtagccgg 60 ttcccctcct acgggagcag cataccgctc gacactatgc tttacgaagg taatggacac 120 cgctaggtgc aaggcaaggc actgcaagga gagg 154 <210> SEQ ID NO 176 <211> LENGTH: 350 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 176 cgctcggccc gtggtattgg aactaacctg tccctgactt ctggtaacgg gaaaagccat 60 aactcccgcg ggaggtagaa gggccaaatc ggacagtttt gtgactaagg ttttaacccc 120 atcaagaaga gaaacagtct catcaatggg accggagggt ttggctaggg ctacaccggg 180 caagtttggg gccgtggggg aaccaggaac gcctgaagta ggggcatgca aaacaggagc 240 cgcaactgcc actgggggca ctgctgtaga aacataggac ggtggccgga aaggtggcaa 300 tgccggggtg ttagttaatt ggggccaatc agggttgtta tattgggcag 350 <210> SEQ ID NO 177 <211> LENGTH: 159 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 177 aaagtctttc cgtctcccta aaataaaaac cagaatcata attttcaaga gaagaaaaaa 60 ttaagagata cattccctat caaaacatat caattcaaca cattacttgc acaagcttgt 120 atatacatat tataaataaa tgccaacata cccttcttt 159 <210> SEQ ID NO 178 <211> LENGTH: 430 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 422, 423 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 178 cctccttcgg ccttcttcct cttctgctct gagtatcgcc caaaaatcaa aggagaacat 60 cctggcctgt ccattggtga tgttacgaag aaactgggag agatgtggaa taacactgct 120 gcagatgaca agcagcctta tgaaaagaag gctgcgaagc tgaaggaaaa atacgaaaag 180 gatattgctg catatcgagc taaaggaaag cctgatgcag caaaaaaggg agttgtcaag 240 gctgaaaaaa gcaagaaaaa gaaggaagag gaggaagatg aggaagatga agaggatgag 300 gaggaggagg aagatgaaga agatgaagat gaagaagaag atgatgatga tgaataagtt 360 ggttctagcg cagttttttt tttcttgtct ataaagcatt taacccccct gtacacaact 420 cnntcctttt 430 <210> SEQ ID NO 179 <211> LENGTH: 467 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 376, 377 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 179 aaaatgtgta aaaattactg tgataaaaaa taatgaaaaa gcttcttaat aatgccatac 60 acagtataat atagatttgt ccccattata tagcatttaa tatacaaaat agaatattga 120 cacacttgaa tctatatgta gttaagcaag ttatttgagg agggtatttt catacagcct 180 ttcatcagaa aataaaatcc tttcagacat tttctagaga gaagcaaatc ctttcctgaa 240 aacctggtca ctaatcctgg gtggaccagg ttgcttgaaa atagtctggg aaattacgaa 300 actccaccca aagggtttcc tttctgcagg gcagcaaggc catccacctt gccgatggtg 360 atgaaggcat ggaagnnatt tcggtagtgc cgctggtatg tgccaggggc ctgcagttct 420 ccttgcaact gcatcctggt cttcaccacc tccaggggat tggtgaa 467 <210> SEQ ID NO 180 <211> LENGTH: 327 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 11, 16, 35, 38, 43, 49, 58, 88, 104 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 180 agaagacctc naacanagac gcaaggcact tgcanacnat ccnttcctna ccggcctnaa 60 tggacttctc ccttacctcc tccccttnct tggaccctta ttcnctatca tcctgttctt 120 ctcttttgcc ccttggatcc taagacgagt aacagcgtta atcagggatc agctcaattc 180 cctactggga aagcccatac aaatccacta tcaccaacta gcaacgcgtg atctagaata 240 tggcagactg tagccggttc ccctcctacg ggagcagcat accgctcgac actatgcttt 300 acgaaggtaa tggacaccgc taggtgc 327 <210> SEQ ID NO 181 <211> LENGTH: 417 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 169, 190, 246, 286 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 181 ttggtgcagc ttggtcaact ctagaggtgg tccctccagg tcagggttga ggcacatgga 60 cggggtggtg tggggaaagc tcgcactgtc gcctgcctgt gctgtacctg tcctgaccac 120 ctgcaaagat gaccggagag ctggacggct tgggccggta cgggatggnc acgcccttcg 180 ggggggactn caacatgacc acgcagatct gtttgacaca ctcaatgatg gattgtggaa 240 tgccancaat agtgatggcc cgctcagttg agttgggtag catatnccct gccacctgga 300 cctgagcccc tgtactctct cgtatttcct tgatcttgca tccacctttt ccaatgagag 360 agccacactg actagcaggg accaccagcc tcagggtgac cgggggtcta ctggcag 417 <210> SEQ ID NO 182 <211> LENGTH: 171 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 182 tggatctctg gcggggtgca gaactgagcc caggccacag taccctattc acgctctgtg 60 cttgtgccaa gggggcaatg gcggcttcct gtgttctact gcacactggg cagaagatgc 120 ctctgattgg tctgggtacc tggaagagtg agcctggtca ggtaaaagca g 171 <210> SEQ ID NO 183 <211> LENGTH: 231 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 183 aaagatggaa tcagaaacta cgtggtgtgg aggctgttga tgtttctggt gtcaagttct 60 cagaagttgc tgccaccaac tctttaagaa ggcgacagga tcagtccttc tctcgggttc 120 tggcccccaa ggtcagagca agcatcttcc tgacagcatt ttgtcatcta aagtccagtg 180 acatggttcc ccgtggtggc ccgtggcagc ccgtggcatg gcgtggctca g 231 <210> SEQ ID NO 184 <211> LENGTH: 390 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 184 aaaatccaaa ttttcacaag gcaggaaatg cttcagttat catctaagtg gagttgtttt 60 attccatatt actctcagaa ttctgtgaat cagactgaat cacacacatg tacttcatct 120 atagttttct tcctgtataa gtgtattgaa atgtttcctt atacgattaa acatgatttt 180 aggtacagca catcacaact gtttattcac cttaaaaaaa tgtctgtagt ggtaacattt 240 caagaaatga aaaagggaac agtttgggat ccgcagtttc tccctatctt ctttcagcta 300 catttacaag catttgacca aacaaaaatt agtaaacagt tactagtatt tataaaaaac 360 ttaaaatatt taacatataa tactcacttt 390 <210> SEQ ID NO 185 <211> LENGTH: 501 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 185 cctcagcaat ggctgtggtg ttgctcagca tgcacacagc tctctgtacc ttggccaggt 60 ctccaccagg caccacagtg ggaggctggt agttgatgcc aaccttgaag ccagtggggc 120 accaatccac aaactggatg ctgcgcttgg ttttgatggt ggcaatggca gcattgacat 180 ctttgggaac cacgtcacca cggtacaaca ggcagcaagc catgtattta ccatggcgag 240 ggtcacattt caccatctgg ttggctggct caaagcaagc attggtgatc tctgctacag 300 aaagctgttc atggtaggct ttctcagcag agatgacagg ggcatatgtg gccagaggga 360 agtggatgcg ggggtagggc accaggttgg tctggaattc tgtcaggtca acattcaggg 420 ctccatcaaa tctcagggaa gcagtgatgg aggacacaat ttgacctatt aacctattca 480 ggttagtata ggttggacgc t 501 <210> SEQ ID NO 186 <211> LENGTH: 339 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 186 cctcctgcac tccgcccgga cccccggccc cgccgtggct atccagtcag ttcgctgcta 60 ttcccatggg tcacaggaga cagatgagga gtttgatgct cgctgggtaa catacttcaa 120 caagccagat atagatgcct gggaattgcg taaagggata aacacacttg ttacctatga 180 tatggttcca gagcccaaaa tcattgatgc tgctttgcgg gcatgcagac ggttaaatga 240 ttttgctagt acagttcgta tcctagaggt tgttaaggac aaagcaggac ctcataagga 300 aatctacccc tatgtcatcc aggaacttag accaacttt 339 <210> SEQ ID NO 187 <211> LENGTH: 268 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 187 gtagttctga acgttagata ttttttttcc atggggtcaa aaggtaccta agtatatgat 60 tgcgagtgga aaaatagggg acagaaatca ggtattggca gtttttccat tttcatttgt 120 gtgtgaattt ttaatataaa tgcggagacg taaagcatta atgcaagtta aaatgtttca 180 gtgaacaagt ttcagcggtt caactttata ataattataa ataaacctgt taaatttttc 240 tggacaatgc cagcatttgg attttttt 268 <210> SEQ ID NO 188 <211> LENGTH: 92 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 188 acaaatctcc gattgggaag aaaggacaac agaagactgt ctaaaggatg cctggattcc 60 ttgttatctc aggactctaa atactctaac ag 92 <210> SEQ ID NO 189 <211> LENGTH: 300 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 189 cggcctcaat ggacttctcc cttacctcct ccccttcctt ggacccttat tcgctatcat 60 cctgttcttc tcttttgccc cttggatcct aagacgagta acagcgttaa tcagggatca 120 gctcaattcc ctactgggaa agcccataca aatccactat caccaactag caacgcgtga 180 tctagaatat ggcagactgt agccggttcc cctcctacgg gagcagcata ccgctcgaca 240 ctatgcttta cgaaggtaat ggacaccgct aggtgcaagg caaggcactg caaggagagg 300 <210> SEQ ID NO 190 <211> LENGTH: 569 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 538 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 190 aaaactgggt aggactagag acactgatct gcccaacctc tgggtattca caactgcaca 60 ggtaaccaga tcctgtacgc gaggcatcac cattaaacag atgagcatta gatgaggagg 120 acacattctg agtagttgca tgatttccca ttcagaggca ggtgctgccc tcatatcaga 180 aaagtagcag atcaatgatg ggatgggtgg agatggagat gatatggaaa tattcatgga 240 ggagatgaga gaaatcagaa gaaaacttag ggagctgcag ttgaggaatt gtctgcgtat 300 ccttatgggg gagctctcta atcaccatga ccatcatgat gaattttgcc ttatgccttg 360 actcctgcca tttatcatga gattaatact gtgattcccg ctgttttctt tttccttgca 420 ttttcctaat atgcctttac tgatccgttt gctgtgaacc ctatgttatt tccatgtgtc 480 aagtgggtct tgtgttgcca gcttctattt gaagattgcc tttgcactca gtgtaagntt 540 tctgtcagca gtagtttcac ccatttgca 569 <210> SEQ ID NO 191 <211> LENGTH: 295 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 191 ctgtagcaca agtcaaagct ttcagatctc tctggcccag tgatatcttt ggcagttgtg 60 aagatgaccc tgtacagaca ctgttacata tatatttcca tcatcagacg ctgggccaga 120 caggaagctt tgcagttata ggctctaacc tggacatgtc agaagccaac tacaaactga 180 tggaacttaa tctggaaata agagagtctc tgcgcatggt gcaatcatac caacttctag 240 cacaggccaa accaatggga aatatggtga gcactggatt ctgagacact tcagg 295 <210> SEQ ID NO 192 <211> LENGTH: 171 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 21 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 192 tggatctctg gcggggtgca naactgagcc caggccacag taccctattc acgctctgtg 60 cttgtgccaa gggggcaatg gcggcttcct gtgttctact gcacactggg cagaagatgc 120 ctctgattgg tctgggtacc tggaagagtg agcctggtca ggtaaaagca g 171 <210> SEQ ID NO 193 <211> LENGTH: 171 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 193 aaaacggggg tctggtcttg ctaaacacta caggtaggtt ggtctttgaa gtccactagt 60 ggagaatgtc aagacaagat acttattacc atgacatctg atgcatgtgc agcagtgggg 120 agttctagat tgatctctga atgtgatcga cgcccagcaa ggacaagctt t 171 <210> SEQ ID NO 194 <211> LENGTH: 465 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 194 cctcagcaat ggctgtggtg ttgctcagca tgcacacagc tctctgtacc ttggccaggt 60 ctccaccagg caccacagtg ggaggctggt agttgatgcc aaccttgaag ccagtggggc 120 accaatccac aaactggatg ctgcgcttgg ttttgatggt ggcaatggca gcattgacat 180 ctttgggaac cacgtcacca cggtacaaca ggcagcaagc catgtattta ccatggcgag 240 ggtcacattt caccatctgg ttggctggct caaagcaagc attggtgatc tctgctacag 300 aaagctgttc atggtaggct ttctcagcag agatgacagg ggcatatgtg gccagaggga 360 agtggatgcg ggggtagggc accaggttgg tctggaattc tgtcaggtca acattcaggg 420 ctccatcaaa tctcagggaa gcagtgatgg aggacacaat ctggc 465 <210> SEQ ID NO 195 <211> LENGTH: 295 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 195 ctgtagcaca agtcaaagct ttcagatctc tctggcccag tgatatcttt ggcagttgtg 60 aagatgaccc tgtacagaca ctgttacata tatatttcca tcatcagacg ctgggccaga 120 caggaagctt tgcagttata ggctctaacc tggacatgtc agaagccaac tacaaactga 180 tggaacttaa tctggaaata agagagtctc tgcgcatggt gcaatcatac caacttctag 240 cacaggccaa accaatggga aatatggtga gcactggatt ctgagacact tcagg 295 <210> SEQ ID NO 196 <211> LENGTH: 427 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 196 ccgccaacaa gcgtctcaag gatgctctcc agaaacaacg ggaggttgca gataagcgga 60 aagagactca gagccgtgga atggaaggca ctgcagctcg agtgaagaat tggcttggaa 120 acgaaattga ggttatggtc agtactgagg aagccaaacg ccatctgaat gacctccttg 180 aagatagaaa gatcctggct caagatgtgg ctcaactcaa agaaaaaaag gaatctgggg 240 agaatccacc tcctaaactc cggaggcgta cattctccct tactgaagtg cgtggtcaag 300 tttcggagtc agaagattct attacaaagc agattgaaag cctagagact gaaatggaat 360 tcaggagtgc tcagattgct gacctacagc agaagctgct ggatgcagaa agtgaagaca 420 gaccaaa 427 <210> SEQ ID NO 197 <211> LENGTH: 113 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 197 ctgtcaatgc attccaggaa gcagctagtc ttttaggtaa gaagtatgga gagacagcta 60 atgagtgtgg agaagccttc tttttctatg ggaaatcact tctggagttg gca 113 <210> SEQ ID NO 198 <211> LENGTH: 463 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 413 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 198 cctcagcaat ggctgtggtg ttgctcagca tgcacacagc tctctgtacc ttggccaggt 60 ctccaccagg caccacagtg ggaggctggt agttgatgcc aaccttgaag ccagtggggc 120 accaatccac aaactggatg ctgcgcttgg ttttgatggt ggcaatggca gcattgacat 180 ctttgggaac cacgtcacca cggtacaaca ggcagcaagc catgtattta ccatggcgag 240 ggtcacattt caccatctgg ttggctggct caaagcaagc attggtgatc tctgctacag 300 aaagctgttc atggtaggct ttctcagcag agatgacagg ggcatatgtg gccagaggga 360 agtggatgcg ggggtagggc accaggttgg tctggaattc tgtcaggtca acnttcaggg 420 ctccatcaaa tctcagggaa gcagtgatgg aggacacaat ctg 463 <210> SEQ ID NO 199 <211> LENGTH: 244 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 199 aacagaagca gctctgtttc cagtagtgct gcatcaagcc ctgaaaggaa aaaaaggatc 60 ttaaaacccc agctaaaatc agaaagctct acctctgcat tctctacacc tacacgatca 120 ataccgccaa gacacaatgc tgctcagata aacggtaaaa cagaatctag ttctgtggtt 180 cgaaccagaa gcaaccgagt ggttgtagat ccagttgtca ctgagcaacc atctacttct 240 tcag 244 <210> SEQ ID NO 200 <211> LENGTH: 204 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 200 ggcggataag gagaagaaga aaaaggagag catcttggac ttgtccaagt acatcgacaa 60 gacgatccgg gtaaagttcc agggaggccg cgaagtggaa tcctgaaggg cttcgaccca 120 ctcctcaacc ttgtgctgga cggcaccatt gagtacatgc gagaccctga cgaccagtac 180 aagctcacgg aggacacccg gcag 204 <210> SEQ ID NO 201 <211> LENGTH: 388 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 304, 324, 368, 369 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 201 aaagaaaaaa atagcactgg ctgcaataca attaaaatgg aaaaagcata atttctaata 60 atttcaaata taacacaaat gacaaataga tacattatca ttctgtgaac tccacttaag 120 acttccttta tgtgacaagt tgtagtttaa gcttacttga gacatgagta tttggaattt 180 tcaaaaaata ccaaatatat aaaaaataga cacaacaaat ggaagagtat atcatgattc 240 attagacact tttaatgaaa atagtgcttg acaattagaa aacagttaaa atttttgctt 300 tagnaaaaaa ctacctcaaa ctantgttca tattagaggt gacagtgcta tttgtgtttc 360 tagcattnna tattgaagtt tatctttt 388 <210> SEQ ID NO 202 <211> LENGTH: 296 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 57, 60, 84, 98, 113, 153, 160, 193, 215 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 202 ctgtagcaca agtcaaagct ttcagatctc tctggcccag tgatatcttt ggcagtngtn 60 aagatgaccc tgtacagaca ctgntacata tatatttnca tcatcagacg ctnaggccag 120 acaggaagct ttgcagttat aggctctaac ctngacatgn cagaagccaa ctacaaactg 180 atggaactta atntggaaat aagagagtct ctgcncatgg tgcaatcata ccaacttcta 240 gcacaggcca aaccaatggg aaatatggtg agcactggat tctgagacac ttcagg 296 <210> SEQ ID NO 203 <211> LENGTH: 445 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 382, 437, 438 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 203 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tncctgactt gttggcataa aagcagcaac gttcctgtag 420 agccaaacag atacctnnct gttct 445 <210> SEQ ID NO 204 <211> LENGTH: 426 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 393, 395 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 204 aaagatagtt cccctgagac cacttgtaaa taggttagat tggttccctg tggtgaccta 60 gagaaaaaat agacttgttt ctgctctcat ttttgtcatc gtctgacttg aagattcaga 120 caccttctcc ccaggagatg tatgccatca aattgccagt cacctctttg tctctctctt 180 ctttctgagt atggtttcta ttctgtgttt tgaattttta ttttctaatg cagtggaaaa 240 gaaacagatc atcctaaatg aggaggtaac agggaaagca ctggggttcg gtttctgcat 300 cttctggatc aattcacgga acagagatcg tggattacat gggctccttc ttggtttttg 360 ctgctgggca ggacttgact tagcattatc cangnaccag tccaagtggg gttccctgtt 420 gccagt 426 <210> SEQ ID NO 205 <211> LENGTH: 240 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 11, 14, 29, 47 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 205 atgggaacta natnacatac ttcttactng tctgtacagt accttgntgc agatgggtga 60 tatataatgg taatagaata gcacagccag acttgcttcc tgcatggtag ggagagacac 120 aaaagatggg aaactgcttt tccacaagga atctccgtag aattttgcgg cgaccagatg 180 gtgcataggt ctggaaggtc tgatctccct tggtcttcca tgggatggtt agtgtggagg 240 <210> SEQ ID NO 206 <211> LENGTH: 267 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 206 aaaacggaaa aaaagaaagc aacaggatct tcaaccttca taactcaaaa aacccagcct 60 cagccgagcg cctggaatag gttaagatcc cccacgaagt acagaccagc attccgagcc 120 gtcgtatcgc tcagcctgct cggccagctt cgcctggtac accagatcct ctcgatcatc 180 catagcggca gcggctccgg cagggtctgc gcgacggatg gaagcggata gtgtctccga 240 ctctctcagc ctctcgctcc gcgtccg 267 <210> SEQ ID NO 207 <211> LENGTH: 420 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 207 gatttgcctt caaggaaact ggggagtcag aaaattggga actcatatca acatggcaaa 60 cctattgaaa gcagtggtga ctggctgctc gtgtccttta cttagcaatt tggggtcctg 120 taagggtcta cgtgtgaaga aggatttttt acgaacattt tatactcacc aagaactgtg 180 gtgtaaagcg cctgtaaaac caggaattcc atataagcaa ctgactgttg gagtccccaa 240 agagatattc caaaatgaga agcgagtggc attgtctcct gctggtgttc agaacttggt 300 caagcagggt tttaatgttg tcgtggaatc gggtgcgggc gaagcttcca agttctcaga 360 tgatcactat agagtggcag gtgcccaaat ccaaggggca aaggaagtgc tggcttctga 420 <210> SEQ ID NO 208 <211> LENGTH: 189 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 208 aaaatttatt cacaaaaccc attaactgca cagttgctat tagctgcctg ttctaaaacg 60 atagtctttt tattgaaaca caaataaact tttctgtaat attttatggt atataaagag 120 actttaattg tttgacttgt ttaacttggc actgttagtt tttattaata aaacgcgcat 180 gggcatttt 189 <210> SEQ ID NO 209 <211> LENGTH: 189 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 209 aaaatttatt cacaaaaccc attaactgca cagttgctat tagctgcctg ttctaaaacg 60 atagtctttt tattgaaaca caaataaact tttctgtaat attttatggt atataaagag 120 actttaattg tttgacttgt ttaacttggc actgttagtt tttattaata aaacgcgcat 180 gggcatttt 189 <210> SEQ ID NO 210 <211> LENGTH: 147 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 210 ctgctcggcc aatgaaggtg gagtggaaaa tgagtccata ttttggggtg ttaccccttg 60 tcttcagggc tctggaaact tggtcccttt gctgggccct gggaatcact cagacaccag 120 gactggccat cacccccata gcagagg 147 <210> SEQ ID NO 211 <211> LENGTH: 278 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 211 atagcttcct gccacgaacc aattgacaca aaacagaata gcttgttaaa ggacagattt 60 tttccccctt cagggagcaa agcattaaca tgtcatttcc tgaccaggat attaaatagt 120 ttatttagaa gaaatgagtt gaagtgagcg attaagagac acaaactgga cttttgtttt 180 cttttactgt agcacccagg tttcatgtca gtctgtgtgc accgaatttt ttttttaagt 240 gaacctcatt aattaccagc taggtggttg gcttgttt 278 <210> SEQ ID NO 212 <211> LENGTH: 287 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 212 aaatctttga gataagaatg gcttgttgtt aaatattgag gcaattattt cattctaggt 60 ccaatacgca ataaccatgt gtttcggttt tccactcagc accttcaaaa ctgttgcaaa 120 tgaatgttta ctaacaagac aaaagagaca attataaacc aaactctcaa caaaattcgg 180 aatggccaca tcacaacctg aaaaagaaac aagtacttaa aggacttgat cacttcctaa 240 caagtccatc ttcaacctga accacttctc ttgtttaatc aaatttt 287 <210> SEQ ID NO 213 <211> LENGTH: 181 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 213 cctcggcctc tctgtcatgc tgggaagtgc ctactctctg ggccactgct gcagaggccg 60 tggcacttgt catgggtttg gaagacccag ccatctgcag cagaggcagc ctatcccatt 120 gcaaggagag gaactgaacg gagtaattat tctactcttc tttttacata cctgtttatt 180 t 181 <210> SEQ ID NO 214 <211> LENGTH: 457 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 214 ctgccagttt attacatgaa gtgtcaggct gtggactgca ggcatgccat tttgtcttca 60 agaacaggtg ggatcagagg tccttgactg atcagaatac actgctttca accaaaacat 120 tattagcatt gatttcttaa aaaataatag caaagtagaa aacctttagc tggtctgttt 180 cttcgtgtcc tgaaacttcc ttattagtgt aattaaaagt actaagttaa gaattagcct 240 gggaaaggac cctacttatg gcaaagtctt cagaaaagta aagagcaaaa ccagatatgt 300 gccttgttct catggtgctg acagtatagc gaagaggaaa tactttaatc atacgaataa 360 ataaatgtaa agttagaact gtgcaactgc tacgaagaga ggatatagca ctaaaaagcc 420 ctagaatggg agatttgacc tggccaggga tgtcaag 457 <210> SEQ ID NO 215 <211> LENGTH: 294 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 215 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgagc cgcc 294 <210> SEQ ID NO 216 <211> LENGTH: 254 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 216 aaaaaaggca actgcttaag cgtttctatc aattcgaacg tcaatctctc ggccactcag 60 cttcatgcca ttcatcatcc ggcaggctct ctcggccacc tctggcgact cgaacttaac 120 cacaccacac cccttggact tcccattctc catcttgatg tcggcgtaca gcacgtggcc 180 gcactcgttg aatttgtcct ttagcatctt ccatgtgaaa tcgaatggca gatttctcac 240 aaatatctgg cagg 254 <210> SEQ ID NO 217 <211> LENGTH: 530 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 217 aaaaagagaa acactgcttc ctcaatgtca ctgaaggata tgaacaggca agaggaaagt 60 aactgtccat atttgcctta tatacagtat tgggtaatta aatgccagtt gggctgttta 120 ggaatggctt gctaaaacat tgaaaaaatg aaagacttca tccttgtcgt agactgccac 180 ttcagtggaa cattcagtgc acatgactgg gtgatagatt tcttccacat ctgtctctgc 240 cttctcggca gcatcttccc ggttagacct catcttctta tggacccgcc ttttcttcct 300 gttctctgag gctttatatc ttagaacctc ctctttgtta atagaacaat tcattacaaa 360 cattgctcta tattgagttt tgtatgattc atgcctttgg caatcaaggc aaagtgtggt 420 catgcaggca ggacaattca agacagcatc actatttgga acaggctgtt gttgacgtga 480 tctctgtggt cccaaaccat ggtaacccct tctctgtgca tcaacccagg 530 <210> SEQ ID NO 218 <211> LENGTH: 190 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 218 aaaattcatg ctgcataaag ggtagggtgg cctttcacct tttccgggtc attttggtta 60 aaaagataaa gatgttcgaa gtaattactc agagcgcagg ggccggggct tggctttact 120 gttgcaggtg ataaccttgt caactgctta ttagtgaatg ctgaacaaat ttcccaaagt 180 ttgtattttt 190 <210> SEQ ID NO 219 <211> LENGTH: 213 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 219 cctaagacga gtaacagcgt taatcaggga tcagctcaat tccctactgg gaaagcccat 60 acaaatccac tatcaccaac cagcaacgcg tgatctagaa tatggcagac tgtagccggt 120 tcccctccta cgggagcagc ataccgctcg acactatgcc ttacgaaggt aatggacacc 180 gctaggtgca aggcaaggca ctgcaaggag agg 213 <210> SEQ ID NO 220 <211> LENGTH: 351 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 333 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 220 ggcgcggcgt ccggaggccc cagggttatg agactatcac tgctcaggac ctactaacaa 60 caaaggaaat cgaaacatga ccaaatcgta cagcgagagt gggctgatgg gcgagcctca 120 gccccaaggt cctccaagct ggacagacga gtgtctcagt tctcaggacg aggagcacga 180 ggcagacaag aaggaggacg acctcgaaac catgaacgca gaggaggact cactgaagaa 240 cgggggagag gaggaggacg aagatgagga cctggaagag gaggaagaag aggaagagga 300 ggatgacgat caaaagccca agagacgcgg ccncaaaaag aagaagatga c 351 <210> SEQ ID NO 221 <211> LENGTH: 289 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 221 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgag 289 <210> SEQ ID NO 222 <211> LENGTH: 424 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 222 cagcactttc ggtggccggg gtgggtggat cacttgaggc caggagttca agaccaccct 60 gaccaacttg gtgaaatccc atctctacta aaaatacaaa aattagctgg gtgcagtggc 120 gcatgcttgt aatcccagct actcaggagg cagaggcagg agaatcgctt gaacccggga 180 ggtggaggct gcagtgaaca gagacagtgc cactgcacat cagcctgagt gacagagaga 240 ctttgtctca aaaaaaaaaa gaaaatttta attttaatgt agacagtatg aattatcttg 300 ttctgcagtt ggttgctttt tgattgctta tttaatagag ttgttaagat attttacatc 360 ttctcctgtt agctgttcag cttttccttt catattgaga acactacaca gtgctgaagt 420 ccag 424 <210> SEQ ID NO 223 <211> LENGTH: 322 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 223 aaattatgtt gacaggtgaa attgtgaata ctaaataaaa tcttcagttt aatttgtaag 60 aatgtatgtt tgtatttcta ggtatagact atgtgatacc taaaacaggg ttttactgta 120 agctgtgttc actcttttat acaaatgaag aagttgcaaa gaatactcat tgcagcagcc 180 ttcctcatta tcagaaatta aagaaatttc tgaataaatt ggcagaagaa cgcagacaga 240 agaaggaaac ttaagatgtg caaggagatt taatgatttc aaagaaaata atggttcttt 300 gtttttaatg ttaacctttt tt 322 <210> SEQ ID NO 224 <211> LENGTH: 183 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 224 ctgtgtgcca gagcctggac agcctcatgg ggtaaggcca cgccaccctc ccatcccaca 60 gttgagtgtg gaagactgga tgtctcaggg ccagcagacg cccgacacgc agcctcattc 120 cccaggtgga atccacctgc agttatggga ggacaaacca accatcacta ttagaggatt 180 agg 183 <210> SEQ ID NO 225 <211> LENGTH: 362 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 336, 358 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 225 caggaggcgc ggcgtccgga ggccccaggg ttatgagact atcactgctc aggacctact 60 aacaacaaag gaaatcgaaa catgaccaaa tcgtacagcg agagtgggct gatgggcgag 120 cctcagcccc aaggtcctcc aagctggaca gacgagtgtc tcagttctca ggacgaggag 180 cacgaggcag acaagaagga ggacgacctc gaaaccatga acgcagagga ggactcactg 240 aggaacgggg gagaggagga ggacgaagat gaggacctgg aagaggagga agaagaggaa 300 gaggaggatg acgatcaaaa gcccaagaga cgcggnccca aaaagaagaa gatgactnag 360 gc 362 <210> SEQ ID NO 226 <211> LENGTH: 377 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 226 ctgttaacaa gtggttttta gtacattctg ggctttgctg tatctatcta gtgcctgttt 60 gtgcgttttt ttctttcttc cgctgcttcc ccattttcct tctgtccttt ttctcctgct 120 ccttgttttc ccagcagcac atggggttcc tcggaggagc agaggtggcc gccgtggggg 180 ggcgtttggg ctgcggtgct gcgtcatttt tcctttgctt tctctttact ttagacactg 240 gcccaactcc aggcgtttcc tttcattccc tcagtgcttc tcttctgacc tgcatgttga 300 gttctgtatt gctggggctt ccaacaaaaa ccagagtcac tgacagaggg aacagcagag 360 accttgttgg tattcag 377 <210> SEQ ID NO 227 <211> LENGTH: 507 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 392 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 227 aaattaccga gagatggggg aaaaaatctg ttcttcctaa agaaatccct tcagatagag 60 ctcatggtgt ttagtgatgt acttgcagta ttgtttgaag aattgttttg tcttaaggaa 120 aaaagacgtt gcacatgatt tgtactgcag caaatcagca aaagtgatct gagttggata 180 tatttgaagg tattttgaaa gttacgttca aggctaacac ctgagctttg tgtaatgtaa 240 ataagacctt gtgtttatga acctttcagc taatttaatt ttttttccct tacatgccaa 300 gtgatgttca ggttttgaat gtttttgtat cagttttttc ctttgtaaat ggcattaaca 360 ttgttacttg aggtcttgct taatcacttt tnttgtcctg aggacttgaa tttacagtgc 420 atcagatttg ttgcaaattt tgtctgtaga tagtctagct tcagacctgc ccgggcggcc 480 gtcgagccct atagtgagtc gtattag 507 <210> SEQ ID NO 228 <211> LENGTH: 390 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 228 ccggagcgag tctgggtctc agccccgcga acagcctttc acgagtcttc aagctttcag 60 gctatcttct agtcaagatg agtgataagc cagacttgtc ggaagtggag aagtttgaca 120 ggtcaaaact gaagaaaact aatactgaag aaaaaaatac tcttccctca aaggaaacta 180 tccagcaaga gaaagagtgt gttcaaacat cataaaatgg ggatcgcctc ccaacagcag 240 atttcgacat tacctgagag tcttgatttt aggcttgttt tttgtaaacc catgtgtttg 300 tagagatttt aggcgtcttc ggatatcttc tcacctatgt tccctggcta agaagtcaga 360 ggtagccaat gtttccttaa attcattttt 390 <210> SEQ ID NO 229 <211> LENGTH: 401 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 9, 111, 127, 136 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 229 cctcaccgnc gatgcaagga tagtcatcaa cagggcccgg gtggagtgcc agagccaccg 60 gctgactgtg gaggacccgg tcactgtgga gtacatcacc cgctacatcg ncagtctgaa 120 gcagcgntat acgcanagca acgggcgcag gccgtttggc atctctgccc tcatcgtggg 180 tttcgacttt gatggcactc ctaggctcta tcagactgac ccctcgggca cataccatgc 240 ctggaaggcc aatgccatag gccggggtgc caagtcagtg cgcgagttcc tggagaagaa 300 ctatactgac gaagccattg aaacagatga tctgaccatt aagctggtga tcaaggcact 360 cctggaagtg gttcagtcag gtggcaaaaa cattgaactt g 401 <210> SEQ ID NO 230 <211> LENGTH: 199 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 230 aaatagatga cattgactat ttttgttttt attaaaagga agcttacatg cctaccaata 60 tttaatcttt tatgattgcc tttttataac tttttatatt ctcagcagag tgctttacca 120 attgaagtaa aatgtggcag gctggagtta ttgaagcaga gtggcagtct tcagtttgca 180 gagtaggggt ctgtctttt 199 <210> SEQ ID NO 231 <211> LENGTH: 383 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 19, 31, 42, 46, 71, 83, 89, 96, 112, 119, 130, 197, 203, 254, 255, 299, 314, 316, 355 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 231 agcgagtctg ggtctcagnc ccgcgaacag nctttcacga gncttnaagc tttcaggcta 60 tcttctagtc nagatgagtg atnagccana cttgtnggaa gtggagaagt tngacaggnt 120 caaaactgan gaaaactaat actgaagaaa aaaatactct tccctcaaag gaaactatcc 180 agcaagagaa agagtgngtt canacatcat aaaatgggga tcgcctccca acagcagatt 240 tcgacattac ctgnnagtct tgattttagg cttgtttttt gtaaacccat gtgtttgtng 300 agattttagg cgtntncgga tatcttctca cctatgttcc ctggctaaga agtcngaggt 360 agccaatgtt tccttaaatt cat 383 <210> SEQ ID NO 232 <211> LENGTH: 181 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 232 cttcgacatg cattgggtga tactaatatc agtagtttgg cagactataa tgcatctagg 60 ctttataatc gcagaagata aaaaagcaga agaagttaat atttcttcac ttatgattgc 120 acaaaaaatg caatcacaat caaaccttgc tttcgcttag ttaaaagtga caagtggttt 180 t 181 <210> SEQ ID NO 233 <211> LENGTH: 202 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 233 ctgccctggg cccagatgcc cccatacttg gcatttacca gaacctgtcc cagctcagac 60 cctgcctaga cccaccaggt acccaaagtt ctctggggag ggccagggaa gaggctgggt 120 gtcaaaccaa acagattttt atttgcagtc gtcactgggg ccgtttcttg ctgcttattt 180 gtctgctagc ctgctcttcc ag 202 <210> SEQ ID NO 234 <211> LENGTH: 127 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 234 aaatagcaca aagccaaaac cccttgatcg ccctgtgata ggatctaact tcagagtgca 60 gtctacaact tcaccaaatt tggaaaagta gtccttcaga tctttctttg tagtgtccca 120 gctaagg 127 <210> SEQ ID NO 235 <211> LENGTH: 215 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 235 aaattagttt ttatttttat gatggtttta tcaaaagact tttattatta gattgggacc 60 cccttcaaac ctaaaaatca agttatttcc ttttataata cttttcttcc ccatggaaca 120 aatgggatca atttgtgagt ttttccttta atgataacta aaatccctct aatttctcat 180 ttatgctttt gtctttttta tgaaatattt ctttt 215 <210> SEQ ID NO 236 <211> LENGTH: 329 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 236 ctgctctctc cagctattac ttctgcatcg ccttaggcta taccaacagt agcctgaatc 60 ccattctcta cgcctttctt gatgaaaact tcaagcggtg tttccgggac ttctgctttc 120 cactgaagat gaggatggag cggcagagca ctagcagagt ccgaaataca gttcaggatc 180 ctgcttacct gagggacatc gatgggatga ataaaccagt atgactagtc gtggagatgt 240 cttcgtacag ttcttcggga agagaggagt tcaatgatct aggtttaact cagatcacta 300 ctgcagtctg acatgaaaag atagaattt 329 <210> SEQ ID NO 237 <211> LENGTH: 390 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 237 ccggagcgag tctgggtctc agccccgcga acagcctttc acgagtcttc aagctttcag 60 gctatcttct agtcaagatg agtgataagc cagacttgtc ggaagtggag aagtttgaca 120 ggtcaaaact gaagaaaact aatactgaag aaaaaaatac tcttccctca aaggaaacta 180 tccagcaaga gaaagagtgt gttcaaacat cataaaatgg ggatcgcctc ccaacagcag 240 atttcgacat tacctgagag tcttgatttt aggcttgttt tttgtaaacc catgtgtttg 300 tagagatttt aggcgtcttc ggatatcttc tcacctatgt tccctggcta agaagtcaga 360 ggtagccaat gtttccttaa attcattttt 390 <210> SEQ ID NO 238 <211> LENGTH: 445 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 441 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 238 ctgtcagtag gctgacctaa cgttctagca tgcctcttga gggcctttcc aactgagctc 60 tctggaggag ggtaggaaag tcagggaaat catgcaatcc catttgggga agggaaagca 120 tctcaagatt tgtgaggttc cctgggaaag gtgtttacca caaatgtcac atcaattaaa 180 ggaaagtctg cagagagaga gagaaagcca agatcagggg taaaagagaa aggcaaggta 240 gcaccgggga gcttgggcat gacacagaaa catctctgct tttaccagca gaagagacca 300 agcatcccca gtgaaggggc tggcagtgtg tttggaattc tcatcctgac ccgagcatca 360 ggtggaactc cttcttacct tcagatcttt accttcaact ctctccttaa tgtttcctgt 420 gacatcccag atgtaccccc nccct 445 <210> SEQ ID NO 239 <211> LENGTH: 170 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 239 ccttacatcc aatctgatta gtgttctcac tggaagagac tatgacaaat gaaaagccac 60 ataaaacact atattagtca taaaaccgat tatttaattg aagctataaa aaaggtagta 120 taagtgataa aataattagg aaagaatatt tagcatgttt caaaacattt 170 <210> SEQ ID NO 240 <211> LENGTH: 196 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 169 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 240 tgaaagtcga tgaaggacgt gattacctgc gatgagcctc gtggagccgg aaatatgcta 60 tgaaacgggg atttccgaat ggggaaacct aactagggta atgcctagtt gccttgttct 120 gaattcatag gaacttgagt gagacacctt gtgaactgaa acatcttant agcaagaaaa 180 aaaaaaaaaa aaaaag 196 <210> SEQ ID NO 241 <211> LENGTH: 300 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 241 aaagaacaga gttctggagt aaagaagcag gttccctttt cagtagacac ctcccgtctg 60 ctgttggaac acatcaattg tatcttcatc ctccatttcc aactgtgcag gtgtgtctgt 120 ttcattgatt ggttgcccgt caaatcggaa tctgatctgc ctcattgaca atccctgtcg 180 ttcacaatag gctttcatta gtttactaag tggtgtatgc ctcttaatct taaactgcac 240 cacagaacca tcctgccccg ccaccttcaa attaatatga tcgttgttct cagtcttgac 300 <210> SEQ ID NO 242 <211> LENGTH: 348 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 242 ctgctcgatg gtggcccact gctcagacct cttccatgtc tgggcgagct cctcatttct 60 ggtccgcacg gcctccagca gcaagctgat gctgtcctgc agaggcataa cttcattggt 120 gaccaggaac agcaagaggt ggaaatctga gatggtatcc aagaacacag atgaggtatt 180 ctgagacaaa taggtggcca agctatggaa gtcctgtgtc tcacccaata catcccggtt 240 ttcaatagga aatggatttt gcgaaataga aaaagtgtaa actggatcct tggggaaagt 300 tgttgtgatg tctatgatga gatactccac aggcaggggc cgggccag 348 <210> SEQ ID NO 243 <211> LENGTH: 375 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 243 aaaaatgaat ttaaggaaac attggctacc tctgacttct tagccaggga acataggtga 60 gaagatatcc gaagacgcct aaaatctcta caaacacatg ggtttacaaa aaacaagcct 120 aaaatcaaga ctctcaggta atgtcgaaat ctgctgttgg gaggcgatcc ccattttatg 180 atgtttgaac acactctttc tcttgctgga tagtttcctt tgagggaaga gtattttttt 240 cttcagtatt agttttcttc agttttgacc tgtcaaactt ctccacttcc gacaagtctg 300 gcttatcact catcttgact agaagatagc ctgaaagctt gaagactcgt gaaaggctgt 360 tcgcggggct gagac 375 <210> SEQ ID NO 244 <211> LENGTH: 334 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 244 cctaggacag acagggcccc aactcctcat caccccatga cttggcctgg aggaacctgg 60 ggtgggaaac aagtagtccc ccaacctcag aggccagaac cacaggtggg ggacagggac 120 ctcgacagag ctgtgcctgc tcaacgctcg agagcatctt aacctaagaa accaaaacaa 180 agccttcgaa aataaaaaga aaaaaagatg taaaatatac acccccaatc agagagggga 240 agtgggaaat gaagatagta gttaacagca cgtccaatgg gcccagtgtc tacactcgta 300 cgagcagccc cccaagctgg gcgggggtcc cagg 334 <210> SEQ ID NO 245 <211> LENGTH: 205 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 245 aaatgataca gtattttagg tatgatttaa gactatgatt tacctataca ttatatatat 60 tttataaaga tactaaacca gcataccctt actctgccag agtagtgaag ctaattaaac 120 acgtttggtt tctgaataaa ttgaactaaa tccaaactat ttcctaaaat cacaggacat 180 taaggaccaa tagcatctgt gccag 205 <210> SEQ ID NO 246 <211> LENGTH: 111 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 246 aaaagacaaa aacaaaacaa aaataccaca gctcaagata aagagtccta tacagaaatc 60 acaaaaagga cagaccatct aaggaaaaat taaaaagacg acacaaggac a 111 <210> SEQ ID NO 247 <211> LENGTH: 226 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 247 aaagagacct tcccacccac ccaaccaaaa ataacaaaag aaacaaaaaa gcactggtcc 60 tacctcttcc tctgaactcc agagggtatg accagccctg ctctaacact gcccctcccc 120 acaacgggca gcctgaccag gagccacagg ggcctcaacc ccaggggctg ttgttcagcc 180 ttgcagattg tcactggccc aagctgagca ggacaggcca gtgagg 226 <210> SEQ ID NO 248 <211> LENGTH: 379 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 248 aaaaatcaca tagcactcag taggtacatg tatacatgta catttcagaa gacaacaaat 60 aaaattactc tcagaaagct gcaaagatgg acacatataa tctaagaatg tggtaatggc 120 cagagggagt acccaagaga ccatatttta ttatgcttaa ggctactact ttccacaata 180 cctctgcagt taagactctt aacttacaat cacagaaatg aaaacatgat aatacactgc 240 tttatacaga catacagata ctgggatata gtataatttc ttatggctta aaaaaattta 300 atttgctttt ggagtctata ttgctaaact taactttcca caaaatacaa tatatcatga 360 aagcaaagta ttatttttt 379 <210> SEQ ID NO 249 <211> LENGTH: 119 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 249 ctggaggtac cgccggacgt tagcatcttt aggctgccta ttcacggcag ccaggaggta 60 gtggcgggcc tggtcatagt cctgcagatg gaaaaaggcc actccggccc gatacaagg 119 <210> SEQ ID NO 250 <211> LENGTH: 472 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 440, 465 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 250 aaaaatttta tctgttcttt ttcttgctca gggctggtag gttggatctg aaccattaaa 60 atcaaatggt ccactaggcg tatgatctct ttgagccaaa tcagttcctg aatataaagg 120 aggaaatgat gaggatgtac tgaggcaacg gggaagtata gaaacatcca agacaaaagc 180 caagggatgc aaaggcagag acacaggtgc tttttggtga cccagtggat atggcaacca 240 gtgtaactgc catacaagaa accctaggag caaacccaca ccactcattc tcagctaaga 300 gattttacac aggcaaacgt gtcttaaacc atctataaat cagttatttt atatgacagt 360 caaaacctta gaaaccttag gatcattata tctattttct gcctattaat tgctgtgagg 420 tttgatttga ccaatctggn caatttattc atcagcttcc cttgnagtgc ac 472 <210> SEQ ID NO 251 <211> LENGTH: 163 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 251 atctgcacga gtctgactgg cctttgggtg gcctttgtgg acggctcgta gctggaaagt 60 gttgatctgg gttttctggc attcttttaa gttaaaaagt taacatcggg acatgggttt 120 gatcttttgt tgtacctgat gacagtgcag agattctcca cag 163 <210> SEQ ID NO 252 <211> LENGTH: 110 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 252 aaatatgtcc cagtatagaa gcataacttc aattaatttg ttgacactaa cttcttaaaa 60 acttacaaat attcaaaaca aagggaaaaa attttagata gccaagagtt 110 <210> SEQ ID NO 253 <211> LENGTH: 156 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 253 aaatttagaa tcttgtttac aacacattag catcattaac agaaaaacga ccatttacat 60 agtaactaaa aaaccagcca cttaagacta taatgtagta atcaaccact accagagaaa 120 ataggtcctc tcatttgatt ttactggtaa gtccag 156 <210> SEQ ID NO 254 <211> LENGTH: 242 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 254 gaatgttccc acatgccctc aagtacttac cacccaactc tgtagcagtg cacagtggac 60 ataaggtggt gttggcagtc tcagtcctat ttaatgatgg ccagagatac ctcctggtca 120 gccaaagccc tggctgactg ccaggcagtt gcgcagtagc tcttcctgta gtgaaactgt 180 tcttcttatc attgttgact aaactctgtt ggaagttgtc tcactagcca tatgagccac 240 ag 242 <210> SEQ ID NO 255 <211> LENGTH: 119 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 255 ctgctgctgc agaacatccg gcatcacagt cattttcact ctggggacga cagccaggtc 60 ctcgcctggg cgcttcttac tctcctcacc accgaaagcc aggaactgag ccgatattt 119 <210> SEQ ID NO 256 <211> LENGTH: 186 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 256 aaaattcaga tttaataaac tgatttaaga cagtaaattt gaaagacaaa attaagtctc 60 attcaggagt ggtccattat gttgatcatc tagaatcaac actgattaac caaactctga 120 aagccaagag ccccaactcc agagaaacat taaatttctt taatgtaaaa gtatattatt 180 tttgag 186 <210> SEQ ID NO 257 <211> LENGTH: 147 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 257 aaaaaaagag gaggcggacc ttaaccagct aggggaggta gaggctgtgc tcctcctgag 60 ccttaatttt caggcttaca ggtacctttt tgggaggaga ggatttttcg agtaccaacc 120 tctatgcagc cagcttacct ctcagga 147 <210> SEQ ID NO 258 <211> LENGTH: 277 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 258 ctgtgccttc cggcactgcc cgttcccatg acgatgagga aggagcgggt aaccctccca 60 ttccggagca agaccgccca ttgctccgtg tgccccggga gaaggaggcc aaaactggcg 120 tcagctactt ctttccttag atgtttttcc ttctataagg tgccagacag gggaaaaggg 180 tgggggtaca tctgggatgt cacaggaaac attaaggaga gagttgaagg taaagatctg 240 aaggtaagaa ggagttccac ctgatgctcg ggtcagg 277 <210> SEQ ID NO 259 <211> LENGTH: 250 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 259 ctgtggtcat gggaaatcac ctacagcatg ttaaagtcct ctagtcatca tctcgtcacc 60 tgaaatggaa gtcctttttc cctcaccctc cacttctttc caaaggaggg catcaaggaa 120 cttaacctgc ctgcctggtg ggtttctatt taagacatct ttgtgattat atttaacctg 180 caattgtgct ttggcttaat gtctagctca ctgtacttgt aaatgattaa tattcaataa 240 aaccattttt 250 <210> SEQ ID NO 260 <211> LENGTH: 200 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 260 aaagacaatt ggtgtttaca ccctcttgtc agcaaaacag ctagttaggt aaggacatat 60 agttccaagt aggtaaagtc acttgattac aaatgttctt aactatcgtc tctgtaattc 120 ctttatacag gacagtacaa aattgtggga catgctctgg taacacacag atatgggttg 180 catatgatcc agaattacag 200 <210> SEQ ID NO 261 <211> LENGTH: 299 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 261 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgagc cgccacctg 299 <210> SEQ ID NO 262 <211> LENGTH: 235 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 262 ggagaaacga gatgggggtg aagctggaga tatttcggat gataatctac ctcactttcc 60 ctgtggctat gttctgggtt tccaatcagg ccgagtggtt tgaggacgat gtcatacagc 120 gcaagaggga gctgtggcca cctgagaagc ttcaagagat agaggaattc aaagagaggt 180 tacggaagcg gcgggaggag aagctccttc gcgacgccca gcagaactcc tgagg 235 <210> SEQ ID NO 263 <211> LENGTH: 415 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 263 aaaagaggtt catggaagtt aatgcaaata gacaactggc agtaaacaat aaatttaacc 60 tgtgagtttt agacttgtgg tgaacaacta tccaaatact aaaatctctc tttgaaacat 120 gcaccagtag atatatttct agaaaaagtt gttatgaagt aggcttaaat tatattaaca 180 tatcttgacg gaggaggatc acttgaggcc aggagttcca gaccagcctg ggcaagactg 240 cccccacgcc cacacacaaa aatgaaaaaa ttagccaggt gtggtgggac aggcccgtag 300 tccttcctag ccacttagga gactaaggca agaggactgc ttgagcccag gaatcccagg 360 ttagagagag ctatatggca ctactgcact ccagcctggg caacagagcc aagac 415 <210> SEQ ID NO 264 <211> LENGTH: 208 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 264 aaagttaatc aaatggttat caaaaattaa tatacaacaa agattcctgg gaaggtaatg 60 cttatataaa ataaggccat gtttctaaaa atccctcaaa tcagtccaag ataagatttt 120 taatgaagaa cataaaggtt aaagaaattc tttctctcca ggttagctgt ttttccctac 180 ttgttttctt cttgcttttc ctgttgtt 208 <210> SEQ ID NO 265 <211> LENGTH: 463 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 386, 387, 429, 461 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 265 ctgttagagt atttagagtc ctgagataac aaggaatcca ggcatccttt agacagtctt 60 ctgttgtcct ttcttcccaa tcagagattt gtggatgtgt ggaatgacac caccaccagc 120 aattgtagcc ttgatgagag aatccaattc ttcatctcca cgaatagcaa gttgcaagtg 180 acgaggggta atacgcttta cctttaagtc ttttgatgca tttcctgcca gttcaagtac 240 ctctgcggtg aggtactcca ggatggctgc gctgtacaca gcggcagtcg cgcccacacg 300 tccatgactg gtcgtcctag attttaggtg tcgatgaata cggcccactg ggaactgcaa 360 gccggctctc tgcgagcggg aaaccnncct ttgtcttggc ctttccggag tcctttccag 420 ccttaccgnc agccatttcg aattccgctg aagctcaagc nag 463 <210> SEQ ID NO 266 <211> LENGTH: 395 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 266 aaattaccga gagatggggg aaaaaatctg ttcttcctaa agaaatccct tcagatagag 60 ctcatggtgt ttagtgatgt acttgcagta ttgtttgaag aattgttttg tcttaaggaa 120 aaaagacgtt gcacatgatt tgtactgcag caaatcagca aaagtgatct gagttggata 180 tatttgaagg tattttgaaa gttacgttca aggctaacac ctgagctttg tgtaatgtaa 240 ataagacctt gtgtttatga acctttcagc taatttaatt ttttttccct tacatgccaa 300 gtgatgttca ggttttgaat gtttttgtat cagttttttc ctttgtaaat ggcattaaca 360 ttgttacttg aggtcttgct taatcacttt tgttg 395 <210> SEQ ID NO 267 <211> LENGTH: 61 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 267 ctgtactcct gttctggaat tccaagttgt tcaacatcta aatccatcaa cttcatttca 60 t 61 <210> SEQ ID NO 268 <211> LENGTH: 372 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 268 aaatcaatta ctccttttgc ctgcaacagg gtccagcaaa gccttaccac ctcaagcaaa 60 cccactatac ctatctatgc tcaagaagta gtttggctac tgaagacatg ctggtctctt 120 ccaagtcttt cctcaggatc cacacatcag acattcatct ctattctcca aagagcacac 180 catggctgct gtgttcctct ccttctcttc ttcctctttt gatacctttt ctttatcttt 240 tagcttctcc ttatttagag tgaactggat tggattagct gctggtcttg tccttaaata 300 atacatccca gtcttcaaac cctgcttcca gccgtagaag tgcatactag tgagtttgcc 360 atagttaggc tc 372 <210> SEQ ID NO 269 <211> LENGTH: 176 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 269 ggcggctcgg actgagcagg actttcctta tcccagttga ttgtgcagaa tacactgcct 60 gtcgcttgtc ttctattcac catggcttct tctgatatcc aggtgaaaga actggagaag 120 cgtgcctcag gccaggcttt tgagctgatt ctcagccctc ggtcaaaaga atctgt 176 <210> SEQ ID NO 270 <211> LENGTH: 284 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 270 cttcttcctg ttattggtag ttctgaacgt tagatatttt ttttccatgg ggtcaaaagg 60 tacctaagta tatgattgcg agtggaaaaa taggggacag aaatcaggta ttggcagttt 120 ttccattttc atttgtgtgt gaatttttaa tataaatgcg gagacgtaaa gcattaatgc 180 aagttaaaat gtttcagtga acaagtttca gcggttcaac tttataataa ttataaataa 240 acctgttaaa tttttctgga caatgccagc atttggattt tttt 284 <210> SEQ ID NO 271 <211> LENGTH: 389 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 271 aaaaatgaat ttaaggaaac attggctacc tctgacttct tagccaggga acataggtga 60 gaagatatcc gaagacgcct aaaatctcta caaacacatg ggtttacaaa aaacaagcct 120 aaaatcaaga ctctcaggta atgtcgaaat ctgctgttgg gaggcgatcc ccattttatg 180 atgtttgaac acactctttc tcttgctgga tagtttcctt tgagggaaga gtattttttt 240 cttcagtatt agttttcttc agttttgacc tgtcaaactt ctccacttcc gacaagtctg 300 gcttatcact catcttgact agaagatagc ctgaaagctt gaagactcgt gaaaggctgt 360 tcgcggggct gagacccaga ctcgctccg 389 <210> SEQ ID NO 272 <211> LENGTH: 429 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 381 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 272 ctggaacagt atatgaagac ctgaggtata agctctcgct agagttcccc agtggctacc 60 cttacaatgc gcccacagtg aagttcctca cgccctgcta tcaccccaac gtggacaccc 120 agggtaacat atgcctggac atcctgaagg aaaagtggtc tgccctgtat gatgtcagga 180 ccattctgct ctccatccag agccttctag gagaacccaa cattgatagt cccttgaaca 240 cacatgctgc cgagctctgg aaaaacccca cagcttttaa gaagtacctg caagaaacct 300 actcaaagca ggtcaccagc caggagccct gacccaggct gcccagcctg tccttgtgtc 360 gtctttttaa tttttcctta natggtctgt cctttttgtg atttctgtat aggactcttt 420 atcttgagc 429 <210> SEQ ID NO 273 <211> LENGTH: 478 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 273 ggccatctta gcggctgctg ttggttgggg gccgtcccgc tcctaaggca ggaagatggt 60 ggccgcaaag aagacgaaaa agtcgctgga gtcgatcaac tctaggctcc aactcgttat 120 gaaaagtggg aagtacgtcc tggggtacaa gcagactctg aagatgatca gacaaggcaa 180 agcgaaattg gtcattctcg ctaacaactg cccagctttg aggaaatctg aaatagagta 240 ctatgctatg ttggctaaaa ctggtgtcca tcactacagt ggcaataata ttgaactggg 300 cacagcatgc ggaaaatact acagagtgtg cacactggct atcattgatc caggtgactc 360 tgacatcatt agaagcatgc cagaacagac tggtgaaaag taaacctttt cacctacaaa 420 atttcacctg caaaccttaa acctgcaaaa ttttccttta ataaaatttg cttgtttt 478 <210> SEQ ID NO 274 <211> LENGTH: 478 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 274 tggcgccacc agagtttatg ccatcttgac tcatggaatc ttctccggtc ctgctatttc 60 tcgcatcaac aacgcatgct ttgaggcagt agtagtcacc aataccatac ctcaggagga 120 caagatgaag cattgctcca aaatacaggt gattgatatc tctatgatcc ttgcagaagc 180 catcaggaga actcacaatg gagaatccgt ttcttaccta ttcagccatg tccctttata 240 atagagtaac ttctgaggct ttttgagaat aaaatccacc ccacccttgt ttccccttgg 300 tatttgatga caaattcagc agaagacccg gcttgctcca gtgtagcttt ctacatccca 360 catcaggtat attagagctt atccgaactg gggaaagacg gattgagatt aactgctggg 420 acctcctacc tgcattatct cattctggct tccttgataa ttctgtgggc cttgcagc 478 <210> SEQ ID NO 275 <211> LENGTH: 306 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 275 aaacaatcct gggttcaagt taaacagttc cagttcccga aaagttcaca gccttgtttt 60 gtgggcagtt ctgctgttcc tggcttcccc ttccaggagg ggacgtttgc aggtctgggg 120 gtcctggtga ctaagctgtt agctccactc cctgcctgtt tccgtcctca cagccctggg 180 agggccccgg tggacagagt ccttacaatt taggagatgc tgctggcaaa ggaactgttg 240 acccaaagca ggtggcctga atgggaagtg ccaggctgga cacttggggg ctgagggcac 300 tgccag 306 <210> SEQ ID NO 276 <211> LENGTH: 154 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 276 tcatccggtt tagtcatcca acaagaagaa atatgaaatt ccagcaataa gaaatgaaca 60 aaagattgga gctgaagacc taaagtgctt gctttttgcc cgttgaccag ataaatagaa 120 ctatctgcat tatctatgca ccatgcgctt ttta 154 <210> SEQ ID NO 277 <211> LENGTH: 455 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 277 ctgtgacctt gccaaggagc agggcccata cgaaacctat gagggctctc cagttagcaa 60 aggaattctt cagtatgata tgtggaatgt tactcctaca gacctatggg actggaaggt 120 tctcaaggag aagattgcaa agtatggtat aagaaacagt ttacttattg ccccgatgcc 180 tacagcttcc actgctcaga tcctggggaa taatgagtcc attgaacctt acaccagcaa 240 catctatact cgcagagtct tgtcaggaga atttcagatt gtaaatcctc acttattgaa 300 agatcttacc gagcggggcc tatggcatga agagatgaaa aaccagatta ttgcatgcaa 360 tggctctatt cagagcatac cagaaattcc tgatgacctg aagcaacttt ataaaactgt 420 gtgggaaatc tctcagaaaa ctgttctcaa gatgg 455 <210> SEQ ID NO 278 <211> LENGTH: 226 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 278 ccttgatgag gccaaaaata attatattgt tttgcaatct tcagtgaatg gcctcattca 60 agaagtagaa gatggcaagc agaaactgga gaagaaggat gaagaaatca gtagactgaa 120 aaatcaaatt caagaccaag agcagcttgt ctctaaactg tcccaggtgg aaggagagca 180 ccaactttgg aaggagcaaa acttagaact gagaatctga cagtgg 226 <210> SEQ ID NO 279 <211> LENGTH: 194 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 279 ttctagggga gaagagaaat gccttagatg ttctgacagc actgcacctt tggcttgttt 60 tcagtggttg gtggaacatg aataggaacc acattgttgc ttggagacat gtcattttcg 120 cgtctgtctg acatttgctt ctgagaaaca atgcggtaaa tctctgttaa aattgtctga 180 aaagcagctt ctac 194 <210> SEQ ID NO 280 <211> LENGTH: 290 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 280 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgagc 290 <210> SEQ ID NO 281 <211> LENGTH: 168 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 281 aaactcagta tggaaaatac atttaataaa ttaaagcaaa aaccaaagat ctgaggagat 60 ccaagagatc aagacaatct gtaaccagag tctgaagtat ccaaggagct actctttttg 120 aggcatattc tcctcagctt ccagttatca tttgataaac acatcagc 168 <210> SEQ ID NO 282 <211> LENGTH: 369 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 282 aaaatcccag atactctgaa ttttagaaaa caaactaatt ctgattgtgt cgtgcccaag 60 tacccttttt ttttaatgaa tagggaccaa tgccacattg ctttttatat ttctttcttt 120 tttaatgttg ccaaaaccaa aagtagcttt gttttccttt gtattttgct actttgcagt 180 atttgtgtgt gtggtttttt ttccttaatt tgaaagggac agcactgtgt atgtttataa 240 actaaatgaa gataagatat tattttgtat aaacattcat ctgagaacaa tcaaagcagt 300 agccacatgg tgctggctcc tttgcagcac aaacctggtc attttgatga ctgtacaaca 360 ggaagactt 369 <210> SEQ ID NO 283 <211> LENGTH: 282 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 283 ctgcggacgc caactcgttc ccccaaggct cggccattct ttagggtcct gacgatcagg 60 aaaagatgaa ttagtcgttt ttctttttcc cctttccttt gctcctaacc aggctgcatg 120 atggcatcgg agactgacag aaggactggg atggttaatc tggagtagag cttggtagta 180 aatactagta agatctgcct gccaaaagcc cgcccctcga ttcacacgtg attattcagc 240 aaaactgagc cattggagag gggctcctcg cctcgctttt tt 282 <210> SEQ ID NO 284 <211> LENGTH: 211 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 284 cctcagccac aatagaagcc tggtagaacc gaggtagggc cagaatacag tccatcagct 60 tgtggcggcc caagttgatg agcattgtgt tctggccagt gttcagaaag tgaatctgca 120 gagttatcaa cttggtgagc cgctgacagt gctgggcctg tcgcacacag gagtccttgg 180 cataactctc tgctgcatcc acatcagagt c 211 <210> SEQ ID NO 285 <211> LENGTH: 67 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 285 ctgaggggag aggatgatcc tgggaactgg ggaacttctc ccccttgaga atccaaccat 60 caaatac 67 <210> SEQ ID NO 286 <211> LENGTH: 225 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 286 caaagaagaa taagcaagaa agaaaagaag gaaggaagag aggtagacag atacaagatg 60 aaatcctgtc aaaaaatgga aggaaaacca gaaaatgaga gtgaaccaaa gcatgaggaa 120 gagccaaagc ctgaggaaaa gccagaagag gaggagaagc tagaggagga ggccaaagca 180 aaaggaactt ttagagaaag gctgattcaa tctctccagg agttt 225 <210> SEQ ID NO 287 <211> LENGTH: 380 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 287 ctggaacagt atattgaaga cctgaggtat aagctctcgc tagagttccc cagtggctac 60 ccttacaatg cgcccacagt gaagttcctc acgccctgct atcaccccaa cgtggacacc 120 cagggtaaca tatgcctgga catcctgaag gaaaagtggt ctgccctgta tgatgtcagg 180 accattctgc tctccatcca gagccttcta ggagaaccca acattgatag tcccttgaac 240 acacatgctg ccgagctctg gaaaaacccc acagctttta agaagtacct gcaagaaacc 300 tactcaaagc aggtcaccag ccaggagccc tgacccaggc tgcccagcct gtccttgtgt 360 cgtcttttta atttttcctt 380 <210> SEQ ID NO 288 <211> LENGTH: 275 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 288 cctacgattt tgttccagat tgggctgaaa ttttatacca gcaagtgatt cttaaaggag 60 actttaatta cttggaagaa tttaagcagc aaaggttatt aaagtccagt atatttgaag 120 agatttccaa aaaatataaa caacatcagc ctactgacat ggtcatggaa aacctgaaga 180 aattactcac atattgtgaa gatgtttacc tgtattacaa gttggcatac gaacacaagt 240 tttatgaaat tgtaatgtgc ttctgaagga ccctc 275 <210> SEQ ID NO 289 <211> LENGTH: 361 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 289 ctgccctcgt tctttcgctc agaggactgg ctggtggcct tggcttcact actcatttcc 60 agaggcttag ctgagatgta gtcctttact ttaatctcca tattcttggc tttcagagtg 120 gccatgtgca gcttctccag gaaatctggc atgccactgg aaaccatcca actaacacag 180 tagcgaggaa acaccgtttg gggattgtca ctgtatgtta gtaagtagtc aaagccattc 240 tcatcaaatg acttgtgggg acggataacc atttgggatt catatgatct gaccctgacg 300 aattctggag actctggcac actcggatgc tccacagcac gcgacaccaa caccatcatg 360 t 361 <210> SEQ ID NO 290 <211> LENGTH: 202 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 290 ctgtcagtag gctgacctaa cgttctagca tgcctcttga gggcctttcc aactgagctc 60 tctggaggag ggtaggaaag tcagggaaat catgcaatcc catttgggga agggaaagca 120 tctcaagatt tgtgaggttc cctgggaaag gtgtttacca caaatgtcac atcaattaaa 180 ggaaagtctg cagagagaga ga 202 <210> SEQ ID NO 291 <211> LENGTH: 254 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 84 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 291 ctggattctt cctcttggat ctctcgaact cttcagtccc ccatgtgtag ataagataaa 60 acactacaaa ctgcggcacc acgngaaaga aagactcccg aatgcggcgc agaacattgg 120 ggattccttt agtgaagacg tgcggatagg cgcgctgctc gaacggtgac aagctgtagc 180 tgatcacatg ccgcatccgc gtcagattcc caaactcgcg gcccattggt ggcggcggcc 240 agggctcagc tcgc 254 <210> SEQ ID NO 292 <211> LENGTH: 273 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 292 aaaaatagaa aacaatgata aaaattcagt tgccaactta gaggatttta tacattatga 60 agtgttctat tttccttcca gggtctgaaa tttatttctc aagaaaacag attttatttc 120 taagccttta ctatctttgc tagaaacaga aaaaccagtt ttctctttga caaaattgtc 180 ccaggagaac aacacaaatg ctttttccaa attagagcat aagtcttcct taaatgtcct 240 agtgtgacaa taaggataca acagccatct ttt 273 <210> SEQ ID NO 293 <211> LENGTH: 197 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 293 ggcaccagag gcagtaacca tgcccgcata gatgccgcgg aaggtccctc agacatcccc 60 gattgaaaga accagagagg ctctgagaaa cctccggaaa cttagatcat cagtcaccga 120 aggtcctaca gggctacaac tgcccccgcc acaacccacc ccgctttcgt agttttcatt 180 tagaaaatag agctttt 197 <210> SEQ ID NO 294 <211> LENGTH: 404 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 294 ctgttaaatt ctgggcatat gaacagtaca agaagttact tactgaagaa ggacaaaaaa 60 taggaacatt tgagagattt atttctggtt ccatggctgg agcaactgca cagactttta 120 tatatccaat ggaggttatg aaaaccaggc tggctgtagg caaaactggg cagtactctg 180 gaatatatga ttgtgccaag aagattttga aacatgaagg cttgggagct ttttacaaag 240 gctatgttcc caatttatta ggtatcatac cttatgcagg catagatctt gctgtgtatg 300 agctcttgaa gtcctactgg ctggataatt ttgcaaaaga ttctgtaaac cctggagtca 360 tggtgttgct gggatgcggt gccttatcca gcacctgtgg tcag 404 <210> SEQ ID NO 295 <211> LENGTH: 603 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 540 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 295 cctctgggac ccacagaact tgtggccttt atgttctttc acccatccta ggaaccagcc 60 aaccatcatg tgtagagccc ctactgtggg caaagtcctc ctttcattac cctacagaca 120 gcttacagga gccagcctgc ttcccacaac tactagtgtg actccttatc tctttccacc 180 ataccttaga gactttgata ctaccagggt ctctcaggga tggagggaag acctgaaaga 240 gaggactggt tctgaggcca gaaaggtgtg aggagagagg aggaaaagtc ttcctaattg 300 tgcccctaaa gagcatcctg ataccattct attctccaga catggagggg atgataaagg 360 aaataggatc tccactggac ccttgattca ttctgaaccc tccaaaggaa ctctagaggg 420 cgagggatga tgagggaagc aataggtagc tggggagccc tattgctgct aagtcattgg 480 caaagtgaca aagcaattta ctgatgagag aatgtggaaa tagatgtgca gtttggaatn 540 atgttggtgt gaatttgcca gaggaccaat gcttgcatgg agaatgggac gaggacattt 600 gtg 603 <210> SEQ ID NO 296 <211> LENGTH: 449 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 296 aaaaaatgat gcccttaggt tgggccagac ctctgttaac ttcagtaggg atggcaccag 60 gttcaagagg ccaaagaaga gacctggagc tagtgaagga aacatagggt ttatttgggg 120 aatcttacag ggtggtccag tggccgcggg ctggacagaa ctgcaaccac ttataaaaag 180 catgcagttt acatagcact ttcactcagc accctcccct cagcagcctc cacgtggcaa 240 ccctcacttc ttaagttatt gctgtcagat gcatctgcca tacagggtca ttctcagggg 300 atgcttaagt tatttctgtc aggtacatct tccatacact ttactacctt ggagtaaagt 360 agtaagaata cagctttttc cttaaccttt accagctaac tcagtgctta ggggccttgg 420 aatgcctgct gtccagcagg tgtcacagg 449 <210> SEQ ID NO 297 <211> LENGTH: 227 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 297 ctgctccggg ccttcatcct gaagatcagc gtgtgcgatg ccgtcccgga ccacaacccc 60 ccagactgta ccttcacagt cctggtgcac acgagagaag ccgccactcg caacatggag 120 aagatccagg tcatcaagga tttcccctgg atcctggcgg atgagcagga tgtccacatg 180 catgaccccc ggctgatacc actaaaaacc atgacgtcgg acatttt 227 <210> SEQ ID NO 298 <211> LENGTH: 260 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 298 gaccattgtg ctcttggctc ttgggctgga gtaccgtggt gagggagtaa acactagaag 60 tctttagtac aaaactgctc tagggacacc tggtgattcc tacacaagtg atgtttatat 120 ttctcataaa gagtcttccc tatcccaagg tcttcatgat gccagtagcc atatatgata 180 aattatgttc agtgataact tagttatcag aaatcagctc agtggtcttc cccgccatga 240 ttcacatttg atgagttttt 260 <210> SEQ ID NO 299 <211> LENGTH: 64 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 299 aaaatttccc ccatggaaat cactctcctg ttgactattt ccagagctct aggcgtttag 60 gcag 64 <210> SEQ ID NO 300 <211> LENGTH: 158 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 300 ctgctactca gccccaacct gtcattgttt gtaaaaatgt aagcacagtg tagtggaatc 60 ttccaatttg gaagggaagc cggaaatcca gatttaatgg aaaaaatctg atttttcaac 120 gtcgggtttt ttgtttgttt gtttttgttt tttttaac 158 <210> SEQ ID NO 301 <211> LENGTH: 231 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 301 ctgacctgga aaccgtgggg attggttcta atgagccata aatgcttccc ctcttccttc 60 agcactagta gactaccagc tttaggcatt taaccaaacg aattggagac agaaaatatt 120 aaaatccagc catcctatat cagatgatga actcatttcc agactaacta cccaagaaag 180 caagttaaac actgtaaaag cctaaaacgg ggcaagttgg gattagcttt t 231 <210> SEQ ID NO 302 <211> LENGTH: 216 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 302 ctgggatggg agggtgaaca gacagctcta cctaactggt gtgggaatag cacgtctgaa 60 ttcctgaatt cccttagagg aacatggctc cttgctctgg aacttcacac tcaaacaata 120 agcctgaagg gaagaagtct cttcagggtc ccagaagtgc ccattaaaag tccatcctgt 180 caactttggt gtctcatttg tgggtccgta tgctgc 216 <210> SEQ ID NO 303 <211> LENGTH: 227 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 303 ctggctcggg ctgacgacta tgaacaggtc aagaacgtgg ccgattacta cccggagtac 60 aagctgctct tcgagggtgc aggtagcaac cctggagaca agacgctgga ggaccgattc 120 tttgagcacg aggtaaagct gaacaagttg gccttcctga accagttcca ctttggtgtc 180 ttctatgcct tcgtgaagct caaggagcag gagtgtcgca acatcgt 227 <210> SEQ ID NO 304 <211> LENGTH: 129 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 304 cctaaaacaa gagggcacag gaacaagtag tcagatggat ttaggtgagc actgtacaca 60 agctttgagg aagtgcaaag gactgacctc taggccagaa caagatggaa aactaccagg 120 cccatcagg 129 <210> SEQ ID NO 305 <211> LENGTH: 445 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 395, 410 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 305 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tcctgacttg ttggnataaa agcagcaacn ttcctgtaga 420 gccaaacaga tacctccctg ttctg 445 <210> SEQ ID NO 306 <211> LENGTH: 177 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 306 gcttcgacat gcattgggtg atactaatat cagtagtttg gcagactata atgcatctag 60 gctttataat cgcagaagat aaaaaagcag aagaagttaa tatttcttca cttatgattg 120 cacaaaaaat gcaatcacaa tcaaaccctg ctttcgctta gttaaaagtg acaagtg 177 <210> SEQ ID NO 307 <211> LENGTH: 220 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 307 aaatttacaa cctggaagag cacataaacc gagaaactga gaacaattca ctcgtgacaa 60 agatagccat gatatatgaa ttggagtctg ttcatcttca ataggctctt catctgatga 120 gtcaaactca cttgtttgta ttgaactggg cggcttcatc gctggccgcc ccacgtcgag 180 accagtgccg cctccctctg cagcgccggc gactcaccgg 220 <210> SEQ ID NO 308 <211> LENGTH: 284 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 28 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 308 ctgctaaaag gagtcaccat agccagtngg gggtgtgtta cccaacatcc accccgagtt 60 gctagcgaag aagcggggat ccaaaggaaa gttggaagcc atcatcacac cacccccagc 120 caaaaaggcc aagtctccat cccagaagaa gcctgtatct aaaaaagcag gaggcaagaa 180 aggggcccgg aaatccaaga agcagggtga agtcagtaag gcagccagcg ccgacagcac 240 aaccgagggc acacctgccg acggcttcac agtcctctcc acca 284 <210> SEQ ID NO 309 <211> LENGTH: 282 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 309 tctgacttct tagccaggga acataggtga gaagatatcc gaagacgcct aaaatctcta 60 caaacacatg ggtttacaaa aaacaagcct aaaatcaaga ctctcaggta atgtcgaaat 120 ctgctgttgg gaggcgatcc ccattttatg atgtttgaac acactctttc tcttgctgga 180 tagtttcctt tgagggaaga gtattttttt cttcagtatt agttttcttc agttttgacc 240 tgtcaaactt ctccacttcc gacaagtctg gcttatcact ca 282 <210> SEQ ID NO 310 <211> LENGTH: 296 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 310 cctggagaag gagctggcat gtcactgttc tctgtactgg cattccccac atcctctggg 60 gacaatgatt caggaaccag agagaccacc tccttttcgg gctccacatg taaatatgga 120 ttctggattt ctactgggct ttctgagctg gcagtcacag aagctgactt ggatgggtat 180 gatgggacag agatggtctc catggccgct atggtggtcc tctgatataa aagcttctga 240 atatttggcc cattaggacc ctctggctct gtaatagaac tacgtttctt tagagg 296 <210> SEQ ID NO 311 <211> LENGTH: 155 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 311 aaactgtgtg agatattaac cagccgccct gttataaaat caggaaatcc aaacagcgat 60 ttacaccgat taacaccccc tttatatatt ttttacaaaa atacactgag aaaataatca 120 aacgttttca tctctcttgt ctttttttgt ttttt 155 <210> SEQ ID NO 312 <211> LENGTH: 263 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 312 gggagcggga gctcgagaat actgcccagt tactctagcg cgccaggccg aaccgcagct 60 tcttggctta ggtacttcta ctcacagcgg ccgattccga ggccaactcc agcaatggct 120 tttgcaaatc tgcggaaagt gctcatcagt gacagcctgg acccttgctg ccggaagatc 180 ttgcaagatg gagggctgca ggtggtggaa aagcagaacc ttagcaaaga ggagctgata 240 gcggagctgc aggactgtga agg 263 <210> SEQ ID NO 313 <211> LENGTH: 416 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 313 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tcctgacttg ttggcataaa agcagcaacg ttcctg 416 <210> SEQ ID NO 314 <211> LENGTH: 133 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 314 aaagaataaa gtccaaagtc agatctggtc tagttaacct agaagtattt ttgtctctta 60 gaaatacttg tgatttttat aatacaaaag ggtcttgact ctaaatgcag ttttaagaat 120 tgtttttgaa ttt 133 <210> SEQ ID NO 315 <211> LENGTH: 487 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 436 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 315 cgtgcacagc cttatgatcc caatttttac gatgaaacct atgattatgg tggttttaca 60 atgatgtttg atgaccgtcg cggacgccca gtgggatttc ccatgcgggg aagaggtggt 120 tttgacagaa tgcctcctgg tcggggtggg cgtcccatgc ctccatctag aagagattat 180 gatgatatga gccctcgtcg aggaccacct ccccctcctc ccggacgagg cggccggggt 240 ggtagcagag ctcggaatct tcctcttcct ccaccaccac cacctagagg gggagacctc 300 atggcctatg acagaagagg gagacctgga gaccgttacg acggcatggt tggtttcagt 360 gctgatgaaa cttgggactc tgcaatagat acatggagcc catcagaatg gcagatggct 420 tatgaaccac agggtngctc cggatatgat tattcctatg cagggggtcg tggctcatat 480 ggtgatc 487 <210> SEQ ID NO 316 <211> LENGTH: 294 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 316 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgagc cgcc 294 <210> SEQ ID NO 317 <211> LENGTH: 528 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 317 aaaggaatgg attttgagag aaaacaacgt gggcagaagt atggaataga aaataaatac 60 aaatgtaggc tattctgcta attgttttat aaccacgaca aactagtaca gagaatgccc 120 tgtacaaaac acaacaaagg ttcaaacatc gagatgttcc cttagcaagg ctgaaaattt 180 cagtctctgg tatttggaat ttaggctgca gtccttgttt ttggatggat cactgggtgt 240 gtggcacagt ccatgctttt aaccagattt gaacagaaga atggccactt ggcccaggta 300 gaagtagatg aagtgtttgg tttcatgtgt cacataacta ccgaagttcc tccccacgat 360 gcaatgccag gtgggattgt acttcttgtc aaattccttc ttgatatgag ccgcaatgtc 420 cttctctatg ttgtatttct ccagcgcctg agtagcgcac tccaccgagt cctgttgcat 480 ctcttccgac atgtccgcat ttttgatcac ggcctttcgg tcgcacat 528 <210> SEQ ID NO 318 <211> LENGTH: 84 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 318 ccttatgtat gtggggaatg tgggaaagct tttatgttca aatctaaact tgttaggcac 60 cagagaactc acactggaga aagg 84 <210> SEQ ID NO 319 <211> LENGTH: 303 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 319 ccgggcaggt ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt 60 ctaatttctt ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga 120 attctggaac agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg 180 cacgcttctc cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag 240 cgacaggcag tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgagc 300 cgc 303 <210> SEQ ID NO 320 <211> LENGTH: 186 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 320 cctcgttgat gaggtccttg agtgcctcca acaccttctt gaggatggag ccctggacca 60 ggcgcgcctc gaacatggtg gcggagtggc aacaacgccg ctacaggcag gcgggaagga 120 ggaaagtcta gctggtttcg gcttcaggag cctcagagcg agcgggcgaa cgtcgcgacg 180 accggc 186 <210> SEQ ID NO 321 <211> LENGTH: 305 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 321 ccttgtagtt ctctaagccc ctctagcaac atgtggatat gggctttgat attcatggag 60 tccttggtga ggctgttgct gagctctgtg aggagagagc tcttacgatc aatgaacttg 120 agagcttctg ccagtgtcaa ctccaggaaa aaaccatatc ccagggccac atagatgcgt 180 gaagtatctg ggaccactgt gtcaacgaag aagttacagc ccaaatccac ctgcatatat 240 aactccgagt gcttagcttc ctggagtcgc tcaatgacat ttctcagttg aaggtatttg 300 gccag 305 <210> SEQ ID NO 322 <211> LENGTH: 204 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 322 aaaaaagcta atctataaat accgtttttc caaaggtatt ttacaatatt tcaacagcag 60 accttctgct cttcgagtag tttgatttgg tttagtaacc agattgcatt atgaaatggg 120 ccttttgtaa atgtaattgt ttctgcaaaa tacctagaaa agtgatgctg aggtaggatc 180 agcagatatg ggccatctgt tttt 204 <210> SEQ ID NO 323 <211> LENGTH: 301 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 323 aaacaataaa caccatcaac cttattgact ttattgtccc ttaaattata ttgactgttg 60 tgattccatc aagtttgtac actcttttct ctccctgttt tgcagcaaca aattgcgaag 120 tgcttttgtt tgtttgtttt cgtttggtta aagcttattg ccatgctggt gcggctatgg 180 agactgtctg gaaggcttgg aatggtttat tgcttatggt aaaatttgcc tgatttctta 240 caggcagcgt ttggaaacct tttattatat agttgtttac atacttataa gtctatcatt 300 t 301 <210> SEQ ID NO 324 <211> LENGTH: 305 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 324 cctctaatcg actagtatga gttttgagct aaatatgtat ttagttatta gtgagaaaat 60 ggacaatggg caattgtgag tcaaataaat gctaaatttt tgcctctcca agaaggcagc 120 aggtggctga aatcctggtg tgatatggct gaataatgca tgatctgagg accctgtact 180 ggttactcct gtacacgttc acaatttttc tgtaaatgta ttaatatact gagcagtcca 240 ggagcagcca ttaggcaaac accactcctt gcttccttca tgtgacctat cactgagctc 300 accag 305 <210> SEQ ID NO 325 <211> LENGTH: 503 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 325 gttaagacct gcaataatcc agaatggcta ctctgatcta tgttgataag gaaaatggag 60 aaccaggcac ccgcgtggtt gctaaggatg ggctgaagct ggggtctgga ccttcaatca 120 aagccttaga tgggagatct caagtttcaa caccacgttt tggcaaaacg ttcgatgccc 180 caccagcctt acctaaagct actagaaagg ctttgggaac tgtcaacaga gctacagaaa 240 agtctgtaaa gaccaaggga cccctcaaac aaaaacagcc aagcttttct gccaaaaaga 300 tgactgagaa gactgttaaa gcaaaaagct ctgttcctgc ctcagatgat gcctatccag 360 aaatagaaaa attctttccc ttcaatcctc tagactttga gagttttgac ctgcctgaag 420 agcaccagat tgcgcacctc cccttgagtg gagtgcctct catgatcctt gacgaggaga 480 gagagcttga aaagctgttt cag 503 <210> SEQ ID NO 326 <211> LENGTH: 157 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 326 ctggcggcct gaggagccca tcatggcgac gccccctaag cggcgggcgg tggaggccac 60 gggggagaaa gtgctgcgct acgagacctt cataagtgac gtgctgcagc gggacttgcg 120 aaaggtgctg gaccatcgag acaaggtata tgagcag 157 <210> SEQ ID NO 327 <211> LENGTH: 325 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 327 cctgctggga tattagctcc agcggtgtaa acctgcagag catggactcg tcccacgtct 60 ctttggtgca gctcaccctg cggtctgagg gcttcgacac ctaccgctgc gaccgcaacc 120 tggccatggg cgtgaacctc accagtatgt ccaaaatact aaaatgcgcc ggcaatgaag 180 atatcattac actaagggcc gaagataacg cggatacctt ggcgctagta tttgaagcac 240 caaaccagga gaaagtttca gactatgaaa tgaagttgat ggatttagat gttgaacaac 300 ttggaattcc agaacaggag tacag 325 <210> SEQ ID NO 328 <211> LENGTH: 531 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 328 cctcagcaat ggctgtggtg ttgctcagca tgcacacagc tctctgtacc ttggccaggt 60 ctccaccagg caccacagtg ggaggctggt agttgatgcc aaccttgaag ccagtggggc 120 accaatccac aaactggatg ctgcgcttgg ttttgatggt ggcaatggca gcattgacat 180 ctttgggaac cacgtcacca cggtacaaca ggcagcaagc catgtattta ccatggcgag 240 ggtcacattt caccatctgg ttggctggct caaagcaagc attggtgatc tctgctacag 300 aaagctgttc atggtaggct ttctcagcag agatgacagg ggcatatgtg gccagaggga 360 agtggatgcg ggggtagggc accaggttgg tctggaattc tgtcaggtca acattcaggg 420 ctccatcaaa tctcagggaa gcagtgatgg aggacacaat ctggctaata aggcggttaa 480 ggttagtgta ggttgggcgc tcgatatcga ggtttctacg acagatgtca t 531 <210> SEQ ID NO 329 <211> LENGTH: 157 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 329 aaaaacaaac tatacagaag acttcatacc gtaacaataa atgtatagtt tcttcaaagg 60 gagaagagat tcacatatct gataacaaaa taaactagca atctagtttt ctaatctact 120 ttatgaggct ggattttttt tttagaaaag ctaattt 157 <210> SEQ ID NO 330 <211> LENGTH: 353 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 330 ctgccatttg caaaaacaag gaaaaaaatc cgaaactttc ttttgttgca ctgacagggt 60 ctgtactttt ttttttcttt ttgagtcagg actatggagc cgagtagttg atcttttaat 120 atagccgtgt ttacttgtat taacttacag ttaacatagg aaaaatacaa gtaaggatgt 180 gagaatttgc attttaatgg gaaattttca accgttaatc tgaaaacaga agacagtctt 240 aatataaatg tactgtgaag aatgctattg atgtttatgg tttctgatta cttttcaaat 300 tttgatgttt ttttgccagt tggcttttct taaatgaaaa cactgttcca ttt 353 <210> SEQ ID NO 331 <211> LENGTH: 449 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 331 aaaaagaaaa aaaggtctat ttttttttct cctatacttg ggctacattt tttgattgta 60 aaaatatttg atggcctttt gatgaatgtc ttccacagta aagaaaactt agtggcttaa 120 tttaggaaac atgttaacag gacactatgt ttttgaaatt gtaacaaaat ctacataaat 180 gatttacagg ttaaaagaat aaaaataaag gtaactttac ctttcttaaa tatttcctgc 240 cttaaagaga gcatttccat gactttagct ggtgaaaggg tttaatatct gcagagcttt 300 ataaaaatat atttcagtgc atactggtat aatagatgat catgcagttg cagttgagtt 360 gtatcacctt ttttgtttgt cttttataat gtcttcagtc tgagtgtgca aagtcaattt 420 gtaatatttt gcaaccctag gattttttt 449 <210> SEQ ID NO 332 <211> LENGTH: 218 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 332 cagtctcgcg cggctactgc agcactgggg tgtcagttgt tggcccgacc cagaacgctt 60 cagttctgct ctgcaaggat atataataac tgattggtgt gcccgtttaa taaaagaata 120 tggaaactga acagccagaa gaaaccttcc ctaacactga aaccaatggt gaatttggta 180 aacgccctgc agaagatatg gaagaggaac aagcattt 218 <210> SEQ ID NO 333 <211> LENGTH: 274 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 333 aaaacatgtc catggttccc ccaggaaggg tctattgact cccgtgtttg gggacgtgtt 60 ggtgattgtc tgaacgacta ttaccgtgtt tttggtcctg agactattcc gatcaccact 120 tttaattatt ataatttaat aagggacgtc cttactaatc agagcgactc ccctgacatt 180 caacgcctct gcaaggaggg tcacaaaatt cttattagcc actcccgacc tccatctaga 240 caagcccctg taacaattac cacctctgaa aagg 274 <210> SEQ ID NO 334 <211> LENGTH: 385 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 334 aaaaatagaa aaggtcctca agagaatgag agaaataaaa aatgaacttc tccaagcaca 60 aaacccttct gaattgtacc tgagctccaa aacagaattg cagggtttaa ttggacagtt 120 ggatgaggta agtcttgaaa aaaacccctg catccgggaa gccaggagaa gagcagtgat 180 cgaggtgcaa actctgatca catatattga cttgaaggag gcccttgaga aaagaaagct 240 gtttgcttgt gaggagcacc catcccataa agccgtctgg aacgtccttg gaaacttgtc 300 tgagatccag ggagaagttc tttcatttga tggaaatcga accgataaga actacatccg 360 gctggaagag ctgctcacca agcag 385 <210> SEQ ID NO 335 <211> LENGTH: 414 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 335 ctgccagggg ggacctagag caacttacta gtttgttgca aaataatgta aacgtcaatg 60 cacaaaatgg atttggaagg actgcgctgc aggttatgaa acttggaaat cccgagattg 120 ccaggagact gctacttaga ggtgctaatc ccgatttgaa agaccgaact ggtttcgctg 180 tcattcatga tgcggccaga gcaggtttcc tggacacttt acagactttg ctggagtttc 240 aagctgatgt taacatcgag gataatgaag ggaacctgcc cttgcacttg gctgccaaag 300 aaggccacct ccgggtggtg gagttcctgg tgaagcacac ggccagcaat gtggggcatc 360 ggaaccataa gggggacacc gcctgtgatt tggccaggct ctatgggagg aatg 414 <210> SEQ ID NO 336 <211> LENGTH: 457 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 336 cctcagcaat ggctgtggtg ttgctcagca tgcacacagc tctctgtacc ttggccaggt 60 ctccaccagg caccacagtg ggaggctggt agttgatgcc aaccttgaag ccagtggggc 120 accaatccac aaactggatg ctgcgcttgg ttttgatggt ggcaatggca gcattgacat 180 ctttgggaac cacgtcacca cggtacaaca ggcagcaagc catgtattta ccatggcgag 240 ggtcacattt caccatctgg ttggctggct caaagcaagc attggtgatc tctgctacag 300 aaagctgttc atggtaggct ttctcagcag agatgacagg ggcatatgtg gccagaggga 360 agtggatgcg ggggtagggc accaggttgg tctggaattc tgtcaggtca acattcaggg 420 ctccatcaaa tctcagggaa gcagtgatgg aggacac 457 <210> SEQ ID NO 337 <211> LENGTH: 543 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 337 gtaaagatgc cttctggtga atttgcacgt atatgccgag atttcagcca tattggagat 60 gctgttgtaa tttcctgtgc aaaagacgga gtgaaatttt ctgcaagtgg agaacttgga 120 aatggaaaca ttaaattgtc acagacaagt aatgtcgata aagaggagga agctgttacc 180 atagagatga atgaaccagt tcaactaact tttgcactga ggtacctgaa cttctttaca 240 aaagccactc cactctcttc aacggtgaca ctcagtatgt ctgcagatgt accccttgtt 300 gtagagtata aaattgcgga tatgggacac ttaaaatact acttggctcc caagatcgag 360 gatgaagaag gatcttaggc attcttaaaa ttcaagaaaa taaaactaag ctctttgaga 420 actgcttcta agatgccagc atatactgaa gtcttttctg tcaccaaatt tgtacctcta 480 agtacatatg tagatattgt tttctgtaaa taacctattt ttttctctat tctctgcaat 540 ttg 543 <210> SEQ ID NO 338 <211> LENGTH: 235 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 234 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 338 ggcggctcgg actgagcagg gctttcctta tcccagttga ttgtgcagaa tacactgcct 60 gtcgcttgtc ttctattcac catggcttct tctgatatcc aggtgaaaga actggagaag 120 cgtgcctcag gccaggcttt tgagctgatt ctcagccctc ggtcaaaaga atctgttcca 180 gaattccccc tttcccctcc aaagaagaag gatctttccc tggaggaaat tcana 235 <210> SEQ ID NO 339 <211> LENGTH: 192 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 20 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 339 cctaccacct tcagaagtcn acctgtggca aatgtggcta ccctgccaag cgcaagagaa 60 agtataactg gagtgccaag gctaaaagac gaaataccac cggaactggt cgaatgaggc 120 acctaaaaat tgtataccgc agattcaggc atggattccg tgaaggaaca acacctaaac 180 ccaagagggc ag 192 <210> SEQ ID NO 340 <211> LENGTH: 294 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 340 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgagc cgcc 294 <210> SEQ ID NO 341 <211> LENGTH: 525 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 341 ttttttttgc tttgaaattt agaaacaaat tttatttaag atctgaaata caattcctaa 60 aatatcaact tttccagaaa accgtggcta cacaataatg cattgcctct atcatgttag 120 aacgtgcatt agactcaaat acaaaaacca tgaaacaaat caccatcctt caacaatttg 180 agcaaagata gaatgcctaa gaacaacata gatggacttg cagaggatgg gctgttttac 240 ttcaagcacc ataaaaaaaa aagagcacaa atgcatgggt tttcaggtat atacattaag 300 ttgaaccttt ggcactagga atcagggcgt tttgtcacat agcattaaca catattagaa 360 aattgtgtag tgtcaaaggg ataggaacca ccagcattca agcaatgttg tcaactaggc 420 aataaaatgt tctactgaat gtttcttctt tgttctaatt actgcataca ctggtagcaa 480 ctttgaaatg agaaaaggag cttacactcc ttttattttc tgttt 525 <210> SEQ ID NO 342 <211> LENGTH: 226 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 342 gtgtccatta ccttcgtaaa gcatagtgtc gagcggtatg ctgctcccgt aggaggggaa 60 ccggctacag tctgccatat tctagatcac gcgttgctag ttggtgatag tggatttgta 120 tgggctttcc cagtagggaa ttgagctgat ccctgattaa cgctgttact cgtcttagga 180 tccaaggggc aaaagagaag aacaggatga tagcgaataa gggtcc 226 <210> SEQ ID NO 343 <211> LENGTH: 184 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 343 ctggcttccc tgagaactca acaatgcctt ttcctgaggg ccttcctcga tcatccacaa 60 tgactacagc cctctctacc tggccaaaca cagaaaaggc ttcttccagc agttcgttgg 120 acacatactg aggaaggttt cgaactgtaa gggatgcact atggcaggca aagcgcacac 180 gcag 184 <210> SEQ ID NO 344 <211> LENGTH: 112 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 344 cggccgaggt aaaaattgca tagatcctaa ttattgcttg tgattttgtt atcccgatca 60 gataattaat acgatctgaa tacagccaca ccaaattcgt ggtgtatttt tt 112 <210> SEQ ID NO 345 <211> LENGTH: 334 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 345 ctggctttgc tgagccaaac catattattg atccgtcttg actgtgattc cacttgtgag 60 ataaagtccc aactgggagc tttctcataa attgggtcaa gacaggaaga actctaggta 120 gccagaggtg tctctgtgtc tcttttcaaa taattgaagg ccatttcttc tggtgtctgg 180 aagaagtaaa atatccttgt ctaacgggta ttgcttcagt ataccacatg cccaataagt 240 tctagcatct aggagcatgc aatagcagct aatattagct atgcagtcat ggtattatta 300 gtgtttaatt atatcatgtg cattgagata tttt 334 <210> SEQ ID NO 346 <211> LENGTH: 293 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 346 gcggctcgga ctgagcagga ctttccttat cccagttgat tgtgcagaat acactgcctg 60 tcgcttgtct tctattcacc atggcttctt ctgatatcca ggtgaaagaa ctggagaagc 120 gtgcctcagg ccaggctttt gagctgattc tcagccctcg gtcaaaagaa tctgttccag 180 aattccccct ttcccctcca aagaagaaga atctttccct ggaggaaatt cagaagaaat 240 tagaagctgc agaagaaaga cgcaagtccc atgaagctga ggtcttgaag cag 293 <210> SEQ ID NO 347 <211> LENGTH: 287 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 279, 280, 283 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 347 aaagtagctt gccagcttca tttctttggt ttcttgggta gtgggcgccg gaacagcaag 60 atgtgaggtt ctggttcatg gatcatataa tggacccatc cctgactctg ctgaacgcca 120 agattcctcc attcagattc agacatcaga tgggttttag ggaccagctt ggctatgtcc 180 ttgggcagca tgacatgtcg atactcaaac tcctcgtcgt cgtatttgtc cgaatagtaa 240 atttgtttgt gcgacatgat cgctcggttt gctagcctnn aancccg 287 <210> SEQ ID NO 348 <211> LENGTH: 406 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 162, 393, 401, 404 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 348 aaaaacaaag tcttcaactt gggtgttgag attggcaaaa ggggaagcaa gggaaaagcc 60 aaggaaagat aaaatattca gaagaaagtc aaagttatct gcaattacat gttagaacag 120 attttgcagg ttaaaaagat gttgcttaaa tatattcata ancctgttgt aagattttca 180 cttatgcagt ttcagaaaat ttagctgctt aacatatgac agaactgtat tttaacaaat 240 gacattaaaa gtcaggagag ctactcagtt aattgataaa gtagaggcaa cgtgggggag 300 ccctccccac gtttattgaa gatttgtggc tcccccagcc ccgtttgcct gcatcaggct 360 aacaacctca ttcctcccat agagcctggc canatcacag ncgntg 406 <210> SEQ ID NO 349 <211> LENGTH: 426 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 349 ctgctgggca tgctgtgtgc ttgcatcgtg ttgtgcagaa ggagtagaga tcctgcttac 60 gagctcctca tcactggcgg aacctatgca tagttgacaa ctcaagcctg agctttttgg 120 tcttgttctg atttggaagg tgaattgagc aggtctgctg ctgttggcct ctggagttca 180 tttagttaaa gcacatgtac actggtgttg gacagagcag cttggctttt catgtgccca 240 cctacttacc tactacctgc gactttcttt ttccttgttc tagctgactc ttcatgcccc 300 taagatttta agtacgatgg tgaacgttct aatttcagaa ccaattgcga gtcatgtagt 360 gtggtagaat taaaggagga cacgagcctg cttctgttac ctccaagtgg taacaggact 420 gatgcc 426 <210> SEQ ID NO 350 <211> LENGTH: 178 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 350 aaattcctct ctggaaatgg atatggaagg actagaagat tactttagtg aagattctta 60 ggcagtttta taaccctttt tcctcaatag cctgtttcct gtttttaaga ttttgccttt 120 gttgttgaaa aagggtttca ctctgtcacc aaggcttagt gcagtgacac aattacag 178 <210> SEQ ID NO 351 <211> LENGTH: 459 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 82, 123, 141, 150, 152, 183, 235, 305, 307, 387 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 351 gctttttttt tttttttttt tttttttttt gaaaaatgta taatttatta tatatgtatg 60 tattccttaa caatatgttg tntaacccaa caatgaaata tacatcaatg aaaatgacag 120 ctntaaaaca ataaaacttg ngaattctan anacatgttg agtgaaaaaa accaaatcct 180 tanactacat agagtatgat acaatttttt tgaagttcaa aaagaaagaa aactntaaaa 240 taagtcactt tagggataca tatgtatttt aggtctttct acattcgaac aaatctatta 300 aaaananagc gggggggtcg gcaaagatag gagaagagct caaattagat aaaatacaag 360 cctcataatg ttattcttaa gttaggngat gagttattat gcttgataat ttatttgtat 420 tccccattta cccttttata agcatcaaat attacattt 459 <210> SEQ ID NO 352 <211> LENGTH: 334 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 352 aaacattgat ttgcagttaa gaataaacct taaagcaaag acaaccacat tttaatttgt 60 tcacagtatg taaatctgtc taaatttcag tgaatttctg gtcagtatga tgcagcctct 120 gagcagaata ttgaccagta agagggtaaa taaagtgggg gcaacccctg gatatgaatg 180 ttacccccta agtctccaat attgcaggtt tccctgtata acgtaaacac acttgccctc 240 atgcctccca gaatatgagg tctaattaag aagtcccatc aggtttattt tgtaaccaaa 300 gtctttttta gaggtcagac ttcctaatca aagg 334 <210> SEQ ID NO 353 <211> LENGTH: 138 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 353 aaaaatgaat ttaaggaaac attggctacc tctgacttct tagccaggga acataggtga 60 gaagatatcc gaagacgcct aaaatctcta caaacacatg ggtttacaaa aaacaagcct 120 aaaatcaaga ctctcagg 138 <210> SEQ ID NO 354 <211> LENGTH: 95 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 87, 88 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 354 aaagtgaaat gaattgctca aattgtgcaa tttttttttt tttttttttt tttttttttt 60 tttttttttt tttttttttt ttttttnnca attgg 95 <210> SEQ ID NO 355 <211> LENGTH: 252 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 355 ctgctccaaa gtctttccat ccagtcccaa gcatatacag agcaattctg atcagtatcc 60 catctttgag aaaggacgaa taaagagaaa aaacaaagaa aaccggaact ccagcccccc 120 aagccggtgc acacgatgac gctgatgcga ggatctcggg accagaacgc ggaggtcact 180 gtttccatgt cccaggtcat agccatcctg tcagtggcag cctctcccac tctgcgccag 240 gccaccaccc ag 252 <210> SEQ ID NO 356 <211> LENGTH: 472 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 460 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 356 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tcctgacttg ttggcataaa agcagcaacg ttcctgtaga 420 gccaaacaga tacctccctg ttctgcagtg agtaggtctn agcctcttct gt 472 <210> SEQ ID NO 357 <211> LENGTH: 259 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 357 aaataaccga agcaacagcc gtggcacagc agagggaagc tgggttgggg cgtgtgagag 60 gtggcagcag tgtggcctga tggggggact aggtcacagt gaactcccca cacgcctgtc 120 aggttcagca gtcatggcca taggattggg agcactacgg aggagccatc agttagtgat 180 gtctctccaa gtcccagaga ccttagggac gggagctaag tcagctccct caagtagcag 240 ggccagggca tcccagtca 259 <210> SEQ ID NO 358 <211> LENGTH: 401 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 358 gctaacctgg tccggagcga gtctgggtct cagccccgcg aacagccttt cacgagtctt 60 caagctttca ggctatcttc tagtcaagat gagtgataag ccagacttgt cggaagtgga 120 gaagtttgac aggtcaaaac tgaagaaaac taatactgaa gaaaaaaata ctcttccctc 180 aaaggaaact atccagcaag agaaagagtg tgttcaaaca tcataaaatg gggatcgcct 240 cccaacagca gatttcgaca ttacctgaga gtcttgattt taggcttgtt ttttgtaaac 300 ccatgtgttt gtagagattt taggcgtctt cggatatctt ctcacctatg ttccctggct 360 aagaagtcag aggtagccaa tgtttcctta aattcatttt t 401 <210> SEQ ID NO 359 <211> LENGTH: 443 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 359 gtttacatcc caacaatgga aacatctgag caatgatttc ttgaagaccc agcaggagaa 60 gaggcacagt tggttcaagg caagtggtac catcaagaag ttccgagctg gcctcagcat 120 cttttcaccc atccccaagt ctcccagttt ccctatcata caggactcca tgctgaaagg 180 caaactaggt gtaccagagc ttcgggttgg gcgcctcatg aaccgttcca tctcctgtac 240 catgaagaac cccaaagtgg aagtgtttgg ctaccctccc agcccccagg tcagtggtca 300 ctgcaagaac attcccactc tggagtatgg attcctcgtt cagatcatga agtatgcaga 360 acagaggatt ccaacattga atgagtactg tgtggtgtgt gatgagcagc atgtcttcca 420 aaatggatct atgctgaagc cag 443 <210> SEQ ID NO 360 <211> LENGTH: 294 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 360 ggcggctcgg actgagcagg actttcctta tcccagttga ttgtgcagaa tacactgcct 60 gtcgcttgtc ttctattcac catggcttct tctgatatcc aggtgaaaga actggagaag 120 cgtgcctcag gccaggcttt tgagctgatt ctcagccctc ggtcaaaaga atctgttcca 180 gaattccccc tttcccctcc aaagaagaag gatctttccc tggaggaaat tcagaagaaa 240 ttagaagctg cagaagaaag acgcaagtcc catgaagctg aggtcttgaa gcag 294 <210> SEQ ID NO 361 <211> LENGTH: 185 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 361 gccttgggtc tgaaagtcga tgaaggacgt gattacctgc gataagcctc gtggagccgg 60 aaatatgcta tgaaacgggg atttccgaat ggggaaacct agctagggta atgcctagtt 120 gccttgttct gaattcatag gaacttgagt gagacacctt gtgaactgaa acatcttagt 180 agcaa 185 <210> SEQ ID NO 362 <211> LENGTH: 139 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 362 cctgggcagg ggtctctacc cctaccctcc ccgccaccgc ctgtcttttc cctctctgtc 60 accccagaac agcgatttct tgcgggagct cgtgatcacc atcgccaggg agggccttga 120 ggacaaatac aacttgcag 139 <210> SEQ ID NO 363 <211> LENGTH: 409 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 363 ccttggtttg caagcaacag accttaaaca tacaggaaac tattaaaatt ggctcgatca 60 gtagtcatag gaattggtat aagaagagac tcatttagag ctcagagttt tcttcacata 120 atgggggtat taattatttg tgctgttgcg aaattatgtg tcttattctt aaagccatgg 180 taaaaatagg gatctgtgaa ggaaatttct aaaattggat gtattaggtt ttgaactctg 240 agattgcaca aatattcaat taacttgaag ttgtgtacat agagaagaaa atttggtttt 300 agcaaatgac agagccttca aaaatatttt tggaataatg tgaatcaacc gaaaactggg 360 ggcaaggcag aggacaggtt ttctcaggtt aagagaaaaa cgaaatttt 409 <210> SEQ ID NO 364 <211> LENGTH: 320 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 364 gtcaagagaa agtacagtaa acactattat cttatcttga ctttaagggg aaataatttc 60 tcagaggatt ataattgtca ccgaagcctt aagtccttct gtcttcctga ctgaatgaaa 120 cttgaattgg tagagcattt tccttatgga agggatgaga ttcccagaga cctgcattgc 180 tttctcctgg ttttatttaa caatcgacaa atgaaattct tacagcctga aggcagacgt 240 gtgcccagat gtgaaagaga ccttcagtat cagccctaac tcttctctcc caggaaggac 300 ttgctgggct ctgtggccag 320 <210> SEQ ID NO 365 <211> LENGTH: 556 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 543 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 365 ctgacgtttt ggaagaatct atccatgtgt ctgcctccat atgcatctgg gcatttcatc 60 ttcagtcccc tcattagact gtagcattag gatgtgtgga gagaggagaa atgatttagc 120 acccagattc acactcctat gcctggaagg gggacatctt tgaagaagag gaattagggc 180 tgtggacact gtcttgagga tgtggacttc cttagtgagc tccacattac ttgatggtaa 240 ccacttcaaa aggatcagaa tccacgtaat gaaaaaggtc cctctagagg atggagctga 300 tgtgaagctg ccaatggatg aaaagcctca gaaagcaact caaaggactc aaagcaacgg 360 acaacacaag agttgtcttc agcccagtga cacctctgat gtcccctgga agctttgtgc 420 taacctggga ctgcctgact tcctttagcc tggtcccttg ctactacctt gaactgtttt 480 atctaacctc tctttttctg tttaattctt tgctactgcc attgaccctg ctgcaggatt 540 tgngtcattt tcctgc 556 <210> SEQ ID NO 366 <211> LENGTH: 362 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 366 ctgtcagtga ggactcatct gttacccaga tctaccatgc agttgcagct ctaagtggct 60 ttggccttcc cttggcatcc caagaagcac tcagtgccct tactgctcgt ctcagcaagg 120 aggagactgt gctggcaaca gtccaggctc tgcagacagc atcccacctg tcccagcagg 180 ctgacctgag gagcatcgtg gaggagattg aggaccttgt tgctcgcctg gatgaactcg 240 ggggcgtgta tctccagttt gaagaaggac tggaaacaac agcgttattt gtggctgcca 300 cctacaagct catggatcat gtggggactg agccatccat taaggaggat caggtcatcc 360 ag 362 <210> SEQ ID NO 367 <211> LENGTH: 349 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 367 aaaggtgata aacacaaaac ctcgtctttt gttcaacttt ggatccattg gcaattcaat 60 ggcctcaatc tccccaaact cgccaaagta ctccctgatc ttttcctcag tggcttcagg 120 attcagaccc ccaacgaaga ttttcttcac cgggtccttc ttcatagcca tggccttttt 180 agggtcaatg acacggccat ccagcctgtg ctccttctgg tctaggacct tctccacact 240 ggctgcatct ttgaacagga taaacccaaa ccctcttgac cgtccagtgt tgggatccat 300 ttttattgta cagtcaacga cctctccaaa tttagtaaaa tagtctttt 349 <210> SEQ ID NO 368 <211> LENGTH: 498 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 368 ccttgagctg cccagggcaa ccgagtaact gtgtcaccat tccccgctct ctggatggca 60 ggctgcaagt ctcccaccgg aagggactgc ctcatgtcat ttactgccgt gtgtggcgct 120 ggcccgatct tcagagccac catgaactaa aaccactgga atgctgtgag tttccttttg 180 gttccaagca gaaggaggtc tgcatcaatc cctaccacta taagagagta gaaagccctg 240 tacttcctcc tgtgctggtt ccaagacaca gcgaatataa tcctcagcac agcctcttag 300 ctcagttccg taacttagga caaaatgagc ctcacatgcc actcaacgcc acttttccag 360 attctttcca gcaacccaac agccacccgt ttcctcactc tcccaatagc agttacccaa 420 actctcctgg gagcagcagc agcacctacc ctcactctcc caccagctca gacccaggaa 480 gccctttcca gatgccag 498 <210> SEQ ID NO 369 <211> LENGTH: 127 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 369 ccttagctgg gacactacaa agaaagatct gaaggactac ttttccaaat ttggtgaagt 60 tgtagactgc actctgaagt tagatcctat cacagggcga tcaaggggtt ttggctttgt 120 gctattt 127 <210> SEQ ID NO 370 <211> LENGTH: 162 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 125 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 370 ctgtgggtcc cccctgggta aatcacttag cctcagtttc cccaactcta aaatggggat 60 actgacccat atttcatggt gtggctctga aatgaaatga aacgtgagct tccttctctc 120 cttanccacc atttggtcta tagctagcaa tgcctttctc tt 162 <210> SEQ ID NO 371 <211> LENGTH: 216 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 371 cctgcctcat cagcctgggc tacgacgtgg agaacgaccg gcagggtgag gccgagttca 60 accgcatcat gagcctggtc gaccccaacc atagcggcct tgtgaccttc caagccttca 120 tcgacttcat gtcgcgggag accaccgaca cggacacggc tgaccaggtc atcgcttcct 180 tcaaggtctt agcaggggac aagaacttca tcacag 216 <210> SEQ ID NO 372 <211> LENGTH: 223 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 372 caaccttcca gcctgcgacc tgcggagaaa aaaaattact tattttcttg ccccatacat 60 accttgaggc gagcaaaaaa attaaatttt aaccatgagg gaaatcgtgc acatccaggc 120 tggtcagtgt ggcaaccaga tcggtgccaa gttctgggag gtgatcagtg atgaacatgg 180 catcgacccc accggcacct accacgggga cagcgacctg cag 223 <210> SEQ ID NO 373 <211> LENGTH: 213 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 373 ctggtgcggc ccggtgtggc ccagcccgag gacaccgtgc agttccggat ccccatggaa 60 atgacaaggg tggacctcag gaattacctc gagggcatct ataacgtgcc cgtggctgct 120 gtgcggacac gggtgcagca tggctctaac aagagaagag atcacagaaa cgtgaggatc 180 aagaagccgg actacaaggt cgcctacgtg cag 213 <210> SEQ ID NO 374 <211> LENGTH: 260 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 374 ctgcaggtcg ctgtccccgt ggtaggtgcc ggtggggtcg atgccatgtt catcactgat 60 cacctcccag aacttggcac cgatctggtt gccacactga ccagcctgga tgtgcacgat 120 ttccctcatg gttaaaattt aatttttttg ctcgcctcaa ggtatgtatg gggcaagaaa 180 ataagtaatt ttttttctcc gcaggtcgca ggctggaagg ttggaatgcg ccccagaggc 240 tggagcagcg aggtgcaaac 260 <210> SEQ ID NO 375 <211> LENGTH: 238 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 375 cctcttttta ccagctccga ggtgattttc atattgaatt gcaaattcga agaagcagct 60 tcaaacctgc cggggcttct cccgcctttt ttcccggcgg cgggagaagt agattgaagc 120 cagttgatta gggtgcttag ctgttaacta agtgtttgtg ggtttaagtc ccattggtct 180 agtaagggct tagcttaatt aaagtggctg atttgcgttc agttgatgca gagtgggg 238 <210> SEQ ID NO 376 <211> LENGTH: 376 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 376 ccttggccaa agagcagcta gtgcccacta catggatccc agcagggcca aattctcaac 60 ttgttggctt aacaaaagaa tgaaaaagct caaacagaaa acatactgga caaggttggt 120 ccagaacatg caatcctaaa tggctatgga ataaatttat tctgagcaat atctcagtct 180 cacactcact aaattctagg gtagttctat tgaagatgtt taccatggtt tagcgcactg 240 agccctgcac ccttccccag gctgccaggg aagcagagag gtacaaacat tcctaatgcc 300 ccagtcagcc tgttctccct atggggtccc tggattacct gcagggacct gggggaaatt 360 ggctccctgt cttcag 376 <210> SEQ ID NO 377 <211> LENGTH: 279 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 377 cctaaggaga agcgagtaac cctgttaacc cccgccgggg ccacgggcag cggtggtggg 60 acctcggggg acagctccaa gggggaagat aagcaggatc gcaacaagga gaagaaagaa 120 gcgctgagca aggtggtaat tcgaagatta cctcccactt tgaccaagga gcagcttcag 180 gaacatcttc aacctatgcc tgagcatgat tattttgagt ttttttctaa tgatacgagt 240 ttgtatcctc atatgtatgc cagagcatac atcaacttt 279 <210> SEQ ID NO 378 <211> LENGTH: 463 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 378 gcttagacct actcactgca gaacagggag gtatctgttt ggctctacag gaacgttgct 60 gcttttatgc caacaagtca ggaattgtcc gagataaaat aaaaaatcta caagaagacc 120 tcgaacaaag acgcaaggca cttgcagaca atcccttcct caccggcctc aatggacttc 180 tcccttacct cctccccttc cttggaccct tattcgctat catcctgttc ttctcttttg 240 ccccttggat cctaagacga gtaacagcgt taatcaggga tcagctcaat tccctactgg 300 gaaagcccat acaaatccac tatcaccaac tagcaacgcg tgatctagaa tatggcagac 360 tgtagccggt tcccctccta cgggagcagc ataccgctcg acactatgct ttacgaaggt 420 aatggacacc gctaggtgca aggcaaggca ctgcaaggag agg 463 <210> SEQ ID NO 379 <211> LENGTH: 193 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 379 ctgctagagg ctggttgctg actccaggcc gcgttccagg aaatatcggt gggaagaacg 60 gggacgggct tgggaccctt cattgaggaa gtaggatgtg atcttcctga gtccctcctg 120 attctcggat gctgagtcct cccatataac atcttccgcc tctttctcca ggatggtctg 180 ggccgtgcgc cag 193 <210> SEQ ID NO 380 <211> LENGTH: 299 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 380 ctgcagtgga ggcattactc acccatgttc agaggcaacg gaaacgattt agaatcacaa 60 gcttgtcaag tattggagct ggaagggacc ttagggagca ttgaatctac tcacttcatt 120 ttacagatga aatgaagaca agatagatgg agagtcttgc ccaaagtcac atagagctgg 180 catccaaatc actattgttt ctcaaaaata tcacatggtg gcaaatggag cataactctg 240 tggggctgga cgacagctaa attcaagcaa catttgttca ttaagcacct actatgtac 299 <210> SEQ ID NO 381 <211> LENGTH: 469 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 416, 429 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 381 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag gggagaagtc cattgaggcc 300 ggtgaggaag ggattgtctg caagtgcctt gcgtctttgt tcgaggtctt cttgtagatt 360 ttttatttta tctcggacaa ttcctgactt ggttggcata aaagcagcaa cgttcntgta 420 gagccaaana gatacctccc tgttctgcag tgagtaggtc taagcctct 469 <210> SEQ ID NO 382 <211> LENGTH: 211 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 382 gatgccttgg gtctgaaagt cgatgaagga cgtgattacc tgcgataagc ctcgtggagc 60 cggaaatatg ctatgaaacg gggatttccg aatggggaaa cctaactagg gtaatgccta 120 gttgccttgt tctgaattca taggaacttg agtgagacac cttgtgaact gaaacatctt 180 agtagcaaaa aaaaaaaaaa aaaaaagctt g 211 <210> SEQ ID NO 383 <211> LENGTH: 289 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 383 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgag 289 <210> SEQ ID NO 384 <211> LENGTH: 183 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 384 aaaagagact actgcctgtc cttaaattcc tttttctttt tataaaaaaa gaactattaa 60 aaatgattga caaattttga gttaaaaaat tgttaaaaca ttctctatat ttaatttcaa 120 ttttataata gattacagga agatgcttat gaaacaaata catttgtttc agtacatgtc 180 ttt 183 <210> SEQ ID NO 385 <211> LENGTH: 289 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 385 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgag 289 <210> SEQ ID NO 386 <211> LENGTH: 398 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 386 gctaaaggtg accccaagaa accaaagggc aagatgtccg cttatgcctt ctttgtgcag 60 acatgcagag aagaacataa gaagaaaaac ccagaggtcc ctgtcaattt tgcggaattt 120 tccaagaagt gctctgagag gtggaagacg atgtccggga aagagaaatc taaatttgat 180 gaaatggcaa aggcagataa agtgcgctat gatcgggaaa tgaaggatta tggaccagct 240 aagggaggca agaagaagaa ggatcctaat gctcccaaaa ggccaccgtc tggattcttc 300 ctgttctgtt cagaattccg ccccaagatc aaatccacaa accccggcat ctctattgga 360 gacgtggcaa aaaagctggg tgagatgtgg aataattt 398 <210> SEQ ID NO 387 <211> LENGTH: 212 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 387 agcgcttttc caagtacatg cccagcgtca aggtgtctgt gttcttcggt ggtctctcca 60 tcaagaagga tgaagaagtg ttgaagaaga actgtcccca tgtcgtggtg gggaccccgg 120 gccgcatcct ggcgctcgtg cggaatagga gcttcagcct aaagaatgtg aagcactttg 180 tgctggacga gtgtgacaag atgctggagc ag 212 <210> SEQ ID NO 388 <211> LENGTH: 203 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 388 gttcttccag ccttgggcaa ctgttctctt gtaactactt tacagtttct aaaagcagtt 60 attgtccaaa gctggaagaa cttaagtctt ctcagatgag catgtgaatg aatggaggga 120 ggtaaacaaa aaataaaatt aaaaaagatg aggtctgata ggggagcagc cggataagaa 180 aatcaaaaaa ggaacagtaa ttt 203 <210> SEQ ID NO 389 <211> LENGTH: 212 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 389 agcgcttttc caagtacatg cccagcgtca aggtgtctgt gttcttcggt ggtctctcca 60 tcaagaagga tgaagaagtg ttgaagaaga actgtcccca tgtcgtggtg gggaccccgg 120 gccgcatcct ggcgctcgtg cggaatagga gcttcagcct aaagaatgtg aagcactttg 180 tgctggacga gtgtgacaag atgctggagc ag 212 <210> SEQ ID NO 390 <211> LENGTH: 468 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 400, 413, 420, 425, 427, 434, 435 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 390 cctctcctcg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tcctgacttg ttggcataan agcagcaacg ttnctgtagn 420 gccananaga tacnntccct gttctgcagt gagtaggtct aagcctct 468 <210> SEQ ID NO 391 <211> LENGTH: 356 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 391 aaaaacatag gtgtaaagga aagacattca gactggtcca cgtgggcttg ttagcaggca 60 gaggaaccct gctttccaaa aactgatata gtccagagtc acggcatgtg ggaaggtttc 120 catggacact ggatcttaac agatgctata gtgtttacaa aactacacac acagagaaag 180 cccaaggaag cctgcaggct aagccctatg cttttagggg gctgaaggaa ccaaacctag 240 tttaatcctg tttgtttgct ccatgcaaaa ctttatggaa gactccccag actaggctat 300 ttagcagctt ccatgaatgg tcctcagatc atgtgattct acggcataga cgacag 356 <210> SEQ ID NO 392 <211> LENGTH: 126 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 392 aagaaagacc attctagatc agagctacaa gttcactttc tgtctctgag aatctccatc 60 tagggcagta gttcttatga tgtgtaggct ccctcctagg gcctactcaa tcagagcctg 120 tgggga 126 <210> SEQ ID NO 393 <211> LENGTH: 293 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 393 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc att 293 <210> SEQ ID NO 394 <211> LENGTH: 449 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 394 aaagaagcaa gggtatactt gggaaggcat gggctggact ctaaagggta agctgggggt 60 gcaattattt tgtgaggcat taaaactaga tatattgaca gggaaggcta ggggcatgga 120 ggtaccttga tttaagcata accagcaatt ttgggctagg ctggggttgg agatattgag 180 ggcctggtgg gtggctgaca gaatatcaag catttgtgca tcaatgtcag gtcctcttgg 240 ttttgagcga gctagggggt ggtaggataa cttagggaat tggctttgaa taacaagctc 300 tatttgtttt tgtacataaa gctctctcac agcatcttgg ggtccgccac cgtcggagac 360 gtgaataggg gcttgctgat tccaacaaac cgattttcca accgtgccat cgcatccggc 420 ctggaggacc ccatgaggtt gtaggccgc 449 <210> SEQ ID NO 395 <211> LENGTH: 116 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 395 tgcattaatg ctttacgtct ccgcatttat attaaaaatt cacacacaaa tgaaaatgga 60 aaaactgcca atacctgatt tctgtcccct atttttccac tcgcaatcat atactt 116 <210> SEQ ID NO 396 <211> LENGTH: 181 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 396 cttcgacatg cattgggtga tactaatatc agtagtttgg cagactataa tgcatctagg 60 ctttataatc gcagaagata aaaaagcaga agaagttaat atttcttcac ttatgattgc 120 acaaaaaatg caatcacaat caaaccttgc tttcgcttag ttaaaagtga caagtggttt 180 t 181 <210> SEQ ID NO 397 <211> LENGTH: 136 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 397 cctctggttg caggactcgt gaatggagca gttctgagaa ccaccctttt gctaagggag 60 cttgggagcc acatggctgc tcccttcaca ctgggtaaca gtgtagtatc ctgtgagaga 120 ataaatgtat tcattt 136 <210> SEQ ID NO 398 <211> LENGTH: 433 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 398 ctgaatagag gtcaacacag ttgcgatgtt gagggatggt ctccaagcac cttttggtgg 60 caatttgaga acatccagac aaatccttcc agcagaatca atgtttggat gataaattgg 120 agtgagaaat cggatctgag gaggttcaaa tgggtacctc tcaggaatga taacttctag 180 cttaaaaaca cctttctcat aaggtgtgtt ggctccacct aatatttgag ctcgcaggtc 240 atccatttgg tctttatctt gccaacatgt gatgcctggg ggtggctctg tggctaacat 300 gtgcagctct ctcttcagac gtgaagctct ctgcatgatc cccaagtaga aggaaccaca 360 cacagttcac tgctccacac taagagctgc ctgggatgca ctgagctgac acccctcaca 420 acgcagcaac gcg 433 <210> SEQ ID NO 399 <211> LENGTH: 274 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 399 ctgagaattc gtccgctccc gaggctgagc agggcggggc tgagtaaatg ccggcttacc 60 atctctacca tcatccggtt tagtcatcca acaagaagaa atatgaaatt ccagcaataa 120 gaaatgaaca aaagattgga gctgaagacc taaagtgctt gctttttgcc cgttgaccag 180 ataaatagaa ctatctgcat tatctatgca gcatggggtt tttattattt ttacctaaag 240 acgtctcttt ttggtaataa caaatgtgtt tttt 274 <210> SEQ ID NO 400 <211> LENGTH: 478 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 400 ccgagattgc caggagactg ctacttagag gtgctaatcc cgatttgaaa gaccgaactg 60 gtttcgctgt cattcatgat gcggccagag caggtttcct ggacacttta cagactttgc 120 tggagtttca agctgatgtt aacatcgagg ataatgaagg gaacctgccc ttgcacttgg 180 ctgccaaaga aggccacctc cgggtggtgg agttcctggt gaagcacacg gccagcaatg 240 tggggcatcg gaaccataag ggggacaccg cctgtgattt ggccaggctc tatgggagga 300 atgaggttgt tagcctgatg caggcaaacg gggctggggg agccacaaat cttcaataaa 360 cgtggggagg gctcccccac gttgcctcta ctttatcaat taactgagta gctctcctga 420 cttttaatgt catttgttaa aatacagttc tgtcatatgt taagcagcta aattttct 478 <210> SEQ ID NO 401 <211> LENGTH: 127 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 401 ccttagctgg gacactacaa agaaagatct gaaggactac ttttccaaat ttggtgaagt 60 tgtagactgc actctgaagt tagatcctat cacagggcga tcaaggggtt ttggctttgt 120 gctattt 127 <210> SEQ ID NO 402 <211> LENGTH: 210 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 43, 70 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 402 tgagtgagtc tctggcgtcc caaattgcct gtttttctcg cangctctat tccgttcgct 60 ggttcgcccn ctcaggggaa cgatggccat ggagtccaca gccactgccg ccgtcgccgc 120 ggaagctggt ttctgccgac aaaattgaag atgttcctgc tccttctaca tctgcagata 180 aagtggagag tctggatgtg gatagtgaag 210 <210> SEQ ID NO 403 <211> LENGTH: 251 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 403 aaaaggtcca agatgactgc agttttacaa aaatgggcag ggtggaaagt tgcaaacttc 60 atgtgcttct ggatatcaag atttgttttt atacaatagt cacagttaaa aacaccctgc 120 tggtaataca taattacact ttattaaggt cataaaccag caataaacaa taaagcctat 180 acaacttgta gttctactta atcactgact ggtacagcta acatgagata agtgaaaagt 240 tcctatggtt t 251 <210> SEQ ID NO 404 <211> LENGTH: 147 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 404 cctataaccc agacaccagc atggacaaaa ctcagttata ctgaattcag agacaaaatt 60 cagtgacact cttctaccac ttatttaggg ttctacagca tttcactgag cagacttagt 120 tttttgtttt tgttttacaa acctttt 147 <210> SEQ ID NO 405 <211> LENGTH: 354 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 405 aaaaaactcg gttgtgaggt ttgcccagag gcacttgttc cagaatttcc cctcctgctt 60 cagccatgtc cttgtcactt ggcattctaa gctaaagctt tagcttccca attcgtgatg 120 tgctaggcca agattcggga gctgttgcca gcctcgtcaa atatggaaga gaaacaacct 180 gcggtcaaaa gggagtgatt tgttaagtgg tgcgcgtcta tctcataact agatgtacca 240 accagggaag ggccaaggat ggaaaggggt aacttttgtg cttccaaagt agctaagcag 300 aagtggggga gcagtttagc cagatgatct ttgattaggc aaacattgag tttt 354 <210> SEQ ID NO 406 <211> LENGTH: 371 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 406 gtaaagggca gggcacagct tggagtccaa gcatttgctg atgcattgct cattattccc 60 aaggttcttg ctcagaactc tggttttgac cttcaggaaa cattagttaa aattcaagca 120 gaacattcag aatcgggtca gcttgtgggt gtggacctga acacaggtga gccaatggtg 180 gcagcagaag taggcgtatg ggataactat tgtgtaaaga aacagcttct tcactcctgc 240 actgtgattg ccaccaacat tctcttggtt gatgagatca tgcgagctgg aatgtcttct 300 ctgaaaggtt gaattgaagc ttcctctgta tctgaatctt gaagactgca aagtgatcct 360 gaggattaca g 371 <210> SEQ ID NO 407 <211> LENGTH: 369 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 407 ctgcagcagc cgtgtcagac tttaacttcg tgacatccca gggccggaaa agaaactgtc 60 gattcagatt tgacttctca atggtgtcca tgtctgtaac gatgatttct ccaccctccc 120 cgcagcccag cccaatcatg gcaaagttct tgagcagctc acagccaatg gcccccgcac 180 ccaccaggaa atacttctgc ttgcccagct tctcttgcag gtctgagcca aacacagcca 240 cttgcccgtc ataacggttc tggcgctgga ggcacttgtc ctctgtgagg acctctttgt 300 cctcagggag acactcaagg gcatcaaagt atagccactg catgatgggc atgaacttcc 360 cggagcagg 369 <210> SEQ ID NO 408 <211> LENGTH: 217 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 408 ggcgcgacaa gatggcggat aaggagaaga agaaaaagga gagcatcttg gacttgtcca 60 agtacatcga caagacgatc cgggtaaagt tccagggagg ccgcgaagtg gaatcctgaa 120 gggcttcgac ccactcctca accttgtgct ggacggcacc attgagtaca tgcgagaccc 180 tgacgaccag tacaagctca cggaggacac ccggcag 217 <210> SEQ ID NO 409 <211> LENGTH: 373 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 409 ggcgcggcgt ccggaggccc cagggttatg agactatcac tgctcaggac ctactaacaa 60 caaaggaaat cgaaacatga ccaaatcgta cagcgagagt gggctgatgg gcgagcctca 120 gccccaaggt cctccaagct ggacagacga gtgtctcagt tctcaggacg aggagcacga 180 ggcagacaag aaggaggacg acctcgaaac catgaacgca gaggaggact cactgaggaa 240 cgggggagag gaggaggacg aagatgagga cctggaagag gaggaagaag aggaagagga 300 ggatgacgat caaaagccca agagacgcgg ccccaaaaag aagaagatga ctaaggctcg 360 cctggagcgt ttt 373 <210> SEQ ID NO 410 <211> LENGTH: 220 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 410 cggccgaggt aaattatact attattttgc ttaattttat attgggttaa aacaaccttc 60 aagaaggtta actaggaaag aagacctttt tgttttattt ttactattta tatatagaag 120 acaaatcagc atttggtgat agttttacat gaccagttat caaacggtca tagtatgaag 180 tgtgcagttg ttcattatta gtaaattatg tttgattttt 220 <210> SEQ ID NO 411 <211> LENGTH: 102 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 411 aaaaattgca tagatcctaa ttattgcttg tgattttgtt atcccgatca gataattaat 60 acgatctgaa tacagccaca ccaaattcgt ggtgtatttt tt 102 <210> SEQ ID NO 412 <211> LENGTH: 382 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 325, 375 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 412 ctgacgatac tcaaaagtca cacgatttac gtgttttcca ctggagacca tgcgcaccac 60 agtgttgtca cagccaactt tcatctgggc cgggccatga aaggggtagc agagatcagc 120 taaaggcgtc atcttggaag ggtccaatcc agttcctccc agcagctcca caaagtctcc 180 tattccctcg caacctgctg aggatttctt taactgaaga ccatttacgt gtcccagggt 240 aagatcagat attttgatca ccacaggata aattatggag aagctgcagt ttcgatgctg 300 gtgtggaact accagggtaa acttnccatt tggagtctga gaaatgacat tgcaaggaaa 360 gaggttgggg tctgncttta tg 382 <210> SEQ ID NO 413 <211> LENGTH: 320 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 289 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 413 aaaaatgaat ttaaggaaac attggctacc tctgacttct tagccaggga acataggtga 60 gaagatatcc gaagacgcct aaaatctcta caaacacatg ggtttacaaa aaacaagcct 120 aaaatcaaga ctctcaggta atgtcgaaat ctgctgttgg gaggcgatcc ccattttatg 180 atgtttgaac acactctttc tcttgctgga tagtttcctt tgagggaaga gtattttttt 240 cttcagtatt agttttcttc agttttgacc tgtcaaactt ctccacttnc gacaagtctg 300 gcttatcact catcttgact 320 <210> SEQ ID NO 414 <211> LENGTH: 217 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 414 aaatttctct aaatttaatt tgaataaggc aggcaacagc atctcagggc acagactcat 60 aactggagac cttcatccac gagcttagct agctagattt tccgtgtggc caggacgcct 120 gctgaaactt ccagcagtcc tcagaaaaac tgatgagata cccttgggct gaatgagtaa 180 gaactttctg gagagtggaa gactggtgaa agtccag 217 <210> SEQ ID NO 415 <211> LENGTH: 490 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 415 cctcggatac caccatcata gcagagacca gacgctcatc cttggtttga gacatgaagt 60 cacaggaact gagatgggct tcccacatac caaccactgg gagggcaaag gtggggaagg 120 gcacaggcta aaaattaaca aggtgcccaa ggtaaagggc aagcccttgt cagcctggga 180 tactgtctcc tactcccaac ctttgggccc aacagaggaa ccagttgaaa aggagggcca 240 aagacattgc agtaagtaag caacaggaca atgaactcca tgttgcccag atcccactga 300 gagtgaacgt gcagtcatgc ccataaccga cacacatccc agtccatgtg ggtcagtcct 360 tcatcaccct ccctgccttc tgacaacagc agactccagc cattccatta tcattcacag 420 cccaacccaa gcagtcagtg gctgaagaaa gagaatcagg tatactctat gtccacatat 480 accttcctgc 490 <210> SEQ ID NO 416 <211> LENGTH: 439 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 416 aaatgaaatg gggttgaagt gaacatgatt ttgttgacca tgttcgtgaa ttacagatgc 60 aacatgcatt ggtagaatcg tgtgatggtc ttttgtgata cttaattttt acatatccca 120 gtctctgtat gtatctgcat agacaaagaa aaaacaaact cctgctttgc ttttattgaa 180 gggtttccag gactgcgtgt ctgctcctga gctctgtttt aagtatgtgt atcctctgct 240 tgtattttgt attaaaaaaa taagaaaaag aagcctttat tgttgagcat gttggcattg 300 tcccctttat ttttttctct ttttgggaca tatgaagcaa gttattcttt ttctgtatct 360 ttttttcttt tgtaaacttt ttttttgttt tgtttaccgg cccgggcggc cgctcgagcc 420 ctatagtgag tcgtattag 439 <210> SEQ ID NO 417 <211> LENGTH: 183 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 417 ggcttcgaca tgcattgggt gatactaata tcagtagttt ggcagactat aatgcatcta 60 ggctttataa tcgcagaaga taaaaaagca gaagaagtta atatttcttc acttatgatt 120 gcacaaaaaa tgcaatcaca atcaaacctt gctttcgctt agttaaaagt gacaagtggt 180 ttt 183 <210> SEQ ID NO 418 <211> LENGTH: 112 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 418 aaaaaataca ccacgaattt ggtgtggctg tattcagatc gtattaatta tctgatcggg 60 ataacaaaat cacaagcaat aattaggatc tatgcaattt ttacctcggc cg 112 <210> SEQ ID NO 419 <211> LENGTH: 127 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 419 aaatagcaca aggccaaaac cccttgatcg ccctgtgata ggatctaact tcagagtgca 60 gtctacaact tcaccaaatt tggaaaagta gtccttcaga tctttctttg tagtgtccca 120 gctaagg 127 <210> SEQ ID NO 420 <211> LENGTH: 347 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 420 tggttgcata acatctgtca tttttaactt agtaaaattc ttttccagat aagctccgaa 60 gaagtgtgcc taacctagcc cggatgccaa gtacaactgc cattagtagc aacattagtt 120 ctccggtcac cgtgcgaaat agtcagagtt ttgactcaag cttgcatgga gctggaaatg 180 gaatttcaag aatacaatct tgtattccat caccgggaca gcttcaacac agggtccaca 240 gcgtggggca tttcccagtg tctatccgac agcctcttaa agccacagcc tatgtgagtc 300 caaccgttca aggcagcagt aacatgcctt tatcaaacgg cttacag 347 <210> SEQ ID NO 421 <211> LENGTH: 141 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 421 gcaagagaaa gtataactgg agtgccaagg ctaaaagacg aaataccacc ggaactggtc 60 gaatgaggca cctaaaaatt gtataccgca gattcaggca tggattccgt gaaggaacaa 120 cacctaaacc caagagggca g 141 <210> SEQ ID NO 422 <211> LENGTH: 144 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 422 ctcagccctc ggtcaaaaga atctgttcca gaattccccc tttcccctcc aaagaagaag 60 gatctttccc tggaggaaat tcagaagaaa ttagaagctg cagaagaaag acgcaagtcc 120 catgaagctg aggtcttgaa gcag 144 <210> SEQ ID NO 423 <211> LENGTH: 239 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 423 ccttccacta cctcctttct ttctcccact ttctaggatc atttttatgt aaagtcacat 60 atcccaggcc ctcaggttga atccagagct gtagaggtta cagtagcatc accagccttg 120 ggggtccaga gcctaattta tattcactat ccttccaagt cccgggtagc agaagggttg 180 ccatagatct cagtttgatc aaaaagaagg cttagaattc tgcagttaag ctgaggttt 239 <210> SEQ ID NO 424 <211> LENGTH: 436 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 424 ctgcggacgc caactcgttc ccccaaggct cggccattct ttagggtcct gacgatcagg 60 aaaagatgaa ttagtcgttt ttctttttcc cctttccttt gctcctaacc aggctgcatg 120 atggcatcgg agactgacag aaggactggg atggttaatc tggagtagag cttggtagta 180 aatactagta agatctgcct gccaaaagcc cgcccctcga ttcacacgtg attattcagc 240 aaaactgagc cattggagag gggctcctcg cctcgctttt ttagcttaac ccctatgaag 300 aattctgacg actccacaga gagacacaca gacacacata cattcctggt taatgactcc 360 ggacgtcaga tgtaggcaga gctgtcacgt acctacgcta cagatctctg tgaggagtgt 420 gtgtggagac tcaagg 436 <210> SEQ ID NO 425 <211> LENGTH: 470 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 425 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tcctgacttg ttggcataaa agcagcaacg ttcctgtaga 420 gccaaacaga tacctccctg ttctgcagtg agtaggtcta agcctcttct 470 <210> SEQ ID NO 426 <211> LENGTH: 452 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 426 ctggatatta taattcatag cttgaagaaa tgtgacatct ccctgcaatt cttcttgcct 60 ttctcacttg gcaaggaaga tggaagtggg gacagaggag atggcccctt tcgcttaggt 120 ggccatgggc cttcctttcc actaaaagga attaccgaac agcaaaaaga aggtcttgag 180 atagtgaaaa tggtgatgat atctttagaa ggtgaagatg ggttggatga aatttattca 240 ttcagtgaga gtctgagaaa actgtgcgtc ttcaagaaaa ttgagaggca ttccattcac 300 tggccctgcc gactgaccat tggctccaat ttgtctataa ggattgcagc ctataaatcg 360 attctacagg agagagttaa aaagacttgg acagttgtgg atgcaaaaac cctaaaaaaa 420 gaagatatac aaaaagaaac agtttattgc tt 452 <210> SEQ ID NO 427 <211> LENGTH: 302 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 427 aaaagcaaat tctatgccat ctttgtgtag catggcaatg gcttctcttg ttttcaactg 60 atcaagtcca aaagttaaag caaaacgtcg agcaagttct tttatgccac taaatgtaga 120 ggatgatcta tcaaaattat agccattttc ttgtatcatt tcattaaaaa gctgttgcag 180 actgagaata agggtcttag cacactgaat tttgtctatc tgccttgttt tactcattgt 240 ttctttgatg atatctccat agtcattata atacttcata tactgtttga agatatctgc 300 ag 302 <210> SEQ ID NO 428 <211> LENGTH: 297 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 428 aaaaacaaag tcttcaacct tgggtgttga gattggcaaa aggggaagca agggaaaagc 60 caaggaaaga taaaatattc agaagaaagt caaagttatc tgcaattaca tgttagaaca 120 gattttgcag gttaaaaaga tgttgcttaa atatattcat aagcctgttg taagattttc 180 acttatgcag tttcagaaaa tttagctgct taacatatga cagaactgta ttttaacaaa 240 tgacattaaa agtcaggaga gctactcagt taattgataa agtagaggca acgtggg 297 <210> SEQ ID NO 429 <211> LENGTH: 295 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 429 ctgctcttcc tgctacaaag gggactgctc acagtggcct cagcttggtg gttttgaggg 60 gccgcccccc ggccctccat aagggtatcc tgggcctgag aattctgcat ctgccattgg 120 aggatggaca gcctcaaatg gaaggagtcc cacgggagat gggtccgagg tccggctgtg 180 gccatccagc cccctgtggc ttgtccagcc tctgtgcacc cctggtgtct tcactccagg 240 ggcagacagc agccactgca gttcctttct tcgtgagtaa cagtagtgat agcag 295 <210> SEQ ID NO 430 <211> LENGTH: 107 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 430 gtcacctggg acttcaatcc cctgataacc catgccttgc acagcctaag agggtgtttc 60 ttcaactgaa gatggcctga aatgggccag acccaaattt tcatcag 107 <210> SEQ ID NO 431 <211> LENGTH: 406 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 431 aaattttatt tcaaaagctt ggatagcttc aatatccagg ttgtggcaaa atcaggacac 60 gtgtaaaata ccttacaata cactagattc ccaaaaggta ccaaaaagta cagtaaaatt 120 aacacttccg ttacaggaaa tgtatgacgc aaataatata aaattaaaag gtgaaaaaaa 180 ggtgacactg gtttcctaag atacaattta ctctttacaa ccagggtcca caggtccagg 240 ctgcagagcg gcagcaggaa gcagagcctc ccacctgctt ctgggggacc tggtaataaa 300 aatcagccca tgatggcgct atggcctctc agacaccaca cgctgcctaa acacctagag 360 ctctggaaat agtcaacagg agagtgattt ccatggggga aatttt 406 <210> SEQ ID NO 432 <211> LENGTH: 488 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 432 aaaagcactt gggaagttcc tcctccaccc cgcaggtggg aaggctcaga gaagggtgtc 60 atcagtacag ccgccttcta ggccgtaacg gaattcctga aggttggaga ctccatagaa 120 gtggacaaag gctgctgcca ccaccaggac atggaaaatc tgatgagact ggaaccatat 180 gtcaaatttt ccaggaaaga agcgctcagg aattcgagca gcataaaggc cagctccagt 240 gatgtacatc acagccatga ggaagaacca gcccatctgg cccactgtgg tggccttgac 300 aaagccctca gcgatagtaa agtgcatggt gggcacgacg ccactcaagc caagtcccag 360 gaacacgcct gctcttgtct gccggtgctt aggagtggca aaccggtccc actgcgccac 420 aatgatggca gaaatgccca ggacacagac gatggagagg tagatgagcc gtggctgtgg 480 ggagcagt 488 <210> SEQ ID NO 433 <211> LENGTH: 368 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 261 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 433 cgcgcggcca cgacacgagg aattcgccca cgcaggaggc gcggcgtccg gaggccccag 60 ggttatgaga ctatcactgc tcaggaccta ctaacaacaa aggaaatcga aacatgacca 120 aatcgtacag cgagagtggg ctgatgggcg agcctcagcc ccaaggtcct ccaagctgga 180 cagacgagtg tctcagttct caggacgagg agcacgaggc agacaagaag gaggacgacc 240 tcgaaaccat gaacgcagag naggactcac tgaggaacgg gggagaggag gaggacgaag 300 atgaggacct ggaagaggag gaagaagagg aagaggagga tgacgatcaa aagcccaaga 360 gacgcggc 368 <210> SEQ ID NO 434 <211> LENGTH: 293 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 434 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgagc cgc 293 <210> SEQ ID NO 435 <211> LENGTH: 293 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 435 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgagc cgc 293 <210> SEQ ID NO 436 <211> LENGTH: 469 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 436 ctggtgaaga cacacaacct gctgaccacc aggaactata tctttggata ccacccccat 60 ggtatcatgg gcctgggtgc cttctgcaac ttcagcacag aggccacaga agtgagcaag 120 aagttcccag gcatacggcc ttacctggct acactggcag gcaacttccg aatgcctgtg 180 ttgagggagt acctgatgtc tggaggtatc tgccctgtca gccgggacac catagactat 240 ttgctttcaa agaatgggag tggcaatgct atcatcatcg tggtcggggg tgcggctgag 300 tctctgagct ccatgcctgg caagaatgca gtcaccctgc ggaaccgcaa gggctttgtg 360 aaactggccc tgcgtcatgg agctgacctg gttcccatct actcctttgg agagaatgaa 420 gtgtacaagc aggtgatctt cgaggagggc tcctggggcc gatgggtcc 469 <210> SEQ ID NO 437 <211> LENGTH: 174 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 437 aaaaaagatg ccaagttttt taatctaatc attatattat tggtgtattt tgggcaacat 60 agggtgagtt ataaaaagat ccgctactga tagtgaaaat taccggtttg taaaacatta 120 agagaaaaaa taggatattt tatacatgtg gtgagtggag aacagggtaa cttt 174 <210> SEQ ID NO 438 <211> LENGTH: 466 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 438 ccttgtcgtc tcacatgtat tcagcatcct tacttcgtct gagccagcct gctgcaggtg 60 gggtacttac ctgtgaggca gagttgggcg ttgaggcttg cagactcaca gacactgacg 120 ctgccattgc agaagatcca ccagatgcta ttgctgggct ccaagcagaa tggatgcaga 180 tgagttcact tgggactgtt gatgctccaa acttcattgt tgggaaccca tgggatgata 240 agctgatttt caaactttta tctgggcttt ctaaaccagt gagttcctat ccaaatactt 300 ttgaatggca atgtaaactt ccagccatca agcccaagac tgaatttcaa ttgggttcta 360 agctggtcta tgtccatcac cttcttggag aaggagcctt tgcccaggtg tacgaagcta 420 cccagggaga tctgaatgat gctaaaaata aacagaaatt tgtttt 466 <210> SEQ ID NO 439 <211> LENGTH: 237 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 439 gtcataaacc gctccaccac cgagctgccc ctcaccgtgt cctacgacaa ggtctcactg 60 gggcggctgc gcttctggat ccacatgcag gacgccgtgt actccctgca gcagttcggg 120 ttttcagaga aagatgctga tgaggtgaaa ggaatttttg tagataccaa cttatacttc 180 ctggcgctga ccttctttgt cgcagcgttc catcttctct ttgatttcct ggccttt 237 <210> SEQ ID NO 440 <211> LENGTH: 498 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 440 ccggagatca cggtccccgg gccgccgccg ccacaggagc cgctccagct ccaactcctc 60 ccgataaaca ggccactgaa gctctcgccc ctgtaactta taccccaccc agctcagttt 120 tgtcactttt ctagccaaag gaagaccagt aggaaagcaa acccttgact ctggcaggat 180 ttgcaggcag caggcagcac ccctctgcca gccgggcccc ggctgcagaa gtgctgttgg 240 tttggatgct gtgtgcctgt caagattccc tccggttttc tggctagaaa gctcatccgt 300 ttccggtttc taagagtcag ttcagtggca gagccaccag ggaaaagtga ggctcttggg 360 ggtggtttga ccctgcttac ctgggagcac acttttccct tccccgatga cctgggatgg 420 tggccaggcc gtgcccttgc tgttgctggg cagtgtcctt ttggaaaagg gagctgcccc 480 aggctttagt gcagacct 498 <210> SEQ ID NO 441 <211> LENGTH: 434 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 441 tggaaaaggc caaagagagt cttaagaacg tggatgagaa cattcgcaag ctcaccgggc 60 gggatccgaa tgacgtgagg cccatccaag ccagattgct ggccctttct ggtcctggtg 120 gaggtagagg acgtggtagt ttattactga ggcgtggatt ctcagatagt ggaggaggac 180 ccccagccaa acagagagac cttgaagggg cagtcagtag gctgggcggg gagcgtcgga 240 ccagaagaga atcacgccag gaaagcgacc cggaggatga tgatgttaaa aagccagcat 300 tgcagtcttc agttgtagct acctccaaag agcgcacacg tagagacctt atccaggatc 360 aaaatatgga tgaaaaggga aagcaaagga accggcgaat atttggcttg ttgatgggta 420 cccttcaaaa attt 434 <210> SEQ ID NO 442 <211> LENGTH: 414 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 442 cctgagagtc cattaaaaga caccgcatta actacaacaa aaagaagagc agcaccaccc 60 accagtggtg ccccagacac acctctcctc caagctctgg gctgctcctc ttggagtcta 120 cacttagacc ctgggggtgg gggtgggcac acaaatggac agagtggtct aaatgcaggt 180 ctcctggggt tctgcgaaat ctagccagaa gcatctccat ctcggtgtcc atttcgatcc 240 aactaagctt ccagtaaaga cactgcagca atgtaaacat gcaacctaag ctagcatgag 300 gttctagata gtaagcctga actaggaata aggcaactga actgtgactt tcgggccagg 360 gtcatccaga cctgcccggg cggcggctcc gagccctata gtgagtcgta ttag 414 <210> SEQ ID NO 443 <211> LENGTH: 288 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 443 aaaaacaaag tcttcaactt gggtgttgag attggcaaaa ggggaagcaa gggaaaagcc 60 aaggaaagat aaaatattca gaagaaagtc aaagttatct gcaattacat gttagaacag 120 attttgcagg ttaaaaagat gttgcttaaa tatattcata agcctgttgt taagattttc 180 acttatgcag tttcagaaaa tttagctgct taacatatga cagaactgta ttttaacaaa 240 tgacattaaa agtcaggaga gctactcagt taattgataa agtagagg 288 <210> SEQ ID NO 444 <211> LENGTH: 381 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 444 aaacactaaa tgaagcttct cacaatttct aattataaac aaaaggctga aaacagtatg 60 ggaaacaaag tttcaaaaca aagaaaagtt gagtaaaagg tgccccctct atggctcatc 120 tgaaagaaac attttactca gagaggcaaa catttctgat ctaggagtaa gtttcccact 180 cactttgcaa ggacccactc attctgcaga aagacctaca agtctttctg gtctcaattg 240 caaagtacgt gaaaatgtgt atgaaagatc taaaagctaa atattagaat aaggctaatt 300 gaaatcaaaa ttgtgtgctg gtctaaatat acatcttcgg cttcttcctt tttagtaagt 360 atttttattt cagatgtatt t 381 <210> SEQ ID NO 445 <211> LENGTH: 171 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 445 ctgtattact cagagctttt acttcttaca cctagaatat taaaatataa aacaagggga 60 gaaatgtgac agtctatttt cagttgcaca tatgttcctt atatataatg tttgacagtt 120 caatctctgg gtggaataaa gaacacttac gtatcagtaa tgggaatttt t 171 <210> SEQ ID NO 446 <211> LENGTH: 332 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 278, 306, 310, 324, 325 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 446 cgaggtataa aataaaaaat ctacaagaag acctcgaaca aagacgcaag gcacttgcag 60 acaatccctt cctcaccggc ctcaatggac ttctccctta cctcctcccc ttccttggac 120 ccttattcgc tatcatcctg ttcttctctt ttgccccttg gatcctaaga cgagtaacag 180 cgttaatcag ggatcagctc aattccctac tgggaaagcc catacaaatc cactatcacc 240 aactagcaac gcgtgatcta gaatatggca gactgtancc ggttcccctc ctacgggagc 300 agcatnccgn tcgacactat gctnnacgaa gg 332 <210> SEQ ID NO 447 <211> LENGTH: 317 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 170, 288, 314 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 447 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtan ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagncc attgaggccg 300 gtgaggaagg gatngac 317 <210> SEQ ID NO 448 <211> LENGTH: 255 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 448 ctggggtccg tcaccgacct ttggggaact gggctacggg gaccacaagc ccaagtcttc 60 cactgcagcc caggaggtaa agactctgga tggcattttc tcagagcagg tcgccatggg 120 ctactcacac tccttggtga tagcaagaga tgaaagtgag actgagaaag agaagatcaa 180 gaaactgcca gaatacaacc cccgaaccct ctgatgctcc cggagactcc tccgactcca 240 cacctctcgc ggcag 255 <210> SEQ ID NO 449 <211> LENGTH: 253 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 449 aaaatctctt cttcctcagg agtcagcttg gctcccttct tgcggcccag gggcagcgca 60 tagtgggact cgtaccactg tcggtacggt gtgctgtcga tgagcacgat gcaattcttc 120 accagggtct tggtacgaac cagctcgtta ttagatgcat tgtagacaac atcgatgatc 180 cttgttttac gagtacaacc tccccgcaca cggactgtgt ggatgcggcg ggggccaatc 240 ttggtgttgg cag 253 <210> SEQ ID NO 450 <211> LENGTH: 97 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 450 gtgggccgtg ccaaagagat ggatgagact gttgctgagt tcatcaagag gaccatcttg 60 aaaatcccca tgaatgaact gacaacaatc ctaaagg 97 <210> SEQ ID NO 451 <211> LENGTH: 526 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 519 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 451 aaaagatgta tgttgatgaa attgcccctt tataagaaaa acaacagcaa gtcttttagt 60 agaaatttga aagaagtgtt tgctaccatt ttgacccatt attcccttac ctatcagatg 120 aatttgccat tcactggata gaaaccattc ttggatttgg taagaggtga gcaagacaaa 180 tcttgtacca tactcttatg taccagcact tctgatggag aagcagtgaa gttcagaacg 240 ttcttcacat agtccagata ctgttagagt caggcaaatc agcaaagcac tttgttatgg 300 agatgaccca tgatggctgc agttgtaagt gggcatacat gttctatcat tttgaaggag 360 aaagaaaacc gttctcacat gtcgcaaata tgtgaatcat actatattcc cctaaagtaa 420 aaccagtgac ttagtggttt ttggtttatt tagaagttgg tttagaccct tatgaaacat 480 tatttacgag ttggccttat ccttaaggga aaagttctna attttt 526 <210> SEQ ID NO 452 <211> LENGTH: 498 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 452 ctgtattttg ggaacgttgc aatgaattac aggacattga gaaaattatg gctcaaattg 60 aacgtggaga agcaagaatt caacgaagga tcagtatcaa gaaagccctg gatgccaaaa 120 ttgcaagata caaggctcca tttcatcagt tgcgcattca gtatggaacc agcaaaggaa 180 agaactatac tgaggaagaa gatagattct tgatttgtat gttacacaaa atgggctttg 240 atagagaaaa tgtatatgaa gaattaagac agtgtgtacg aaatgctccc cagtttagat 300 ttgactggtt tatcaagtct aggactgcca tggaattcca gagacgctgt aacactctga 360 tttcattgat tgagaaagaa aatatggaaa ttgaggaaag agagagagca gaaaagaaga 420 aacgggcaac taaaactcca atgtcacaga aaagaaaagc agagtcagct actgagagct 480 ctggaaagaa ggatgtca 498 <210> SEQ ID NO 453 <211> LENGTH: 514 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 410, 413 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 453 cgcggtgcga cgaaggagta ggtggtggga tctcaccgtg ggtccgatta gccttttctc 60 tgccttgctt gcttgagctt cagcggaatt cgaaatggct ggcggtaagg ctggaaagga 120 ctccggaaag gccaagacaa aggcggtttc ccgctcgcag agagccggct tgcagttccc 180 agtgggccgt attcatcgac acctaaaatc taggacgacc agtcatggac gtgtgggcgc 240 gactgccgct gtgtacagcg cagccatcct ggagtacctc accgcagagg tacttgaact 300 ggcaggaaat gcatcaaaag acttaaaggt aaagcgtatt acccctcgtc acttgcaact 360 tgctattcgt ggagatgaag aattggattc tctcatcaag gctacaattn ctngtggtgg 420 tgtcattcca cacatccaca aatctctgat tgggaagaaa ggacaacaga agactgtcta 480 aaggatgcct ggattccttg ttatctcagg actc 514 <210> SEQ ID NO 454 <211> LENGTH: 403 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 264, 267, 268 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 454 cgctaacctg gtccggagcg agtctgggtc tcagccccgc gaacagcctt tcacgagtct 60 tcaagctttc aggctatctt ctagtcaaga tgagtgataa gccagacttg tcggaagtgg 120 agaagtttga caggtcaaaa ctgaagaaaa ctaatactga agaaaaaaat actcttccct 180 caaaggaaac tatccagcaa gagaaagagt gtgttcaaac atcataaaat ggggatcgcc 240 tcccaacagc agatttcgac attnccnnga gagtcttgat tttaggcttg ttttttgtaa 300 acccatgtgt ttgtagagat tttaggcgtc ttcggatatc ttctcaccta tgttccctgg 360 ctaagaagtc agaggtagcc aatgtttcct taaattcatt ttt 403 <210> SEQ ID NO 455 <211> LENGTH: 120 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 455 caagtcaata ccaatacttt ttacagttta tcatttctaa ttaatctata ctaccgaaat 60 gcaaacaata tagatttttg gaaccctttc agactcctgt tctccttaaa agccgatttt 120 <210> SEQ ID NO 456 <211> LENGTH: 504 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 456 aaaaggtggc tgcttctgag ccaacttcct agttgtttat gaaacctcac aacctttctc 60 acttaacacg attttgggac cttagccggc gatctgggtt gttgccctcg cgagccggga 120 cgttagcacc ccggttccga ctgcatagca atacatagtg gtattcggag tttgattata 180 gtcagtaccc ctaggcgagg ccattccata ttcagtgctc taccaccact acttaacact 240 acacgctagc cctaaagcta tttcgaggag aaccagctat ctccaagttc gattggaatt 300 tctccactat tcacaagtca tccgggcact tttcacagtg tactacggtt cggccctccg 360 cttggggtta gccaagtttc agcctgctca tgaatagatc acatggtttc gggtatataa 420 caacatacta agacgcccta ttaagactcg atttctctac ggctccgctt ttttctgctt 480 aacctcgcat gctgtcataa ctcg 504 <210> SEQ ID NO 457 <211> LENGTH: 581 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 447 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 457 ctgccagggg ggacctagag caacttacta gtttgttgca aaataatgta aacgtcaatg 60 cacaaaatgg atttggaagg actgcgctgc aggttatgaa acttggaaat cccgagattg 120 ccaggagact gctacttaga ggtgctaatc ccgatttgaa agaccgaact ggtttcgctg 180 tcattcatga tgcggccaga gcaggtttcc tggacacttt acagactttg ctggagtttc 240 aagctgatgt taacatcgag gataatgaag ggaacctgcc cttgcacttg gctgccaaag 300 aaggccacct ccgggtggtg gagttcctgg tgaagcacac ggccagcaat gtggggcatc 360 ggaaccataa gggggacacc gcctgtgatt tggccaggct ctatgggagg aatggaggtt 420 gttagcctga tgcaggcaaa cggggcntgg gggagccaca aatcttcaat aaacgtgggg 480 agggctcccc cacgttgcct ctactttatc aattaactga gtagctctcc tgacttttaa 540 tgtcatttgt taaaatacag ttctgtcata tgttaagcag c 581 <210> SEQ ID NO 458 <211> LENGTH: 434 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 458 tggaaaaggc caaagagagt cttaagaacg tggatgagaa cattcgcaag ctcaccgggc 60 gggatccgaa tgacgtgagg cccatccaag ccagattgct ggccctttct ggtcctggtg 120 gaggtagagg acgtggtagt ttattactga ggcgtggatt ctcagatagt ggaggaggac 180 ccccagccaa acagagagac cttgaagggg cagtcagtag gctgggcggg gagcgtcgga 240 ccagaagaga atcacgccag gaaagcgacc cggaggatga tgatgttaaa aagccagcat 300 tgcagtcttc agttgtagct acctccaaag agcgcacacg tagagacctt atccaggatc 360 aaaatatgga tgaaaaggga aagcaaagga accggcgaat atttggcttg ttgatgggta 420 cccttcaaaa attt 434 <210> SEQ ID NO 459 <211> LENGTH: 182 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 459 gcttcgacat gcattgggtg atactaatat cagtagtttg gcagactata atgcatctag 60 gctttataat cgcagaagat aaaaaagcag aagaagttaa tatttcttca cttatgattg 120 cacaaaaaat gcaatcacaa tcaaaccttg ctttcgctta gttaaaagtg acaagtggtt 180 tt 182 <210> SEQ ID NO 460 <211> LENGTH: 182 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 460 gcttcgacat gcattgggtg atactaatat cagtagtttg gcagactata atgcatctag 60 gctttataat cgcagaagat aaaaaagcag aagaagttaa tatttcttca cttatgattg 120 cacaaaaaat gcaatcacaa tcaaaccttg ctttcgctta gttaaaagtg acaagtggtt 180 tt 182 <210> SEQ ID NO 461 <211> LENGTH: 457 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 461 aaacttccag atcaagtaac taacatagtc cagaaatttt atgtactgca attttttttg 60 tgatgtttta cattctattt cctctgaaca catttgaaac agggaaaaaa tttatgacat 120 attccaaaaa ttgtggaagt tcaaaaaagc tgagattatg aaagctatca ataatttcaa 180 tattctaata ctattttgac ttttgaccaa aaattctagt gctttataaa gattaactta 240 gatacaatgt aaagtctatt taaccttaaa ggctaatgtt ctgttttagg aaagcattct 300 atcctttaga ttttaactat ctgcatttac aggaaaacaa attgtagaca accatacaaa 360 gataaaatca aactaacttc aagaggaata atggtctgtt ggttttttga catagactgt 420 atcagtgatt gtataaaatg gatagctttt ctacttt 457 <210> SEQ ID NO 462 <211> LENGTH: 263 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 462 ctggctgagc tgttgattaa acagaacatc ctggctctag ggttcgggaa ctcccagaca 60 ccaagtcaac atccatctgg tggaaagagg gggatggtgc gtgaggctgc agcttctcca 120 attttgtctc agctttgctg ggagagcatt tttcacattt gactagctca ctcccctgtc 180 tctcttctaa cccagctatc tgcggaactt gccacttggg gagtcagtaa ttagcaagga 240 gagaaaaaga agcataaaaa cag 263 <210> SEQ ID NO 463 <211> LENGTH: 402 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 463 aaggccacct ccgggtggtg gagttcctgg tgaagcacac ggccagcaat gtggggcatc 60 ggaaccataa gggggacacc gcctgtgatt tggccaggct ctatgggagg aatgaggttg 120 ttagcctgat gcaggcaaac ggggctgggg gagccacaaa tcttcaataa acgtggggag 180 ggctccccca cgttgcctct actttatcaa ttaactgagt agctctcctg acttttaatg 240 tcatttgtta aaatacagtt ctgtcatatg ttaagcagct aaattttctg aaactgcata 300 agtgaaaatc ttacaacagg cttatgaata tatttaagca acatcttttt aacctgcaaa 360 atctgttcta acatgtaatt gcagataact ttgactttct tc 402 <210> SEQ ID NO 464 <211> LENGTH: 466 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 464 ccttgtcgtc tcacatgtat tcagcatcct tacttcgtct gagccagcct gctgcaggtg 60 gggtacttac ctgtgaggca gagttgggcg ttgaggcttg cagactcaca gacactgacg 120 ctgccattgc agaagatcca ccagatgcta ttgctgggct ccaagcagaa tggatgcaga 180 tgagttcact tgggactgtt gatgctccaa acttcattgt tgggaaccca tgggatgata 240 agctgatttt caaactttta tctgggcttt ctaaaccagt gagttcctat ccaaatactt 300 ttgaatggca atgtaaactt ccagccatca agcccaagac tgaatttcaa ttgggttcta 360 agctggtcta tgtccatcac cttcttggag aaggagcctt tgcccaggtg tacgaagcta 420 cccagggaga tctgaatgat gctaaaaata aacagaaatt tgtttt 466 <210> SEQ ID NO 465 <211> LENGTH: 473 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 465 aaaagatgta tgttgatgaa attgcccctt tataagaaaa acaacagcaa gtcttttagt 60 agaaatttga aagaagtgtt tgctaccatt ttgacccatt attcccttac ctatcagatg 120 aatttgccat tcactggata gaaaccattc ttggatttgg taagaggtga gcaagacaaa 180 tcttgtacca tactcttatg taccagcact tctgatggag aagcagtgaa gttcagaacg 240 ttcttcacat agtccagata ctgttagagt caggcaaatc agcaaagcac tttgttatgg 300 agatgaccca tgatggctgc agttgtaagt gggcatacat gttctatcat tttgaaggag 360 aaagaaaacc gttctcacat gtcgcaaata tgtgaatcat actatattcc cctaaagtaa 420 aaccagtgac ttagtggttt ttggtttatt tagaagttgg tttagaccct tat 473 <210> SEQ ID NO 466 <211> LENGTH: 82 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 466 aaagtgaaat gaattgctca aattgtgcaa tttttttttt tttttttttt tttttttttt 60 tttttttttt tttttttttt tt 82 <210> SEQ ID NO 467 <211> LENGTH: 236 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 467 tccttggccc tcccccgtgg acaccaggca gctccacttg gcctccgggt cagccctcag 60 ggccaccgtg atggggtgga ggagggttaa ataaccatct ttacagaaat aacagtctcc 120 tacagaaagt gcctgagctc agcccatggt ccgataacct catggaaaac aaacaacaaa 180 taaaaaaaaa agtgctgctg acacctctca gaatctggtg gacatgaagc tctcag 236 <210> SEQ ID NO 468 <211> LENGTH: 435 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 468 aaggccacct ccgggtggtg gagttcctgg tgaagcacac ggccagcaat gtggggcatc 60 ggaaccataa gggggacacc gcctgtgatt tggccaggct ctatgggagg aatgaggttg 120 ttagcctgat gcaggcaaac ggggctgggg gagccacaaa tcttcaataa acgtggggag 180 ggctccccca cgttgcctct actttatcaa ttaactgagt agctctcctg acttttaatg 240 tcatttgtta aaatacagtt ctgtcatatg ttaagcagct aaattttctg aaactgcata 300 agtgaaaatc ttacaacagg cttatgaata tatttaagca acatcttttt aacctgcaaa 360 atctgttcta acatgtaatt gcagataact ttgactttct tctgaatatt ttatctttcc 420 ttggcttttc ccttg 435 <210> SEQ ID NO 469 <211> LENGTH: 247 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 469 aaagcagatc caggcaataa aatctaaatt ttcctctaac tttggatccc agaaacacta 60 attagaccta cacttgaggt ttccctgttg gcgtgacctg agcaaaactg tacagaattt 120 tgggagaggc catttggcaa gccattggtc tgaataattt ggagggggaa atcctaaggt 180 ggtggagttg ctgcgtggac acggctatgg gttggtgtga catgatttcg cattaattgt 240 ttgtcag 247 <210> SEQ ID NO 470 <211> LENGTH: 332 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 470 cccctccttg cagtgccttg ccttgcacct ggcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cg 332 <210> SEQ ID NO 471 <211> LENGTH: 592 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 577, 580 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 471 cctcagcaat ggctgtggtg ttgctcagca tgcacacagc tctctgtacc ttggccaggt 60 ctccaccagg caccacagtg ggaggctggt agttgatgcc aaccttgaag ccagtggggc 120 accaatccac aaactggatg ctgcgcttgg ttttgatggt ggcaatggca gcattgacat 180 ctttgggaac cacgtcacca cggtacaaca ggcagcaagc catgcattta ccatggcgag 240 ggtcacattt caccatctgg ttggctggct caaagcaagc attggtgatc tctgctacag 300 aaagctgttc atggtaggct ttctcagcag agatgacagg ggcatatgtg gccagaggga 360 agtggatgcg ggggtagggc accaggttgg tctggaattc tgtcaggtca acattcaggg 420 ctccatcaaa tctcagggaa gcagtgatgg aggacacaat ctggctaata aggcggttaa 480 ggttagtgta ggttgggcgc tcgatatcga ggtttctacg acagatgtca tagatggcct 540 cattgtctac catgaaggca caatcagagt gctccanggn ggtgtgggtg gt 592 <210> SEQ ID NO 472 <211> LENGTH: 501 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 446 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 472 ctgacgatac tcaaaagtca cacgatttac gtgttttcca ctggagacca tgcgcaccac 60 agtgttgtca cagccaactt tcatctgggc cgggccatga aaggggtagc agagatcagc 120 taaaggcgtc atcttggaag ggtccaatcc agttcctccc agcagctcca caaagtctcc 180 tattccctcg caacctgctg aggatttctt taactgaaga ccatttacgt gtcccagggt 240 aagatcagat attttgatca ccacaggata aattatggag aagctgcagt ttcgatgctg 300 gtgtggaact accagggtaa actttccatt tggagtctga gaaatgacat tgcaaggaaa 360 gaggttgggg tctgtcttta tggttaatgt gaatccattt cctggttcat ggactcggaa 420 gaagatcatg gccacattct gggaangatc tgatgctcct cctgctaaga ccactctcac 480 agaaatctat gtaccgctca g 501 <210> SEQ ID NO 473 <211> LENGTH: 197 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 473 aaaagctcta ttttctaaat gaaaactacg aaagcggggt gggttgtggc gggggcagtt 60 gtagccctgt aggaccttcg gtgactgatg atctaagttt ccggaggttt ctcagagcct 120 ctctggttct ttcaatcggg gatgtctgag ggaccttccg cggcatctat gcgggcatgg 180 ttactgcctc tggtgcc 197 <210> SEQ ID NO 474 <211> LENGTH: 504 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 467, 468 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 474 gaaggacaag cctaatggga gacaaagcct cgctttatct acaaaagggg gaaaaggttg 60 tttttcaaag ttaaagataa agccatctgt catatttggc caagcatctc atggcaagtc 120 cttctgacaa gcacttaaag agttaaaggt caagatgaag ttgaatgatg gccaagatta 180 aaggagtcat acctgatcac atttgaggat gttcgtgatg ctgaagacgc tttacataat 240 ttggacagaa agtggatttg tggacggcag attgaaatac agtttgccca gggggatcga 300 aagacaccaa atcagatgaa agccaaggaa gggaggaatg tgtacagttc ttcacgctat 360 gatgattatg acagatacag acgttctaga agccgaagtt atgaaaggag gagatcaaga 420 agtcggtctt ttgattacaa ctatagaaga tcgtatagtc ctagaannaa gtgtgctgtg 480 tagcacagtg atctgtttac ctgc 504 <210> SEQ ID NO 475 <211> LENGTH: 192 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 475 aaactggtac acactgttca cacctatatt tcaagtttgg aaatgcatat ttgcaagcag 60 caatacaaaa gtattcatga agaatgcata atctctgaaa attatgaaaa catccctgct 120 accaatacat ttctaaatac aaaactgact accatatttg ttacttctgt gtagcgggag 180 aagttcattt tt 192 <210> SEQ ID NO 476 <211> LENGTH: 499 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 488 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 476 aaagaagcaa gggtatactt gggaaggcat gggctggact ctaaagggta agctgggggt 60 gcaattattt tgtgaggcat taaaactaga tatattgaca gggaaggcta ggggcatgga 120 ggtaccttga tttaagcata accagcaatt ttgggctagg ctggggttgg agatattgag 180 ggcctggtgg gtggctgaca gaatatcaag catttgtgca tcaatgtcag gtcctcttgg 240 ttttgagcga gctagggggt ggtaggataa cttagggaat tggctttgaa taacaagctc 300 tatttgtttt tgtacataaa gctctctcac agcatcttgg ggtccgccac cgtcggagac 360 gtgaataggg gcttgctgat tccaacaaac cgattttcca accgtgccat cgcatccggc 420 ctggaggacc ccatgaggtt gtaggccgct ggtgacagga ttggtttctg aggtgctctt 480 tgttcttnta gaatggcag 499 <210> SEQ ID NO 477 <211> LENGTH: 506 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 407, 408, 443, 481 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 477 aaaacactgg aagctctctt tgaaaacaaa agatgagaat tgaaatggat ggcactggaa 60 gctgttcttg tctactgggg tttggagctg ccaggggacc tgctcacatc cactcctcac 120 tcagcccctc ccgcccctcc cttctccacg cactgtgact gacttccatg tgtgagagcc 180 tgcagttaat tctcctgtgt cttgaatggt tgggagatga gttggtcaga cccttagtga 240 aatgatgtgg gaaggaacag gaatgctgtg gctctgaaga aggtagtaga acatcccaca 300 cctgctaata agcacatttt gcaaactcag ttgactcacc tcagatttgc ctagtgaaaa 360 ctgaagggct ggatgtagac ccagagagca gggtggacag agcccannct ggaagtactg 420 agcatcagga ctgtatgggg ctngctttag catcatcatt ctgtgcaaag acaaataaat 480 nattaatgtc acactgtctg aaattt 506 <210> SEQ ID NO 478 <211> LENGTH: 295 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 290, 293 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 478 aaaaaagtca cagctcaaaa ttgctctttg taaaagtcac acacatttcc aagtatcaag 60 tcgcagtcct gcttgtttac ttggattttc ttcgcttgga ttgcaccgca ctggttatgt 120 ctttagtaga gctggaggct gaagcaggtc gagaagatcg tttacgatgt ccattttcca 180 cactttcaga ggccacagtt ggctcttcag ttcgggagtt tcttcggcct gggattttgg 240 acttttcaac tatctctttg ggctcactgc tttgcccaga gactatggcn gcntt 295 <210> SEQ ID NO 479 <211> LENGTH: 178 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 479 aaatttacaa cctggaagag cacataaacc gagaaactga gaacaattca ctcgtgacaa 60 agatagccat gatatatgaa ttggagtctg ttcatcttca ataggctctt catctgatga 120 gtcaaactca cttgtttgta ttgaactggg cggcttcatc gctggccgcc ccacgtcg 178 <210> SEQ ID NO 480 <211> LENGTH: 483 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 480 cgagcccatt cagtcccgct gtgcagtcct ccggtacaca aagctgaccg acgcccagat 60 cctcaccagg ctgatgaatg ttatcgagaa ggagagggta ccctacactg atgacggcct 120 agaagccatc atcttcacgg cccagggaga catgaggcag gcgctgaaca acctgcagtc 180 caccttctca ggatttggct tcattaacag tgagaacgtg ttcaaggtct gtgacgagcc 240 ccacccactg ctggtaaagg agatgatcca gcactgtgtg aatgccaaca ttgacgaagc 300 ctacaagatt cttgctcact tgtggcatct gggctactca ccagaagata tcgttggcaa 360 catctttcga gtgtgtaaaa ctttccaaat ggcagaatac ctgaaactgg agtttatcaa 420 ggaaattgga tacactcaca tgaaaatagc ggaaggagtg aactctcttt tgcagatggc 480 agg 483 <210> SEQ ID NO 481 <211> LENGTH: 238 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 481 ctgcagcccc ttgaacaggt gaaagctgga atagaagctc attcggaagc caaaaccagt 60 ggactcctgt gggctggatt ggcactgctg tccattcagg gtggggcact ggcctggctc 120 acgtggtggg tgtactcctg ggatatcatg gagccagtta cattcttcat cacatttgca 180 aattctatgg tcttttttgc atactttata gtcactcgac aggattatac ttactcag 238 <210> SEQ ID NO 482 <211> LENGTH: 548 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 482 aaactttccc atcaacttat taacgacgtc caagccttgt ctagcaccat taatgactta 60 caggaccaac tagattccct agccgaagta gtcctccaaa acagaagagg cttagaccta 120 ctcactgcag aacagggagg tatctgtttg gctctacagg aacgttgctg cttttatgcc 180 aacaagtcag gaattgtccg agataaaata aaaaatctac aagaagacct cgaacaaaga 240 cgcaaggcac ttgcagacaa tcccttcctc accggcctca atggacttct cccttacctc 300 ctccccttcc ttggaccctt attcgctatc atcctgttct tctcttttgc cccttggatc 360 ctaagacgag taacagcgtt aatcagggat cagctcaatt ccctactggg aaagcccata 420 caaatccact atcaccaact agcaacgcgt gatctagaat atggcagact gtagccggtt 480 cccctcctac gggagcagca taccgctcga cactatgctt tacgaaggta atggacaccg 540 ctaggtgc 548 <210> SEQ ID NO 483 <211> LENGTH: 293 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 483 gcggctcgga ctgagcagga ctttccttat cccagttgat tgtgcagaat acactgcctg 60 tcgcttgtct tctattcacc atggcttctt ctgatatcca ggtgaaagaa ctggagaagc 120 gtgcctcagg ccaggctttt gagctgattc tcagccctcg gtcaaaagaa tctgttccag 180 aattccccct ttcccctcca aagaagaagg atctttccct ggaggaaatt cagaagaaat 240 tagaagctgc agaagaaaga cgcaagtccc atgaagctga ggtcttgaag cag 293 <210> SEQ ID NO 484 <211> LENGTH: 503 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 484 ctgaaacagc ttttcaagct ctctctcctc gtcaaggatc atgagaggca ctccactcaa 60 ggggaggtgc gcaatctggt gctcttcagg caggtcaaaa ctctcaaagt ctagaggatt 120 gaagggaaag aatttttcta tttctggata ggcatcatct gaggcaggaa cagagctttt 180 tgctttaaca gtcttctcag tcatcttttt ggcagaaaag cttggctgtt tttgtttgag 240 gggtcccttg gtctttacag acttttctgt agctctgttg acagttccca aagcctttct 300 agtagcttta ggtaaggctg gtggggcatc gaacgttttg ccaaaacgtg gtgttgaaac 360 ttgagatctc ccatctaagg ctttgattga aggtccagac cccagcttca gcccatcctt 420 agcaaccaca cgggtgcctg gttctccatt ttccttatca acatagatca gagtagccat 480 tctggattat tgcaggtctt aac 503 <210> SEQ ID NO 485 <211> LENGTH: 174 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 485 aaaaatatat tccatataca caaaattaga aaatgcatga ctttacttgg ttgctcttga 60 aatcctcctc agtcttgtca acgagcttct gcagcacaag aagccacagt ggttatgccc 120 attcagccac acgcattacc cgacgcagcc ctcctgacat cggcactcta gcag 174 <210> SEQ ID NO 486 <211> LENGTH: 189 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 486 aaaaatcaaa gtgattttga aaatctctaa tggctcagaa aataaaaaca tccagtttgt 60 ggatgactat atttagattt ctctagactc tagtggaaga cctttggaaa ggccatgcca 120 accgtgcttg tactgctaga agcactttat gtttcctttt tgggtgaaat ggatttatgt 180 gagtgcttt 189 <210> SEQ ID NO 487 <211> LENGTH: 325 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 487 cctgctggga tattagctcc agcggtgtaa acctgcagag catggactcg tcccacgtct 60 ctttggtgca gctcaccctg cggtctgagg gcttcgacac ctaccgctgc gaccgcaacc 120 tggccatggg cgtgaacctc accagtatgt ccaaaatact aaaatgcgcc ggcaatgaag 180 atatcattac actaagggcc gaagataacg cggatacctt ggcgctagta tttgaagcac 240 caaaccagga gaaagtttca gactatgaaa tgaagttgat ggatttagat gttgaacaac 300 ttggaattcc agaacaggag tacag 325 <210> SEQ ID NO 488 <211> LENGTH: 202 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 488 aaaagctccc cccaaaattc tgttatacaa tcagtgttga gaatcatggc caaaggcaca 60 tgagaaaaca gtcattctga actctacata tatcaactga ctgtctgcag gtatcattca 120 ctcagtgaca tattctcaat cttaaggaat tccatgtata aaagatagtc atggaagcca 180 aaatgaagac atagtaagct tt 202 <210> SEQ ID NO 489 <211> LENGTH: 449 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 489 aaatggaaac tttaatatct gattactttt gcaggcgaag tgccccttta tatatccaaa 60 aacatctatt tgtgacctta aacatgtgga cccataggtg cagttagaaa aagacaacct 120 atttttattt atgttagaag gagtagagta tttttttcaa gacatttatt tttcagagtg 180 gtgatacttt tactttggat actctgtgcc aatttattta tagtcaagtg tttacacttt 240 ttcctgtgga ataattatgt ctaacttttt acgtgtttgt tgagattata ctgtggtctt 300 tctttctgct ctaattatat tgcacttgta taacaaattt cccacttctc cctgtttcta 360 aacatatttt atatattaag atgtttgttc ttgaaaggtt cttttgttgt gagatcagca 420 acactagcac ttcactatta tagtttttt 449 <210> SEQ ID NO 490 <211> LENGTH: 414 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 490 tggcggacca gctttatctg gaaaatatag acgagttcgt cacggaccaa aacaagatcg 60 tgacatacaa atggctgagc tatacactag gggttcatgt taaccaggcc aaacagatgc 120 tgtatgatta tgttgaaagg aaacgaaaag aaaattcagg agcccaactg catgttacct 180 acttggtgtc tggcagtctc attcagaatg gacattcctg ccacaaggtt gcagtagtga 240 gagaagataa attggaagca gtgaagtcca agctagctgt gactgccagc atccatgtgt 300 acagcatcca gaaagccatg ctaaaggaca gtgggcctct gttcaatact gactatgaca 360 tccttaaaag caacttgcag aactgcagca aatttagtgc tatacaatgt gcag 414 <210> SEQ ID NO 491 <211> LENGTH: 489 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 491 cctacgattt tgttccagat tgggctgaaa ttttatacca gcaagtgatt cttaaaggag 60 actttaatta cttggaagaa tttaagcagc aaaggttatt aaagtccagt atatttgaag 120 agatttccaa aaatataaac aacatcagcc tactgacatg gtcatggaaa acctgaagaa 180 attactcaca tattgtgaag atgtttacct gtattacaag ttggcatacg aacacaagtt 240 ttatgaaatt gtaaatgtgc ttctgaagga ccctcagaca ggttgctgtc taaaggacat 300 gctagcaggt tagatgattt cataggtgtc tgttttcttg tactgttagc agattctgac 360 agatgtgatg agaagaagaa tgcattggag atctttgcta aagttgaaca atcccggtac 420 tgtaccatat cagtcctttg tgggtagtag gtagcaagta agaaactttt caggaggaaa 480 ttcctattt 489 <210> SEQ ID NO 492 <211> LENGTH: 373 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 492 cggtatccca gagtgccaga gaaccgttgc ttttccgagt tgctcttctt ccaggctccg 60 ttggtggtcg gcatggcccg tggaaatcaa cgagaacttg cccgccagaa aaacatgaag 120 aaaacccagg aaattagcaa gggaaagagg aaagaggata gcttgactgc ctctcagaga 180 aagcagaggg actctgagat catgcaagaa aagcagaagg cagctaatga gaagaagtct 240 atgcagacaa gagaaaagtg atgactggct atttggaaaa cctgggtgct actgccaact 300 gggtgtatca taagctctaa gatcaagatt ttgtagagtg gacagtcatt acatatgtta 360 taacttatcc ttt 373 <210> SEQ ID NO 493 <211> LENGTH: 427 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 493 aaaatagatg attataacgg ggcagagaac tttcttttct ctgcaagaat gttacatatt 60 gtatagataa atgagtgaca tttcatacca tgtatatata gagatgttct ataagtgtga 120 gaaagtatat gctttaatag atactgtaat tataagatat ttttaattaa atattttttt 180 gtaaatatta tgtgtgtgtt tttttttaat ctatgggaat atttcttttg gaaaatcatt 240 tttcagctca attacagagc tcttgatatc ttgaatgtct tttctgtttg gcctggctct 300 taatttgctt ttgttttgcc cagtatagac tcggaagtaa cagttatagc tagtggtctt 360 gcatgattgc atgagatgtt taatcacaaa ttaaacttgt tctgagtcca ttcaaatgtg 420 ttttttt 427 <210> SEQ ID NO 494 <211> LENGTH: 273 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 494 gcttgaaaga gtagaggaaa gtccacgcta gcacaacctg cgatggttgt agtgatcatg 60 ctaggcccaa taagcctagg cttagacgac tagtgccaca gagacgagaa ttgtgaaacg 120 cggtaaactc catgagttag aaacccaaat atcggtaggg gaacttttca atggaaattg 180 aaccaaagaa aagagttgat taatcaacta gataaattgt tagcacctga gagggtacaa 240 aacgtggctt ataaatgcta aaacgcctgc tcg 273 <210> SEQ ID NO 495 <211> LENGTH: 379 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 495 gcaggaggcg cggcgtccgg aggccccagg gttatgagac tatcactgct caggacctac 60 taacaacaaa ggaaatcgaa acatgaccaa atcgtacagc gagagtgggc tgatgggcga 120 gcctcagccc caaggtcctc caagctggac agacgagtgt ctcagttctc aggacgagga 180 gcacgaggca gacaagaagg aggacgacct cgaaaccatg aacgcagagg aggactcact 240 gaggaacggg ggagaggagg aggacgaaga tgaggacctg gaagaggagg aagaagagga 300 agaggaggat gacgatcaaa agcccaagag acgcggcccc aaaaagaaga agatgactaa 360 ggctcgcctg gagcgtttt 379 <210> SEQ ID NO 496 <211> LENGTH: 168 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 496 aaaccactgg atctatctaa atgccgattt gagttcgcga cactatgtac tgcgtttttc 60 attcttgtat ttgactattt aatcctttct acttgtcgct aaatataatt gttttagtct 120 tatggcatga tgatagcata tgtgttcagg tttatagctg ttgtgttt 168 <210> SEQ ID NO 497 <211> LENGTH: 484 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 497 ttggccgcat ccggcgcttt ttcagtcgca ggcggaatga gcccaccttg ccccgggagt 60 tcactcgccg tgggcgtcga ggtgcagtgt ctgtggatag tctggctgag ctggaagacg 120 gagccctgct gctgcagacc ctgcagcttt caaaaatttc ctttccaatt ggccaacgac 180 ttctgggatc caaaaggaag atgagtctca atccgattgc gaaacaaatc ccccaggttg 240 ttgaggcttg ctgccaattc attgaaaaac atggcttaag cgcagtgggg atttttaccc 300 ttgaatactc cgtgcagcga gtgcgtcagc tccgtgaaga atttgatcaa ggtctggatg 360 tagtgctgga tgacaatcag aatgtgcatg atgtggctgc actcctcaag gagtttttcc 420 gtgacatgaa ggattctctg ctgccagatg atctgtacat gtcattcctc ctgacagcaa 480 cttt 484 <210> SEQ ID NO 498 <211> LENGTH: 327 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 498 gtacaagctt tttttttttt ttttctgggt ttttcgactt gcagaactct ggaggagggc 60 ctttagctct gcacctgcca gatatttgtg agaaatctgc cattcgattt cacatggaag 120 atgctaaagg acaaattcaa cgagtgcggc cacgtgctgt acgccgacat caagatggag 180 aatgggaagt ccaaggggtg tggtgtggtt aagttcgagt cgccagaggt ggccgagaga 240 gcctgccgga tgatgaatgg catgaagctg agtggccgag agattgacgt tcgaattgat 300 agaaacgctt aagcagttgc ctttttt 327 <210> SEQ ID NO 499 <211> LENGTH: 387 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 499 ccaagccttg tctagcacca ttaatgactt acaggaccaa ctagattccc tagccgaagt 60 agtcctccaa aacagaagag gcttagacct actcactgca gaacagggag gtatctgttt 120 ggctctacag gaacgttgct gcttttatgc caacaagtca ggaattgtcc gagataaaat 180 aaaaaatcta caagaagacc tcgaacaaag acgcaaggca cttgcagaca atcccttcct 240 caccggcctc aatggacttc tcccttacct cctccccttc cttggaccct tattcgctat 300 catcctgttc ttctcttttg ccccttggat cctaagacga gtaacagcgt taatcaggga 360 tcagctcaat tccctactgg gaaagcc 387 <210> SEQ ID NO 500 <211> LENGTH: 228 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 500 aaataataaa aaataaaact caaagcaacc gcaaagataa tgtacaacta tgttatgcat 60 agcacattgc ctgttctaag gggaagcatg tgagcatctc agtttataca aaaagcagga 120 cgtaactata tagttctcag tgcatcctga tgaaggcatt tttgccttca gcttttttga 180 aaatttatta taagctagat gctaatcaga aaatattttg tatttttt 228 <210> SEQ ID NO 501 <211> LENGTH: 181 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 501 cttcgacatg cattgggtga tactaatatc agtagtttgg cagactataa tgcatctagg 60 ctttataatc gcagaagata aaaaagcaga agaagttaat atttcttcac ttatgattgc 120 acaaaaaatg caatcacaat caaaccttgc tttcgcttag ttaaaagtga caagtggttt 180 t 181 <210> SEQ ID NO 502 <211> LENGTH: 491 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 502 ctgaaacagc ttttcaagct ctctcccctc gtcaaggatc atgagaggca ctccactcaa 60 ggggaggtgc gcaatctggt gctcttcagg caggtcaaaa ctctcaaagt ctagaggatt 120 gaagggaaag aatttttcta tttctggata ggcatcatct gaggcaggaa cagagctttt 180 tgctttaaca gtcttctcag tcatcttttt ggcagaaaag cttggctgtt tttgtttgag 240 gggtcccttg gtctttacag acttttctgt agctctgttg acagttccca aagcctttct 300 agtagcttta ggtaaggctg gtggggcatc gaacgttttg ccaaaacgtg gtgttgaaac 360 ttgagatctc ccatctaagg ctttgattga aggtccagac cccagcttca gcccatcctt 420 agcaaccaca cgggtgcctg gttctccatt ttccttatca acatagatca gagtagccat 480 tctggacctg c 491 <210> SEQ ID NO 503 <211> LENGTH: 360 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 503 aaaggtggtc actggagatg ctctcaggcc agaactcaac agctattttt gggaataggg 60 atctcccgtg tgcctaacgc agtagctatt ggtttgaaca atgtccagac aagacctgta 120 cctttgagaa tataactgtg tttggcacct gcatagcacc atgaggaaga ccagccacca 180 gtggaagcgg ggtcactgcc ccacagactg gatgcaatga ggggctcaca ggaggcccag 240 ccagcccgat tgtgggctga ggggtctgca ttcaagcacg atgttctaga ataggagttt 300 aacgtgtcta cgtaacctag aatgtggtta ttaggaaagg ggctgtgcat gtgggtgcag 360 <210> SEQ ID NO 504 <211> LENGTH: 313 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 504 aaatgatcag aattggcagc acaaagaaaa cgccctctcc tgacttgtat tgtggcagtc 60 tgaacgcccc cagaaaattg tgccaaagag tttagaaaaa taaatataca ataaaagtaa 120 acacatacac acaaaacagc aaacttcagg taactatttt ggattgcaaa caggataaat 180 taaatgttca aacaatctga taaaataacc atttggaaac tgcttggcct tctgttcttt 240 tatttgattg actacaatgc ggtattggtc tcttgctgca cttcaaaagc aaccaacaaa 300 acaaaaacaa aaa 313 <210> SEQ ID NO 505 <211> LENGTH: 123 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 505 ctgatacaaa tacagaaaac tctgcccatt atccaagaaa caaataatta agactaaaat 60 gcaagctgat gtgttgcagc attgtagggc cactaaatag ccatctgtga ttcgtggcaa 120 ttt 123 <210> SEQ ID NO 506 <211> LENGTH: 390 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 506 aaaagacaaa aacaaaacaa aaataccaca gctcaagata aagagtccta tacagaaatc 60 acaaaaagga cagaccatct aaggaaaaat taaaaagacg acacaaggac aggctgggca 120 gcctgggtca gggctcctgg ctggtgacct gctttgagta ggtttcttgc aggtacttct 180 taaaagctgt ggggtttttc cagagctcgg cagcatgtgt gttcaaggga ctatcaatgt 240 tgggttctcc tagaaggctc tggatggaga gcagaatggt cctgacatca tacagggcag 300 accacttttc cttcaggatg tccaggcata tgttaccctg ggtgtccacg ttggggtgat 360 agcagggcgt gaggaacttc actgtgggcg 390 <210> SEQ ID NO 507 <211> LENGTH: 256 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 507 cctgagaaaa ggtacaattt caaatcagaa gtaaagggag aaagttcttc cagctcctat 60 ggactagtct tcagttccca tcgacacact gacgctggat ccagctcctg ctgtgggcag 120 tgcatgttgg cactgcaggg aggagaaggc cccagagacc cgagaaggaa ggtagggacc 180 gtggcttcct ctttctttat tgggcgcttt gtagatgtca cgcaggtcta aaagttacac 240 tgctaaataa ttattt 256 <210> SEQ ID NO 508 <211> LENGTH: 551 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 508 ctgcgaacaa tggtggaagc tgctgacagg gagaaggtgg agcttctcaa ccagcttgaa 60 gaggagaaaa ggaaggttga ggaccttcag ttccgggttg aagaagaatc aattaccaaa 120 ggtgatcttg agacgcagac caaactggag catgcccgca ttaaggagct tgaacagagc 180 ctgctctttg aaaagaccaa agctgacaaa ctccagaggg agttagaaga cactagggtg 240 gctacagttt cagaaaagtc acgtataatg gaactggaga aagacctagc attgagagta 300 caggaagtag ctgagctccg aagaaggcta gagtccaata agcctgctgg ggatgtggac 360 atgtcacttt cccttttgca agagataagc tctttgcaag aaaagttaga agtcacccgt 420 actgaccacc agagagaaat aacttctctg aaggagcatt ttggagcccg ggaagaaact 480 catcagaagg agataaaggc tctgtatacc gccacggaaa agctttccaa agagaacgag 540 tcattgaaaa g 551 <210> SEQ ID NO 509 <211> LENGTH: 528 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 472 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 509 aaactacgga tgcttttcaa agatgattat ccatcttcgc caccaaaatg taaattcgaa 60 ccaccattat ttcacccgaa tgtgtaccct tcggggacag tgtgcctgtc catcttagag 120 gaggacaagg actggaggcc agccatcaca atcaaacaga tcctattagg aatacaggaa 180 cttctaaatg aaccaaatat ccaagaccca gctcaagcag aggggtggtg ggcgcctgta 240 gtcccagcta cttgggaggc tgaggcagga gaatcgcctg aacccaggaa gcagatgttg 300 taccgagctg agatcatgcc attacactcc agcctgggcg acagaacgag acgccatcaa 360 taaataaata aataaagtaa agtaaaaaac ctattaaatt gaggctagag ctggagatgt 420 aattggtttt tgagaaacat tagtataaag cttgcccttg ttgtgtggaa gnagccattt 480 tgtactgctt taaagttaga ctaatattct cagcacgggt gtatgggg 528 <210> SEQ ID NO 510 <211> LENGTH: 199 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 510 aaactgcaat gagtcaacat cagacataat aattatttgc tgcagaatga actagcaaca 60 gagtttcgga aatctcctct cactacagag catgaaatat tgtcaatcac aaaaccagga 120 tcagttaaga acagctcaga ctgcaggtaa cttataagct aaaaaacttg ctaaataaat 180 ggcttttccc ccaattttt 199 <210> SEQ ID NO 511 <211> LENGTH: 182 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 511 ccttactaag gctactgtcg agtctcctga gaggtaagct ggcttgcata gaggttggta 60 ctcgaaaaat cctctcctcc caaaaaggta cctgtaagcc tgaaaattaa ggctcaggag 120 gagcacagcc tctacctccc ctagctggtt aaggtccgcc tcctcttttt ttacctgccc 180 gg 182 <210> SEQ ID NO 512 <211> LENGTH: 442 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 512 ccttttaatg tgtacatttc tcatgtatga tcaccaaacc attatttacc taatgaaatt 60 gtgaaaaact atacatattc agcaaaatgt tttaatttgg tcctatatta aaagacccaa 120 ttgccaaggg attttacaca aatttaattc acaagcatgt acacaagaga atcactataa 180 agaacattgc ttcctggttt atgaataaaa agtttatctt ctacttacac taaaacatac 240 aaaaaataat ctacaaaaat cgtttacaat tgattttagc taaagaaaaa gctttcttca 300 ggaaaaaaag atgattgtgt ggtggtagta ttttagccat caaaaaagga atgtaagtaa 360 ccaataaata taatgtgctt tctccatata gacatattta cacttgagtc tttggcttat 420 gttattttct aaaaagaact tt 442 <210> SEQ ID NO 513 <211> LENGTH: 495 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 513 ctcagcctcc caaaatgctg ggattacagg catgagccac tgtacccagc caaaattgtt 60 ttctttttta agtgaattca acaatttctg tgagtggctc tttgcatgaa cactgtgcaa 120 ggtgttggag aaatccaaag ctgaccaaaa catggtcccc accttttgga gcttacagtc 180 tgttctgggg aacagagatt cagccaaagt caagaaacac tggatgccag ctagattatc 240 tgttctgtgc tttggtgtct ataagtacat atgtggatat gggttcattt tatccctaaa 300 cttagtacca aaccagcatt taatatctaa ttataaatct aatttggcct aaactttatt 360 attgcacact gcctgaacaa aacctatttg tctctatgta aattttttcc tcatggaaca 420 agggtgtgaa atgaaaatat tttaggattt attcaaaaac agactattct gttttcagct 480 tcagaattgt tcttt 495 <210> SEQ ID NO 514 <211> LENGTH: 346 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 340 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 514 aaaaagaaaa aaaaagccaa atacattttc tgacattgta agattgcctt actgtctgtc 60 attccttatt gctggcccct ttctcaggcc ggaggccaag tggtggagaa ggaaaggaaa 120 tgatcgaacg ggcatgttgt caagtgggca tgccactggg aaataccacc agtttaccct 180 gaaacattgt cctcagagga gtaggaaagt ggattttgaa tctctatttt gctcaaaagt 240 tcagttcctg agatactgat gactgagagt gctgctggga aattttcagg attgtgtggt 300 cttttggggt tttttgtttt tttttttttt taagacaaan ttgacc 346 <210> SEQ ID NO 515 <211> LENGTH: 226 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 515 ctgagcaggc gagaatatcc tctttgatac gcatgggttt ggggccaaag cgcagctcat 60 cacccttgct ggtttctcca ttggcatatt ttgactgcac ccagcacttc caagcattga 120 caccatatga atagctgagc ccggtacaac taggctgact gctcatggag tcccgggagc 180 agctttcgga aagcaccagc cgcttttgac ccttcctcat ggttcg 226 <210> SEQ ID NO 516 <211> LENGTH: 286 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 516 cctgaactag tctcaaagtc tcatccacag agcggccaac agggaggtca tttacagtga 60 tctgccgaag aataccctta tcatcaatga taaaaaggcc cctgaacgag atgccttcat 120 cagcctttaa gaccccataa tcctgagcaa tggtgcgctt cgggtctgat accaaaggaa 180 tgttcatggg tcccagtcct ccttgtttct taggtgtatt gacccatgct agatgacaga 240 agtgagaatc cacagaagca ccaatcactt ggcagttgag tttctt 286 <210> SEQ ID NO 517 <211> LENGTH: 192 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 517 aaaaatgaac ttctcccgct acacagaagt aacaaatatg gtagtcagtt ttgtatttag 60 aaatgtattg gtagcaggga tgttttcata attttcagag attatgcatt cttcatgaat 120 acttttgtat tgctgcttgc aaatatgcat ttccaaactt gaaatatagg tgtgaacagt 180 gtgtaccagt tt 192 <210> SEQ ID NO 518 <211> LENGTH: 129 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 518 aaaaatggtt tgaatttgaa catatacgcc atggcacaga atttcgaatc tgatgattaa 60 aatcaggtaa ataatgatag ttaagaatta tatcctgaaa atagaggggc ctaatataag 120 gcttaattt 129 <210> SEQ ID NO 519 <211> LENGTH: 464 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 519 ctgaagctag actatctaca gacaaaattt gcaacaaatc tgatgcactg taaattcaag 60 tcctcaggac aacaaaagtg attaagcaag acctcaagta acaatgttaa tgccatttac 120 aaaggaaaaa actgatacaa aaacattcaa aacctgaaca tcacttggca tgtaagggaa 180 aaaaaattaa attagctgaa aggttcataa acacaaggtc ttatttacat tacacaaagc 240 tcaggtgtta gccttgaacg taactttcaa aataccttca aatatatcca actcagatca 300 cttttgctga tttgctgcag tacaaatcat gtgcaacgtc ttttttcctt aagacaaaac 360 aattcttcaa acaatactgc aagtacatca ctaaacacca tgagctctat ctgaagggat 420 ttctttagga agaacagatt ttttccccca tctctcggta attt 464 <210> SEQ ID NO 520 <211> LENGTH: 138 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 520 ctgctcaggc agctttaaga cgtaccatgg agaaggagtc gaaaaccacc cgattctgtc 60 ttatctgtaa ctatgtcagt cgaataattg aacccctgac ctctagatgt tcaaaattcc 120 gcttcaagcc tctgtcag 138 <210> SEQ ID NO 521 <211> LENGTH: 456 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 521 aaaacgaaca gctaaatgct ctacttttct ttctccatct gcaaaatcac atgcagtcca 60 caaccatact ctttctgtcc ctttcatatt ttgcaaagtc atgtctggag ttattctgtg 120 attggcacaa agttttaata cttggtccct tctcatcact atacgaactt gcttattatc 180 ataattctgt aaaatcttta tatcaccaat gcccctttct ttccattgac caacatcttt 240 atcatatctg tagagttttg ccctgtgact aaaaacaact tgttcatttt cctcaccact 300 ggatacttca actagatcag gtaaaggaac aacaggttca aagtgctgtc catctctctc 360 ttcttcttga gtaacatcag attcttcatc agtgccaact gaagtcccac tctgattcaa 420 cttggcagga gacttagatg gactcaaagc agattt 456 <210> SEQ ID NO 522 <211> LENGTH: 81 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 36 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 522 cctcgctgtc aatgtcgctc tcctctgagc tgtccnactc ctcgctgctg tctttcctgc 60 gcttcttctc ctgcggggtg g 81 <210> SEQ ID NO 523 <211> LENGTH: 348 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 523 ctgaaacagc ttttcaagct ctctctcctc gtcaaggatc atgagaggca ctccactcaa 60 ggggaggtgc gcaatctggt gctcttcagg caggtcaaaa ctctcaaagt ctagaggatt 120 gaagggaaag aatttttcta tttctggata ggcatcatct gaggcaggaa cagagctttt 180 tgctttaaca gtcttctcag tcatcttttt ggcagaaaag cttggctgtt tttgtttgag 240 gggtcccttg gtctttacag acttttctgt agctctgttg acagttccca aagcctttct 300 agtagcttta ggtaaggctg gtggggcatc gaacgttttg ccaaaacg 348 <210> SEQ ID NO 524 <211> LENGTH: 470 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 524 aaatgtttta ggcaacctaa gaacaaatgt aaaagtaaag atgcaggaaa aatgaattgc 60 ttggtattca ttacttcatg tatatcaagc acagcagtaa aacaaaaacc catgtattta 120 actttttttt aggatttttg cttttgtgat tttttttttt tttttttgat acttgcctaa 180 catgcatgtg ctgtaaaaat agttaacagg gaaataactt gagatgatgg ctagctttgt 240 ttaatgtctt atgaaatttt catgaacaat ccaagcataa ttgttaagaa cacgtgtatt 300 aaattcatgt aagtggaata aaagttttat gaatggactt ttcaactact ttctctacag 360 cttttcatgt aaattagtct tggttctgaa acttctctaa aggaaattgt acattttttg 420 aaatttattc cttattccct cttggcagct aatgggctct taccaagttt 470 <210> SEQ ID NO 525 <211> LENGTH: 228 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 73 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 525 aaataaaatt ttgtaaagta atgtgaatta aaaattttgg aacaattaga attcattcac 60 tattgtatag aanatgctgt taaaacatag gaagggtatt tttcttgatc caaagtttgt 120 gaatttggct ttgctacctc aattgcaggt gtttgtttgc ctttataaac tgttgcaaat 180 agaaaaaaaa tagaataagt atatattttt ggagtaacat caatattt 228 <210> SEQ ID NO 526 <211> LENGTH: 458 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 526 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tcctgacttg ttggcataaa agcagcaacg ttcctgtaga 420 gccaaacaga tacctccctg ttctgcagtg agtaggtc 458 <210> SEQ ID NO 527 <211> LENGTH: 464 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 31, 79, 150, 256, 293 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 527 cttttttttt tttttttttt tttttttttg ncaacagtgt ttttatttat acctacaaaa 60 agaaaacaag atgatggtnt caaaaggaca atttacaaac taagaatagt aacatagctt 120 tcagcatcct gtgcctgaac atcacacatn tacaagtctt tcaagtctta atgcaacagg 180 aatgtgtctg gagaccagca agaacatcaa tagagagcac tgatcccaag caaaagccac 240 taacctttta gatganaagt ccacacaacg aattgttagg gaggattggg ganaagcagc 300 ccattgctta atacattgga accctttccc taagttgagt ttcaaccatg aatgcaataa 360 ctagcataaa acgattcttc tgctcatgtt ctgaagccaa cagcagaacc tgaattataa 420 gtgacagaca tggaggcaga agagttaaac tctgctagat ttca 464 <210> SEQ ID NO 528 <211> LENGTH: 292 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 528 cctgcttttc acacctcagt ttatttaata cgaggcaagt tgtaagacaa cactcattct 60 aggtgattct gtggtgccat gaaatttaag gtaatttggg gaaaaggatt agtcagtttt 120 aagcaagagt cacatctttt gagctttcga ttatcagtgt agtacctgac taaaaatgaa 180 gtaataccct taaaccattt ataatttcta gtatttctct gaaagatcgt tttggggaca 240 aaagtgactt gacatgtcca atttcatttc agaataaaaa gctagcatct tt 292 <210> SEQ ID NO 529 <211> LENGTH: 490 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 529 gcgtaatacc accattccta ccaagcagac acagaccttc actacctatt ctgacaacca 60 gcctggtgtg cttattcagg tttatgaagg cgagcgtgcc atgacaaagg ataacaacct 120 gcttggcaag tttgaactca caggcatacc tcctgcaccc cgaggtgttc ctcagattga 180 agtcactttt gacattgatg ccaatggtat actcaatgtc tctgctgtgg acaagagtac 240 gggaaaagag aacaagatta ctatcactaa tgacaagggc cgtttgagca aggaagacat 300 tgaacgtatg gtccaggaag ctgagaagta caaagctgaa gatgagaagc agagggacaa 360 ggtgtcatcc aagaattcac ttgagtccta tgccttcaac atgaaagcaa ctgttgaaga 420 tgagaaactt caaggcaaga ttaacgatga ggacaaacag aagattctgg acaagtgtaa 480 tgaaattatc 490 <210> SEQ ID NO 530 <211> LENGTH: 412 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 530 cggccgaggt ctgctgtgac agcagtctgc ccaggcacag aaaaggagga agcaggtggt 60 actgcctccg tcctggcatc agggaccccc gtggtggctg gggtagcctc tgcagaaagt 120 gctacaagac tagtactaga tgctgcagtg ccagagttgc tgactgcagg ctgggcaaga 180 acaggttctt ttttaacaga gtcagaagtt tgcggaggag cctggggaag ctgggctgac 240 tgttgctcct ctagaagtga ggctgctgat gctgagacct cactgtcacc tggcttctca 300 ggcaaagctg atgaagtggc ctcttctgtg cttctgccag cggacatagg cagggagggg 360 gtagttgctg aactcaggag gctaccaaat gacaatgtgg ggaatgatgt tg 412 <210> SEQ ID NO 531 <211> LENGTH: 454 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 391, 393, 435 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 531 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tcctgacttg ntngcataaa agcagcaacg ttcctgtaga 420 gccaaacaga taccntccct gttctgcagt gagt 454 <210> SEQ ID NO 532 <211> LENGTH: 294 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 532 ggcggctcgg actgagcagg actttcctta tcccagttga ttgtgcagaa tacactgcct 60 gtcgcttgtc ttctattcac catggcttct tctgatatcc aggtgaaaga actggagaag 120 cgtgcctcag gccaggcttt tgagctgatt ctcagccctc ggtcaaaaga atctgttcca 180 gaattccccc tttcccctcc aaagaagaag gatctttccc tggaggaaat tcagaagaaa 240 ttagaagctg tagaagaaag acgcaagtcc catgaagctg aggtcttgaa gcag 294 <210> SEQ ID NO 533 <211> LENGTH: 344 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 533 aaaaagagca aattgacact cgtggtggtc gaggatgatg atcagggacg tgagcaagag 60 cacacgtttg tgttccggtt agacagtgcc aggacctgca aacacctttg gaagtgtgca 120 gttgagcacc acgcattctt ccgactgcgg acgccaggaa acagcaaatc caatagatcc 180 gactttatca ggctgggctc tcgcttcaga ttcagtgggc ggacagaata tcaagctaca 240 catggctcca ggttacgaag aaccagcacc tttgagagga agcctagtaa acgttatcca 300 tcccggagac attcaacgtt caaagcaagc aacccagtga tagc 344 <210> SEQ ID NO 534 <211> LENGTH: 482 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 534 gatggacccc tcagcccgcc gctcagcatc aatggcaact tctctttcaa acacgaaccg 60 tccgccgagt ttgaaaaaaa ttatgccttt accatgcact atcctgcagc gacactggca 120 ggggcccaaa gccacggatc aatcttctca ggcaccgctg cccctcgctg cgagatcccc 180 atagacaata ttatgtcctt cgatagccat tcacatcatg agcgagtcat gagtgcccag 240 ctcaatgcca tatttcatga ttagaggcac gccagtttca ccatttccgg gaaacgaacc 300 cactgtgctt acagtgactg tcgtgtttac aaaaggcagc cctttgggta ctactgctgc 360 aaagtgcaaa tactccaagc ttcaagtgat atatgtattt attgtcatta ctgcctttgg 420 aagaaacagg ggatcaaagt tcctgttcac cttatgtatt attttctata gctcttctat 480 tt 482 <210> SEQ ID NO 535 <211> LENGTH: 495 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 535 gatgacgaag atgagtcgag tgagcagacc tttatgtatt atgtgaatga tggcgtctat 60 ggatcattta attgcatact ctatgaccac gcacatgtaa agccccttct gcaaaagaga 120 cctaaaccag atgagaagta ttattcatcc agcatatggg gaccaacatg tgatggcctc 180 gatcggattg ttgagcgctg tgacctgcct gaaatgcatg tgggtgattg gatgctcttt 240 gaaaacatgg gcgcttacac tgttgctgct gcctctacgt tcaatggctt ccagaggccg 300 acgatctact atgtgatgtc agggcctgcg tggcaactca tgcagcaatt ccagaacccc 360 gacttcccac ccgaagtaga ggaacaggat gccagcaccc tgcctgtgtc ttgtgcctgg 420 gagagtggga tgaaacgcca cagagcagcc tgtgcttcgg ctagtattaa tgtgtagata 480 gcactctggt agctg 495 <210> SEQ ID NO 536 <211> LENGTH: 190 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 536 ccttccctcc ccaccaccat caacctcttc aaaacctact ccctccctct aagtatctct 60 caacacagta tgtctggggc tagatttcaa aacccacgta atgaaaaagt cagttttaca 120 agcctaattt tgttgttttt tttttatatc aattaacgtt aaaaattgca tcaactattt 180 aattcatgag 190 <210> SEQ ID NO 537 <211> LENGTH: 391 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 537 tgcggagcga gtctgggtct cagccccgcg aacagccttt cacgagtctt caagctttca 60 ggctatcttc tagtcaagat gagtgataag ccagacttgt cggaagtgga gaagtttgac 120 aggtcaaaac tgaagaaaac taatactgaa gaaaaaaata ctcttccctc aaaggaaact 180 atccagcaag agaaagagtg tgttcaaaca tcataaaatg gggatcgcct cccaacagca 240 gatttcgaca ttacctgaga gttttgattt taggcttgtt ttttgtaaac ccatgtgttt 300 gtagagattt taggcgtctt cggatatctt ctcacctatg ttccctggct aagaagtcag 360 aggtagccaa tgtttcctta aattcatttt t 391 <210> SEQ ID NO 538 <211> LENGTH: 495 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 538 gatgacgaag atgagtcgag tgagcagacc tttatgtatt atgtgaatga tggcgtctat 60 ggatcattta attgcatact ctatgaccac gcacatgtaa agccccttct gcaaaagaga 120 cctaaaccag atgagaagta ttattcatcc agcatatggg gaccaacatg tgatggcctc 180 gatcggattg ttgagcgctg tgacctgcct gaaatgcatg tgggtgattg gatgctcttt 240 gaaaacatgg gcgcttacac tgttgctgct gcctctacgt tcaatggctt ccagaggccg 300 acgatctact atgtgatgtc agggcctgcg tggcaactca tgcagcaatt ccagaacccc 360 gacttcccac ccgaagtaga ggaacaggat gccagcaccc tgcctgtgtc ttgtgcctgg 420 gagagtggga tgaaacgcca cagagcagcc tgtgcttcgg ctagtattaa tgtgtagata 480 gcactctggt agctg 495 <210> SEQ ID NO 539 <211> LENGTH: 384 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 539 ccttcgagct gtttgaccga gtgggggatg gcaagatcct gtacagccag tgtggggacg 60 tgatgagggc cctgggccag aaccccacca acgccgaggt gctcaaggtc ctggggaacc 120 ccaagagtga tgagctgaag tcgcggcgtg tggactttga gactttcctg cccatgctcc 180 aggcagtggc caagaaccga ggccaaggca catatgagga ctacttggag gggtttcgtg 240 tgtttgacaa ggaggggaac ggcaaagtca tgggagcaga gctcagacat gttctcacca 300 cccttggaga gaagatgact gaggaggagg tggagaccgt tctggcagga cacgaggaca 360 gcaacggctg catcaactac gagg 384 <210> SEQ ID NO 540 <211> LENGTH: 213 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 540 aaagaaaaaa atcaatcaaa ataatgaaca acaaaaagtg gggtttaaga acaaatggaa 60 aataaaaaat gaaacagttg cttggtggca ggtgcccggc ggcggtacct gtacatgggc 120 acggtgaccg ttcgctcgta gtactgccac gtggagtgca ggtctgtgcg cgagaggttg 180 gtggcgtaga atctccaggc cgactggatc agg 213 <210> SEQ ID NO 541 <211> LENGTH: 217 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 541 aaaatttctt agaaaacaat ggaatgagaa tttaagcctc aaatttgaac atgtggcttg 60 aattaagaag aaaattatgg catatattaa aagcaggctt ctatgaaaga ctcaaaaagc 120 tgcctgggag gcagatggaa cttgagcctg tcaagaggca aaggaatcca tgtagtagat 180 atcctctgct taaaaactca ctacggagga gaattaa 217 <210> SEQ ID NO 542 <211> LENGTH: 387 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 542 aaaaatgaat ttaaggaaac attggctacc tctgacttct tagccaggga acataggtga 60 gaagatatcc gaagacgcct aaaatctcta caaacacatg ggtttacaaa aaacaagcct 120 aaaatcaaga ctctcaggta atgtcgaaat ctgctgttgg gaggcgatcc ccattttatg 180 atgtttgaac acactctttc tcttgctgga tagtttcctt tgagggaaga gtattttttt 240 cttcagtatt agttttcttc agttttgacc tgtcaaactt ctccacttcc gacaagtctg 300 gcttatcact catcttgact agaagatagc ctgaaagctt gaagactcgt gaaaggctgt 360 tcgcggggct gagacccaga ctcgctc 387 <210> SEQ ID NO 543 <211> LENGTH: 498 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 543 ctgcgctgca ggttatgaaa cttggaaatc ccgagattgc caggagactg ctacttagag 60 gtgctaatcc cgatttgaaa gaccgaactg gtttcgctgt cattcatgat gcggccagag 120 caggtttcct ggacacttta cagactttgc tggagtttca agctgatgtt aacatcgagg 180 ataatgaagg gaacctgccc ttgcacttgg ttgccaaaga aggtcacctc cgggtggtgg 240 agttcctggt gaagcacacg gccagcaatg tggggcatcg gaaccataag ggggacaccg 300 cctgtgattt ggccaggctc tatgggagga atgaggttgt tagcctgatg caggcaaacg 360 gggctggggg agcaacaaat cttcaataaa cgtggggagg gctcccccac gttgcctcta 420 ctttatcaat taactgagta gctctcctga cttttaatgt catttgttaa aatacagttc 480 tgtcatatgt taagcagc 498 <210> SEQ ID NO 544 <211> LENGTH: 91 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 544 ctgttaggcg atccatgggg ttaaaggtca ggatcttctc cagaaagtcg atggcttcac 60 tgttcacttc agggagcagc ttgcgcagag g 91 <210> SEQ ID NO 545 <211> LENGTH: 313 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 545 cctatcaggc tatgctgctt cgaatcgcca ggatcccctg aagggtctgg gatgggggcc 60 aggagattag caacaaggat tcattctgtt acttacttgc ccctttttat ctttccctct 120 tgccccagtc ccttctctcc agcttcatgt gaagctctgc acagacaaga cactcagtgt 180 ccttggcagt gctgctactc ctcaggtgca gcatacataa ccagtaagag actaaatctg 240 caatatataa agagctccta caaatcagta acatgaagaa cactcaaaaa ttggcaaatg 300 tcatcagtgt ttt 313 <210> SEQ ID NO 546 <211> LENGTH: 428 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 546 cggaggccct gcagctccca atggactatg tccagcgggt caagcggacc cactctcagg 60 gcggctacgg ctcacagggg tacaagtata actggaagct ggacgaggcc cggaaaaacc 120 tactgcgaac ccacaccaca tcagccagcg cccgtgcgct ctaccgcctt gcccagaaga 180 agcccttcac tccggtcaag tacttctcca tcgaccgcgt attccggaat gagaccctgg 240 acgccacgca cctggctgag ttccaccaga tcgagggcgt ggtggcggat catggtctca 300 ccttgggcca cctcatgggc gttctgcggg agttcttcac caagctgggt atcacgcaac 360 tccgcttcaa gccagcctac aacccataca cagagcccag catgggaggt gttcagctac 420 caccaagg 428 <210> SEQ ID NO 547 <211> LENGTH: 447 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 547 gagcacctat cagttgcaaa agccatgcct gcaaccgatg gaaaatgtaa gagggagttc 60 ttaaggttct tggtggcatc acccaaggca ttctgggaaa acctagggcc tggccccaaa 120 acttccctac tctgtggcta gtcctgctgc caacaaaatc gtagcgacct ggcttttcac 180 agctttgctt ttatttccaa gtcaaggaca agccgcttca ttcactcctg ggcatttact 240 cttcttgtgg gtctgtgata ttccttgctt tccagggaga atgtgcttgg caaggtctgg 300 agaactaatt cagaatctta ggggaagggg agagatggaa atacaaacct gcttactgga 360 aaggtgcaaa tatatgggtt gagctggagg taggaataca ggtaattaag gtttctagtt 420 taagggaaaa cagatctatt gccattt 447 <210> SEQ ID NO 548 <211> LENGTH: 247 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 548 aaagcagatc caggcaataa aatctaaatt ttcctctaac tttggatccc agaaacacta 60 attagaccta cacttgaggt ttccctgttg gcgtgacctg agcaaaactg tacagaattt 120 tgggagaggc catttggcaa gccattggtc tgaataattt ggagggggaa atcctaaggt 180 ggtggagttg ctgcgtggac acggctatgg gttggtgtga catgatttcg cattaattgt 240 ttgtcag 247 <210> SEQ ID NO 549 <211> LENGTH: 422 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 549 aaaatctatt tatgctttat agagaaacca gacattaaaa cttcatgcac tacttatttc 60 gaattactgt accttatcca aatttacacc tagctattag gatcttcaac ccaggtaaca 120 ggaataattc tgtggtttca tttttctgta aacaactgaa agaataatta gatcatattc 180 tagtatgttc tgaaatatct ttaagactga tcttaaaaac taacttctaa gatgatttca 240 tcttctcata gtatagagtt tactttgtac acgtttgaaa ccaactactg tagaagatga 300 ggaatctatt gtaatttttt gctttatttt catctgccag tggacttatt tgaaattttc 360 actttagtca aattattttt tgtattagtt tttgatgcag acataaaaat agcaatcatt 420 tt 422 <210> SEQ ID NO 550 <211> LENGTH: 473 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 550 aaaaaaaaaa aaaagtaaaa caaaattctg catttttata aaacttgata aaaaatagta 60 tttcaaactg tacagtcacc agaagtacac agttatcaaa aatgcacaca cttcacttgg 120 catctccagc accttcagct ttctgtgcct ggtctgtttt ggcatctcca ttttctgcag 180 ggttattccc ctccttgcca gcatcagctt ttcccttttt ccctttgggt accttctctc 240 ccttctttgc aggggccttt ttaggcttgg gctctggctt tggaggagca ggtttagcag 300 acaacctcgc ggatcttctc tgtggttcgt ccttcacctt tgctttatct cccttagcat 360 ccccttcagc ctttctcttg ggcatggtgg cggcggcgac ggcagcggga cgtaggtgct 420 ggacgcggga tgcagcggcg cgcgggcttt ggtcggtccg ggggtcgttc tcg 473 <210> SEQ ID NO 551 <211> LENGTH: 195 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 180 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 551 ctggctggaa acctggcagt gataccatca agcttgatgc ccaaaagagc aaagaatatt 60 tctccaagca gaagtgagcg ctgggctgtt ttagtgccag gctgcggtgg gcagccatga 120 gaacaaaacc tcttctgtat ttttttttcc attagtaaaa cacaagactt cagattcagn 180 cgaattgtgg tgtct 195 <210> SEQ ID NO 552 <211> LENGTH: 386 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 552 ccttccggcg gaacatggca gtgaactgct ccgagatgcg cttgaagagc tcctggatgg 60 ctgtgctatt gccaatgaag gtgactgcca tcttgaggcc acgaggtggg atgtcacaga 120 cggctgtctt gacattgttg gggatccatt ccacaaagta gctgctgttc ttgttctgca 180 cgttaagcat ctgctcatcg acctccttca tggacatccg accacggaag acagcagcca 240 cggtgaggta tcggccgtgg cgggggtcac aggcagccat catgttcttg gcatcgaaga 300 cctgctgggt gagttccggc actgtgagag ctcgatactg ctggcttcca cggctggtga 360 gaggggcaaa gccaggcata aagaaa 386 <210> SEQ ID NO 553 <211> LENGTH: 166 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 553 ctgaggggag aggatgatcc tgggaactgg ggaacttctc ccccttgaga atccaaccat 60 caaatacctt caggaagtcg ccgccctgac agtcgatgga gacctggtcg tagtggatgg 120 taatgaactc ctcgggctcg ctgatgaaga aggctgcgca gtgcag 166 <210> SEQ ID NO 554 <211> LENGTH: 402 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 554 cgctaacctg gtccggagcg agtctgggtc tcagccccgc gaacagcctt tcacgagtct 60 tcaagctttc aggctatctt ctagtcaaga tgagtgataa gccagacttg tcggaagtgg 120 agaagtttga caggtcaaaa ctgaagaaaa ctaatactga agaaaaaaat actcttccct 180 caaaggaaac tatccagcaa gagaaagagt gtgttcaaac atcataaaat ggggatcgcc 240 tcccaacagc agatttcgac attacctgag agtcttgatt ttaggcttgt tttttgtaaa 300 cccatgtgtt tgtagagatt ttaggcgtct tcggatatct tctcacctat gttccctggc 360 taagaagtca gaggtagcca atgtttcctt aaattcattt tt 402 <210> SEQ ID NO 555 <211> LENGTH: 447 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 428 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 555 cttaaagacc tggttaaaga aaaagttggt gaggtaacat acgtggagct cttaatggac 60 gctgaaggaa agtcaagggg atgtgctgtt gttgaattca agatggaaga gagcatgaaa 120 aaagctgcgg aagtcctaaa caagcatagt ctgagcggaa gaccactgaa agtcaaagaa 180 gatcctgatg gtgaacatgc caggagagca atgcaaaagg tgatggctac gactggtggg 240 atgggtatgg gaccaggtgg cccaggaatg attactatcc cacccagtat cctaaataat 300 cccaacatcc caaatgagat tatccatgca ttacaggctg gaagacttgg aagcacagta 360 tttgtagcaa atctggatta taaagttggc tggaagaaac tgaaggaagt atttagtatg 420 gctggtgntg gtggtccgag cagacat 447 <210> SEQ ID NO 556 <211> LENGTH: 469 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 556 gaatctccgt gtgctttggt ggccagccag tacggatggt ctggcaacat ggagagaatc 60 atgaaagcac aagcgtacca aacgggcaag gacatctcta caaattacta tgcgagtcag 120 aagaaaacat ttgaaattaa tcccagacac ccgctgatca gagacatgct tcgacgaatt 180 aaggaagatg aagatgataa aacagttttg gatcttgctg tggttttgtt tgaaacagca 240 acgcttcggt cagggtatct tttaccagac actaaagcat atggagatag aatagaaaga 300 atgcttcgcc tcagttcgaa cattgaccct gatgcaaagg tggaagaaga gcctgaagaa 360 gaacctgaag agacagcaga agacacaaca gaagacacag agcaagacga agatgaagaa 420 atggatgtgg gaacagatga agaagaagaa acagcaaagg aatctacag 469 <210> SEQ ID NO 557 <211> LENGTH: 385 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 557 gcccacgcag gaggcgcggc gtccggaggc cccagggtta tgagactatc actgctcagg 60 acctactaac aacaaaggaa atcgaaacat gaccaaatcg tacagcgaga gtgggctgat 120 gggcgagcct cagccccaag gtcctccaag ctggacagac gagtgtctca gttctcagga 180 cgaggagcac gaggcagaca agaaggagga cgacctcgaa accatgaacg cagaggagga 240 ctcactgagg aacgggggag aggaggagga cgaagatgag gacctggaag aggaggaaga 300 agaggaagag gaggatgacg atcaaaagcc caagagacgc ggccccaaaa agaagaagat 360 gactaaggct cgcctggagc gtttt 385 <210> SEQ ID NO 558 <211> LENGTH: 377 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 558 aaatctgtgg aggaattgga aaactccaac aaaaatgttg atggcagcaa gtcaactcat 60 gaagaacaga gctctatgat acaaacacag gttcctgata tatatgaatt tcttaaagat 120 gcttcagata agatgggtca tagtgatgaa gtggctgatg aatgtttcaa attgcatcaa 180 gtatgggaaa caaaagtgcc tgaaagcatt gaagaattgc cttcaatgga agaaatctca 240 cactctgttg gggaacatct tccaaacaca tacgtagatc taacgaaaga tccagtcact 300 gaaaccaaaa acttggggga attcatagaa gtaacagttt tacatattga tcagttggga 360 tgttctggag gcaattt 377 <210> SEQ ID NO 559 <211> LENGTH: 405 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 559 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tcctgacttg ttggcataaa agcag 405 <210> SEQ ID NO 560 <211> LENGTH: 444 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 560 cctaccacca atctcaccag tccaggaatt atataggaat ggtcacattc ctaatgatgg 60 tgaagcagaa agccctcccc acagagagac agcccactgg ggacccagct caagctcttc 120 aaaacgtggc agctacaggt cacaagactt tggcagagat gtccgaaatt cttcaaggaa 180 ggcgtcacga tcagagggac ggatccagct caaatagctt tctaggtaca gggggagaga 240 ccacagagca tcttcatgtg accccttagt ttgggcctcc agcctccacc agagtgcagt 300 ggcctcatcc ctccgatcta gcctcttcag agtctgaagc aggtgaaagt aagtgtctcg 360 attacctgta gccccagccc agagtacaga gtcttagaac ttgacatagt cttaggcatt 420 gttttataaa aagggaaact gagg 444 <210> SEQ ID NO 561 <211> LENGTH: 257 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 561 cctaggggcg gcgccggcgg ctgccaggga gaggcaagaa ttgagtgttg tgaatagttc 60 tgaactagag accttttgaa accaaaagga agatggtctt gagtctttct tgttacgaat 120 gctatcttct ttgagaagtc aaattgtcag gatcaggaat gtatgttttc ttccatctgg 180 attctagggt tggaaatacc aagtaaggaa ttaacatata tgatgctgga aacttgtaga 240 ggctcatgat tgaaagg 257 <210> SEQ ID NO 562 <211> LENGTH: 100 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 562 aaaataaatt gctgggagag aacaagacag aacagttata aggtgatgca agatggaagt 60 ggtgatgaag caccctagag caagtcagct tcagaaaatg 100 <210> SEQ ID NO 563 <211> LENGTH: 171 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 563 aaaaaaagag gaggcggacc ttaaccagct aggggaggta gaggctgtgc tcctcctgag 60 ccttaatttt caggcttaca ggtacctttt gggaggagag gatttttcga gtaccaacct 120 ctatgcaagc cagcttacct ctcaggagac tcgacagtag ccttagtaag g 171 <210> SEQ ID NO 564 <211> LENGTH: 526 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 564 ctgacccact cactgggcgg gggcacaggc tctggaatgg gcactctcct tatcagcaag 60 atccgagaag aataccctga tcgcatcatg aataccttca gtgtggtgcc ttcacccaaa 120 gtgtctgaca ccgtggtcga gccctacaat gccaccctct ccgtccatca gttggtagag 180 aatactgatg agacctattg cattgacaac gaggccctct atgatatctg cttccgcact 240 ctgaagctga ccacaccaac ctacggggat ctgaaccacc ttgtctcagc caccatgagt 300 ggtgtcacca cctgcctccg tttccctggc cagctcaatg ctgacctccg caagttggca 360 gtcaacatgg tccccttccc acgtctccat ttctttatgc ctggctttgc ccctctcacc 420 agccgtggaa gccagcagta tcgagctctc acagtgccgg aactcaccca gcaggtcttc 480 gatgccaaga acatgatggc tgcctgtgac ccccgccacg gccgat 526 <210> SEQ ID NO 565 <211> LENGTH: 172 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 565 ctgtggaggg gacactgtct ttgaggcatc actggttcca caaaaggtag gggaaggtct 60 tgagggacca cccatgccct cattaatcaa ccagaagctt ggcctggagc agcagcgggg 120 attccagtag ctgtgggcat acaggatgct agggcggcca caacccaggc ag 172 <210> SEQ ID NO 566 <211> LENGTH: 289 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 566 aaaaaggatg atattggacg aaggaatggg caagctccaa atgagaagat gaagcaagtg 60 ttaaagaaga ctatagaaga agccaaagca ataatatcta agaaacaagt ggaagccggt 120 gtctgtgtta ccatggagat ggtgaaagat gccttggacc agcttcgagg cgcggtgatg 180 attgtttacc ccatggggtt gccaccgtat gatcccatcc gcatggagtt tgaaaataag 240 gaagacttgt cgggaacaca ggcagggctc aacgtcatta aagaggcgg 289 <210> SEQ ID NO 567 <211> LENGTH: 280 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 567 ctgccgagcg accttgactg tcaagctgta gaaaatttag ttgaaatagg gcatgactaa 60 gaaggtttct gggttgttgc atagaaaacc caagggggga gcgggctaag cgatttaggg 120 cattttttaa tgtttgatga gctcgttcaa ctactccttg accctggggg ttgtacggta 180 taccagtaac atgtttgatt tggagttttt ggcaaaagtc ttggaagttt tttccagtat 240 atcccgggcc attgtctgtt ttaatggtgt gtggttttcc 280 <210> SEQ ID NO 568 <211> LENGTH: 387 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 568 aaaaatgaat ttaaggaaac attggctacc tctgacttct tagccaggga acataggtga 60 gaagatatcc gaagacgcct aaaatctcta caaacacatg ggtttacaaa aaacaagcct 120 aaaatcaaga ctctcaggta atgtcgaaat ctgctgttgg gaggcgatcc ccattttatg 180 atgtttgaac acactctttc tcttgctgga tagtttcctt tgagggaaga gtattttttt 240 cttcagtatt agttttcttc agttttgacc tgtcaaactt ctccacttcc gacaagtctg 300 gcttatcact catcttgact agaagatagc ctgaaagctt gaagactcgt gaaaggctgt 360 tcgcggggct gagacccaga ctcgctc 387 <210> SEQ ID NO 569 <211> LENGTH: 201 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 569 cctgtgtctg ccttagcccc tttctctaag ctgggggata cctgaagact atgttccttg 60 atgaacgagt gcagggatgg gaatcccagt tgcataggtg gggcatgcac aagctggcta 120 gcaatggctg agaacttggc cacatgaaga gtttcatcat aggtagatgc acagggattc 180 acattgacaa tcatgcagga a 201 <210> SEQ ID NO 570 <211> LENGTH: 293 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 570 ctgcttcaag acctcagctt catgggactt gcgtctttct tctgcagctt ctaatttctt 60 ctgaatttcc tccagggaaa gatccttctt ctttggaggg gaaaggggga attctggaac 120 agattctttt gaccgagggc tgagaatcag ctcaaaagcc tggcctgagg cacgcttctc 180 cagttctttc acctggatat cagaagaagc catggtgaat agaagacaag cgacaggcag 240 tgtattctgc acaatcaact gggataagga aagtcctgct cagtccgagc cgc 293 <210> SEQ ID NO 571 <211> LENGTH: 196 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 571 aaagacaaaa gaaagcagac tcaaaacaca gacaaagcag agaagaaaac aatgcccatg 60 agatggtcac tatttagaca gtattataaa aagctaaaga acacttgggc tttacttcac 120 tttgatgtct tgtactaaaa acaccttccc caaactaaat tcagagggga ggaagttaag 180 agcttcaggt aacttt 196 <210> SEQ ID NO 572 <211> LENGTH: 459 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 572 aaaagacaaa aacaaaacaa aaataccaca gctcaagata aagagtccta tacagaaatc 60 acaaaaagga cagaccatct aaggaaaaat taaaaagacg acacaaggac aggctgggca 120 gcctgggtca gggctcctgg ctggtgacct gctttgagta ggtttcttgc aggtacttct 180 taaaagctgt ggggtttttc cagagctcgg cagcatgtgt gttcaaggga ctatcaatgt 240 tgggttctcc tagaaggctc tggatggaga gcagaatggt cctgacatca tacagggcag 300 accacttttc cttcaggatg tccaggcata tgctaccctg ggtgtccacg ttggggtgat 360 agcagggcgt gaggaacttc actgtgggcg cattgtaagg gtagccactg gggaactcta 420 gcgagagctt atacctcagg tcttcatata ctgttccag 459 <210> SEQ ID NO 573 <211> LENGTH: 458 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 573 ctgtgacctt gccaaggagc agggcccata cgaaacctat gagggctctc cagttagcaa 60 aggaattctt cagtatgata tgtggaatgt tactcctaca gacctatggg actggaaggt 120 tctcaaggag aagattgcaa agtatggtat aagaaacagt ttacttattg ccccgatgcc 180 tacagcttcc actgctcaga tcctggggaa taatgagtcc attgaacctt acaccagcaa 240 catctatact cgcagagtct tgtcaggaga atttcagatt gtaaatcctc acttattgaa 300 agatcttacc gagcggggcc tatggcatga agagatgaaa aaccagatta ttgcatgcaa 360 tggctctatt cagagcatac cagaaattcc tgatgacctg aagcaacttt ataaaactgt 420 gtgggaaatc tctcagaaaa ctgttctcaa gatggcag 458 <210> SEQ ID NO 574 <211> LENGTH: 234 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 574 ccgggcaggt aaaaatattt tagatggtaa ccaaaactaa cttacacaaa ctatttttga 60 tgtagaatag aatgctgttc tataataaga agtctgtagc acactggtaa tccatttgga 120 tctacagaat acttgtttgg aacagaatct gataatgaga gaaaactcaa atgaatgtca 180 gtgcagttgc ttcaaaaaaa ttactgctac cacatgtact atcatccccc aagg 234 <210> SEQ ID NO 575 <211> LENGTH: 247 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 575 aaattagcaa tggttaattc taagcaggaa aagatgaact gcgaagaaca gtaagaatca 60 taaaggaaaa ttttaatttt ttcccccgac tatttgtgga gatgggaaat aattgaaggg 120 gctggagtag gacaatgtga gtaaacagtt tagacgttta cctggggctt gtcttatgct 180 ttgttgctgt caacctaagt agtactcaca gttcaccatc ttttaagtgt ggtatgtaga 240 ggacagg 247 <210> SEQ ID NO 576 <211> LENGTH: 185 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 576 gtgattggca ggatcctggt atccgctaac aggtcaaaat gcagatcttc gtgaaaaccc 60 ttaccggcaa gaccatcacc cttgaggtgg agcccagtga caccatcgaa aatgtgaagg 120 ccaagatcca ggataaggaa ggcattcccc ccgaccagca gaggctcatc tttgcaggca 180 agcag 185 <210> SEQ ID NO 577 <211> LENGTH: 554 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 577 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tcctgacttg ttggcataaa agcagcaacg ttcctgtaga 420 gccaaacaga tacctccctg ttctgcagtg agtaggtcta agcctcttct gttttggagg 480 actacttcgg ctagggaatc tagttggtcc tgtaagtcat taatggtgct agacaaggct 540 tggacgtcgt taat 554 <210> SEQ ID NO 578 <211> LENGTH: 408 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 578 aaaaacaaag tcttcaactt gggtgttgag attggcaaaa ggggaagcaa gggaaaagcc 60 aaggaaagat aaaatattca gaagaaagtc aaagttatct gcaattacat gttagaacag 120 attttgcagg ttaaaaagat gttgcttaaa tatattcata agcctgttgt aagattttca 180 cttatgcagt ttcagaaaat ttagctgctt aacatatgac agaactgtat tttaacaaat 240 gacattaaaa gtcaggagag ctactcagtt aattgataaa gtagaggcaa cgtgggggag 300 ccctccccac gtttattgaa gatttgtggc tcccccagcc ccgtttgcct gcatcaggct 360 aacaacctca ttcctcccat agagcctggc caaatcacag gcggtgtc 408 <210> SEQ ID NO 579 <211> LENGTH: 516 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 579 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcccagtag ggaattgagc 180 tgatccctga ttaacgctgt tactcgtctt aggatccaag gggcaaaaga gaagaacagg 240 atgatagcga ataagggtcc aaggaagggg aggaggtaag ggagaagtcc attgaggccg 300 gtgaggaagg gattgtctgc aagtgccttg cgtctttgtt cgaggtcttc ttgtagattt 360 tttattttat ctcggacaat tcctgacttg ttggcataaa agcagcaacg ttcctgtaga 420 gccaaacaga tacctccctg ttctgcagtg agtaggtcta agcctcttct gttttggagg 480 actacttcgg ctagggaatc tagttggtcc tgtaag 516 <210> SEQ ID NO 580 <211> LENGTH: 172 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 580 ccttactaag gctactgtcg agtctcctga gaggtaagct ggcttgcata gaggttggta 60 ctcgaaaaat cctctcctcc caaaaaggta cctgtaagcc tgaaaattaa ggctcaggag 120 gagcacagcc tctacctccc ctagctggtt aaggtccgcc tcctcttttt tt 172 <210> SEQ ID NO 581 <211> LENGTH: 143 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 581 gacgggactt acgagccggg cttcgtgggt attcgcttct gccaggaatg taacaacatg 60 ctgtacccca aggaagacaa ggagaaccgc attctgctct acgcgtgccg gaactgtgat 120 taccagcagg aggccgacaa cag 143 <210> SEQ ID NO 582 <211> LENGTH: 203 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 582 aaaaagcaag taacaataaa agaaaatgtt tctggtacag gaccagcagt acaaaaaaat 60 agtgtacgag tacctggata atacacccgt tttgcaatag tgcaactttt aagtacatat 120 tgttgactgt ccatagtcca cgcagagtta caactccaca cttcaacaac aacatgctga 180 cagttcctaa agaaaactac ttt 203 <210> SEQ ID NO 583 <211> LENGTH: 238 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 583 ctgcagcccc ttgaacaggt gaaagctgga atagaagctc attcggaagc caaaaccagt 60 ggactcctgt gggctggatt ggcactgctg tccattcagg gtggggcact ggcctggctc 120 acgtggtggg tgtactcctg ggatatcatg gagccagtta cattcttcat cacatttgca 180 aattctatgg tcttttttgc atactttata gtcactcgac aggattatac ttactcag 238 <210> SEQ ID NO 584 <211> LENGTH: 583 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 505, 533, 562 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 584 aaagtggtat tattgacaga agttgacaaa ctcaccaaag atgctcagca tgccttgcga 60 agaaccatgg aaaaatatat gtctacctgc agattgatct tgtgctgcaa ttctacatct 120 aaagtgatcc cacctattcg tagtaggtgc ttggcggttc gtgtgcctgc tcccagcatt 180 gaagatattt gccacgtgtt atctactgtg tgtaagaagg aaggtctgaa tcttccttca 240 caactggctc atagacttgc agagaagtct tgtagaaatc tcagaaaagc cctgcttatg 300 tgtgaagcct gcagagtgca acaatatcct tttactgcag atcaagaaat ccctgagaca 360 gattgggagg tgtatctgag ggagactgca aatgctattg tcagtcagca aactccacaa 420 aggctccttg aagttcgtgg aaggctgtat gagcttctaa ctcattgtat tcctcctgag 480 ataataatga agggccttct ctcanaactg ttacataatt gtgatggaca acntgaaagg 540 ggaggtggca caaatggcag cntactatga gcatcgtcta cag 583 <210> SEQ ID NO 585 <211> LENGTH: 531 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 585 ctgccagggg ggacctagag caacttacta gtttgttgca aaataatgta aacgtcaatg 60 cacaaaatgg atttggaagg actgcgctgc aggttatgaa acttggaaat cccgagattg 120 ccaggagact gctacttaga ggtgctaatt ccgatttgaa agaccgaact ggtttcgctg 180 tcattcatga tgcggccaga gcaggtttcc tggacacttt acagactttg ctggagtttc 240 aagctgatgt taacatcgag gataatgaag ggaacctgcc cttgcacttg gctgccaaag 300 aaggtcacct ccgggtggtg gagttcctgg tgaagcacac ggccagcaat gtggggcatc 360 ggaaccataa gggggacacc gcctgtgatt tggccaggct ctatgggagg aatgaggttg 420 ttagcctgat gcaggcaaac ggggctgggg gagccacaaa tcttcaataa acgtggggag 480 ggctccccca cgttgcctct actttatcaa ttaactgagt agctctcctg a 531 <210> SEQ ID NO 586 <211> LENGTH: 429 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 586 ggtgatgcag atgaaaagct gtttgaagag tcagatgaca aggaagatga agatgcagat 60 ggaaaggaag ttgaagatgc tgacgaaaag ttgttcgaag atgatgattc caatgagaag 120 ttgtttgatg aggaggaaga ttccagtgag aagttgtttg acgattctga tgagaggggg 180 actttgggtg gttttgggag tgttgaagaa gggcccctat ccactggcag cagctttatt 240 ctcagtagcg atgatgatga cgatgatatt taatccctta aacttgcttt ttagggagag 300 tcctccatct acatttgcct gtgcttcagg gtaattacta gtagtgttac atgaacatgt 360 gcatagtggt aggatgccat cagattaaag cattgaagtg tttcattgtt acctgtacct 420 aatggtttt 429 <210> SEQ ID NO 587 <211> LENGTH: 342 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 587 ctcaaattca ccacctcgga ctcctgcgac cgcatcaaag acgaatttca gctactgcaa 60 gctcagtacc acagcctcaa gctcgaatgt gacaagttgg ccagtgagaa gtcagagatg 120 cagcgtcact atgtgatgta ctacgagatg tcctacggct tgaacatcga gatgcacaaa 180 caggctgaga tcgtcaaaag gctgaacggg atttgtgccc aggtcctgcc ctacctctcc 240 caagagcacc agcagcaggt cttgggagcc attgagaggg ccaagcaggt caccgctccc 300 gagctgaact ctatcatccg acagcagctc caagcccacc ag 342 <210> SEQ ID NO 588 <211> LENGTH: 363 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 588 aaaacgtgtt tcaaaaataa gggaacatta aagaacatca aattagtctg aaatatatct 60 cacaatgctg agaggcatac tcttctttat caaattaact gtatgtgtgc tcaagataac 120 atggctttta actaatgaca tttcttgtcc atttcagtaa tttcttggat ccaaaacaaa 180 atctgtgtat ttatttcttt gaaaacatca tttgtcgacc gtcctttcac tgccatggaa 240 tgatttgcct tctcaatcca gtggatttta tggggagctt gcattttctg tgccactttc 300 tccaacaagt tcttttcaca catttcatct gctgagcctg acacaaacag tacaggctct 360 ttt 363 <210> SEQ ID NO 589 <211> LENGTH: 342 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 325, 335 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 589 gtccgagata aaataaaaaa tctacaagaa gacctcgaac aaagacgcaa ggcacttgca 60 gacaatccct tcctcaccgg cctcaatgga cttctccctt acctcctccc cttccttgga 120 cccttattcg ctatcatcct gttcttctct tttgcccctt ggatcctaag acgagtaaca 180 gcgttaatca gggatcagct caattcccta ctgggaaagc ccatacaaat ccactatcac 240 caactagcaa cgcgtgatct agaatatggc agactgtagc cggttcccct cctacgggag 300 cagcataccg ctcgacacta tgctntacga aggtnatgga ca 342 <210> SEQ ID NO 590 <211> LENGTH: 402 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 590 caaggcttgg acgtcgttaa taagttgatg ggaaagtttt gtgtaagatt gaacagccac 60 cccgagtcct gctgtaccgg tagcgactgc tgtagagaca cccaatccta ctagcagggg 120 aatcagtgta acggctcgtt tctgccgccc tgcaatatag tcaaaggtag ggatagggac 180 agggtcatca ccagaaataa tgtctatatc tggcaggagg gcggctaaca cacatgaccc 240 tgtccagttt gcaggcagag cagtaaaggc gaggttgttg ccgcaaacaa aagcttggcc 300 tgggccaggg caaagggcct cactgtggtt ggaactactg gagcagttta caaagttggc 360 aacgccaacc ggaatatcaa agctgttgtt ttgtgcacct tt 402 <210> SEQ ID NO 591 <211> LENGTH: 400 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 591 ctgaaacgtt aactcagagg gtcttttgga gcaagtagtt ttcagaaagc gtctgctctc 60 taggacggta aggatcctct acaagggcac gtgcagatcc aggcgctgga gcgtcaggca 120 tgggcaccat tttcatgctt caactcaaac tccaggtggc agtgagctca acggtccctc 180 attccacaaa acatgacagc aaattcatct tctaaaaaaa gttttgtttt gtttttaccc 240 attcaacagg aaaaaaaatt agacacacac gatgaaattt acaaccagca gcatcatcca 300 tcacactgtc tgtactacca gatcctacac ttaaagctcg gcattattgg tataaaaact 360 taagacggca ttagaattct taagaaaagg tgtaaaattt 400 <210> SEQ ID NO 592 <211> LENGTH: 469 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 592 ctgtcagtag gctgacctaa cgttctagca tgcctcttga gggcctttcc aactgagctc 60 tctggaggag ggtaggaaag tcagggaaat catgcaatcc catttgggga agggaaagca 120 tctcaagatt tgtgaggttc cctgggaaag gtgtttacca caaatgtcac atcaattaaa 180 ggaaagtctg cagagagaga gagaaagcca agatcagggg taaaagagaa aggcaaggta 240 gcaccgggga gcttgggcat gacacagaaa catctctgct tttaccagca gaagagacca 300 agcatcccca gtgaaggggc tggcagtgtg tttggaattc tcatcctgac ccgagcatca 360 ggtggaactc cttcttacct tcagatcttt accttcaact ctctccttaa tgtttcctgt 420 gacatcccag atgtaccccc acccttttcc cctgtctggc accttatag 469 <210> SEQ ID NO 593 <211> LENGTH: 499 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 593 ctgtcagtag gctgacctaa cgttctagca tgcctcttga gggcctttcc aactgagctc 60 tctggaggag ggtaggaaag tcagggaaat catgcaatcc catttgggga agggaaagca 120 tctcaagatt tgtgaggttc cctgggaaag gtgtttacca caaatgtcac atcaattaaa 180 ggaaagtctg cagagagaga gagaaagcca agatcagggg taaaagagaa aggcaaggta 240 gcgccgggga gcttgggcat gacacagaaa catctctgct tttaccagca gaagagacca 300 agcatcccca gtgaaggggc tggcagtgtg tttggaattc tcatcctgac ccgagcatca 360 ggtggaactc cttcttacct tcagatcttt accttcaact ctctccttaa tgtttcctgt 420 gacatcccag atgtaccccc acccttttcc cctgtctggc accttataga aggaaaaaca 480 tctaaggaaa gaagtagct 499 <210> SEQ ID NO 594 <211> LENGTH: 504 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 594 gtgacagtgg aaccctgtta ggttcacaaa tcctagactt tgattatata gcccaggctc 60 aaatttttct cgaatgttac gaacattcaa agcattagga gtcttggttt catttcttaa 120 ttttttttct tctgggtata tttgagactc atcttggatt caaataaatt aataatagtc 180 tcatgaaacc gataaaaatg ggagctccat tgaacatgag agacattgat tcgtagtttc 240 taacatcctc caaatgagga gcccatccct aatttagatg cttctttcaa aggaggctcc 300 tttccttcgt tatccataat atagtcacac cagtcctgaa aaaacatgga acagactcca 360 gatctttata tttcatactc taaagtcgta caagccaatc tgcatttcct ctagtggaaa 420 ctgtatagct ggtcatcttt ccaggaccct tttatcaaga aacaatgcag cttctacatt 480 tgtgctgctt ctacaccaaa acag 504 <210> SEQ ID NO 595 <211> LENGTH: 445 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 595 aaagaagtaa tccatatgtt tgttatggta ttgtttataa agcattcaat aataaaaggc 60 tgatgaaata acatgttcag taggatactg tgcagctact taaaatagca agtgaatatt 120 taatgagcta aaaagctgtt cattattgaa taagtaaaag attatcaaat agttgaatag 180 attcaccaga ataattcata tgctaaactg ttttactggt ttactctggg tgagagataa 240 atcttatagg ggtgggagga atcttcttga ttataaataa gcatgtatga tttctgtgat 300 gggcaaactt tgttttttga aaaggagaga gagaaatcct tgaaaaataa aagtgattat 360 ttgaagcaac cttacatcca tataatgatt tacttttgga acctataaaa gggaatccta 420 ctgtgttgag gaactttaga catga 445 <210> SEQ ID NO 596 <211> LENGTH: 363 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 596 ctggcggcaa gaattcgacc aagggatttg gaagagtttt tctctacagt aggaaaggtt 60 cgagatgtga ggatgatttc tgacagaaat tcaagacgtt ccaaaggaat tgcttatgtg 120 gagttcgtcg atgttagctc agtgcctcta gcaataggat taactggcca acgagtttta 180 ggcgtgccaa tcatagtaca ggcatcacag gcagaaaaaa acagagctgc agcaatggca 240 aacaatttac aaaagggaag tgctggacct atgaggcttt atgtgggctc attacacttc 300 aacataactg aagatatgct tcgtgggatc tttgagcctt ttggaagaat tgaaagtatc 360 cag 363 <210> SEQ ID NO 597 <211> LENGTH: 406 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 597 aaaaatattt cttatagtct cctaacattt gtctctagcc tttgcctttg tacaatcaca 60 gatatcctat ggagatttaa ggatgaaagc cctgagttgt tcttgggttc ttggatctgg 120 actacttgtt atcttatgct tctcacttct ggctaaaact tgcacctctt cttctcttag 180 ctaagcccca aaatgaagat ttccttcaga agtcttgtta gcagaattat ttatcagtca 240 cagagagaaa aatctgctat ttttctaagt aagagtctcg agaagcagag tttttgtctt 300 gtcattgaga ggagtcagca gtcttgttct gtaaaggacc agagatggta aatactgtcc 360 cactcagctc tgctggcgca gtacagcagc agcagcccca gcacag 406 <210> SEQ ID NO 598 <211> LENGTH: 234 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 598 ctggaaacag cctattttgt ggtcactgtc aagtggatgg atattctagc gctcccaaaa 60 aagcactatg gccttatatg cagggaaggc acataccacc aagttcaatg agaaatatta 120 gagctaaccg tactctcttc tctgcgtacg ttcgagtata cgttgcccat atccctccca 180 tattttcttt ttgctgcttt tgctctggaa ctttgctttt agcagggaaa gcag 234 <210> SEQ ID NO 599 <211> LENGTH: 69 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 599 ctgcccagct caatctaaca caaaaaccaa ggtgtccgac ttcttagaca ccacccacag 60 ggacagatc 69 <210> SEQ ID NO 600 <211> LENGTH: 509 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 600 cctcagcaat ggctgtggtg ttgctcagca tgcacacagc tctctgtacc ttggccaggt 60 ctccaccagg caccacagtg ggaggctggt agttgatgcc aaccttgaag ccagtggggc 120 accaatccac aaactggatg ctgcgcttgg ttttgatggt ggcaatggca gcattgacat 180 ctttgggaac cacgtcacca cggtacaaca ggcagcaagc catgtattta ccatggcgag 240 ggtcacattt caccatctgg ttggctggct caaagcaagc attggtgatc tctgctacag 300 aaagctgttc atggtaggct ttctcagcag agatgacagg ggcatatgtg gccagaggga 360 agtggatgcg ggggtagggc accaggttgg tctggaattc tgtcaggtca acattcaggg 420 ctccatcaaa tctcagggaa gcagtgatgg aggacacaat ctggctaata aggcggttaa 480 ggttagtgta ggttgggcgc tcgatatcg 509 <210> SEQ ID NO 601 <211> LENGTH: 294 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 601 ggcggctcgg actgagcagg actttcctta tcccagttga ttgtgcagaa tacactgcct 60 gtcgcttgtc ttctattcac catggcttct tctgatatcc aggtgaaaga actggagaag 120 cgtgcctcag gccaggcttt tgagctgatt ctcagccctc ggtcaaaaga atctgttcca 180 gaattccccc tttcccctcc aaagaagaag gatctttccc tggaggaaat tcagaagaaa 240 ttagaagctg cagaagaaag acgcaagtcc catgaagctg aggtcttgaa gcag 294 <210> SEQ ID NO 602 <211> LENGTH: 406 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 602 gctgctttta tgccaacaag tcaggaattg tccgagataa aataaaaaat ctacaagaag 60 acctcgaaca aagacgcaag gcacttgcag acaatccctt cctcaccggc ctcaatggac 120 ttctccctta cctcctcccc ttccttggac ccttattcgc tatcatcctg ttcttctctt 180 ttgccccttg gatcctaaga cgagtaacag cgttaatcag ggatcagctc aattccctac 240 tgggaaagcc catacaaatc cactatcacc aactagcaac gcgtgatcta gaatatggca 300 gactgtagcc ggttcccctc ctacgggagc agcataccgc tcgacactat gctttacgaa 360 ggtaatggac accgctaggt gcaaggcaag gcactgcaag gagagg 406 <210> SEQ ID NO 603 <211> LENGTH: 528 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 603 cctcgttgag agaaggtctc attcggtgtt ttgggaagag agtcgtgtgg gcccaggtat 60 cgtagcggcg acacgagaga gacgggcggt gtgacagcct tccactacct gcacgagtgt 120 attggtctgt ctgctatcag ctatgccgct gcccgttgcg ctgcagaccc gcttggccaa 180 gagaggcatc ctcaaacatc tggagcctga accagaggaa gagatcattg ccgaggacta 240 tgacgatgat cctgtggact atgaggccac caggttggag ggcctaccac caagctggta 300 caaggtgttc gacccttcct gcgggctccc ttactactgg aatgcagaca cagaccttgt 360 atcctggctc tccccacatg accccaactc cgtggttacc aaatcggcca agaagctcag 420 aagcagtaat gcagatgctg aagaaaagtt ggaccggagc catgacaagt cggacagggg 480 ccatgacaag tcggaccgca gccatgagaa actagacagg ggccacga 528 <210> SEQ ID NO 604 <211> LENGTH: 160 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 604 aaaacaagtt gttaccagtt tcccttaccc ttgaattcgg caaggcccat taattcacaa 60 attccatgat aagatacatg aggttctgta tgcatagtaa atgatttcta gttacaatta 120 aaatacagcc ttgtatatgt ttaagtcaac cttaactttt 160 <210> SEQ ID NO 605 <211> LENGTH: 541 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 605 aaactcacat aggtaggtat ctttatagtt gtagactatg gaatgtcagt gttcagccaa 60 acagtatgat ggaacagtga aagtcaattc agtgatggca acactgaagg aacagttacc 120 ctgctttgcc tcgaaagtgt catcaatttg taattttagt attaactctg taaaagtgtc 180 tgtaggtacg ttttatatta tataaggaca gaccaaaaat caacctatca aagcttcaaa 240 aactttggga aagggtggga ttaagtacaa gcacatttgg cttacagtaa atgaactgat 300 ttttattaac tgcttttgcc catataaaat gctgatattt actggaaacc tagccagctt 360 cacgattatg actaaagtac cagattataa tgccagaata taatgtgcag gcaatcgtgg 420 atgtctctga caaagtgtgt ctcaaaaata atatactttt acattaaaga aatttaatgt 480 ttctctggag ttggggctct tggctttcag agtttggtta atcagtgttg attctagatg 540 a 541 <210> SEQ ID NO 606 <211> LENGTH: 133 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 606 cctccagaca ctccgggcaa tttgggctgt ggtcaggctg cccagggctg cgggcaccaa 60 gtcgggcccc tcagcaggag cctgactcag ttcagcctca ggggcctcct ccaggtcgga 120 gcacaggtcg tcc 133 <210> SEQ ID NO 607 <211> LENGTH: 457 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 438 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 607 aaaaacaaag tcttcaactt gggtgttgag attggcaaaa ggggaagcaa gggaaaagcc 60 aaggaaagat aaaatattca gaagaaagtc aaagttatct gcaattacat gttagaacag 120 attttgcagg ttaaaaagat gttgcttaaa tatattcata agcctgttgt aagattttca 180 cttatgcagt ttcagaaaat ttagctgctt aacatatgac agaactgtat tttaacaaat 240 gacattaaaa gtcaggagag ctactcagtt aattgataaa gtagaggcaa cgtgggggag 300 ccctccccac gtttattgaa gatttgtggc tcccccagcc ccgtttgcct gcatcaggct 360 aacaacctca ttcctcccat agagcctggc caaatcacag gcggtgtccc ccttatggtt 420 ccgatgcccc acattgcngg ccgtgtgctt caccagg 457 <210> SEQ ID NO 608 <211> LENGTH: 434 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 423, 424 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 608 aaaagacaaa aacaagacaa aaataccaca gctcaagata aagagtccta tacagaaatc 60 acaaaaagga cagaccatct aaggaaaaat taaaaagacg acacaaggac aggctgggca 120 gcctgggtca gggctcctgg ctggtgacct gctttgagta ggtttcttgc aggtacttct 180 taaaagctgt ggggtttttc cagagctcgg cagcatgtgt gttcaaggga ctatcaatgt 240 tgggttctcc tagaaggctc tggatggaga gcagaatggt cctgacatca tacagggcag 300 accacttttc cttcaggatg tccaggcata tgttaccctg ggtgtccacg ttggggtgat 360 agcagggcgt gaggaacttc actgtgggcg cattgtaagg gtagccactg gggaactcta 420 gcnnagagct tata 434 <210> SEQ ID NO 609 <211> LENGTH: 508 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 609 ctgtggcttc cccgtggctg cttggtgaca tggattagcg ctacgtgggc tgcagcattt 60 gggatccagg ctacctagag gggcatcggg ccagggaaaa cctcggatta gcaagcaata 120 aaaatatgac ctcactcttc ctcaaaggag cccctggtct tccctgtgtg actcagttct 180 ttccatctgt ttgtcccgct gcaagcctct ttctgcgctg actgtgacat tggaacgtgg 240 ccttcctgtc accccctccg tgccacgcac tgaaggccac ccccacccac ctgggaaact 300 aagaactgga tattttgcct cattcacttg tactgtaaca atgtatataa tttggttggt 360 atttcactat ttaattttta agaagcctat tttactagtg ttttatatga acaaagtact 420 gcagaagtta aacctgtgtt gtattttttc tgagatgttt tgctttaaga gatacttttt 480 gctcagtttt tatatgccag atacagag 508 <210> SEQ ID NO 610 <211> LENGTH: 182 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 610 ccttactaag gctactgtcg agtctcctga gaggtaagct ggcttgcata gaggttggta 60 ctcgaaaaat cctctcctcc caaaaaggta cctgtaaacc tgaaaattaa ggctcaggag 120 gagcacagcc tctacctccc ctagctggtt aaggtccgcc tcctcttttt ttacctgccc 180 gg 182 <210> SEQ ID NO 611 <211> LENGTH: 583 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 473 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 611 aaaaacaaag tcttcaactt gggtgttgag attggcaaaa ggggaagcaa gggaaaagcc 60 aaggaaagat aaaatattca gaagaaagtc aaagttatct gcaattacat gttagaacag 120 attttgcagg ttaaaaagat gttgcttaaa tatattcata aacctgttgt aagattttca 180 cttatgcagt ttcagaaaat ttagctgctt aacatatgac agaactgtat tttaacaaat 240 gacattaaaa gtcaggagag ctactcagtt aattgataaa gtagaggcaa cgtgggggag 300 ccctccccac gtttattgaa gatttgtggc tcccccagcc ccgtttgcct gcatcaggct 360 aacaacctca ttcctcccat agagcctggc caaatcacag gcggtgtccc ccttatggtt 420 ccgatgcccc acattgctgg ccgtgtgctt caccaggaac tccaccaccc ggnggtggcc 480 ttctttggca gccaagtgca agggcaggtt cccttcatta tcctcgatgt taacatcagc 540 ttgaaactcc agcaaagtct gtaaagtgtc caggaaacct gct 583 <210> SEQ ID NO 612 <211> LENGTH: 476 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 612 ctgctcggaa agctctggac agatgcagtg aaggctcctt cctgctaacc acatttcctc 60 gtcctgtgac tgtggagccc atggaccagt tagatgatga agagggactt ccagagaagc 120 tggttataaa aaaccagcaa tttcacaagg aacgagagca gccacccaga tttgcacagc 180 ctggctcctt tgagtatgaa tatgccatgc gctggaaggc actcattgag atggagaagc 240 agcagcagga ccaagtggac cgcaacatca aggaggctcg tgagaagctg gagatggaga 300 tggaagctgc acgccatgag caccaggtca tgctaatgag acaggatttg atgaggcgcc 360 aagaagaact tcggaggatg gaagagctgc acaaccaaga ggtgcaaaaa cgaaagcaac 420 tggagctcag gcaggaggaa gagcgcaggc gccgtgaaga agagatgcgg cggcag 476 <210> SEQ ID NO 613 <211> LENGTH: 116 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 613 aaatgccggg gaaagtattg cacactgtaa tgcacatcct ctggctactg cttcatctgc 60 attgagtgtt gtgctaatat cttttccaaa gaatttggca attctttcct tcacag 116 <210> SEQ ID NO 614 <211> LENGTH: 347 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 614 cttttatgcc aacaagtcag gaattgtccg agataaaata aaaaatctac aagaagacct 60 cgaacaaaga cgcaaggcac ttgcagacaa tcccttcctc accggcctca atggacttct 120 cccttacctc ctccccttcc ttggaccctt attcgctatc atcctgttct tctcttttgc 180 cccttggatc ctaagacgag taacagcgtt aatcagggat cagctcaatt ccctactggg 240 aaagcccata caaatccact atcaccaact agcaacgcgt gatctagaat atggcagact 300 gtagccggtt cccctcctac gggggcagca taccgctcga cactatg 347 <210> SEQ ID NO 615 <211> LENGTH: 215 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 615 aaagtttgaa aaccactcat ctagttttat tcccttttta ctcaaataag gacactgagg 60 cacagaaagt gaaggagact tgctcagggt cacacagcga gccggggatt aatatgcaaa 120 tggatctcat gtttccagaa tcccaggcca gtctccttct gctgcatagt acagaaggtg 180 atgccatccc aatattttag acatggaatg gcagg 215 <210> SEQ ID NO 616 <211> LENGTH: 504 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 616 ctggatagac ttatccaaaa cggcaggatg gttctgtatt aatctttttg gaaagcatgt 60 ctgtattaag attgcaaaac atacagatag ctaccacaaa ttaggtcaaa cgactgatca 120 agttgtaaca tctgtgaggt caaattccag ttataataaa gtgcctagat acacatttat 180 acaacagacc ataagagctg aattctttac aaatgtcttt atgggcatgt aaaattgact 240 ctgcatttct gcatgtgtgc attcacataa gagagaccag tctgcactga gtcatatata 300 ctccaacttg aaaaagtaag tgtaacaact ggttaatcat gcaagtctgt ttgtaatata 360 acaatgactg gtaaaacatg aattctcgca cagtagtaat aggtgcactc attaaaaaca 420 ctacggaaaa acactgtatt tggtgcagta tctgattttc aagtgttagt aacttgacca 480 ttaaaaaata gttttgaaca attt 504 <210> SEQ ID NO 617 <211> LENGTH: 408 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 617 aaaaaaagtt aaatttaagg tcacacctct aagtttgatg tactatatac agatcgtgca 60 gaatatgagt taaacagata caaattagtc catgcccaaa aagatatact agggtacaga 120 atcatcttca taaatacata taaaattctt gtgtaggagc gaactgtcca ggttttctga 180 gacacttcta agtgaatcaa ggcacaaaat gtacatacac cattgtgaat acacacattc 240 tagactttgt gcctctgaca tagcccaagg atttagcttc atgactctta taaaactaaa 300 tgtactgaat gagattctgc ttcttgggtg aaaaaccaca ggaactataa acatcatgta 360 gataattact ccaaaatatg gagaatacaa atacgagcac tttatttt 408 <210> SEQ ID NO 618 <211> LENGTH: 216 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 618 cctgcctcat cagcctgggc tacgacgtgg agaacgaccg gcagggtgag gccgagttca 60 accgcatcat gagcctggtc gaccccaacc atagcggcct tgtgaccttc caagccttca 120 tcgacttcat gtcgcgggag accaccgaca cggacacggc tgaccaggtc atcgcttcct 180 tcaaggtctt agcaggggac aagaacttca tcacag 216 <210> SEQ ID NO 619 <211> LENGTH: 227 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 619 ctgctccggg ccttcatcct gaagatcagc gtgtgcgatg ccgtcctgga ccacaacccc 60 ccaggctgta ccttcacagt cctggtgcac acgagagaag ccgccactcg caacatggag 120 aagatccagg tcatcaagga tttcccctgg atcctggcgg atgagcagga tgtccacatg 180 catgaccccc ggctgatacc actaaaaacc atgacgtcgg acatttt 227 <210> SEQ ID NO 620 <211> LENGTH: 182 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 620 aaaaccttca aggtctctcg ctctttctga gtcttttggt tataccaagg ttcatcattg 60 tatggggtac tttgccaaac atactttaga gtagtgcata ctgcagcttt ggtcagtaag 120 ataaataaat atacaatcag gaaagcatta atagatctga aaaataagat agcatggatt 180 tt 182 <210> SEQ ID NO 621 <211> LENGTH: 110 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 621 aaatatgtcc cagtatagaa gcataacttc aattaatttg ttgacactaa cttcttaaaa 60 acttacaaat attcaaaaca aagggaaaaa attttagata gccaagattt 110 <210> SEQ ID NO 622 <211> LENGTH: 399 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 622 aaagataatc tactgaattt tttttgctga taacacttca gagtgatgtt gtcttcaaat 60 gtagatttcc acagggattc aagagtataa cagtccaata tattttatag gtggtatctg 120 acattacgaa taactgcaaa tcattttttt cccctttttt tttcaaaagt cttggaggat 180 gaagaattat gactttcacc accactatag tgttcatata aagttttagc agctttcaaa 240 atggagttag gagaattcag accaacaagt tggcccagaa catatttcat ttcttcagtg 300 gttcccttgg ccatttggtt aactggatga gtttgaattt gaacatatgg atgagccagg 360 agctcaggaa tggatatcct ctgttttggg tcccttttt 399 <210> SEQ ID NO 623 <211> LENGTH: 516 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 623 ctgctataac tgcttggaca cttggcagag gacagagtac tgcaaaagtg tctaagggag 60 acagcatttt gccttgggtg ctgtagatgt acaagagagg ttccaggagg gggtgatagg 120 cagaattttg gtccccatca ccttccctgc ccagtgttat gcctatgaat gtgttacatt 180 atgtggtaaa agggactttg cagatgtaac taaaatttct aaaatagaga tattatcctg 240 gattacctgg gggaacccag tgtaattaca tgaaccctta aaaatggaag aggatgcagg 300 agtcagattc aaaggaaggc ccaaggtgct attgctgact tgaagataga ggggccatgt 360 ggaaatcaag agaaggaagt gaatccttcc agtgagcttg gaagagagca ccttgaggca 420 cagatgagaa gcttggcctt acctgatgcc ttgattttag cctggtgaga ccccgagcat 480 ataaatttgc tgtgctatgc cacacttctc acctac 516 <210> SEQ ID NO 624 <211> LENGTH: 339 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 624 ctgaggttgt cagtacaatg aaaccaaact ggcgggatgg aagcagatta ttctgccatt 60 tttccaggtc tttgagttgc acgtcaaatc tggggctgat caccccacac ttgtttagcc 120 tgcctgtgag gttcacaaca attttcccag ctctgtggtc atcaatgatt tcaaattcgc 180 caatgtaacc atgcttcatc atcacagtga gaaaccggac gatgactttg gagcacggcc 240 taataagcac ctggcgtttg cctctctttt cggcattgtt gatactcttg agagcatctg 300 ccaggacatt catgcgcacc attgtggcgg cgcggaaag 339 <210> SEQ ID NO 625 <211> LENGTH: 513 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 625 cctgggagat gaagatgaaa agagaaaaat ctcagctatt cggtcatata gagatgtcat 60 gaagttgtgt gctgctcatc tccctactga atcagatgca ccaaatcatt atcaggcagt 120 atgtcgtgca ctgtttgcag aaacaatgga gctccataca tttctgacca aaattaagag 180 tgcgaaagag aatcttaaga agattcaaga aatggaaaag agcgatgaat ctagcacaga 240 cttggaagag ctgaaaaacg ctgactgggc acgattctgg gtacaggtga tgagggattt 300 gaggaatggg gtaaaactta agaaggtcca agagcggcag tacaaccctt tgcccattga 360 atatcagctc accccttatg agatgttaat ggatgacatt cgctgcaaaa gatacacctt 420 gcgaaaagtg atggtgaatg gtgatattcc ccctcggtta aaaaagagtg ctcatgaaat 480 tatcctcgac ttcatcagat ccagacctcc ttt 513 <210> SEQ ID NO 626 <211> LENGTH: 102 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 626 aaaaattgca tagatcctaa ttattgcttg tgattttgtt atcccgatca gataattaat 60 acgatctgaa tacagccaca ccaaattcgt ggtgtatttt tt 102 <210> SEQ ID NO 627 <211> LENGTH: 149 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 627 aaatttaact ttgacatcca gctatagaca gaaacaataa gccaccctgg gtgtaaactt 60 gattttcttt attgagatgt atcatgtatt gaatgtgtga atcagaaaat tagaagatgg 120 tcaaaaaaag tccaagttac caatttttt 149 <210> SEQ ID NO 628 <211> LENGTH: 545 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 485 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 628 ctgccagggg ggacctagag caacttacta gtttgttgca aaataatgta aacgtcaatg 60 cacaaaatgg atttggaagg actgcgctgc aggttatgaa acttggaaat cccgagattg 120 ccaggagact gctacttaga ggtgctaatc ccgatttgaa agaccgaact ggtttcgctg 180 tcattcatga tgcggccaga gcaggtttcc tggacacttt acagactttg ctggagtttc 240 aagctgatgt taacatcgag gataatgaag ggaacctgcc cttgcacttg gctgccaaag 300 aaggccacct ccgggtggtg gagttcctgg tgaagcacac ggccagcaat gtggggcatc 360 ggaaccataa gggggacacc gcctgtgatt tggccaggct ctatgggagg aatgaggttg 420 ttagcctgat gcaggcaaac ggggctgggg gagccacaaa tcttcaataa acgtggggag 480 ggctncccca cgttgcctct actttatcaa ttaactgagt agctctcctg acttttaatg 540 tcatt 545 <210> SEQ ID NO 629 <211> LENGTH: 284 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 629 agcctttgag gtcaggattc tggacctcag ggatagatag caagtggctt gcctaattca 60 ggatgagttc agatttgagc ctttgcctgt ctagccctcc ttaaagtagc ccttctcctc 120 ttaggccatg gcccgtgatg agaagaatta ctatcaagat accccaaaac agattcggag 180 taagatcaac gtctataaac gcttttaccc agcagagtgg caagacttcc tcgattcttt 240 gcagaagagg aagatggagg tggagtgact ggtttacatc acag 284 <210> SEQ ID NO 630 <211> LENGTH: 133 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 630 aaattcaaaa acaattctta aaactgcatt tagagtcaag acccttttgt attataaaaa 60 tcacaagtat ttctaagaga caaaaatact tctaggttaa ctagaccaga tctgactttg 120 gactttattc ttt 133 <210> SEQ ID NO 631 <211> LENGTH: 551 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 631 aaaatcttgt tccatgcctc caggtttatc tttgtcttat ctaccagttt attcctgtga 60 acttcagatt gaaccattca ttgcagcagt agccttaaaa aggcttttgt ttatttcttt 120 ggtttgttaa ctagtgtcat ctatttagag aaacattttt gtttttaatt gctcaaagct 180 gtcgccgcta gtcttatgag ctatctacta aaactatgga gaaactttgt atgtgcacac 240 aaaagtattc aagagacagt attgctaaca tctcatctta atgtcttttg ttattgagaa 300 gttttaggtg cttcaaaaca atataaatgg ataatagttg ttatttgggg aattgtaatg 360 atgttggtgc tgcttccttc taagagctca gacaagtaaa gtatgaaaca ttcttatttc 420 agttagatgg ggaacatttt gctagcccat tagaagcaca cagaattatc cttgtcctcc 480 taatattgac tttcaggaat aaagttcagt gtgctgatca ttcacaatac agtggatagc 540 ttgatatctt c 551 <210> SEQ ID NO 632 <211> LENGTH: 185 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 632 aaaaatgaag aagcttttgg gcattgggtg agcacagtgg ggtggggcaa ggaaagtgct 60 cgttcctgaa ttattcatgc ttttggcttt gacttcagtt agtaacatca attctaagag 120 aactgagaca aactcttcta tgttccgcaa aggaatggag aaaaaagcct gccattcgca 180 agtag 185 <210> SEQ ID NO 633 <211> LENGTH: 239 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 633 cgagcgaggc cggccgcgcc atgcacctga tgaagaagcg ggagaagcag cgcgagcaga 60 tggagcagat gaagcagcgc atcgcggagg agaacatcat gaaatccaac attgacaaga 120 agttctctgc gcactacgac gcggtggagg cagagctcaa gtccagcacc gtgggtctcg 180 tgaccctgaa tgacatgaag gccaagcagg aggctctggt gaaggagcgg gagaagcag 239 <210> SEQ ID NO 634 <211> LENGTH: 395 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 634 ctggtaattc ctcctcatca cgtttctctc attttctttt gttttccatt gcaaggggat 60 ggttgttttc tttctgcctt tagtttgctt ttgcccaagg cccttaacat ttggacactt 120 aaaatagggt taattttcag ggaaaaagaa tgttggcgtg tgtaaagtct ctattagcaa 180 tgaagggaat ttgttaacga tgcatccact tgattgatga cttattgcaa atggcggttg 240 gctgaggaaa acccatgaca cagcacaact ctacagacag tgatgtgtct cttgtttcta 300 ctgctaagaa ggtctgaaaa tttaatgaaa ccacttcata catttaagta ttttgtttgg 360 tttgaactca atcagtagct tttccttaca tgttt 395 <210> SEQ ID NO 635 <211> LENGTH: 185 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 635 aaactcagta tggaaaatac atttaataaa ttaaagcaaa aaccaaagat ctgaggagat 60 ccaagagatc aagacaatct gtaaccagag tctgaagtat ccaaggagct actctttttg 120 aggcatattc tcctcagctt ccagttatca tttgataaac acatcagcaa aaggttcagt 180 gtttt 185 <210> SEQ ID NO 636 <211> LENGTH: 164 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 636 cctctccttg cagtgccttg ccttgcacct agcggtgtcc attaccttcg taaagcatag 60 tgtcgagcgg tatgctgctc ccgtaggagg ggaaccggct acagtctgcc atattctaga 120 tcacgcgttg ctagttggtg atagtggatt tgtatgggct ttcc 164 <210> SEQ ID NO 637 <211> LENGTH: 363 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 637 aaaacaccct aggatgtttt gaatcaggct tgattttgtt agttgagtta caggagaatt 60 ttaagggtga gggtatgggg gtcagggaag aaaaggaaat gggaaatgga ccagaaaaaa 120 tcttgagtca tcatctaaat caacaaagca ctgatagctc caaatattag gtcagacact 180 aaaacgactg atataggctc aagtggttta taaaacctat aaaaagacta caccagcaaa 240 gtccctgtca atctgtcaga gttcagaaac taaaacaggg agtaacattt tagcttaaaa 300 ccttatctca agagaatcat atacacttca catgaataaa aatacctgaa accaaacatt 360 ttt 363 <210> SEQ ID NO 638 <211> LENGTH: 303 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 638 cctgggtggc ttttagatct aattcaatct gctgcagaat tgatatggca aatgtggccg 60 ttttcccagt cccagattgg gcttgagcaa tcacatcata acccttgata caaggtagaa 120 tggctcactg ctggatggca gagggcttct caaaaccata ggcgtagatg ccacggagaa 180 gggactccga gaggttcatg tcatcaaagc tgtcaacaat ctcattccag ttactctcga 240 tgacgccttc gggctccatc ccatcggggc cattgtctct ggatcgggaa tcctggctcg 300 cag 303 <210> SEQ ID NO 639 <211> LENGTH: 185 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 639 ttgctactaa gatgtttcag ttcacaaggt gtctcactca agttcctatg aattcagaac 60 aaggcaacta ggcattaccc tagctaggtt tccccattcg gaaatccccg tttcatagca 120 tatttccggc tccacgaggc ttatcgcagg taatcacgtc cttcatcgac tttcagaccc 180 aaggc 185 <210> SEQ ID NO 640 <211> LENGTH: 378 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 640 caggaggcgc ggcgtccgga ggccccaggg ttatgagact atcactgctc aggacctact 60 aacaacaaag gaaatcgaaa catgaccaaa tcgtacagcg agagtgggct gatgggcgag 120 cctcagcccc aaggtcctcc aagctggaca gacgagtgtc tcagttctca ggacgaggag 180 cacgaggcag acaagaagga ggacgacctc gaaaccatga acgcagagga ggactcactg 240 aggaacgggg gagaggagga ggacgaagat gaggacctgg aagaggagga agaagaggaa 300 gaggaggatg acgatcaaaa gcccaagaga cgcggcccca aaaagaagaa gatgactaag 360 gctcgcctgg agcgtttt 378 <210> SEQ ID NO 641 <211> LENGTH: 399 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 641 aaagataatc tactgaattt tttttgctga taacacttca gggtgatgtt gtcttcaaat 60 gtagatttcc acagggattc aagagtataa cagtccaata tattttatag gtggtatctg 120 acattacgaa taactgcaaa tcattttttt cccctttttt tttcaaaagt cttggaggat 180 gaagaattat gactttcacc accactatag tgttcatata aagttttagc agctttcaaa 240 atggagttag gagaattcag accaacaagt tggcccagaa catatttcat ttcttcagtg 300 gttcccttgg ccatttggtt aactggatga gtttgaattt gaacatatgg atgagccagg 360 agctcaggaa tggatatcct ctgttttggg tcccttttt 399 <210> SEQ ID NO 642 <211> LENGTH: 193 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 642 ctggcgcacg gcccagacca tcctggagaa agaggcggaa gatgttatat gggaggactc 60 agcatccgag aatcaggagg gactcaggaa gatcacatcc tacttcctca atgaagggtc 120 ccaagcccgt ccccgttctt cccaccgata tttcctggaa cgcggcctgg agtcagcaac 180 cagcctctag cag 193 <210> SEQ ID NO 643 <211> LENGTH: 440 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 643 aaatgacagt gaaaagcagc cttacatcac taaggcggta aagctgaagg agaagtatga 60 gaaggatgtt gctgactata agtcgaaagg aaagtttgat ggtgcaaagg gtcctgctaa 120 agttgcccgg aaaaaggtgg aagaggaaga tgaagaagag gaggaggaag aagaggagga 180 ggaggaggag gaggatgaat aaagaaactg tttatctgtc tccttgtgaa tacttagagt 240 aggggagcgc cgtaattgac acatctctta tttgagaagt gtctgttgcc ctcattaggt 300 ttaattacaa aatttgatca cgatcatatt gtagtctctc aaagtgctct agaaattgtc 360 agtggtttac atgaagtggc catgggtgtc tggagcaccc tgaaactgta tcaaagttgt 420 acatatttcc aaacattttt 440 <210> SEQ ID NO 644 <211> LENGTH: 382 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 644 cctctatacc cctcaaacca aagagaaacc aacctttgga aagttgagta taaacaaacc 60 gacatctgaa agaaaagtct cgctatttgg caaaagaact agtggacatg gatcccggaa 120 tagtcaactt ggtatatttt ccagttctga gaaaatcaag gacccgagac cacttaatga 180 caaagcattc attcagcagt gtattcgaca actctgtgag tttcttacag aaaatggtta 240 tgcacataat gtgtccatga aatctctaca agctccctct gttaaagact tcctgaagat 300 cttcacattt ctttatggct tcctgtgccc ctcatacgaa cttcctgaca caaagtttga 360 agaagaggtt ccaagaatct tt 382 <210> SEQ ID NO 645 <211> LENGTH: 452 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 645 gggcgctgac ccactgctct tcctcttaag aaagtgctcc attccttccg gcgcccggag 60 ctgctggccc aaagggatcc ggagcgagct agggcagaca ccatgaccac ccttgatgat 120 aagttgctgg gggagaaact gcagtactac tatagcagca gtgaggatga ggacagtgac 180 cacgaggaca aggaccgagg cagatgtgcc ccagccagca gttctgtgcc tgcagaggct 240 gagctggcag gcgaaggcat ctcagttaac acaggcccaa aaggtgtgat caatgactgg 300 cgccgcttca agcagttgga gacagagcag agggaggagc agtgccggga gatggaaagg 360 ctgatcaaga agctgtcaat gacttgcagg tcccatctgg atgaagagga ggagcaacag 420 aaacagaaag acctccagga gaagatcagt gg 452 <210> SEQ ID NO 646 <211> LENGTH: 102 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 646 aaaaaataca ccacgaattt ggtgtggctg tattcagatc gtattaatta tctgatcggg 60 ataacaaaat cacaagcaat aattaggatc tatgcaattt tt 102 <210> SEQ ID NO 647 <211> LENGTH: 186 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 647 aaaattcaga tttaataaac tgatttaaga cagtaaattt gaaagacaaa attaagtctc 60 attcaggagt ggtccattat gttgatcatc tagaatcaac actgattaac caaactctga 120 aagccaagag ccccaactcc agagaaacat taaatttctt taatgtaaaa gtatattatt 180 tttgag 186 <210> SEQ ID NO 648 <211> LENGTH: 247 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 648 aaagcagatc caggcaataa aatctaaatt ttcctctaac tttggatccc agaaacacta 60 attagaccta cacttgaggt ttccctgttg gcgtgacctg agcaaaactg tacagaattt 120 tgggagaggc catttggcaa gccattggtc tgaataattt ggagggggaa atcctaaggt 180 ggtggagttg ctgcgtggac acggctatgg gttggtgtga catgatttcg cattaattgt 240 ttgtcag 247 <210> SEQ ID NO 649 <211> LENGTH: 174 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 649 aaaaaagatg ccaagttttt taatctaatc attatattat tggtgtattt tgggcaacat 60 agggtgagtt ataaaaagat ccgctactga tagtgaaaat taccggtttg taaaacatta 120 agagaaaaaa taggatattt tatacatgtg gtgagtggag aacagggtaa cttt 174 <210> SEQ ID NO 650 <211> LENGTH: 216 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 650 cctgcctcat cagcctgggc tacgacgtgg agaacgaccg gcagggtgag gccgagttca 60 accgcatcat gagcctggtc gaccccaacc atagcggcct tgtgaccttc caagccttca 120 tcgacttcat gtcgcgggag accaccgaca cggacacggc tgaccaggtc atcgcttcct 180 tcaaggtctt agcaggggac aagaacttca tcacag 216 <210> SEQ ID NO 651 <211> LENGTH: 242 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 234 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 651 aggtctgaaa caactgctgc tgaaggccct gactctgatg ttggatgcag cagagagtta 60 tgccaaggac tcctgtgtgc gacaggccca gcactgtcag cggctcacca agttgataac 120 tctgcagatt cactttctga acactggcca gaacacaatg ctcatcaact tgggccgcca 180 caagctgatg gactgtattc tggccctacc tcggttctac caggcttcta ttgnggctga 240 gg 242 <210> SEQ ID NO 652 <211> LENGTH: 353 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 652 ctggtccagg agcaggagct agcaaaacat gcagatgtgg ccgggacggc tggaggtgct 60 gaggtggcac ctgtggcaca ggttgccctg tgtttagaaa cagtgtcagt tcctgctggc 120 caagaaaacc ctgccatgtc acctgccgtg agccagccct gcacacccag ggcaagtgct 180 ggccatgtag cagtatcatc tcctacacct gaaacagggc cattgcagag gttgctgccc 240 aaagccaggc ccatgtccct gagcaccatt gcaatcctga attctgtcaa gaaagccgtg 300 gagtcaaaga gcaggcatcg gagtcggagc ttaggagtgc tgcctttcac ttt 353 <210> SEQ ID NO 653 <211> LENGTH: 174 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 653 aaaaaagatg ccaagttttt taatctaatc attatattat tggtgtattt tgggcaacat 60 agggtgagtt ataaaaagat ccgctactga tagtgaaaat taccggtttg taaaacatta 120 agagaaaaaa taggatattt tatacatgtg gtgagtggag aacagggtaa cttt 174 <210> SEQ ID NO 654 <211> LENGTH: 172 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 654 aaaaaaagag gaggcggacc ttaaccagct aggggaggta gaggctgtgc tcctcctgag 60 ccttaatttt caggcttaca ggtacctttt tgggaggaga ggatttttcg agtaccaacc 120 tctatgcaag ccagcttacc tctcaggaga ctcgacagta gccttagtaa gg 172 <210> SEQ ID NO 655 <211> LENGTH: 135 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 655 cggacctgga gcttccgcgc ggtggcttca ctctcctgta aaacgctaga gcggcgagtt 60 gttacctgcg tcctctgacc tgagagcgaa ggggaaagcg gcgagatgac tgaccgctac 120 accatccata gccag 135 <210> SEQ ID NO 656 <211> LENGTH: 379 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 656 aaaaatcaca tagcactcag taggtacatg tatacatgta catttcagaa gacaacaaat 60 aaaattactc tcagaaagct gcaaagatgg acacatataa tctaagaatg tggtaatggc 120 cagagggagt acccaagaga ccatatttta ttatgcttaa ggctactact ttccacaata 180 cctctgcagt taagactctt aacttacaat cacagaaatg aaaacatgat aatacactgc 240 tttatacaga catacagata ctgggatata gtataatttc ttatggctta aaaaaattta 300 atttgctttt ggagtctata ttgctaaact taactttcca caaaatacaa tatatcatga 360 aagcaaagta ttatttttt 379 <210> SEQ ID NO 657 <211> LENGTH: 112 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 657 cctgcggact gaatctgggt taaaagccct ggggggaatt gggcctgttt gtcattgttc 60 tgataagggc tggcgcccag gaatttttta agggtccatc ctttggagga gg 112 <210> SEQ ID NO 658 <211> LENGTH: 486 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 211, 212 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 658 aaacaaattg cagagaatag agaaaaaata ggttatttac agaaaacaat atctacatat 60 gtacttagag gtacaaattt ggtgacagaa aagacttcag tatatgctgg catcttagaa 120 gcagttctca aagagcttag ttttattttc ttgaatttta agaatgccta agatccttct 180 tcatccccga tcttgggagc caagtagtat nntaagtgtc ccatatccgc aattttatac 240 tctacaacaa ggggtacatc tgcagacata ctgagtgtca ccgttgaaga gagtggagtg 300 gcttttgtaa agaagttcag gtacctcagt gcaaaagtta gttgaactgg ttcattcatc 360 tctatggtaa cagcttcctc ctctttatcg acattacttg tctgtgacaa tttaatgttt 420 ccatttccaa gttctccact tgcagaaaat ttcactccgt cttttgcaca ggaaattaca 480 acagca 486 <210> SEQ ID NO 659 <211> LENGTH: 315 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 659 ctgcactgat acatttggga gttggtggct tgactttgtc cataaggggc gtggccactt 60 cacatgatgg cgggccttta agagcacaaa gaagtttaat atggacaaca acaggaaaaa 120 gcaagaagaa aacaagtagg gaaaaacagc taacctggag agaaagaatt tctttaacct 180 ttatgttctt cattaaaaat cttatcttgg actgatttga gggattttta gaaacatggc 240 cttattttat ataagcatta ccttcccagg aatctttgtt gtatattaat ttttgataac 300 catttgatta acttt 315 <210> SEQ ID NO 660 <211> LENGTH: 302 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 660 cctattttta ctggggatag gaataggatg atcttcaact gttaaaacat ttcaggttac 60 cccactcagg actccctatg aaacaaaacc cgaaaaatga acactaacta taaccctttc 120 actcccaggt tctcactctt tccagtgcct ggagatcctc agacttacta agtcttcact 180 taggatggta gtgtggacca acactgcagc aacacagttt atccaaaagg tcaaacataa 240 atagaatatt ttatacattc agaaaattac tcatgcaagg aaaagcgctc tgaaattact 300 tt 302 <210> SEQ ID NO 661 <211> LENGTH: 4348 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 661 gggaggccca gggagaacgg ggaagggaca tttagtttga gacggtgctg agataggatc 60 atgaaggaag aggtgaaggg aattcctgta agagtggcgc tgcgttgtcg ccctctggtc 120 cccaaagaga ttagcgaggg ctgccagatg tgcctttcct tcgtgcccgg agagcctcag 180 gtggtggttg gtacagataa atccttcacc tacgattttg tatttgatcc ctctactgaa 240 caggaagaag tcttcaatac agcagtagcg ccactcataa aaggtgtatt taaaggatat 300 aatgcaacgg tcctggccta tgggcagact ggctctggaa aaacctattc aatgggaggt 360 gcatatactg cagagcaaga gaatgaacca acagttgggg ttattcctag ggtaatacaa 420 ctgctcttca aagaaattga taaaaagagt gactttgaat ttactctgaa agtgtcttac 480 ttagagattt acaatgaaga aattttggat cttctatgtc catctcgtga gaaagctcaa 540 ataaatatac gagaggatcc taaggaaggc ataaagattg tgggactcac tgagaagact 600 gttttggttg ccttggatac tgtttcctgt ttggaacagg gcaacaactc taggactgtg 660 gcctccacgg ctatgaactc ccagtcgtcc cgatctcatg ccatctttac aatctcctta 720 gagcaaggaa agaaaagtga caagaatagc agctttcgct ccaagctgca tcttgtagac 780 ctcgctggat cagaaagaca gaagaaaacc aaggctgaag gggatcgtct aaaagagggt 840 attaatatta accgaggcct cctatgcttg ggaaatgtaa tcagtgctct tggagatgac 900 aaaaagggtg gctttgcgcc ctacagagat tccaagttga ctcgactgct tcaagattct 960 ctaggaggta atagccatac tcttatgata gcctgtgtga gtcctgctga ctccaatcta 1020 gaggaaacat taaataccct tcgctatgct gacagagcaa gaaaaatcaa gaacaaacct 1080 attgttaata ttgatcccca gacagctgaa cttaatcatc taaagcaaca ggtacaacag 1140 ctacaagtct tgttgctaca ggcccatgga ggtaccctgc ctggatctat aactgtggaa 1200 ccatcagaga atctacaatc cctgatggag aagaatcagt ccctggtaga ggagaatgaa 1260 aaattaagtc gtggtctgag cgaggcagct ggtcagacag cccagatgtt ggagaggatc 1320 atttggacag agcaagcgaa tgaaaaaatg aacgccaagc tagaagagct caggcagcat 1380 gcggcctgca aactggatct tcaaaagcta gtggagactt tggaagacca ggaattgaaa 1440 gaaaatgtag agataatttg taacctgcag caattgatta cccagttatc ggatgaaact 1500 gttgcttgca tggctgcagc cattgatact gcggtggagc aagaagccca agtagaaacc 1560 agtccagaga cgagcaggtc ttctgacgct tttaccactc agcatgctct ccgtcaagcg 1620 cagatgtcta aggagctggt tgagttgaat aaagcgcttg cactgaaaga ggccctggct 1680 aggaagatga ctcagaatga cagccaactg cagcctattc agtaccaata ccaggataac 1740 ataaaagagc cagaattaga agtcatcaat ctgcaaaagg aaaaggaaga attggttctt 1800 gaacttcaga cagcaaagaa ggatgccaac caagccaagt tgagtgagcg ccgccgcaaa 1860 cgtctccagg agctggaggg tcaaattgct gatctgaaga agaaactgaa tgagcagtcc 1920 aaacttctga aactaaagga atccacagag cgtactgtct ccaaactgaa ccaggagata 1980 cggatgatga aaaaccagcg ggtacagtta atgcgtcaaa tgaaagaaga tgctgagaag 2040 tttagacagt ggaagcagaa aagagacaaa gaagtaatac agttaaaaga acgagaccgt 2100 aagaggcaat atgagctgct gaaacttgaa agaaacttcc agaaacaatc caatgtgctc 2160 agacgtaaaa cggaggaggc agcagctgcc aacaagcgtc tcaaggatgc tctccagaaa 2220 caacgggagg ttgcagataa gcggaaagag actcagagcc gtggaatgga aggcactgca 2280 gctcgagtga agaattggct tggaaacgaa attgaggtta tggtcagtac tgaggaagcc 2340 aaacgccatc tgaatgacct ccttgaagat agaaagatcc tggctcaaga tgtggctcaa 2400 ctcaaagaaa aaaaggaatc tggggagaat ccacctccta aactccggag gcgtacattc 2460 tcccttactg aagtgcgtgg tcaagtttcg gagtcagaag attctattac aaagcagatt 2520 gaaagcctag agactgaaat ggaattcagg agtgctcaga ttgctgacct acagcagaag 2580 ctgctggatg cagaaagtga agacagacca aaacaacgct gggagaatat tgccaccatt 2640 ctggaagcca agtgtgccct gaaatatttg attggagagc tggtctcctc caaaatacag 2700 gtcagcaaac ttgaaagcag cctgaaacag agcaagacca gctgtgctga catgcagaag 2760 atgctgtttg aggaacgaaa tcattttgcc gagatagaga cagagttaca agctgagctg 2820 gtcagaatgg agcaacagca ccaagagaag gtgctgtacc ttctcagcca gctgcagcaa 2880 agccaaatgg cagagaagca gttagaggaa tcagtcagtg aaaaggaaca gcagctgctg 2940 agcacactga agtgtcagga tgaagaactt gagaaaatgc gagaagtgtg tgagcaaaat 3000 cagcagcttc tccgagagaa tgaaatcatc aagcagaaac tgaccctcct ccaggtagcc 3060 agcagacaga aacatcttcc taaggatacc cttctatctc cagactcttc ttttgaatat 3120 gtccagccta agccaaaacc ttctcgtgtt aaagaaaagt tcctggagca aagcatggac 3180 atcgaggatc taaaatattg ttcagagcat tctgtgaatg agcatgagga tggtgatggt 3240 gatgatgatg agggggatga cgaggaatgg aagccaacaa aattagttaa tgtgtccagg 3300 aagaacatcc aagggtgttc ctgcaagggc tggtgtggaa acaagcaatg tgggtgcagg 3360 aagcaaaagt cagactgtgg tgtggactgt tgctgtgacc ccacaaagtg tcggaaccgc 3420 cagcaaggca aggatagctt gggcactgtt gaacggaccc aggattcaga aagctccttc 3480 aaactggagg atcctaccga ggtgacccca ggattgagct tctttaatcc cgtctgtgcc 3540 acccccaata gcaagatcct gaaagagatg tgcgatgtgg agcaggtgct gtcaaagaag 3600 actcccccag ctccctcccc ttttgacctc ccagagttga aacatgtagc aacagaatac 3660 caagaaaaca aggctccagg gaagaaaaag aaacgggctc tggccagcaa caccagcttc 3720 ttctctggct gctcccctat cgaagaagag gcccactgaa gttggagtca tcatctctac 3780 ccccagtctg gcttgggaga tgctttcagg ttgcagccag aaggggtttt ttaaatgact 3840 tctctggatt tcaggtttct tgctgttgaa aaaaggaaca aagcgttact gaaaagaagg 3900 taacctttgt tggatgtggg ccttagcctc caggtccaga ctactactct atgttctcca 3960 gaagggtgct aagtcaccta ctgaagagag aaccaactga ctttcctatt gactcatcag 4020 gaaccagtcc tcagtctggt caagttgttt cttatttgtg agcagttcag gctatctcct 4080 gatggggatg aggccaaggc tttcttatct tttggttgtc tctgcttaat ggaggagcct 4140 ggcctaggat ggaggcctgg cttagatctt tcattccacc tcaggaatga ggttgtgatc 4200 tttcctgtcc tgaccctctc tgaattatgt ttcaatagta ctcttgattg tctgccatgt 4260 tgttgaagca aatgaattat ttttaaatgt taagtaagta aataaacctt agcccgtctt 4320 tttttttttt tttttttttt tttttttt 4348 <210> SEQ ID NO 662 <211> LENGTH: 1425 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 662 cgcggagcga ggtggccgca gcgtctccgc gcgcggccca agcccggcag gagtgcggaa 60 ccgccgcctc ggccatgcgg ctcccggccg gggggcctgg gctggggccc gcgccgcccc 120 ccgcgctccg cccccgctga gcctgagccc gacccggggc gcctcccgcc aggcaccatg 180 gtgcagaagt cgcgcaacgg cggcgtatac cccggcccga gcggggagaa gaagctgaag 240 gtgggcttcg tggggctgga ccccggcgcg cccgactcca cccgggacgg ggcgctgctg 300 atcgccggct ccgaggcccc caagcgcggc agcatcctca gcaaacctcg cgcgggcggc 360 gcgggcgccg ggaagccccc caagcgcaac gccttctacc gcaagctgca gaatttcctc 420 tacaacgtgc tggagcggcc gcgcggctgg gcgttcatct accacgccta cgtgttcctc 480 ctggttttct cctgcctcgt gctgtctgtg ttttccacca tcaaggagta tgagaagagc 540 tcggaggggg ccctctacat cctggaaatc gtgactatcg tggtgtttgg cgtggagtac 600 ttcgtgcgga tctgggccgc aggctgctgc tgccggtacc gtggctggag ggggcggctc 660 aagtttgccc ggaaaccgtt ctgtgtgatt gacatcatgg tgctcatcgc ctccattgcg 720 gtgctggccg ccggctccca gggcaacgtc tttgccacat ctgcgctccg gagcctgcgc 780 ttcctgcaga ttctgcggat gatccgcatg gaccggcggg gaggcacctg gaagctgctg 840 ggctctgtgg tctatgccca cagcaaggag ctggtcactg cctggtacat cggcttcctt 900 tgtctcatcc tggcctcgtt cctggtgtac ttggcagaga agggggagaa cgaccacttt 960 gacacctacg cggatgcact ctggtggggc ctgatcacgc tgaccaccat tggctacggg 1020 gacaagtacc cccagacctg gaacggcagg ctccttgcgg caaccttcac cctcatcggt 1080 gtctccttct tcgcgctgcc tgcaggcatc ttggggtctg ggtttgccct gaaggttcag 1140 gagcagcaca ggcagaagca ctttgagaag aggcggaacc cggcagcagg cctgatccag 1200 tcggcctgga gattctacgc caccaacctc tcgcgcacag acctgcactc cacgtggcag 1260 tactacgagc gaacggtcac cgtgcccatg tacaggtacc gccgccgggc acctgccacc 1320 aagcaactgt ttcatttttt attttccatt tgttcttaaa ccccactttt tgttgttcat 1380 tattttgatt gatttttttt ctttaaaatg tatttttcac aaagg 1425 <210> SEQ ID NO 663 <211> LENGTH: 3866 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 663 ggaattcctt tttttttttt tttgagatgg agtttcactc ttgttggcca ggctggagtg 60 caatggcaca atctcagctt actgcaacct ccgcctcccg ggttcaagcg attctcctgc 120 ctcagcctct caagtagctg ggattacagg catgtgccac cacccctggc taactaattt 180 cttttctatt tagtagagat ggggtttcac catgttggtc aggctggtct tgaactcctg 240 acctcaggtg atccacttgc cttggcctcc caaagtgcta ggattacagc cgtgaaactg 300 tgcctggctg attctttttt tgttgttgga tttttgaaac agggtctccc ttggtcgccc 360 aggctggagt gcagtggtgc gatcttggct cactataacc tccacctcct ggtttcaagt 420 gatcctccca ctttagcctc ctgagtagct gtgattacag gcgtgcacca ccacacccgg 480 ctaatttttg tatttttatt agagacaggg tttcaccatg ttggccaggc tgttctcaaa 540 ctcctggact caagggatcc gcctgcctcc acttcccaaa gtcccgagat tacaggtgtg 600 agtcaccatg cctgacctta taattcttaa gtcatttttt ctggtccatt tcttccttag 660 ggtcctcaca acaaatctgc attaggcggt acaataatcc ttaacttcat gattcacaaa 720 aggaagatga agtgattcat gatttagaaa ggggaagtag taagcccact gcacactcct 780 ggatgatgat cctaaatcca gatacagtaa aaatggggta tgggaaggta gaatacaaaa 840 tttggtttaa attaattatc taaatatcta aaaacatttt tggatacatt gttgatgtga 900 atgtaagact gtacagactt cctagaaaac agtttgggtt ccatcttttc atttccccag 960 tgcagttttc tgtagaaatg gaatccgagg atttaagtgg cagagaattg acaattgatt 1020 ccataatgaa caaagtgaga gacattaaaa ataagtttaa aaatgaagac cttactgatg 1080 aactaagctt gaataaaatt tctgctgata ctacagataa ctcgggaact gttaaccaaa 1140 ttatgatgat ggcaaacaac ccagaggact ggttgagttt gttgctcaaa ctagagaaaa 1200 acagtgttcc gctaagtgat gctcttttaa ataaattgat tggtcgttac agtcaagcaa 1260 ttgaagcgct tcccccagat aaatatggcc aaaatgagag ttttgctaga attcaagtga 1320 gatttgctga attaaaagct attcaagagc cagatgatgc acgtgactac tttcaaatgg 1380 ccagagcaaa ctgcaagaaa tttgcttttg ttcatatatc ttttgcacaa tttgaactgt 1440 cacaaggtaa tgtcaaaaaa agtaaacaac ttcttcaaaa agctgtagaa cgtggagcag 1500 taccactaga aatgctggaa attgccctgc ggaatttaaa cctccaaaaa aagcagctgc 1560 tttcagagga ggaaaagaag aatttatcag catctacggt attaactgcc caagaatcat 1620 tttccggttc acttgggcat ttacagaata ggaacaacag ttgtgattcc agaggacaga 1680 ctactaaagc caggttttta tatggagaga acatgccacc acaagatgca gaaataggtt 1740 accggaattc attgagacaa actaacaaaa ctaaacagtc atgcccattt ggaagagtcc 1800 cagttaacct tctaaatagc ccagattgtg atgtgaagac agatgattca gttgtacctt 1860 gttttatgaa aagacaaacc tctagatcag aatgccgaga tttggttgtg cctggatcta 1920 aaccaagtgg aaatgattcc tgtgaattaa gaaatttaaa gtctgttcaa aatagtcatt 1980 tcaaggaacc tctggtgtca gatgaaaaga gttctgaact tattattact gattcaataa 2040 ccctgaagaa taaaacggaa tcaagtcttc tagctaaatt agaagaaact aaagagtatc 2100 aagaaccaga ggttccagag agtaaccaga aacagtggca agctaagaga aagtcagagt 2160 gtattaacca gaatcctgct gcatcttcaa atcactggca gattccggag ttagcccgaa 2220 aagttaatac agagcagaaa cataccactt ttgagcaacc tgtcttttca gtttcaaaac 2280 agtcaccacc aatatcaaca tctaaatggt ttgacccaaa atctatttgt aagacaccaa 2340 gcagcaatac cttggatgat tacatgagct gttttagaac tccagttgta aagaatgact 2400 ttccacctgc ttgtcagttg tcaacacctt atggccaacc tgcctgtttc cagcagcaac 2460 agcatcaaat acttgccact ccacttcaaa atttacaggt tttagcatct tcttcagcaa 2520 atgaatgcat ttcggttaaa ggaagaattt attccatatt aaagcagata ggaagtggag 2580 gttcaagcaa ggtatttcag gtgttaaatg aaaagaaaca gatatatgct ataaaatatg 2640 tgaacttaga agaagcagat aaccaaactc ttgatagtta ccggaacgaa atagcttatt 2700 tgaataaact acaacaacac agtgataaga tcatccgact ttatgattat gaaatcacgg 2760 accagtacat ctacatggta atggagtgtg gaaatattga tcttaatagt tggcttaaaa 2820 agaaaaaatc cattgatcca tgggaacgca agagttactg gaaaaatatg ttagaggcag 2880 ttcacacaat ccatcaacat ggcattgttc acagtgatct taaaccagct aactttctga 2940 tagttgatgg aatgctaaag ctaattgatt ttgggattgc aaaccaaatg caaccagata 3000 caacaagtgt tgttaaagat tctcaggttg gcacagttaa ttatatgcca ccagaagcaa 3060 tcaaagatat gtcttcctcc agagagaatg ggaaatctaa gtcaaagata agccccaaaa 3120 gtgatgtttg gtccttagga tgtattttgt actatatgac ttacgggaaa acaccatttc 3180 agcagataat taatcagatt tctaaattac atgccataat tgatcctaat catgaaattg 3240 aatttcccga tattccagag aaagatcttc aagatgtgtt aaagtgttgt ttaaaaaggg 3300 acccaaaaca gaggatatcc attcctgagc tcctggctca tccatatgtt caaattcaaa 3360 ctcatccagt taaccaaatg gccaagggaa ccactgaaga aatgaaatat gttctgggcc 3420 aacttgttgg tctgaattct cctaactcca ttttgaaagc tgctaaaact ttatatgaac 3480 actatagtgg tggtgaaagt cataattctt catcctccaa gacttttgaa aaaaaaaggg 3540 gaaaaaaatg atttgcagtt attcgtaatg tcagatagga ggtataaaat atattggact 3600 gttatactct tgaatccctg tggaaatcta catttgaaga caacatcact ctgaagtgtt 3660 atcagcaaaa aaaattcagt gagattatct ttaaaagaaa actgtaaaaa tagcaaccac 3720 ttatggcact gtatatattg tagacttgtt ttctctgttt tatgctcttg tgtaatctac 3780 ttgacatcat tttactcttg gaatagtggg tggatagcaa gtatattcta aaaaactttg 3840 taaataaagt tttgtggcta aaatga 3866 <210> SEQ ID NO 664 <211> LENGTH: 1232 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 664 Met Lys Glu Glu Val Lys Gly Ile Pro Val Arg Val Ala Leu Arg Cys 1 5 10 15 Arg Pro Leu Val Pro Lys Glu Ile Ser Glu Gly Cys Gln Met Cys Leu 20 25 30 Ser Phe Val Pro Gly Glu Pro Gln Val Val Val Gly Thr Asp Lys Ser 35 40 45 Phe Thr Tyr Asp Phe Val Phe Asp Pro Ser Thr Glu Gln Glu Glu Val 50 55 60 Phe Asn Thr Ala Val Ala Pro Leu Ile Lys Gly Val Phe Lys Gly Tyr 65 70 75 80 Asn Ala Thr Val Leu Ala Tyr Gly Gln Thr Gly Ser Gly Lys Thr Tyr 85 90 95 Ser Met Gly Gly Ala Tyr Thr Ala Glu Gln Glu Asn Glu Pro Thr Val 100 105 110 Gly Val Ile Pro Arg Val Ile Gln Leu Leu Phe Lys Glu Ile Asp Lys 115 120 125 Lys Ser Asp Phe Glu Phe Thr Leu Lys Val Ser Tyr Leu Glu Ile Tyr 130 135 140 Asn Glu Glu Ile Leu Asp Leu Leu Cys Pro Ser Arg Glu Lys Ala Gln 145 150 155 160 Ile Asn Ile Arg Glu Asp Pro Lys Glu Gly Ile Lys Ile Val Gly Leu 165 170 175 Thr Glu Lys Thr Val Leu Val Ala Leu Asp Thr Val Ser Cys Leu Glu 180 185 190 Gln Gly Asn Asn Ser Arg Thr Val Ala Ser Thr Ala Met Asn Ser Gln 195 200 205 Ser Ser Arg Ser His Ala Ile Phe Thr Ile Ser Leu Glu Gln Gly Lys 210 215 220 Lys Ser Asp Lys Asn Ser Ser Phe Arg Ser Lys Leu His Leu Val Asp 225 230 235 240 Leu Ala Gly Ser Glu Arg Gln Lys Lys Thr Lys Ala Glu Gly Asp Arg 245 250 255 Leu Lys Glu Gly Ile Asn Ile Asn Arg Gly Leu Leu Cys Leu Gly Asn 260 265 270 Val Ile Ser Ala Leu Gly Asp Asp Lys Lys Gly Gly Phe Ala Pro Tyr 275 280 285 Arg Asp Ser Lys Leu Thr Arg Leu Leu Gln Asp Ser Leu Gly Gly Asn 290 295 300 Ser His Thr Leu Met Ile Ala Cys Val Ser Pro Ala Asp Ser Asn Leu 305 310 315 320 Glu Glu Thr Leu Asn Thr Leu Arg Tyr Ala Asp Arg Ala Arg Lys Ile 325 330 335 Lys Asn Lys Pro Ile Val Asn Ile Asp Pro Gln Thr Ala Glu Leu Asn 340 345 350 His Leu Lys Gln Gln Val Gln Gln Leu Gln Val Leu Leu Leu Gln Ala 355 360 365 His Gly Gly Thr Leu Pro Gly Ser Ile Thr Val Glu Pro Ser Glu Asn 370 375 380 Leu Gln Ser Leu Met Glu Lys Asn Gln Ser Leu Val Glu Glu Asn Glu 385 390 395 400 Lys Leu Ser Arg Gly Leu Ser Glu Ala Ala Gly Gln Thr Ala Gln Met 405 410 415 Leu Glu Arg Ile Ile Trp Thr Glu Gln Ala Asn Glu Lys Met Asn Ala 420 425 430 Lys Leu Glu Glu Leu Arg Gln His Ala Ala Cys Lys Leu Asp Leu Gln 435 440 445 Lys Leu Val Glu Thr Leu Glu Asp Gln Glu Leu Lys Glu Asn Val Glu 450 455 460 Ile Ile Cys Asn Leu Gln Gln Leu Ile Thr Gln Leu Ser Asp Glu Thr 465 470 475 480 Val Ala Cys Met Ala Ala Ala Ile Asp Thr Ala Val Glu Gln Glu Ala 485 490 495 Gln Val Glu Thr Ser Pro Glu Thr Ser Arg Ser Ser Asp Ala Phe Thr 500 505 510 Thr Gln His Ala Leu Arg Gln Ala Gln Met Ser Lys Glu Leu Val Glu 515 520 525 Leu Asn Lys Ala Leu Ala Leu Lys Glu Ala Leu Ala Arg Lys Met Thr 530 535 540 Gln Asn Asp Ser Gln Leu Gln Pro Ile Gln Tyr Gln Tyr Gln Asp Asn 545 550 555 560 Ile Lys Glu Pro Glu Leu Glu Val Ile Asn Leu Gln Lys Glu Lys Glu 565 570 575 Glu Leu Val Leu Glu Leu Gln Thr Ala Lys Lys Asp Ala Asn Gln Ala 580 585 590 Lys Leu Ser Glu Arg Arg Arg Lys Arg Leu Gln Glu Leu Glu Gly Gln 595 600 605 Ile Ala Asp Leu Lys Lys Lys Leu Asn Glu Gln Ser Lys Leu Leu Lys 610 615 620 Leu Lys Glu Ser Thr Glu Arg Thr Val Ser Lys Leu Asn Gln Glu Ile 625 630 635 640 Arg Met Met Lys Asn Gln Arg Val Gln Leu Met Arg Gln Met Lys Glu 645 650 655 Asp Ala Glu Lys Phe Arg Gln Trp Lys Gln Lys Arg Asp Lys Glu Val 660 665 670 Ile Gln Leu Lys Glu Arg Asp Arg Lys Arg Gln Tyr Glu Leu Leu Lys 675 680 685 Leu Glu Arg Asn Phe Gln Lys Gln Ser Asn Val Leu Arg Arg Lys Thr 690 695 700 Glu Glu Ala Ala Ala Ala Asn Lys Arg Leu Lys Asp Ala Leu Gln Lys 705 710 715 720 Gln Arg Glu Val Ala Asp Lys Arg Lys Glu Thr Gln Ser Arg Gly Met 725 730 735 Glu Gly Thr Ala Ala Arg Val Lys Asn Trp Leu Gly Asn Glu Ile Glu 740 745 750 Val Met Val Ser Thr Glu Glu Ala Lys Arg His Leu Asn Asp Leu Leu 755 760 765 Glu Asp Arg Lys Ile Leu Ala Gln Asp Val Ala Gln Leu Lys Glu Lys 770 775 780 Lys Glu Ser Gly Glu Asn Pro Pro Pro Lys Leu Arg Arg Arg Thr Phe 785 790 795 800 Ser Leu Thr Glu Val Arg Gly Gln Val Ser Glu Ser Glu Asp Ser Ile 805 810 815 Thr Lys Gln Ile Glu Ser Leu Glu Thr Glu Met Glu Phe Arg Ser Ala 820 825 830 Gln Ile Ala Asp Leu Gln Gln Lys Leu Leu Asp Ala Glu Ser Glu Asp 835 840 845 Arg Pro Lys Gln Arg Trp Glu Asn Ile Ala Thr Ile Leu Glu Ala Lys 850 855 860 Cys Ala Leu Lys Tyr Leu Ile Gly Glu Leu Val Ser Ser Lys Ile Gln 865 870 875 880 Val Ser Lys Leu Glu Ser Ser Leu Lys Gln Ser Lys Thr Ser Cys Ala 885 890 895 Asp Met Gln Lys Met Leu Phe Glu Glu Arg Asn His Phe Ala Glu Ile 900 905 910 Glu Thr Glu Leu Gln Ala Glu Leu Val Arg Met Glu Gln Gln His Gln 915 920 925 Glu Lys Val Leu Tyr Leu Leu Ser Gln Leu Gln Gln Ser Gln Met Ala 930 935 940 Glu Lys Gln Leu Glu Glu Ser Val Ser Glu Lys Glu Gln Gln Leu Leu 945 950 955 960 Ser Thr Leu Lys Cys Gln Asp Glu Glu Leu Glu Lys Met Arg Glu Val 965 970 975 Cys Glu Gln Asn Gln Gln Leu Leu Arg Glu Asn Glu Ile Ile Lys Gln 980 985 990 Lys Leu Thr Leu Leu Gln Val Ala Ser Arg Gln Lys His Leu Pro Lys 995 1000 1005 Asp Thr Leu Leu Ser Pro Asp Ser Ser Phe Glu Tyr Val Gln Pro Lys 1010 1015 1020 Pro Lys Pro Ser Arg Val Lys Glu Lys Phe Leu Glu Gln Ser Met Asp 1025 1030 1035 1040 Ile Glu Asp Leu Lys Tyr Cys Ser Glu His Ser Val Asn Glu His Glu 1045 1050 1055 Asp Gly Asp Gly Asp Asp Asp Glu Gly Asp Asp Glu Glu Trp Lys Pro 1060 1065 1070 Thr Lys Leu Val Asn Val Ser Arg Lys Asn Ile Gln Gly Cys Ser Cys 1075 1080 1085 Lys Gly Trp Cys Gly Asn Lys Gln Cys Gly Cys Arg Lys Gln Lys Ser 1090 1095 1100 Asp Cys Gly Val Asp Cys Cys Cys Asp Pro Thr Lys Cys Arg Asn Arg 1105 1110 1115 1120 Gln Gln Gly Lys Asp Ser Leu Gly Thr Val Glu Arg Thr Gln Asp Ser 1125 1130 1135 Glu Ser Ser Phe Lys Leu Glu Asp Pro Thr Glu Val Thr Pro Gly Leu 1140 1145 1150 Ser Phe Phe Asn Pro Val Cys Ala Thr Pro Asn Ser Lys Ile Leu Lys 1155 1160 1165 Glu Met Cys Asp Val Glu Gln Val Leu Ser Lys Lys Thr Pro Pro Ala 1170 1175 1180 Pro Ser Pro Phe Asp Leu Pro Glu Leu Lys His Val Ala Thr Glu Tyr 1185 1190 1195 1200 Gln Glu Asn Lys Ala Pro Gly Lys Lys Lys Lys Arg Ala Leu Ala Ser 1205 1210 1215 Asn Thr Ser Phe Phe Ser Gly Cys Ser Pro Ile Glu Glu Glu Ala His 1220 1225 1230 <210> SEQ ID NO 665 <211> LENGTH: 393 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 665 Met Val Gln Lys Ser Arg Asn Gly Gly Val Tyr Pro Gly Pro Ser Gly 5 10 15 Glu Lys Lys Leu Lys Val Gly Phe Val Gly Leu Asp Pro Gly Ala Pro 20 25 30 Asp Ser Thr Arg Asp Gly Ala Leu Leu Ile Ala Gly Ser Glu Ala Pro 35 40 45 Lys Arg Gly Ser Ile Leu Ser Lys Pro Arg Ala Gly Gly Ala Gly Ala 50 55 60 Gly Lys Pro Pro Lys Arg Asn Ala Phe Tyr Arg Lys Leu Gln Asn Phe 65 70 75 80 Leu Tyr Asn Val Leu Glu Arg Pro Arg Gly Trp Ala Phe Ile Tyr His 85 90 95 Ala Tyr Val Phe Leu Leu Val Phe Ser Cys Leu Val Leu Ser Val Phe 100 105 110 Ser Thr Ile Lys Glu Tyr Glu Lys Ser Ser Glu Gly Ala Leu Tyr Ile 115 120 125 Leu Glu Ile Val Thr Ile Val Val Phe Gly Val Glu Tyr Phe Val Arg 130 135 140 Ile Trp Ala Ala Gly Cys Cys Cys Arg Tyr Arg Gly Trp Arg Gly Arg 145 150 155 160 Leu Lys Phe Ala Arg Lys Pro Phe Cys Val Ile Asp Ile Met Val Leu 165 170 175 Ile Ala Ser Ile Ala Val Leu Ala Ala Gly Ser Gln Gly Asn Val Phe 180 185 190 Ala Thr Ser Ala Leu Arg Ser Leu Arg Phe Leu Gln Ile Leu Arg Met 195 200 205 Ile Arg Met Asp Arg Arg Gly Gly Thr Trp Lys Leu Leu Gly Ser Val 210 215 220 Val Tyr Ala His Ser Lys Glu Leu Val Thr Ala Trp Tyr Ile Gly Phe 225 230 235 240 Leu Cys Leu Ile Leu Ala Ser Phe Leu Val Tyr Leu Ala Glu Lys Gly 245 250 255 Glu Asn Asp His Phe Asp Thr Tyr Ala Asp Ala Leu Trp Trp Gly Leu 260 265 270 Ile Thr Leu Thr Thr Ile Gly Tyr Gly Asp Lys Tyr Pro Gln Thr Trp 275 280 285 Asn Gly Arg Leu Leu Ala Ala Thr Phe Thr Leu Ile Gly Val Ser Phe 290 295 300 Phe Ala Leu Pro Ala Gly Ile Leu Gly Ser Gly Phe Ala Leu Lys Val 305 310 315 320 Gln Glu Gln His Arg Gln Lys His Phe Glu Lys Arg Arg Asn Pro Ala 325 330 335 Ala Gly Leu Ile Gln Ser Ala Trp Arg Phe Tyr Ala Thr Asn Leu Ser 340 345 350 Arg Thr Asp Leu His Ser Thr Trp Gln Tyr Tyr Glu Arg Thr Val Thr 355 360 365 Val Pro Met Tyr Arg Tyr Arg Arg Arg Ala Pro Ala Thr Lys Gln Leu 370 375 380 Phe His Phe Leu Phe Ser Ile Cys Ser 385 390 <210> SEQ ID NO 666 <211> LENGTH: 841 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 666 Met Asn Lys Val Arg Asp Ile Lys Asn Lys Phe Lys Asn Glu Asp Leu 5 10 15 Thr Asp Glu Leu Ser Leu Asn Lys Ile Ser Ala Asp Thr Thr Asp Asn 20 25 30 Ser Gly Thr Val Asn Gln Ile Met Met Met Ala Asn Asn Pro Glu Asp 35 40 45 Trp Leu Ser Leu Leu Leu Lys Leu Glu Lys Asn Ser Val Pro Leu Ser 50 55 60 Asp Ala Leu Leu Asn Lys Leu Ile Gly Arg Tyr Ser Gln Ala Ile Glu 65 70 75 80 Ala Leu Pro Pro Asp Lys Tyr Gly Gln Asn Glu Ser Phe Ala Arg Ile 85 90 95 Gln Val Arg Phe Ala Glu Leu Lys Ala Ile Gln Glu Pro Asp Asp Ala 100 105 110 Arg Asp Tyr Phe Gln Met Ala Arg Ala Asn Cys Lys Lys Phe Ala Phe 115 120 125 Val His Ile Ser Phe Ala Gln Phe Glu Leu Ser Gln Gly Asn Val Lys 130 135 140 Lys Ser Lys Gln Leu Leu Gln Lys Ala Val Glu Arg Gly Ala Val Pro 145 150 155 160 Leu Glu Met Leu Glu Ile Ala Leu Arg Asn Leu Asn Leu Gln Lys Lys 165 170 175 Gln Leu Leu Ser Glu Glu Glu Lys Lys Asn Leu Ser Ala Ser Thr Val 180 185 190 Leu Thr Ala Gln Glu Ser Phe Ser Gly Ser Leu Gly His Leu Gln Asn 195 200 205 Arg Asn Asn Ser Cys Asp Ser Arg Gly Gln Thr Thr Lys Ala Arg Phe 210 215 220 Leu Tyr Gly Glu Asn Met Pro Pro Gln Asp Ala Glu Ile Gly Tyr Arg 225 230 235 240 Asn Ser Leu Arg Gln Thr Asn Lys Thr Lys Gln Ser Cys Pro Phe Gly 245 250 255 Arg Val Pro Val Asn Leu Leu Asn Ser Pro Asp Cys Asp Val Lys Thr 260 265 270 Asp Asp Ser Val Val Pro Cys Phe Met Lys Arg Gln Thr Ser Arg Ser 275 280 285 Glu Cys Arg Asp Leu Val Val Pro Gly Ser Lys Pro Ser Gly Asn Asp 290 295 300 Ser Cys Glu Leu Arg Asn Leu Lys Ser Val Gln Asn Ser His Phe Lys 305 310 315 320 Glu Pro Leu Val Ser Asp Glu Lys Ser Ser Glu Leu Ile Ile Thr Asp 325 330 335 Ser Ile Thr Leu Lys Asn Lys Thr Glu Ser Ser Leu Leu Ala Lys Leu 340 345 350 Glu Glu Thr Lys Glu Tyr Gln Glu Pro Glu Val Pro Glu Ser Asn Gln 355 360 365 Lys Gln Trp Gln Ala Lys Arg Lys Ser Glu Cys Ile Asn Gln Asn Pro 370 375 380 Ala Ala Ser Ser Asn His Trp Gln Ile Pro Glu Leu Ala Arg Lys Val 385 390 395 400 Asn Thr Glu Gln Lys His Thr Thr Phe Glu Gln Pro Val Phe Ser Val 405 410 415 Ser Lys Gln Ser Pro Pro Ile Ser Thr Ser Lys Trp Phe Asp Pro Lys 420 425 430 Ser Ile Cys Lys Thr Pro Ser Ser Asn Thr Leu Asp Asp Tyr Met Ser 435 440 445 Cys Phe Arg Thr Pro Val Val Lys Asn Asp Phe Pro Pro Ala Cys Gln 450 455 460 Leu Ser Thr Pro Tyr Gly Gln Pro Ala Cys Phe Gln Gln Gln Gln His 465 470 475 480 Gln Ile Leu Ala Thr Pro Leu Gln Asn Leu Gln Val Leu Ala Ser Ser 485 490 495 Ser Ala Asn Glu Cys Ile Ser Val Lys Gly Arg Ile Tyr Ser Ile Leu 500 505 510 Lys Gln Ile Gly Ser Gly Gly Ser Ser Lys Val Phe Gln Val Leu Asn 515 520 525 Glu Lys Lys Gln Ile Tyr Ala Ile Lys Tyr Val Asn Leu Glu Glu Ala 530 535 540 Asp Asn Gln Thr Leu Asp Ser Tyr Arg Asn Glu Ile Ala Tyr Leu Asn 545 550 555 560 Lys Leu Gln Gln His Ser Asp Lys Ile Ile Arg Leu Tyr Asp Tyr Glu 565 570 575 Ile Thr Asp Gln Tyr Ile Tyr Met Val Met Glu Cys Gly Asn Ile Asp 580 585 590 Leu Asn Ser Trp Leu Lys Lys Lys Lys Ser Ile Asp Pro Trp Glu Arg 595 600 605 Lys Ser Tyr Trp Lys Asn Met Leu Glu Ala Val His Thr Ile His Gln 610 615 620 His Gly Ile Val His Ser Asp Leu Lys Pro Ala Asn Phe Leu Ile Val 625 630 635 640 Asp Gly Met Leu Lys Leu Ile Asp Phe Gly Ile Ala Asn Gln Met Gln 645 650 655 Pro Asp Thr Thr Ser Val Val Lys Asp Ser Gln Val Gly Thr Val Asn 660 665 670 Tyr Met Pro Pro Glu Ala Ile Lys Asp Met Ser Ser Ser Arg Glu Asn 675 680 685 Gly Lys Ser Lys Ser Lys Ile Ser Pro Lys Ser Asp Val Trp Ser Leu 690 695 700 Gly Cys Ile Leu Tyr Tyr Met Thr Tyr Gly Lys Thr Pro Phe Gln Gln 705 710 715 720 Ile Ile Asn Gln Ile Ser Lys Leu His Ala Ile Ile Asp Pro Asn His 725 730 735 Glu Ile Glu Phe Pro Asp Ile Pro Glu Lys Asp Leu Gln Asp Val Leu 740 745 750 Lys Cys Cys Leu Lys Arg Asp Pro Lys Gln Arg Ile Ser Ile Pro Glu 755 760 765 Leu Leu Ala His Pro Tyr Val Gln Ile Gln Thr His Pro Val Asn Gln 770 775 780 Met Ala Lys Gly Thr Thr Glu Glu Met Lys Tyr Val Leu Gly Gln Leu 785 790 795 800 Val Gly Leu Asn Ser Pro Asn Ser Ile Leu Lys Ala Ala Lys Thr Leu 805 810 815 Tyr Glu His Tyr Ser Gly Gly Glu Ser His Asn Ser Ser Ser Ser Lys 820 825 830 Thr Phe Glu Lys Lys Arg Gly Lys Lys 835 840 <210> SEQ ID NO 667 <211> LENGTH: 4348 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 667 gggaggccca gggagaacgg ggaagggaca tttagtttga gacggtgctg agataggatc 60 atgaaggaag aggtgaaggg aattcctgta agagtggcgc tgcgttgtcg ccctctggtc 120 cccaaagaga ttagcgaggg ctgccagatg tgcctttcct tcgtgcccgg agagcctcag 180 gtggtggttg gtacagataa atccttcacc tacgattttg tatttgatcc ctctactgaa 240 caggaagaag tcttcaatac agcagtagcg ccactcataa aaggtgtatt taaaggatat 300 aatgcaacgg tcctggccta tgggcagact ggctctggaa aaacctattc aatgggaggt 360 gcatatactg cagagcaaga gaatgaacca acagttgggg ttattcctag ggtaatacaa 420 ctgctcttca aagaaattga taaaaagagt gactttgaat ttactctgaa agtgtcttac 480 ttagagattt acaatgaaga aattttggat cttctatgtc catctcgtga gaaagctcaa 540 ataaatatac gagaggatcc taaggaaggc ataaagattg tgggactcac tgagaagact 600 gttttggttg ccttggatac tgtttcctgt ttggaacagg gcaacaactc taggactgtg 660 gcctccacgg ctatgaactc ccagtcgtcc cgatctcatg ccatctttac aatctcctta 720 gagcaaggaa agaaaagtga caagaatagc agctttcgct ccaagctgca tcttgtagac 780 ctcgctggat cagaaagaca gaagaaaacc aaggctgaag gggatcgtct aaaagagggt 840 attaatatta accgaggcct cctatgcttg ggaaatgtaa tcagtgctct tggagatgac 900 aaaaagggtg gctttgcgcc ctacagagat tccaagttga ctcgactgct tcaagattct 960 ctaggaggta atagccatac tcttatgata gcctgtgtga gtcctgctga ctccaatcta 1020 gaggaaacat taaataccct tcgctatgct gacagagcaa gaaaaatcaa gaacaaacct 1080 attgttaata ttgatcccca gacagctgaa cttaatcatc taaagcaaca ggtacaacag 1140 ctacaagtct tgttgctaca ggcccatgga ggtaccctgc ctggatctat aactgtggaa 1200 ccatcagaga atctacaatc cctgatggag aagaatcagt ccctggtaga ggagaatgaa 1260 aaattaagtc gtggtctgag cgaggcagct ggtcagacag cccagatgtt ggagaggatc 1320 atttggacag agcaagcgaa tgaaaaaatg aacgccaagc tagaagagct caggcagcat 1380 gcggcctgca aactggatct tcaaaagcta gtggagactt tggaagacca ggaattgaaa 1440 gaaaatgtag agataatttg taacctgcag caattgatta cccagttatc ggatgaaact 1500 gttgcttgca tggctgcagc cattgatact gcggtggagc aagaagccca agtagaaacc 1560 agtccagaga cgagcaggtc ttctgacgct tttaccactc agcatgctct ccgtcaagcg 1620 cagatgtcta aggagctggt tgagttgaat aaagcgcttg cactgaaaga ggccctggct 1680 aggaagatga ctcagaatga cagccaactg cagcctattc agtaccaata ccaggataac 1740 ataaaagagc cagaattaga agtcatcaat ctgcaaaagg aaaaggaaga attggttctt 1800 gaacttcaga cagcaaagaa ggatgccaac caagccaagt tgagtgagcg ccgccgcaaa 1860 cgtctccagg agctggaggg tcaaattgct gatctgaaga agaaactgaa tgagcagtcc 1920 aaacttctga aactaaagga atccacagag cgtactgtct ccaaactgaa ccaggagata 1980 cggatgatga aaaaccagcg ggtacagtta atgcgtcaaa tgaaagaaga tgctgagaag 2040 tttagacagt ggaagcagaa aagagacaaa gaagtaatac agttaaaaga acgagaccgt 2100 aagaggcaat atgagctgct gaaacttgaa agaaacttcc agaaacaatc caatgtgctc 2160 agacgtaaaa cggaggaggc agcagctgcc aacaagcgtc tcaaggatgc tctccagaaa 2220 caacgggagg ttgcagataa gcggaaagag actcagagcc gtggaatgga aggcactgca 2280 gctcgagtga agaattggct tggaaacgaa attgaggtta tggtcagtac tgaggaagcc 2340 aaacgccatc tgaatgacct ccttgaagat agaaagatcc tggctcaaga tgtggctcaa 2400 ctcaaagaaa aaaaggaatc tggggagaat ccacctccta aactccggag gcgtacattc 2460 tcccttactg aagtgcgtgg tcaagtttcg gagtcagaag attctattac aaagcagatt 2520 gaaagcctag agactgaaat ggaattcagg agtgctcaga ttgctgacct acagcagaag 2580 ctgctggatg cagaaagtga agacagacca aaacaacgct gggagaatat tgccaccatt 2640 ctggaagcca agtgtgccct gaaatatttg attggagagc tggtctcctc caaaatacag 2700 gtcagcaaac ttgaaagcag cctgaaacag agcaagacca gctgtgctga catgcagaag 2760 atgctgtttg aggaacgaaa tcattttgcc gagatagaga cagagttaca agctgagctg 2820 gtcagaatgg agcaacagca ccaagagaag gtgctgtacc ttctcagcca gctgcagcaa 2880 agccaaatgg cagagaagca gttagaggaa tcagtcagtg aaaaggaaca gcagctgctg 2940 agcacactga agtgtcagga tgaagaactt gagaaaatgc gagaagtgtg tgagcaaaat 3000 cagcagcttc tccgagagaa tgaaatcatc aagcagaaac tgaccctcct ccaggtagcc 3060 agcagacaga aacatcttcc taaggatacc cttctatctc cagactcttc ttttgaatat 3120 gtccagccta agccaaaacc ttctcgtgtt aaagaaaagt tcctggagca aagcatggac 3180 atcgaggatc taaaatattg ttcagagcat tctgtgaatg agcatgagga tggtgatggt 3240 gatgatgatg agggggatga cgaggaatgg aagccaacaa aattagttaa tgtgtccagg 3300 aagaacatcc aagggtgttc ctgcaagggc tggtgtggaa acaagcaatg tgggtgcagg 3360 aagcaaaagt cagactgtgg tgtggactgt tgctgtgacc ccacaaagtg tcggaaccgc 3420 cagcaaggca aggatagctt gggcactgtt gaacggaccc aggattcaga aagctccttc 3480 aaactggagg atcctaccga ggtgacccca ggattgagct tctttaatcc cgtctgtgcc 3540 acccccaata gcaagatcct gaaagagatg tgcgatgtgg agcaggtgct gtcaaagaag 3600 actcccccag ctccctcccc ttttgacctc ccagagttga aacatgtagc aacagaatac 3660 caagaaaaca aggctccagg gaagaaaaag aaacgggctc tggccagcaa caccagcttc 3720 ttctctggct gctcccctat cgaagaagag gcccactgaa gttggagtca tcatctctac 3780 ccccagtctg gcttgggaga tgctttcagg ttgcagccag aaggggtttt ttaaatgact 3840 tctctggatt tcaggtttct tgctgttgaa aaaaggaaca aagcgttact gaaaagaagg 3900 taacctttgt tggatgtggg ccttagcctc caggtccaga ctactactct atgttctcca 3960 gaagggtgct aagtcaccta ctgaagagag aaccaactga ctttcctatt gactcatcag 4020 gaaccagtcc tcagtctggt caagttgttt cttatttgtg agcagttcag gctatctcct 4080 gatggggatg aggccaaggc tttcttatct tttggttgtc tctgcttaat ggaggagcct 4140 ggcctaggat ggaggcctgg cttagatctt tcattccacc tcaggaatga ggttgtgatc 4200 tttcctgtcc tgaccctctc tgaattatgt ttcaatagta ctcttgattg tctgccatgt 4260 tgttgaagca aatgaattat ttttaaatgt taagtaagta aataaacctt agcccgtctt 4320 tttttttttt tttttttttt tttttttt 4348 <210> SEQ ID NO 668 <211> LENGTH: 3753 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 668 tgtttgagac ggtgctgaga taggatcatg aaggaagagg tgaagggaat tcctgtaaga 60 gtggcgctgc gttgtcgccc tctggtcccc aaagagatta gcgagggctg ccagatgtgc 120 ctttccttcg tgcccggaga gcctcaggtg gtggttggta cagataaatc cttcacctac 180 gattttgtat ttgatccctc tactgaacag gaagaagtct tcaatacagc agtagcgcca 240 ctcataaaag gtgtatttaa aggatataat gcaacggtcc tggcctatgg gcagactggc 300 tctggaaaaa cctattcaat gggaggtgca tatactgcag agcaagagaa tgaaccaaca 360 gttggggtta ttcctagggt aatacaactg ctcttcaaag aaattgataa aaagagtgac 420 tttgaattta ctctgaaagt gtcttactta gagatttaca atgaagaaat tttggatctt 480 ctatgcccat ctcgtgagaa agctcaaata aatatacgag aggatcctaa ggaaggcata 540 aagattgtgg gactcactga gaagactgtt ttggttgcct tggatactgt ttcctgtttg 600 gaacagggca acaactctag gactgtggcc tccacggcta tgaactccca gtcgtcccga 660 tctcatgcca tctttacaat ctccttagag caaagaaaga aaagtgacaa gaatagcagc 720 tttcgctcca agctgcatct tgtagacctc gctggatcag aaagacagaa gaaaaccaag 780 gctgaagggg atcgtctaaa agagggtatt aatattaacc gaggcctcct atgcttggga 840 aatgtaatca gtgctcttgg agatgacaaa aagggtggct ttgtgcccta cagagattcc 900 aagttgactc gactgcttca agattctcta ggaggtaata gccatactct tatgatagcc 960 tgtgtgagtc ctgctgactc caatctagag gaaacattaa atacccttcg ctatgctgac 1020 agagcaagaa aaatcaagaa caaacctatt gttaatattg atccccagac agctgaactt 1080 aatcatctaa agcaacaggt acaacagcta caagtcttgt tgctacaggc ccatggaggt 1140 accctgcctg gatctataac tgtggaacca tcagagaatc tacaatccct gatggagaag 1200 aatcagtccc tggtagagga gaatgaaaaa ttaagtcgtg gtctgagcga ggcagctggt 1260 cagacagccc agatgttgga gaggatcatt ttgacagagc aagcgaatga aaaaatgaac 1320 gccaagctag aagagctcag gcagcatgcg gcctgcaaac tggatcttca aaagctagtg 1380 gagactttgg aagaccagga attgaaagaa aatgtagaga taatttgtaa cctgcagcaa 1440 ttgattaccc agttatcgga tgaaactgtt gcttgcatgg ctgcagccat tgatactgcg 1500 gtggagcaag aagcccaagt agaaaccagt ccagagacga gcaggtcttc tgacgctttt 1560 accactcagc atgctctccg tcaagcgcag atgtctaagg agctggttga gttgaataaa 1620 gcgcttgcac tgaaagaggc cctggctagg aagatgactc agaatgacag ccaactgcag 1680 cccattcagt accaatacca ggataacata aaagagctag aattagaagt catcaatctg 1740 caaaaggaaa aggaagaatt ggttcttgaa cttcagacag caaagaagga tgccaaccaa 1800 gccaagttga gtgagcgccg ccgcaaacgt ctccaggagc tggagggtca aattgctgat 1860 ctgaagaaga aactgaatga gcagtccaaa cttctgaaac taaaggaatc cacagagcgt 1920 actgtctcca aactgaacca ggagatacgg atgatgaaaa accagcgggt acagttaatg 1980 cgtcaaatga aagaagatgc tgagaagttt agacagtgga agcagaaaaa agacaaagaa 2040 gtaatacagt taaaagaacg agaccgtaag aggcaatatg agctgctgaa acttgaaaga 2100 aacttccaga aacaatccaa tgtgctcaga cgtaaaacgg aggaggcagc agctgccaac 2160 aagcgtctca aggatgctct ccagaaacaa cgggaggttg cagataagcg gaaagagact 2220 cagagccgtg gaatggaagg cactgcagct cgagtgaaga attggcttgg aaacgaaatt 2280 gaggttatgg tcagtactga ggaagccaaa cgccatctga atgacctcct tgaagataga 2340 aagatcctgg ctcaagatgt ggctcaactc aaagaaaaaa aggaatctgg ggagaatcca 2400 cctcctaaac tccggaggcg tacattctcc cttactgaag tgcgtggtca agtttcggag 2460 tcagaagatt ctattacaaa gcagattgaa agcctagaga ctgaaatgga attcaggagt 2520 gctcagattg ctgacctaca gcagaagctg ctggatgcag aaagtgaaga cagaccaaaa 2580 caacgctggg agaatattgc caccattctg gaagccaagt gtgccctgaa atatttgatt 2640 ggagagctgg tctcctccaa aatacaggtc agcaaacttg aaagcagcct gaaacagagc 2700 aagaccagct gtgctgacat gcagaagatg ctgtttgagg aacgaaatca ttttgccgag 2760 atagagacag agttacaagc tgagctggtc agaatggagc aacagcacca agagaaggtg 2820 ctgtaccttc tcagccagct gcagcaaagc caaatggcag agaagcagtt agaggaatca 2880 gtcagtgaaa aggaacagca gctgctgagc acactgaagt gtcaggatga agaacttgag 2940 aaaatgcgag aagtgtgtga gcaaaatcag cagcttctcc gagagaatga aatcatcaag 3000 cagaaactga ccctcctcca ggtagccagc agacagaaac atcttcctaa ggataccctt 3060 ctatctccag actcttcttt tgaatatgtc ccacctaagc caaaaccttc tcgtgttaaa 3120 gaaaagttcc tggagcaaag catggacatc gaggatctaa aatattgttc agagcattct 3180 gtgaatgagc atgaggatgg tgatggtgat gatgatgagg gggatgacga ggaatggaag 3240 ccaacaaaat tagttaaggt gtccaggaag aacatccaag ggtattcctg caagggctgg 3300 tgtggaaaca agcagtgtgg gtgcaggaag caaaagtcag actgtggtgt ggactgttgc 3360 tgtgacccca caaagtgtcg gaaccgccag caaggcaagg atagcttggg cactgttgaa 3420 cggacccagg attccgaagg ctccttcaaa ctggaggatc ctaccgaggt gaccccagga 3480 ttgagcttct ttaatcccgt ctgtgccacc cccaatagca agatcctgaa agagatgtgc 3540 gatgtggagc aggtgctgtc aaagaagact cccccagctc cctccccttt tgacctccca 3600 gagttgaaac atgtagcaac agaataccaa gaaaacaagg ctccagggaa gaaaaagaaa 3660 cgggctctgg ccagcaacac cagcttcttc tctggctgct cccctatcga agaagaggcc 3720 cactgaagtt ggagtcatca tctctacccc cag 3753 <210> SEQ ID NO 669 <211> LENGTH: 1232 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 669 Met Lys Glu Glu Val Lys Gly Ile Pro Val Arg Val Ala Leu Arg Cys 5 10 15 Arg Pro Leu Val Pro Lys Glu Ile Ser Glu Gly Cys Gln Met Cys Leu 20 25 30 Ser Phe Val Pro Gly Glu Pro Gln Val Val Val Gly Thr Asp Lys Ser 35 40 45 Phe Thr Tyr Asp Phe Val Phe Asp Pro Ser Thr Glu Gln Glu Glu Val 50 55 60 Phe Asn Thr Ala Val Ala Pro Leu Ile Lys Gly Val Phe Lys Gly Tyr 65 70 75 80 Asn Ala Thr Val Leu Ala Tyr Gly Gln Thr Gly Ser Gly Lys Thr Tyr 85 90 95 Ser Met Gly Gly Ala Tyr Thr Ala Glu Gln Glu Asn Glu Pro Thr Val 100 105 110 Gly Val Ile Pro Arg Val Ile Gln Leu Leu Phe Lys Glu Ile Asp Lys 115 120 125 Lys Ser Asp Phe Glu Phe Thr Leu Lys Val Ser Tyr Leu Glu Ile Tyr 130 135 140 Asn Glu Glu Ile Leu Asp Leu Leu Cys Pro Ser Arg Glu Lys Ala Gln 145 150 155 160 Ile Asn Ile Arg Glu Asp Pro Lys Glu Gly Ile Lys Ile Val Gly Leu 165 170 175 Thr Glu Lys Thr Val Leu Val Ala Leu Asp Thr Val Ser Cys Leu Glu 180 185 190 Gln Gly Asn Asn Ser Arg Thr Val Ala Ser Thr Ala Met Asn Ser Gln 195 200 205 Ser Ser Arg Ser His Ala Ile Phe Thr Ile Ser Leu Glu Gln Gly Lys 210 215 220 Lys Ser Asp Lys Asn Ser Ser Phe Arg Ser Lys Leu His Leu Val Asp 225 230 235 240 Leu Ala Gly Ser Glu Arg Gln Lys Lys Thr Lys Ala Glu Gly Asp Arg 245 250 255 Leu Lys Glu Gly Ile Asn Ile Asn Arg Gly Leu Leu Cys Leu Gly Asn 260 265 270 Val Ile Ser Ala Leu Gly Asp Asp Lys Lys Gly Gly Phe Ala Pro Tyr 275 280 285 Arg Asp Ser Lys Leu Thr Arg Leu Leu Gln Asp Ser Leu Gly Gly Asn 290 295 300 Ser His Thr Leu Met Ile Ala Cys Val Ser Pro Ala Asp Ser Asn Leu 305 310 315 320 Glu Glu Thr Leu Asn Thr Leu Arg Tyr Ala Asp Arg Ala Arg Lys Ile 325 330 335 Lys Asn Lys Pro Ile Val Asn Ile Asp Pro Gln Thr Ala Glu Leu Asn 340 345 350 His Leu Lys Gln Gln Val Gln Gln Leu Gln Val Leu Leu Leu Gln Ala 355 360 365 His Gly Gly Thr Leu Pro Gly Ser Ile Thr Val Glu Pro Ser Glu Asn 370 375 380 Leu Gln Ser Leu Met Glu Lys Asn Gln Ser Leu Val Glu Glu Asn Glu 385 390 395 400 Lys Leu Ser Arg Gly Leu Ser Glu Ala Ala Gly Gln Thr Ala Gln Met 405 410 415 Leu Glu Arg Ile Ile Trp Thr Glu Gln Ala Asn Glu Lys Met Asn Ala 420 425 430 Lys Leu Glu Glu Leu Arg Gln His Ala Ala Cys Lys Leu Asp Leu Gln 435 440 445 Lys Leu Val Glu Thr Leu Glu Asp Gln Glu Leu Lys Glu Asn Val Glu 450 455 460 Ile Ile Cys Asn Leu Gln Gln Leu Ile Thr Gln Leu Ser Asp Glu Thr 465 470 475 480 Val Ala Cys Met Ala Ala Ala Ile Asp Thr Ala Val Glu Gln Glu Ala 485 490 495 Gln Val Glu Thr Ser Pro Glu Thr Ser Arg Ser Ser Asp Ala Phe Thr 500 505 510 Thr Gln His Ala Leu Arg Gln Ala Gln Met Ser Lys Glu Leu Val Glu 515 520 525 Leu Asn Lys Ala Leu Ala Leu Lys Glu Ala Leu Ala Arg Lys Met Thr 530 535 540 Gln Asn Asp Ser Gln Leu Gln Pro Ile Gln Tyr Gln Tyr Gln Asp Asn 545 550 555 560 Ile Lys Glu Pro Glu Leu Glu Val Ile Asn Leu Gln Lys Glu Lys Glu 565 570 575 Glu Leu Val Leu Glu Leu Gln Thr Ala Lys Lys Asp Ala Asn Gln Ala 580 585 590 Lys Leu Ser Glu Arg Arg Arg Lys Arg Leu Gln Glu Leu Glu Gly Gln 595 600 605 Ile Ala Asp Leu Lys Lys Lys Leu Asn Glu Gln Ser Lys Leu Leu Lys 610 615 620 Leu Lys Glu Ser Thr Glu Arg Thr Val Ser Lys Leu Asn Gln Glu Ile 625 630 635 640 Arg Met Met Lys Asn Gln Arg Val Gln Leu Met Arg Gln Met Lys Glu 645 650 655 Asp Ala Glu Lys Phe Arg Gln Trp Lys Gln Lys Arg Asp Lys Glu Val 660 665 670 Ile Gln Leu Lys Glu Arg Asp Arg Lys Arg Gln Tyr Glu Leu Leu Lys 675 680 685 Leu Glu Arg Asn Phe Gln Lys Gln Ser Asn Val Leu Arg Arg Lys Thr 690 695 700 Glu Glu Ala Ala Ala Ala Asn Lys Arg Leu Lys Asp Ala Leu Gln Lys 705 710 715 720 Gln Arg Glu Val Ala Asp Lys Arg Lys Glu Thr Gln Ser Arg Gly Met 725 730 735 Glu Gly Thr Ala Ala Arg Val Lys Asn Trp Leu Gly Asn Glu Ile Glu 740 745 750 Val Met Val Ser Thr Glu Glu Ala Lys Arg His Leu Asn Asp Leu Leu 755 760 765 Glu Asp Arg Lys Ile Leu Ala Gln Asp Val Ala Gln Leu Lys Glu Lys 770 775 780 Lys Glu Ser Gly Glu Asn Pro Pro Pro Lys Leu Arg Arg Arg Thr Phe 785 790 795 800 Ser Leu Thr Glu Val Arg Gly Gln Val Ser Glu Ser Glu Asp Ser Ile 805 810 815 Thr Lys Gln Ile Glu Ser Leu Glu Thr Glu Met Glu Phe Arg Ser Ala 820 825 830 Gln Ile Ala Asp Leu Gln Gln Lys Leu Leu Asp Ala Glu Ser Glu Asp 835 840 845 Arg Pro Lys Gln Arg Trp Glu Asn Ile Ala Thr Ile Leu Glu Ala Lys 850 855 860 Cys Ala Leu Lys Tyr Leu Ile Gly Glu Leu Val Ser Ser Lys Ile Gln 865 870 875 880 Val Ser Lys Leu Glu Ser Ser Leu Lys Gln Ser Lys Thr Ser Cys Ala 885 890 895 Asp Met Gln Lys Met Leu Phe Glu Glu Arg Asn His Phe Ala Glu Ile 900 905 910 Glu Thr Glu Leu Gln Ala Glu Leu Val Arg Met Glu Gln Gln His Gln 915 920 925 Glu Lys Val Leu Tyr Leu Leu Ser Gln Leu Gln Gln Ser Gln Met Ala 930 935 940 Glu Lys Gln Leu Glu Glu Ser Val Ser Glu Lys Glu Gln Gln Leu Leu 945 950 955 960 Ser Thr Leu Lys Cys Gln Asp Glu Glu Leu Glu Lys Met Arg Glu Val 965 970 975 Cys Glu Gln Asn Gln Gln Leu Leu Arg Glu Asn Glu Ile Ile Lys Gln 980 985 990 Lys Leu Thr Leu Leu Gln Val Ala Ser Arg Gln Lys His Leu Pro Lys 995 1000 1005 Asp Thr Leu Leu Ser Pro Asp Ser Ser Phe Glu Tyr Val Gln Pro Lys 1010 1015 1020 Pro Lys Pro Ser Arg Val Lys Glu Lys Phe Leu Glu Gln Ser Met Asp 1025 1030 1035 1040 Ile Glu Asp Leu Lys Tyr Cys Ser Glu His Ser Val Asn Glu His Glu 1045 1050 1055 Asp Gly Asp Gly Asp Asp Asp Glu Gly Asp Asp Glu Glu Trp Lys Pro 1060 1065 1070 Thr Lys Leu Val Asn Val Ser Arg Lys Asn Ile Gln Gly Cys Ser Cys 1075 1080 1085 Lys Gly Trp Cys Gly Asn Lys Gln Cys Gly Cys Arg Lys Gln Lys Ser 1090 1095 1100 Asp Cys Gly Val Asp Cys Cys Cys Asp Pro Thr Lys Cys Arg Asn Arg 1105 1110 1115 1120 Gln Gln Gly Lys Asp Ser Leu Gly Thr Val Glu Arg Thr Gln Asp Ser 1125 1130 1135 Glu Ser Ser Phe Lys Leu Glu Asp Pro Thr Glu Val Thr Pro Gly Leu 1140 1145 1150 Ser Phe Phe Asn Pro Val Cys Ala Thr Pro Asn Ser Lys Ile Leu Lys 1155 1160 1165 Glu Met Cys Asp Val Glu Gln Val Leu Ser Lys Lys Thr Pro Pro Ala 1170 1175 1180 Pro Ser Pro Phe Asp Leu Pro Glu Leu Lys His Val Ala Thr Glu Tyr 1185 1190 1195 1200 Gln Glu Asn Lys Ala Pro Gly Lys Lys Lys Lys Arg Ala Leu Ala Ser 1205 1210 1215 Asn Thr Ser Phe Phe Ser Gly Cys Ser Pro Ile Glu Glu Glu Ala His 1220 1225 1230 <210> SEQ ID NO 670 <211> LENGTH: 1232 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 670 Met Lys Glu Glu Val Lys Gly Ile Pro Val Arg Val Ala Leu Arg Cys 5 10 15 Arg Pro Leu Val Pro Lys Glu Ile Ser Glu Gly Cys Gln Met Cys Leu 20 25 30 Ser Phe Val Pro Gly Glu Pro Gln Val Val Val Gly Thr Asp Lys Ser 35 40 45 Phe Thr Tyr Asp Phe Val Phe Asp Pro Ser Thr Glu Gln Glu Glu Val 50 55 60 Phe Asn Thr Ala Val Ala Pro Leu Ile Lys Gly Val Phe Lys Gly Tyr 65 70 75 80 Asn Ala Thr Val Leu Ala Tyr Gly Gln Thr Gly Ser Gly Lys Thr Tyr 85 90 95 Ser Met Gly Gly Ala Tyr Thr Ala Glu Gln Glu Asn Glu Pro Thr Val 100 105 110 Gly Val Ile Pro Arg Val Ile Gln Leu Leu Phe Lys Glu Ile Asp Lys 115 120 125 Lys Ser Asp Phe Glu Phe Thr Leu Lys Val Ser Tyr Leu Glu Ile Tyr 130 135 140 Asn Glu Glu Ile Leu Asp Leu Leu Cys Pro Ser Arg Glu Lys Ala Gln 145 150 155 160 Ile Asn Ile Arg Glu Asp Pro Lys Glu Gly Ile Lys Ile Val Gly Leu 165 170 175 Thr Glu Lys Thr Val Leu Val Ala Leu Asp Thr Val Ser Cys Leu Glu 180 185 190 Gln Gly Asn Asn Ser Arg Thr Val Ala Ser Thr Ala Met Asn Ser Gln 195 200 205 Ser Ser Arg Ser His Ala Ile Phe Thr Ile Ser Leu Glu Gln Arg Lys 210 215 220 Lys Ser Asp Lys Asn Ser Ser Phe Arg Ser Lys Leu His Leu Val Asp 225 230 235 240 Leu Ala Gly Ser Glu Arg Gln Lys Lys Thr Lys Ala Glu Gly Asp Arg 245 250 255 Leu Lys Glu Gly Ile Asn Ile Asn Arg Gly Leu Leu Cys Leu Gly Asn 260 265 270 Val Ile Ser Ala Leu Gly Asp Asp Lys Lys Gly Gly Phe Val Pro Tyr 275 280 285 Arg Asp Ser Lys Leu Thr Arg Leu Leu Gln Asp Ser Leu Gly Gly Asn 290 295 300 Ser His Thr Leu Met Ile Ala Cys Val Ser Pro Ala Asp Ser Asn Leu 305 310 315 320 Glu Glu Thr Leu Asn Thr Leu Arg Tyr Ala Asp Arg Ala Arg Lys Ile 325 330 335 Lys Asn Lys Pro Ile Val Asn Ile Asp Pro Gln Thr Ala Glu Leu Asn 340 345 350 His Leu Lys Gln Gln Val Gln Gln Leu Gln Val Leu Leu Leu Gln Ala 355 360 365 His Gly Gly Thr Leu Pro Gly Ser Ile Thr Val Glu Pro Ser Glu Asn 370 375 380 Leu Gln Ser Leu Met Glu Lys Asn Gln Ser Leu Val Glu Glu Asn Glu 385 390 395 400 Lys Leu Ser Arg Gly Leu Ser Glu Ala Ala Gly Gln Thr Ala Gln Met 405 410 415 Leu Glu Arg Ile Ile Leu Thr Glu Gln Ala Asn Glu Lys Met Asn Ala 420 425 430 Lys Leu Glu Glu Leu Arg Gln His Ala Ala Cys Lys Leu Asp Leu Gln 435 440 445 Lys Leu Val Glu Thr Leu Glu Asp Gln Glu Leu Lys Glu Asn Val Glu 450 455 460 Ile Ile Cys Asn Leu Gln Gln Leu Ile Thr Gln Leu Ser Asp Glu Thr 465 470 475 480 Val Ala Cys Met Ala Ala Ala Ile Asp Thr Ala Val Glu Gln Glu Ala 485 490 495 Gln Val Glu Thr Ser Pro Glu Thr Ser Arg Ser Ser Asp Ala Phe Thr 500 505 510 Thr Gln His Ala Leu Arg Gln Ala Gln Met Ser Lys Glu Leu Val Glu 515 520 525 Leu Asn Lys Ala Leu Ala Leu Lys Glu Ala Leu Ala Arg Lys Met Thr 530 535 540 Gln Asn Asp Ser Gln Leu Gln Pro Ile Gln Tyr Gln Tyr Gln Asp Asn 545 550 555 560 Ile Lys Glu Leu Glu Leu Glu Val Ile Asn Leu Gln Lys Glu Lys Glu 565 570 575 Glu Leu Val Leu Glu Leu Gln Thr Ala Lys Lys Asp Ala Asn Gln Ala 580 585 590 Lys Leu Ser Glu Arg Arg Arg Lys Arg Leu Gln Glu Leu Glu Gly Gln 595 600 605 Ile Ala Asp Leu Lys Lys Lys Leu Asn Glu Gln Ser Lys Leu Leu Lys 610 615 620 Leu Lys Glu Ser Thr Glu Arg Thr Val Ser Lys Leu Asn Gln Glu Ile 625 630 635 640 Arg Met Met Lys Asn Gln Arg Val Gln Leu Met Arg Gln Met Lys Glu 645 650 655 Asp Ala Glu Lys Phe Arg Gln Trp Lys Gln Lys Lys Asp Lys Glu Val 660 665 670 Ile Gln Leu Lys Glu Arg Asp Arg Lys Arg Gln Tyr Glu Leu Leu Lys 675 680 685 Leu Glu Arg Asn Phe Gln Lys Gln Ser Asn Val Leu Arg Arg Lys Thr 690 695 700 Glu Glu Ala Ala Ala Ala Asn Lys Arg Leu Lys Asp Ala Leu Gln Lys 705 710 715 720 Gln Arg Glu Val Ala Asp Lys Arg Lys Glu Thr Gln Ser Arg Gly Met 725 730 735 Glu Gly Thr Ala Ala Arg Val Lys Asn Trp Leu Gly Asn Glu Ile Glu 740 745 750 Val Met Val Ser Thr Glu Glu Ala Lys Arg His Leu Asn Asp Leu Leu 755 760 765 Glu Asp Arg Lys Ile Leu Ala Gln Asp Val Ala Gln Leu Lys Glu Lys 770 775 780 Lys Glu Ser Gly Glu Asn Pro Pro Pro Lys Leu Arg Arg Arg Thr Phe 785 790 795 800 Ser Leu Thr Glu Val Arg Gly Gln Val Ser Glu Ser Glu Asp Ser Ile 805 810 815 Thr Lys Gln Ile Glu Ser Leu Glu Thr Glu Met Glu Phe Arg Ser Ala 820 825 830 Gln Ile Ala Asp Leu Gln Gln Lys Leu Leu Asp Ala Glu Ser Glu Asp 835 840 845 Arg Pro Lys Gln Arg Trp Glu Asn Ile Ala Thr Ile Leu Glu Ala Lys 850 855 860 Cys Ala Leu Lys Tyr Leu Ile Gly Glu Leu Val Ser Ser Lys Ile Gln 865 870 875 880 Val Ser Lys Leu Glu Ser Ser Leu Lys Gln Ser Lys Thr Ser Cys Ala 885 890 895 Asp Met Gln Lys Met Leu Phe Glu Glu Arg Asn His Phe Ala Glu Ile 900 905 910 Glu Thr Glu Leu Gln Ala Glu Leu Val Arg Met Glu Gln Gln His Gln 915 920 925 Glu Lys Val Leu Tyr Leu Leu Ser Gln Leu Gln Gln Ser Gln Met Ala 930 935 940 Glu Lys Gln Leu Glu Glu Ser Val Ser Glu Lys Glu Gln Gln Leu Leu 945 950 955 960 Ser Thr Leu Lys Cys Gln Asp Glu Glu Leu Glu Lys Met Arg Glu Val 965 970 975 Cys Glu Gln Asn Gln Gln Leu Leu Arg Glu Asn Glu Ile Ile Lys Gln 980 985 990 Lys Leu Thr Leu Leu Gln Val Ala Ser Arg Gln Lys His Leu Pro Lys 995 1000 1005 Asp Thr Leu Leu Ser Pro Asp Ser Ser Phe Glu Tyr Val Pro Pro Lys 1010 1015 1020 Pro Lys Pro Ser Arg Val Lys Glu Lys Phe Leu Glu Gln Ser Met Asp 1025 1030 1035 1040 Ile Glu Asp Leu Lys Tyr Cys Ser Glu His Ser Val Asn Glu His Glu 1045 1050 1055 Asp Gly Asp Gly Asp Asp Asp Glu Gly Asp Asp Glu Glu Trp Lys Pro 1060 1065 1070 Thr Lys Leu Val Lys Val Ser Arg Lys Asn Ile Gln Gly Tyr Ser Cys 1075 1080 1085 Lys Gly Trp Cys Gly Asn Lys Gln Cys Gly Cys Arg Lys Gln Lys Ser 1090 1095 1100 Asp Cys Gly Val Asp Cys Cys Cys Asp Pro Thr Lys Cys Arg Asn Arg 1105 1110 1115 1120 Gln Gln Gly Lys Asp Ser Leu Gly Thr Val Glu Arg Thr Gln Asp Ser 1125 1130 1135 Glu Gly Ser Phe Lys Leu Glu Asp Pro Thr Glu Val Thr Pro Gly Leu 1140 1145 1150 Ser Phe Phe Asn Pro Val Cys Ala Thr Pro Asn Ser Lys Ile Leu Lys 1155 1160 1165 Glu Met Cys Asp Val Glu Gln Val Leu Ser Lys Lys Thr Pro Pro Ala 1170 1175 1180 Pro Ser Pro Phe Asp Leu Pro Glu Leu Lys His Val Ala Thr Glu Tyr 1185 1190 1195 1200 Gln Glu Asn Lys Ala Pro Gly Lys Lys Lys Lys Arg Ala Leu Ala Ser 1205 1210 1215 Asn Thr Ser Phe Phe Ser Gly Cys Ser Pro Ile Glu Glu Glu Ala His 1220 1225 1230 

What is claimed:
 1. An isolated polynucleotide comprising a sequence selected from the group consisting of: (a) sequences provided in SEQ ID NOs:1-663, 667-668 and 670; (b) complements of the sequences provided in SEQ ID NOs:1-663, 667-668 and 670; (c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NOs:1-663, 667-668 and 670; (d) sequences that hybridize to a sequence provided in SEQ ID NOs:1-663, 667-668 and 670, under highly stringent conditions; (e) sequences having at least 75% identity to a sequence of SEQ ID NOs:1-663, 667-668 and 670; (f) sequences having at least 90% identity to a sequence of SEQ ID NOs:1-663, 667-668 and 670; and (g) degenerate variants of a sequence provided in SEQ ID NOs:1-663, 667-668 and
 670. 2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) sequences encoded by a polynucleotide of claim 1; (b) sequences having at least 70% identity to a sequence encoded by a polynucleotide of claim 1; and (c) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1; (d) sequences provided in SEQ ID NOs:664-666 and 669; (e) sequences having at least 70% identity to a sequence provided in SEQ ID NOs:664-666 and 669; and (f) sequences having at least 90% identity to a sequence provided in SEQ ID NOs:664-666 and
 669. 3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.
 4. A host cell transformed or transfected with an expression vector according to claim
 3. 5. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim
 2. 6. A method for detecting the presence of a cancer in a patient, comprising the steps of: (a) obtaining a biological sample from the patient; (b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 2; (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.
 7. A fusion protein comprising at least one polypeptide according to claim
 2. 8. An oligonucleotide that hybridizes to a sequence recited in SEQ ID NOs:1-663, 667-668 and 670 under highly stringent conditions.
 9. A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of: (a) polypeptides according to claim 2; (b) polynucleotides according to claim 1; and (c) antigen-presenting cells that express a polynucleotide according to claim 1, under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.
 10. An isolated T cell population, comprising T cells prepared according to the method of claim
 9. 11. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of: (a) polypeptides according to claim 2; (b) polynucleotides according to claim 1; (c) antibodies according to claim 5; (d) fusion proteins according to claim 7; (e) T cell populations according to claim 10; and (f) antigen presenting cells that express a polypeptide according to claim
 2. 12. A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim
 11. 13. A method for the treatment of a lung cancer in a patient, comprising administering to the patient a composition of claim
 11. 14. A method for determining the presence of a cancer in a patient, comprising the steps of: (a) obtaining a biological sample from the patient; (b) contacting the biological sample with an oligonucleotide according to claim 8; (c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and (d) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.
 15. A diagnostic kit comprising at least one oligonucleotide according to claim
 8. 16. A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.
 17. A method for the treatment of lung cancer in a patient, comprising the steps of: (a) incubating CD4+ and/or CD8+T cells isolated from a patient with at least one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; and (iii) antigen presenting cells that express a polypeptide of claim 2, such that T cell proliferate; (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient. 